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ABSTRACT 
During the years of apartheid, South Africa developed two health care systems, public 
and private, that were fragmented and segregated by race. The private health care 
system (almost exclusively white patients) was on the same level as the tertiary care in 
industrialised countries, while the public health care system (almost exclusively black 
and coloured) was similar to the primary health care systems in many developing 
countries. 
Even so, South Africa in 1996 was spending much more than any other African country 
on health care, 8.5% of the GDP per year (McIntyre 1995). The political tide turned in 
1996 and with new governments came a new focus on equity of health care, access and 
services. Equity in health care and access are the main foci of health initiatives in South 
Africa. 
This research evaluated the impact of the National Drug Policy (1996), and the 
National Drug Programme (NDP). The NDP's key component is the Standard 
Treatment GuidelineslEssential Drugs List (STG/EDL) to be used in South Africa's 
public hospitals' outpatient clinics at all levels (primary, secondary, and tertiary). This 
study is a cross-sectional case study that evaluates the effectiveness of the 
implementation of this policy through strategies to encourage prescribers to use the 
STGIEDL as a regular part of their prescribing repertoire. The research techniques 
included a combination of quantitative analyses with a drug utilisation survey (DUS) 
that measured adherence to rational prescribing measures, and qualitative analyses in-
depth interviews with nurses, pharmacists, physicians and administrators. 
The results of both the drug utilisation survey of 1,204 prescriptions from eleven clinics 
and 20 interviews showed that there was little evidence of rational prescribing in public 
hospital clinics. Overall the prescribers at the clinic level did not adhere to the NDP and 
rational prescribing. The one major change observed was that the hospital clinic 
pharmacy would substitute most brand medicines for generic ones, unless the physician 
formally requests the brand drug. The one clinic that was the most adherent to the 
rational prescribing standard had a pharmacist who was enrolled in a rational 
prescribing and monitoring course. In addition, the manager pharmacist developed an 
EDP bulletin for all the staff and encouraged the use of the Standard Treatment 
Guidelines Essential Drugs list for all staff in the hospital clinic. 
In summary, this study shows that the major goals of the National Drug Policy (NDP), 
the rational prescribing of drugs and equity of access to health care and services, have 
note been reached. Even though there is some progress towards attaining these goals 
will require an effort of all stakeholders through enforceable legislation, allocated 
budgets, patient and prescriber education, and a bottom-up approach to policy 
implementation. 
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DEFINITIONS 
Compulsory Licensing: Allows for the cheap local manufacturing or generically 
equivalent drugs still protected by patents. 
District Health System: A health system based on PHC is more or less self-contained. 
It has a well-defined population, living within a geographical region. It includes all the 
institutions and individuals providing health care in the district, whether governmental, 
social security, non-governmental, private, or traditional. The District Health System 
(DHS) therefore consists of a large variety of interrelated elements that contribute to 
health in homes, school, work placed, and communities, through the health and other 
related sectors. It includes self-care and all health care workers and facilities, up to and 
including the hospital at first referral level and appropriate laboratory, other diagnostic, 
and logistical support services. Its component elements need to be well co-ordinated by 
an officer assigned to this function in order to draw together all these elements and 
institutions into a fully comprehensive range of promotive, preventive, curative, and 
rehabilitative health activities. (Source: WHO (1992) The hospital in rural and urban 
districts. WHO technical report series, No 819. Geneva: 1992) 
Essential Drugs: Those drugs considered to be of the utmost importance and hence 
basic, indispensable and necessary for the health need of the population. They should 
be available at all times, in the proper dosage forms, to all segments of society." 
Essential drugs are drugs that satisfy the health care need of the majority (90%) of the 
population. (WHO. The use of essential drugs. WHO technical report series, no 722. 
Geneva: 1985) 
Generic Drugs: non-proprietary. A drug name not protected by a trademark. The name 
is usually descriptive of its chemical structure. It can be manufactured without license 
from the innovator company and marketed after the expiration of the patent or other 
exclusive rights. Generic drugs are marketed .under either and International Non- . 
proprietary Name (INN) or brand name. (WHOIDAP/98.9) 
Healthlink: South African based web site that shares health information, articles, 
research, etc. 
Hospital Types and Levels2 : 
Community Hospital- District (Levell): Patients requiring treatment which may be 
adequately and appropriately provided at the first level of referral (e.g. community 
hospital) by a generalist with access to basic diagnostic and therapeutic facilities. 
Hospital - Secondary (Regional Level 2): Hospitals providing specialist services at 
the provincial level. Such hospitals would be equipped with and intensive care unit. 
xiii 
Hospital -Tertiary (Central Level 3): Patients requmng the expertise and care 
associated with the specialities, sub-specialities and less common specialities (such as 
cardiology, endocrinology, oncology, plastic and trauma surgery, neonatology, 
sophisticated paediatrics and specialised imaging), or requiring access to scarce, 
expensive and specialised therapeutic and diagnostic equipment found only at the 
central or tertiary hospital. 
Hospital - National (Level 4): Facilities providing quaternary health care (liver and 
heart transplantation) 
International Nomenclature Number (INN): common, generic names to identify new 
pharmaceutical substances unambiguously. The selection process is conducted by an 
expert committee and is based on a procedure and guiding principles adopted by the 
WHA. The INN is recommended for worldwide use, destined to be unique and public 
property (non-proprietary). (WHOIDAP/98.9) 
Parallel Imports: It is a means of importing drugs that are available locally at higher 
prices than in other countries. The importation of medicines that are manufactured, 
under license, by companies other than the country the country of origin. Products 
imported into a country without the authorisation of the right holder in that country, 
which have been put on the market in another country by that person or with his 
consent. According to the theory of exhaustion of intellectual property rights, the 
exclusive right of the patent holder to import the protected product is exhausted, and 
thus ends, when the product is first launched on the market. (WHOIDAP/98.9) 
Patent: A title granted by the public authorities conferring a temporary monopoly for 
the exploitation of an invention. The person or company, who reveals it, furnishes a 
sufficiently clear and full description of it and claim the monopoly for a set number of 
years (usually 10-15 years). (WHOIDAP/98.9) 
Poly-pharmacy: the inclusion of more than one active ingredient in a single medicinal 
preparation, or the prescription of too many medicines in the treatment of an individual 
patient. 
Rational Drug Use/ Prescribing: The prescriber prescribes and the "patients receive 
medicines appropriate to their clinical needs, in doses that meet their own individual 
requirements, for an adequate period of time, and at the lowest cost to them and the 
community." WHO, The Rational Use of Drugs, Report of Conference of Experts, 
Nairobi, 25-29 November 1985. 
TRIPS: The Agreement on Trade-Related Aspects on Intellectual Property Rights 
covers a new field in multilateral international trade law. The agreement established 
minimum standards of protection for the problems of international privacy and 
infringement of intellectual property rights. The TRIPS agreement binds the obtaining 
and maintenance of customs benefits in the framework of WTO to respect intellectual 
property rights by the State in question. It is the agreement in the Final Ac of the 
Uruguay Round that could have the most implications for the production of and access 
to drugs, particularly in developing countries. (WHOIDAP/98.9) 
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CHAPTER ONE 
INTRODUCTION 
1.1 Introduction 
The focus of the current project is South Africa's recent health sector reform in 1996 that 
aims to address the equity and the quality of all health services, including pharmaceutical 
services. This health sector reform seeks to expand the capacity of South Africa to 
distribute medicines to previously excluded groups at a price that the National and 
Provincial governments can afford. 
To this end in 1996, the South African government adopted a National Drug Policy (NDP) 
for "getting medicines to the people," regardless of residential location, race, or socio-
economic status. Governments and governmental agencies, such as the British Overseas 
Development Agency, have supported the adoption of the NDP. Support has also come 
from International Organisations (World Health Organization) and people at all levels in 
South Africa. In spite of both international and national support for policy reform, there is 
continuous controversy and resistance from stakeholders, including health professionals, 
pharmaceutical companies, pharmaceutical organisations and others. The resistance is to: 
(a) the use of the Standard Treatment Guidelines/ Essential Drug List (STG!EDL) as a tool 
to influence rational drug use; 
(b) the means or approaches taken to implement the National Drug Policy (NDP), 
specifically, rational drug use (RDU) and, 
(c) the appropriate means for monitoring and assessing the impact of the policy on rational 
drug use (RDU). 
The research question posed is: "Has the implementation of South Africa's National Drug 
Policy (January 1996), specifically, the use of the Standard Treatment Guidelines! Essential 
Drugs List,3 4 (for adult hospital use) resulted in rational drug prescribing in South Africa's 
public hospital outpatient clinics?" A cross-sectional study was designed to address this 
question. Both qualitative and quantitative methods were used to evaluate the impact of the 
implementation of the National Drug Policy (SADAP 1996). 
3 Essential Drugs List, 693 drugs for 300 medical problems and conditions. The Standard Treatment 
Guidelines and Essential Drugs List (STG/EDL) are combined into three books separated into three levels: 
primary care, hospital level (adults and paediatrics). . 
4 STG/EDL were published in December 1998~ 
2 
This research evaluated the effectiveness of the policy implementation strategies used to 
encourage prescribers to adopt the Standard Treatment Guidelinesl Essential Drug List 
(STG/EDL). A cross-sectional study of South Africa's Northern Province was 
implemented. Hospitals in six of the seven regions in South Africa's Northern Province 
were included in this study. Quantitative (Rational Drug Use Survey) and Qualitative (open 
interviews and structured observation, participant observation; and document review). 
The aim of the study is to address the development, implementation and evaluation of 
South Africa's National Drug Policy, and in particular the use of tools such as the Standard 
Treatment Guidelines/Essential Drug List to impact rational drugs prescribing. 
The objectives of this study include the evaluation of the policy of Rational Drug 
Prescribing within hospital clinics. Rational prescribing is the right drug, in the correct 
doses, for the right duration, for the correct illness. In addition, the objectives of the study 
are focused on the description analysis of the processes and the impact of the 
implementation of the National Drug Policy. The objectives will be addressed through a 
survey and analysis of rational drug use patterns of prescribers of various levels of 
outpatient hospital clinics. The second objective is to assessment of the knowledge, 
attitudes and pra~tices (KAP) of health personnel (physicians, nurses, pharmacists, and 
administrators) toward the implementation of the NDP and their training in the use of the 
STGI EDL. Third, to identification of factors, which facilitate or hinder the proposed 
implementation of the use of the STG /EDL for rational drug prescribing within various 
levels of outpatient hospital clinics. Fourth, to examine the policy implications of these 
research findings. 
The study makes numerous potential academic and practical contributions. Little 
information is available on the use of STG/EDL tools to facilitate Rational Drug Use 
(RDU). The current research project looks to further develop appropriate methods to assess 
obstacles and opportunities for strengthening prescriber involvement in the goal of RDU 
within a wider process of organisational and institutional change in health reform. 
3 
The goals of this research include making a contribution to the data on NDP surveys in 
developing countries and to achieve greater conceptual clarity regarding the key 
dimensions and goals of implementing social policy within the health reform. This includes 
concepts of policy analysis of implementation and top-down approach to implementation 
evaluation. The practical' contributions of the research will be in the form of policy 
implementation recommendations. Many studies have evaluated and analysed prescribing 
habits and drug utilisation, but few studies go further to evaluate what factors underline 
these results. The findings of this study will identify enabling and hindering factors to 
implementation ofRDU tool initiatives. 
The first five chapters are an introduction to the background of the Essential Drug Policies 
(EDP), South Africa's government, legislation and politics, the National Drug Policies in 
developing, and a review of policy implementation theories. The next three chapters, six 
through eight, are the methods and results, and the last chapters, nine and ten, are the 
discussion and conclusion and recommendations. In Chapter Two, the Background of 
Essential Drug Policies (EDP) is explored, and specifically, the overall drug situation and 
the start of EDP in Africa, especially Kenya, Zimbabwe and Tanzania. Chapter Three 
looks at South Africa's government, health and legislative and political areas are reviewed. 
Chapter Four reviews National Drug Policy Studies in Developing countries, specifically 
South Africa. Chapter Five, examines the theoretical areas of organisational change and 
management; implementation of social programmes; changing behaviour and RDU; and 
finally the pharmaceutical research that has been carried out to date in South Africa and 
other countries. Chapter Six outlines the research framework and methodology, and the 
initial hypotheses that were tested, the ethical and legal aspects of the research. Chapter 
Seven outlines the quantitative research results, specifically the drug utilisation survey, 
while Chapter Eight gives the results of the qualitative data, interviews and observation. 
Chapter Nine is a discussion of the findings, a look at the research outputs, its significance 
and its contributions. Chapter Ten looks at the conclusions and recommendations. 
4 
CHAPTER TWO 
BACKGROUND 
5 
2.1 The Overall Drug Situation 
According to the World Health Organization (WHO) approximately 1.3 and 2.5 billion 
people worldwide (WHO, 1988) have little or no regular access to essential drugs. In 23% 
of developing countries, less than 30% of the population have regular access to essential 
drugs. In 32% of the countries, between 30% and 60% of the population have access to 
essential drugs; and in 45% of the developing countries, 60-90% of the population have 
access. The difference in coverage is largely due to the financial situation of the country. 
However, finances are not the only factor. .Drug policies and their implementation vary 
between developing countries. In 1988, 25% of countries had a well-defined national drug 
policy (WHO: 1988). Of the developing countries, 41 % were developing a policy to 
increase the availability of essential drugs and 29% were considering implementing some 
type of essential drug policy or had no interest in an essential drug policy. In the report The 
World Drug Situation, (1988), WHO states "Although many of the 104 countries show an 
apparent lack of willingness to adopt a strong and effective drug policy, a majority have 
drug legislation as well as an essential drugs list." Drugs included on an essential drugs list 
differ from country to country depending on many factors such as the pattern of prevalent 
diseases, the type and number of available health personnel, financial resources, and 
genetic, demographic, and environmental factors. 
Drugs alone are not sufficient to provide adequate primary health care, but they do play an 
important role in protecting, maintaining, and restoring health to all people. Drugs are an 
important part of equity and good health care for all. The concept of essential drugs 
emerged from two realisations. First, access to drugs for both prevention and treatment is a 
complex issue with multiple problems, but extended access can both reduce costs and 
improve treatment simultaneously. In addition, the limited resources and capabilities of the 
health systems in developing countries created a gap to use drugs for prevention, control 
and cure disease to its full extent. 
This gap according to Reich (1987) has and continues to result from: 
Multiple problems in the interaction of phannaceutical companies 
with social organisations of poor countries. Some companies, both 
domestic and international have engaged in irresponsible business 
practices, including misleading advertising, aggressive production, 
and gift-giving to physicians and pharmacists. Inadequate social 
infrastructure had exacerbated the problems of procurement, 
6 
distribution and prescription, due to a lack of governmental policy, 
implementation difficulties, poor training of physicians and 
pharmacists, and ineffective management capacity. As a result, 
available drugs often are not appropriately prescribed or used .. 
The report on the World Drug Situation (WHO, 1988) goes on to state, "Progress is 
slow ... Many problems remain unsolved: improvement of procurement and distribution, 
strengthening of the drug authority, future training of health workers, and the creation of 
financial mechanisms to allow the programmes to become self-sustaining. The way to 
success is full of pitfalls and the opposition is substantial, but success can still be achieved 
as long as the level of political commitment remains high." 
By the end of 1999, the commitment of governments has remained about the same with 
106 United Nations Member States having a National Drug Policy (NDP), while 146 of all 
191 Member States have drawn up national essential drug lists (EDL) (WHO, 52:19, 1999). 
The change since the 1988 report, The World Drug Situation (WHO, 1988) is that more 
governments have started the process of becoming empowered. They are now looking to 
learn, understand and use their legislative powers in order to increase drug availability. 
WIIO continues to give support to member states in policy development, implementation 
and monitoring. However, member states have increasingly requested guidance in the area 
of international agreements, drug prices, innovation (patents) and local production, the use 
of exceptions, transfer of technology, licensing agreements and the transition period for the 
least developed countries. 
In the World Health Assembly, (WHA52.19:1999). with the requests of Member States in 
mind, a resolution on the revised drug strategy was devised to address the challenges of 
international trade agreements, specifically Trade Related Intellectual Property (TRIPS). 
access to essential drugs, drug quality, and rational use of medicines. The resolution adds to 
the original revised drug strategy, adopted by the Health Assembly in resolution 
WHA39.27 in 1986, and is updated at successive annual Health Assemblies. This strategy 
identified principles and goals for WHO's involvement with member states and the 
pharmaceutical sector. Indeed, a comprehensive approach is necessary to ensure the 
availability and rational use of drugs (WHO, 1988). 
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Moreover, according to Dr. Hogerzeil, the WHO Coordinator of Policy, Access and 
Rational Drug Use, (WHO press release in May 2000), "some countries pay 150% to 
250% of world market prices for the essential drugs, while other countries complain of 
unreliable suppliers and poor quality drugs. The WHO has set up an Interagency 
Pharmaceutical Coordination (IPC) Group, composed of pharmaceutical advisor of WHO, 
the United Nations International Children's Fund (UNICEF), United National Family 
Planing Association UNFPA, and the World Bank.. The IPC has the operational principle 
aim to assist national government, donor agencies and other organisations." 
2.2 The start of the Essential Drug Programme in Africa 
Kenya, Zimbabwe, and Tanzania are the three African countries that have the longest 
history of implementation of an Essential Drug Programme (EDP). The EDP was 
developed 1981 as a formulated response to the problem that a majority of the population 
was not able to get affordable basic drugs within their area. The EDP started slowly and 
spread to rural areas until eighty-five percent of the population had access to essential 
drugs. Kenya, Zimbabwe and Tanzania are evaluated more closely in the following 
paragraphs. 
Kenya 
In an attempt to address the multiple problems of providing drugs, Essential Drug 
Programmes (EDP) were initiated in many African countries. The initial essential drugs 
programme in Africa was started in Kenya by the government in 1981 (WHO, 1987). Most 
of the drugs needed for the entire population could be found in the city of Nairobi. 
However, the majority of people (85%) lived in rural areas. Health care was available to the 
entire population, although the type and quality varied. In government health institutions, 
patients did not pay for outpatient consultation, treatment or medication (WHO, 1987). 
The EDPs greatest advocate and active promoter was Dr. Wilfred Koinange, who was the 
Director of Medical Services in Kenya and also a member of WHO's Executive Board. The 
EDP was started, according to Dr. Koinange, because "In the past, we used to have our 
drugs distributed to the health centres and dispensaries by the district hospitals. What 
happened, obviously, was that the district hospitals first used the medicines for themselves 
and in the long run the health centres and dispensaries ended up with no drugs whatsoever. 
We wanted to correct this situation because most of our people live in the rural areas, and 
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the health facilities closest to them is either the dispensary or the health centre" (Essential 
Drug Monitor No.1, 1985). The project staff designed, developed and initiated an operation 
system of procurement, storage, packing and distribution, training, and information. 
The first part of the analysis included the identification of common diseases in the various 
rural areas. Once the most common diseases were identified, a list of 30 different types of 
medicines was compiled and distributed to the health centres and dispensaries. The 
medicines were packed centrally and dispensed directly to the health units. The 
implementation of the EDP, especially in all the government rural health facilities was 
considered an immediate success. 
The programme was first implemented in the rural areas because Dr. Koinange believed 
that the logical place to start was where the majority of people lived. One innovative 
intervention implemented by the consultants from both WHO and the Danish International 
Development Agency (UNIPAC) was the use of pre-packaged essential drugs in 'drug 
ration kits'. This approach was designed to improve the distribution of a limited number of 
essential drugs to rural health facilities. The use of rations kits comprised of essential drugs 
reduces losses from breakage, pilferage, and wastage. The amount of drugs to be added to 
the kit was determined by the number of patients at the health facility. The system proved 
to be a reliable and regular source of supplies of the most important medicines. The 
facilities received a regular supply of essential drugs at a low price. Each dispensary and 
health centre received a pre-packed kit that was for about 3000 patients; a reserve kit was 
also sent and new supplies were scheduled to arrive before previous stock ran out. This 
ration-kit packaging and distribution has reduced wastage and diversion of drug stocks. The 
cost per patent was US $0.16 at health centres and US $0.19 at the dispensaries. The per 
capita cost per year for the entire population was about US$0.29. 
Kenya's essential drug project was the first to be evaluated in November 1984. The 
evaluation team found that the Kenya programme achieved many of its objectives and 
goals in that period of time. An additional benefit of the programme was the experience 
gained from using specific medications for specific illnesses that standardised some 
common treatments. 
9 
Dr. Koinange believed that the rational use of drugs through prescriptions and the treatment 
given were better with a limited list of essential drugs. Dr. Koinange stated, "I have no 
doubt in my own mind that the more you limit the medicines the better people know how to 
handle those medicines and the more efficient they are, particularly in the rural areas" 
(World Health Organization, Essential Drug Monitor, No.1 1985). 
Zimbabwe 
In the same year, 1981, the Zimbabwe government adopted an essential drug list. The goal 
was to address the shortage of supplies in the government medical stores, which forced 
health care facilities to cover their drug needs by buying in the private sector, while the 
costs were covered by the Ministry of Health. Zimbabwe attempted" to shift the emphasis 
from an elite-centred, curative, sophisticated, urban-based health care system to a majority 
oriented, preventive, rural-based primary health care system" (WHO, World Drug 
Situation, 1988). To improve this costly situation, the Zimbabwe Government proposed an 
essential drug list in 1981 that was published as the Essential Drug List of Zimbabwe, 
(ED LIZ) in 1985. Although Zimbabwe had over 2000 registered drugs, only 375 were put 
in the EDLIZ. Drugs not listed in the EDLIZ could be prescribed only in special cases, with 
the permission of the Secretary for Health. The EDLIZ was an attempt to promote the 
rational use of drugs. However, as shown by a survey in 1985, "personnel's use of the 
ED LIZ was found to be poor and none of the clinical staff had any knowledge about the 
prices of drugs. From the point of view of prescribing, there seems to be a need for further 
training in economical prescribing and dispensing, stock control, ordering, and storage." 
(WHO, World Drug Situation, 1988) Perhaps the programme evaluation was too early to 
reach definitive valid conclusions. After the survey, a training programme for the rational 
use of drugs was developed and carried out to cover all health care levels between 1988-
1989. Zimbabwe is another good example of the perils of EDP implementation. Six years 
after drafting the first EDL, the Zimbabwe Government learned an EDL alone was not 
sufficient to insure availability of essential drugs in rural areas. The list needed to be 
incorporated into a National Drug Policy that includes legislation, EDP, and training. 
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Tanzania 
In 1984, Tanzania, similar to Zimbabwe, implemented its programme on a National level. 
The problems that led to the implementation of a NDP were generally the same as 
Zimbabwe and Kenya, but the dynamics of the health systems and peoples access were 
different. In Tanzania, health services were provided free of charge. This policy was based 
on the Arusha Declaration of 1967, which served as a blueprint for Tanzania's socialism 
that is based on Ujama (collective work and responsibility) and self-reliance. More than 
90% of the population lived within 10krn of a health facility. With a decline in the health 
budget and lower per capita expenditure, Tanzania, like many other countries, experienced 
a lack of essential equipment, medical supplies and most importantly, therapeutic drugs. 
The Tanzanian people use the supply or the lack of drugs as a measurement of the quality 
of health services. This applied so closely that when the "stock of drugs runs out, there is 
virtually no patients, but when the Essential Drug Programme kit arrives, a crowd 
assembles at the dispensary"(WHO, Essential Drug Monitor, 1: 1985). Procurement of 
drugs was done on both the national and international levels. UNICEF bought the drugs for 
the project, and in doing so brought down the market price of the procured generic drugs. 
With the co-operation and active participation of UNICEF and UNIPAC in Copenhagen, 
drugs were packed in kits and then shipped in containers to five destinations in Tanzania. 
Trucks delivered the drugs to the district headquarters, while smaller vehicles then took the 
drugs to various destinations. This system allowed kits to be delivered regularly to 
approximately 3000 health facilities. This system changed the state of the essential drug 
shortage in the rural areas. 
Overview of the EDP in Africa 
This. summary ofNDP implementation in the countries of Kenya, Zimbabwe and Tanzania 
in the 1980' s gives a history of the development, implementation and impact of such 
programmes in a developi'ng country context. The South African government, more than 
two decades later, is attempting to implement the same programmes with some of the same 
hurdles. Regardless of the region, many countries in Africa and all over the world adopt an 
EDL, but only those with a strong commitment and determination, formulate and 
implement a NDP that includes among other strategies an EDP. "The main reason why 
EDPs have not had more impact on the development of national policy within countries has 
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been because of a lack of willingness among governments to restrict the use of inessential 
drugs and introduce restrictive legislation within the private sector" (Kanji et al. 1992). 
The evaluation team from WHO found that the Kenya Essential Drug programme (EDP) 
achieved many of its objectives and goals in that period of time. The Kenya programme 
began with a few districts, and slowly spread to cover all rural areas. After three years 
essential drugs were available to the entire rural population. Zimbabwe started their EDP in 
1984. The focus was shifted from an urban-based health care system to a rural-based 
primary health care system that focused on preventive services. Implementation was much 
more difficult than anticipated and the use of the EDL alone did not bring expected results 
to meet the original goals. In Tanzania, although health care is free, there were difficulties 
with the procurement and distribution of drugs. The NDP was successfully implemented 
with the help of the United Nations organizations and pre-packed medicine kits. 
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CHAPTER THREE 
SOUTH AFRICA 
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3.1 Background of Health Reform 
During the years of apartheid, South Africa developed two health care systems, public and 
private, that were fragmented and segregated by race. "South Africa is not a normal society 
within which the usual pathologies occur. Apartheid and health were incompatible and 
mutually exclusive" (Simpson, 1995). Thus, the health care system reflected both 
industrialised tertiary care and developing country primary care. Even so, South Africa, in 
1996, was spending much more than any other African country on health care, 8.5% of the 
gross domestic product (GDP), or £154 per person per year (McIntyre & Health Systems 
Trust, 1995). 
When the political tide turned in 1996 a new focus on health care access and services came 
to the forefront. The new strategy was to increase primary health care for the masses and 
decrease tertiary health care coverage for the few (Equity and equality became the working 
foundation of health care reform in South Africa). The former (1995-1999) Minister of 
Health, Dr. Nkosazana Dlamini Zuma, directed the painful process of redistribution of 
health spending. Thus far there have been cuts in tertiary care. These resources have been 
shifted to provide free primary health care to children under six and pregnant women. In 
addition, over 500 new clinics have been built in poor areas (Economist, 1998). The new 
(2000-2005) Minister of Health, Dr. Manto Tshabalala-Msimang, has now turned the focus 
to access of drugs for AIDS by using the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) compliant measures, such as parallel import (through 
the Patents' Act) and compulsory licensing. The government will take advantage of 
cheaper imports and manufacturing cheaper generic equivalents locally. The minister 
states, "this is the only way that we can see at present of being able to provide medicines to 
people at reasonable prices" (Thorn 2001). 
3.1.2 Equity in Health 
Equity in health is the focus of most health initiatives in South Africa. The Reconstruction 
and Development Programme (active until 1997, now phased out), through the Department 
of Health, had placed emphasis on Primary Health Care (PH C). Providing access to 
essential drugs is an integral part of a national health system and PHC. Now the nine 
individual provinces are responsible for implementing the mandates, bills, and policies that 
have been passed into law. National law dictates that each of the nine provinces must 
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implement national policies. The overall health care agenda for the Government has been to 
redefine the basic health services available to all while maintaining an emphasis on social 
justice and equity. The challenge will be to balance a basic free level of care for all, while 
continuing to support the highly developed tertiary care services and infrastructure. 
Social class variation has been divided by race first and the economics. Most while South 
Africans were able to receive advances developing world health care in both the private and 
the segregated public hospitals. On the other hand, 'non-white' South Africans regardless 
of economic class were not able to access the same resources through public hospitals, but 
on a limited basis in private 'colored' hospitals. 
Currently, South Africa has 693 hospitals, 72% public and 28% private. Public hospitals 
make up 75% of the 158,567 hospital beds available. Of the over 22,000 physicians 
practising, only 42% do so in the public sector. Four out of five patients in South Africa are 
treated in the public health sector. S in 1996, the private sector treated about 20% of the 
population. Total medical spending in the public and private sector is over 8% of the GDP 
(Economist, 1998). Although this is higher than in most middle-income countries, two-
thirds of it went to a fifth of the population, largely the white population. Some argue that 
they deserve to get more comprehensive and better health services because they pay more 
taxes (Economist, 1998). The private sector "serves only 20% of the population, yet it 
accounts for roughly 60% of the resources spent on health. This sector has seen rampant 
and severe fragmentation that has resulted in the irrational use of resources, and inadequate 
infrastructure" (Cosser 1997, and National Drug Policy for South Africa, 1996). 
3.1.3 Decentralisation of Health Resources and Services 
A key feature of PHC is the decentralisation of services. Budgetary and accounting refonns 
are important for effective decentralisation. Decentralisation is an important part of the 
. success of PHC policy within a country. It provides managers with both responsibility and 
accountability and a limited budget that allows for some flexibility to provide services. 
"The main public sector organisational reform already implemented in many Sub-Sahara 
African (SSA) countries is the decentralisation of planning and management, which aims to 
push responsibility for at least some decisions down the administrative hierarchy. The 
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preferred management level is usually the district, where the management of primary and 
secondary level services can be integrated and planned for a defined population. 
Decentralisation may also involve establishing large institutions, such as teaching hospitals, 
as self-managing enterprises. It is critical complementary policy for financing reforms" 
(Gilson & Mills 1995). 
Similarly, the South African governments' decision making in health care has been 
decentralised. The new power focus and economic decision making lies within the districts 
within the provinces. At the national level public resources are allocated to the provinces, 
based on a formula that takes population into account. The provincial government then 
takes this funding and allocates it to health, education and other public services. The 
Provincial government determines the health focus, goals, strategies, and moneys to be 
allocated. 
3.2 Hospital and Staff 
3.2.1 Hospitals change focus 
The new focus on the primary health care (PHC) approach has necessitated a shift of 
resources away from the hospital sector towards primary care (McMurchy, 1997). The 
public hospital system (academic, tertiary, secondary, community) is central to the 
successful implementation of the PHC approach. The Ministry of Health and specifically, 
Dr. Zuma, as its former Minister had been criticised for focusing on PHC at the expense of 
hospital care. All levels, primary, secondary and tertiary of hospital care are needed in 
order to care for the needs of the population. According to Dr. Zuma, there cannot be a 
strong primary care service without the backup of other levels of care. For the successful 
implementation of the PHC approach, a large proportion of existing allocations to the 
hospital sector will have to be re-channelled to primary health care facilities. This can only 
happen if hospitals make substantial savings, by improving their efficiency (National 
Department of Health, White paper on the Transformation of Health System, 1997). 
The public hospitals have been plagued with problems of inequity, inefficiency and poor of 
quality services. To bring the public hospital system in line with the transformation process 
currently taking place in the national health system these issues must be addressed, and 
systematically resolved. South Africa has spent a disproportionate amount of its resources 
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in the hospital sector. Public acute care hospitals in 1992/3 spent R8.59 billion or 76% of 
the budget of total recurrent public health expenditure. This is the equivalent of 
approximately R200 per person in that year. A large percentage of resources for public 
hospitals have been spent in academic and tertiary hospitals, while they account for 38% of 
the beds, the acute hospital expenditure was 58% (Cossier, 1997). In spite of the resources 
spent, public hospitals have only 2.43 public sector beds per 1,000 population and many 
magisterial districts have no hospital at all. 
The nine provinces within South Africa have marked differences in the availability of 
public sector hospitals. Mpumalanga has the lowest and Northern Cape the highest ratio of 
acute beds to population. Utilisation of hospital services, also show marked differences. 
Public hospitals in Mpumalanga, North-West and Northern Province provided less than 
500 inpatient days per 1,000 population, while KwaZulu-Natal and Western Cape provided 
over 700 days (Cossier, 1997). Moreover, there is also a difference in the mix of public 
sector hospitals. Over half the beds in Gauteng and Western Cape are in academic or 
tertiary facilities. Conversely, Mpumalanga, and Northern Cape have virtually no tertiary 
beds. The Western Cape has a large number of chronic hospital beds per 1000 population 
(ReHMIS Survey 1992/3). Overall in 1991, there were 3.3 beds, per 1000 population. In 
the former homelands, however there were only 2.7 beds per 1000 population. In non-
metropolitan areas the number was 4.0 compared to 7.1 in metropolitan areas. General 
acute beds per 1000 population, were 1.5 per 1000, while tertiary care beds were 1.9 per 
1000 population. 
3.2.2 Staffing 
The success of health care reforms specifically the implementation of the NDP and usage 
by health care staff will ultimately determine the adoption of the STGIEDL. To change the 
foundation of health care delivery, first the environment must be altered for both staff and 
patients. Staff dedication and behaviour is a key to equity and the delivery of basic health 
care service for all. Generally, there is a shortage of most health care professionals within 
South Africa, but the problem is more pronounced in rural, poor and African majority 
Provinces. In 1990, 22,260 medical doctors were registered, 6,087 of them in medical 
specialities. In the metropolitan area, the ratio of population to doctors was approximately 
700 per doctor. However, consistent with other figures, there are only 900 per doctor in 
non-metropolitan areas. In the areas that were former homelands, the estimated figure is 
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10,000 to 30,000 people per doctor. Seventy-seven percent of doctors live in metropolitan 
areas and more than 58% work in the private sector. Many doctors mix both public and 
private sector positions. (South African Pharmacy Council, 1998) Pharmacists show the 
same pattern. Generally, pharmacists are underrepresented in the public sector. Currently, 
only 26% of employees are in the public sector including those in administrative positions 
and at academic institutions. "Research conducted in 1997 showed that the percentage of 
pharmacists actually providing a service in this sector was between 11 % and 15%" (South 
African Pharmacy Council, 1998 :2). This is a grave matter since 80% of the population use 
services of public health facilities. 
Most health care staff in the public sector practice in academic and tertiary hospitals. Of all 
the public sector health staff most work in academic or tertiary hospitals: 51 % general 
physicians, 82% specialist physicians, 35% Nurses, and 51 % pharmacists. The next highest 
concentration of staff is in community hospitals (Table 3.1) with general physicians 
(20.2%) and specialist physicians (4.1%), nurses (26.7%) and pharmacists (21.5%). The 
secondary and chronic hospitals have the lowest percentage of all health professionals. 
Table 3.1 Distribution of Public Sector Health Care Personnel by Level of Care 
(1992/93) 
Pharmacists General Specialist Nurses 
Doctors Doctors 
Facility Type No. (%) No. (%) No. (%) No. 
Academic hospitals 2164 38.0 1367 63.1 21288 19.5 289 
Tertiary hospitals 1287 22.6 419 19.3 17694 16.2 233 
Secondary hospitals 404 7.1 122 5.6 13733 12.6 ,132 
Community hospitals 1146 20.2 89 4.1. 29049 26.7 220 
Chronic hospitals 114 2.0 91 4.2 8665 7.9 44 
Primary care services 575 10.1 80 3.7 18627 17.0 108 
All acute hospitals 5001 87.9 1997 92.1 81764 75.0 874 
TOTAL 5690 100 2168 100 109,056 100 1026 
Source: Regional Health Management InfonnatlOn System (ReHMIS) Survey, 1992/3 
(%) 
28.2 
22.7 
12.9 
21.5 
4.3 
10.5 
85.2 
100 
Note: Academic hospitals by definition will have more staff as they have both a teaching and research function. 
Development Bank of South Africa (1994) 
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In addition, substantial differences exist In staffing between the different levels of 
hospitals. The community and secondary hospitals have similar numbers of doctors and 
nurses per bed. However, in comparison to community hospitals, academic hospitals had 5 
times the number of doctors per bed and 1.7 times the number of nurses, while tertiary 
hospitals had 2.7 times the number of doctors and 1.4 times the number of nurses. 
Academic hospitals have 1.8 times more doctors and 1.3 times more nurses per bed than 
tertiary hospitals. (Regional Health Management Information System (ReHMIS) Survey, 
1992/3) 
Table 3.2 Provinces Distribution of Facilities and Health Personnel 1992/93 
(per 1000 population) 
PROVINCE Hospital Doctors Nurses Pharmacists 
Beds 
Eastern Cape 3.5 30.7 321.3 20.1 
Mpumalanga 2.1 28.3 265.8 23.1 
Gauteng 6.0 127.4 618.4 109.8 
KwaZulu-Natal 3.8 53.5 431.9 28.7 
Northern Cape 4.0 37.6 432.3 28.5 
Northern Province 2.5 15.5 293.2 7.8 
North-West 3.3 22.7 273.5 22.8 
Free State 4.1 46.5 382.3 38.8 
Western Cape 5.4 143.8 686.3 79.8 
The distribution of facilities and health personnel between Provinces in the 1992/93 (Table 
3.2) shows that Gauteng and Western Cape Provinces have the largest hospital bed per 
1000 population. These provinces, mostly urbanised Gauteng and Western Cape also have 
the largest doctor to population ratio of 127.4 and 143.8 per 1000 population, and the 
largest nurse (618.4 and 686.3) and pharmacist ratios (109.8 and 79.8) respectively. In 
direct contrast, the mostly rural Northern Province has the lowest hospital bed to 
population of ratio of 2.5, only second to Mpumalanga. The Northern Province has the 
lowest doctor to population ratio of 15.5 and pharmacist to population ratio of 7.8. The 
trends of table 3.2 shows that the urban, mostly business, white majority provinces have 
substantial resources. The rural, agricultural, African provinces, like the Northern Province, 
are lacking sufficient material and human resources. This lack of adequate hospital beds 
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and human resources makes achieving equity In health care for all South Africans a 
fonnidable challenge. 
3.3 Primary Health Care and Drugs 
The restructured National Health Service in South Africa is based on a Primary Health Care 
(PHC) Strategy. An integral part of PHC is a comprehensive plan to evaluate and 
implement changes in its pharmaceutical policies through a National Drug Policy (NDP). 
The NDP's main goal is to make "effective, safe, low-cost drugs available and affordable to 
meet the needs of the entire population, and to ensure that drugs are of good quality and 
used rationally" (WHO, 1998c). 
The National Drug Policy of South Africa aims to provide a limited number of medicines 
to the majority of people for prevention and treatment of disease in a PHC setting. The 
NDP focus is the providing of drugs that are available, affordable, and accessible and in 
addition the related issues of dispensing, storing, and prescribing. Availability, 
accessibility, equality, and sustainability are the main issues in providing drugs for the 
entire population at all levels of care. The limited funds available to the Health Ministry are 
not used in the maximum costlbenefit manner. The use of resources must be improved and 
wasting reduced. WHO estimates that generic prescribing from an essential drug list has the 
potential to save from 10 to 60 percent of spending (WHO, 1998). One of the most 
important foundation cornerstones for PHC is the implementation of a NDP through an 
Essential Drug Programme. The availability of essential drugs is of major importance in the 
perception of credibility of health services for patients. The selection of essential drugs list 
(EDL) is an important component of managing accessibility and equity in the distribution 
of pharmaceuticals. The EDL should be limited to drugs, which could be used in a wide 
range of settings from common to rare diseases and from primary to tertiary centres. 
3.3.1 Pharmaceutical Reform 
During apartheid, the pharmaceutical industry in South Africa thrived with both private 
insurers and public and private "whites only" hospitals. Since South Africa has an 
advanced tertiary system with a free market atmosphere, multinational pharmaceutical 
companies were most profitable in Africa in South Africa. 
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One of the largest challenges for the Department of Health, and specifically Minister Zuma, 
in its attempt to shift to PHC is the reform of the pharmaceutical policies in South Africa. 
This reform is a necessary and integral part of restructuring the health care sector that is 
recovering from the legacy of apartheid. 
The industry enjoyed a relatively easy pricing environment with relatively no competition. 
However, access to drugs was a part of the apartheid system. To change history and for 
South Africa to provide the majority of the population with access to medicine this political 
and economic isolation and privilege had to change. The former Minister of Health (1995-
2000), 
Dr. Nkosazana Dlamini Zuma speaking about the National Drug Policy stated: 
(Draft speech Dr Zuma to the 19th IFPMA Assembly, Cape Town, Wednesday 11 November 1998) 
In the past, however, drugs have not been available to all South Africans, due to the 
structured inequities and inaccessibility caused by apartheid. This situation will be 
changed through the implementation of our National Drug Policy, to develop fully 
the potential that drugs have to improve the health status within the available 
resources in a country. It is therefore incumbent on all the role players to participate 
fully to enable the country to provide health care for all its inhabitants. 
The drug budget before 1998 of approximately R2 billion/year (US$430 million/year), 
(Moller 1998) for the public sector was inequitably allocated. Moreover, the selection of 
drugs did not reflect the health care needs of the majority of the population. The annual per 
capita expenditure on drugs for 85% of the population who use the public sector is R52 
(US$l1). For the private sector used by 15% of the population this expenditure is about 
R 792 (US$174).) Of the Sub-African counties, twenty-three had drug consumption of less 
than five dollars (US$5) per person in 1990. (Essential Drug Monitor, 1998: 10). In South 
Africa, the cost for medicines distributed in hospitals is Rl.3 billion/year (US$280). 
It has been estimated that 60% to 80% of the total drug procurement and distribution 
systems did not succeed in getting the medicines to the patients. Medicines were wasted 
even though there were supplies of high quality drugs in the private sector, and was a well-
developed pharmaceutical industry (SADAP 2000 and BDDSA, November 1996). The use 
of generic drugs is relatively uncommon. 
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3.3.2 Generic Drugs 
Generic drugs are not new in South Africa. For the past 30 years, use of generic drugs has 
been mostly in the public (government funded) health sector. Generics are used less 
frequently in the private sector. As a whole, in the private sector generics account for only 
28% of drugs prescribed in South Africa at present. South Africa has a lower rate of 
generic prescription than many other countries (Cosser, 1997). The extension of the right to 
dispense drugs to all registered health care workers, linked with the wider use of the 
Standard Treatment Guidelinesl Essential Drugs List (EDL), make safe medicine 
dispensing available to more people who need it. Generics in the US and Europe typically 
cost 30-60% less than patented brand-name medicines. In South Africa, generics cost about 
15% less (Cosser, 1997). So, generic drugs are lower in price than the name brand drug, but 
during apartheid the price of generic drugs in South Africa was higher than other countries 
because during the years of apartheid the phannaceutical industry was protected. 
Adherence to the NDP's foundation of generic prescribing using the Standard Treatment 
GuidelinelEssential Drugs List would allow for the limited public budget for medicines to 
be spent in a manner that would cover more of the population. Non-adherence to 
prescribing generics for a majority of the population would have consequences of lessening 
the budget for essential brand medicines for Multi-Resistant Tuberculosis and HIV/AIDS. 
The cost of non-adherence is the lives of those who are not able to access basic medicinal 
treatment because of limited financial resources. 
In an opening speech at the International Federation of Pharmaceutical Manufacturers 
Association (IFPMA) Bi-annual meeting in Cape Town in November 1998, Dr. Zuma 
stated: 
We need to lower the cost of medicines, and promote the 
cost-effective use of drugs. Our problems are immense, 
and our resources limited. We will have to make decisions 
in the interest of public health that you might not always like. 
It is our duty to rectify that unjust situation: we invite you to 
participate in this process. All people in this world need 
access to affordable, essential medicines. 
(Draft speech Dr Zuma to the 19th IFPMA Assembly, Cape Town. Wednesday II November 
1998) 
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South Africa provides one of the largest profits for pharmaceutical multinationals of the 
low/middle income countries. Changes to the health and phannaceutical legislation in 
South Africa would be closely watched and perhaps emulated by other countries that have 
many people to cover and limited public resources. All health legislation to set up options 
for obtaining medicines both brand and generic introduced by the National Health 
Department was opposed by the pharmaceutical companies. If South Africa was the first to 
change the rules for buying and distributing medications, then other countries would follow 
suite and there would be an overall reduction in pharmaceutical companies profits. Several 
legislative changes were initiated and fought within the courts by phannaceutical 
companies. 
3.4 Health Legislation, Policy and Events in South Africa (1994-2000) 
1. Key Health and Drug Legislation, Policy and Events 
When the new South African laws and regulations facilitate and enable the fulfilment of the 
NDP (Box 3.1). These regulations and laws address price control, parallel importing, 
international tendering, generic prescribing, prescription by nurses, dispensing by 
pharmaceutical technicians, generic substitution and labelling. The emphasis is on 
affordable drugs for a majority of the population, and actions to make it a reality. Dr. 
Zuma continued to encounter significant opposition over the implementation of the NDP 
from stakeholders, especially, multi-national pharmaceutical companies (MNCs), doctors, 
and phannacists. Controversies include the promotion of generic drugs (including 
automatic generic substitution) instead of more expensive brand-named drugs, parallel 
import and intellectual property rights. South African medicines are among the most 
expensive in the world. This is partly a result of the MNC's operating in a sheltered and 
protected economic environment during the apartheid years. The MNC's enjoyed a market 
that did not foster competition. The submission of several Bills and statutes would have put 
an end to the very lucrative pharmaceutical market for many multinational companies. The 
specific bills that are opposed by the pharmaceutical MNC's are the Medicines and Related 
Substances Control Amendment Bill, and the South African Medicines and Medical 
Devices Regulatory Act (SAMMDRA). 
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In 1997, four health related Bills were introduced into Parliament: the Medicines and 
Related Substances Control Amendment Bill; the Pharmacy Amendment Bill; the Medical, 
Dental and Supplementary Health Services Professions Amendment Act; and the South 
African Medicines and Medical Devices Regulatory Act (SAMMDRA). Two of these Bills 
are now law, but as of June 2002 not all have taken effect. The Medicines and Related 
Substances Control Amendment Bill is under consideration by the Pretoria High court. The 
South African Medicines and Medical Devices Regulatory Act (SAMMDRA) was sent to 
South Africa's constitutional court by President Mandela, after pressure from 
pharmaceutical stake holders to determine its legality. 
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Box: 3.1 Key Health and Drug Legislation, Policy and Events in South Africa 
DATE EVENT 
1994-1995 
1994 
1994 
1995 
1995 
1996 
February 1996 
April 1996 
September 1996 
September 1996 
November 1996 
1997 
January 1997 
April 1997 
May 1997 
May 1997 
1998 
January 1998 
January 1998 
January 1998 
February 1998 
February 1998 
February 1998 
February 1998 
March 1998 
July 1998 
November 1998 
November 1998 
November 1998 
December 1998 
December 1998 
1999 
Novemberl999 
2000-2001 
2000 
March 2001 
March 2001 
April 2001 
December 200 1 
Publication of a National Health Plan (NHP) for South Africa 
National Drug Committee appointed 
Evaluation of South Africa's Drug Policy by Consultants in Health 
Development (CHD) 
National Essential Drugs Committee appointed by 
National Drug Policy for South Africa published and adopted 
Publication and Distribution of first EDL for primary care (Green Book) 
Mission to evaluate a South African Drug Action Programme 
by Consultants for Health and Development (CHD) 
DFID approved funding for the National Drug Programme (NDP) 
and the South African Drug Action Programme (SADAP) 
SADAP project started in Pretoria (1 Nov 1996 to Dec 2001) 
Medical and Related Substances Control Amendment Act 90 of 1997 
White Paper on the Transformation of the SA Health System 
Pharmacy Amendment Bill of 1997 introduced 
Medical and Related Substances Control Amendment Act 90 of 1 997 tabled 
Medical, Dental and Supplementary Health Services Professions Amendment 
Act 90 of 1997 passed 
Pharmacy Amendment Act 28 or 1997 passed 
President Mandela signs Medical and Related Substances Control 
Amendment Act 90 of 1997 into Law 
Pharmaceutical Manufacturing Association brings suite against SA Government. 
President Mandela sent the Medical and Related Substances Control 
Amendment Act 90 of 1 997 to constitutional court for repeal 
US adds South Africa put on Trade Violation 'Watch List' 
Phimnaceutical Manufacturing Association (PMA) case starts 
Compulsory community service for new physicians 
South African Medicines and Medical Devices Regulatory Authority Bill 
(SAMMDRA) passes to replace Medicines and Related Control Act of 1965 
and the Medical and Related Substances Control Amendment Act 90 of 1997 
International Federation of Pharmaceutical Manufacturers (lFPMA) 
Assembly in Cape Town, South Africa 
SADAP mid-term Review 
Launch of National Drug Programme (NDP) 
Publication and Distribution of new EDL 
South African Medicines and Medical Devices Regulatory Authority Bill 
(SAMMDRA) sent to court for by Mandela 
US takes South Africa off the 'Watch List' 
Pharmaceutical Manufacturing Association (PMA) case began 
SA Health Minister, Tshabalala-Msimiang repealed the South African 
Medicines and Medical Devices Regulatory Authority Bill 
(SAMMDRA) 
Pharmaceutical Manufacturing Association (PMA) case withdrawn and the 
Medical and Related Substances Control Amendment Act 90 of 1997 effective 
South African Drug Action Program (SADAP) direction under WHO ended. 
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2. Health Legislation 
a) Medical, Dental and Supplementary Health Services Professions Amendment Act 
The Act established a more broadly representative Health Professions' Council to replace 
the Interim National Medical and Dental Council of South Africa. In addition, the Act 
expanded the realm and powers of professional bodies for each of the various professions. 
Disciplinary powers are now in the authority of the professional body, rather than the 
Council. The Act also requires that people who register for the first time with the Council 
must perform remunerated community service for a year (Compulsory community services 
started on 1 July 1998). The Act went into effect on 23 January 1998. 
b) Pharmacy Amendment Act fAct. No., 28 of 1997J 
The Pharmacy Amendment Act passed in January 1998 and went into effect on 1 March 
1998. It established a permanent Pharmacy Council, and also contains the provisions that 
relate to pharmacy education, training and practice and the licensing of pharmacists. The 
Act overturned the former restriction that only pharmacists may own pharmacies, although 
the pharmacy must be under continued supervision by a licensed pharmacist. This opening 
up of pharmacies is an important measure that will help in assuring that there are adequate 
distributions of pharmacies in rural and other under-served areas. 
The second significant change is that pharmacists will now be required to dispense generics 
unless specifically requested not to do so by the doctor or patient. Certain provisions of the 
Act have not gone into effect yet, in order to allow the State to make the necessary changes 
with the requirements of the Act. 
c) Medicines and Related Substances Control Amendment Act fAct No. 90 of 1997J 
The Medicines and Related Substances Control Amendment Act (Act No. 90 of 1997) has 
introduced a number of cost-containment measures to bring down the cost of medicines to 
make health care more accessible and affordable. This legislation aims to address the 
growing crisis of lack of access to affordable medicine in South Africa, by promoting the 
use of generic medicines and by permitting the parallel importation of medicines. Act No. 
90 also includes provisions to better regulate medicines in South Africa and to ensure 
transparency in pharmaceutical pricing by requiring the setting of a "single-exit price" and 
doing away with bonuses and other forms of "perverse incentives." "Currently, a 
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pharmaceutical company can influence a doctor or pharmacist to prescribe or dispense its 
products by offering cut-rate deals for a short amount of time, before raising prices once a 
patient has begun a course of therapy" (Medecins Sans Frontieres, 2001). Drug legislation, 
which had prohibited generic substitution, was revised. Drug legislation, and the Medicine 
and Related Substances Control Act No. 101 of 1965, and the Pharmacy Act No. 53 of 
1974 prohibited generic substitution. Act 90 of 1997 included provisions for international 
tendering, 'parallel importation' of medicines, promotion of generic substitution, regulation 
of supply of medicines through bonuses, rebates and sampling, and the establishment of a 
pricing committee to introduce single exit pricing and other price controls. Parliament and 
former President Mandela passed the Act into law towards the end of 1998. 
1) Minister of Health 
This Act gave more power to the Minister of Health within the Medicines Control Council, 
which regulates medicine. But Dr. Zurna believed that although the Medicines Control 
Council (MCC) was generally well respected, it held too many of the former old guard that 
would not generally act in the interest of the majority of the population. The Minister 
dissolved the MCC in 1998. "The MCC was staffed by white appointees of the former NP 
government, who nevertheless enjoyed a strong reputation among members of the medical 
profession" (Economist, 1998). When it was time to appoint a new Chair to the MCC, Dr. 
Zuma did not re-appoint the former Chair for over a decade, Professor Peter Folb6, but 
appointed a new Chair. This resulted in Prof. Folb resigning from the MCC. Since then 
others have resigned. The former Medicines Control Council (MCC), now the Medicines 
Regulatory Authority (MRA) will have the task, under the new legislation, of reviewing 
drugs every five years, as opposed to the current once-off testing. 
2) Pharmacists 
The Medicines and Related Substances Control Amendment Act affected the pharmacists 
on various levels (Thorn, 2001). First instance, Johnson the president of the Pharmacists' 
Association said, "bon using and business sampling will come to an end. There will be no 
more grey market activity, whereby pharmacists receive "freebie" samples that are then 
resold." Also other incentives such as monetary reimbursement free trips and excessive 
gifts will also come to an end. 
6 Prof. Folb is a professor of Pharmacology at the University of Cape Town and is the Director of the WHO 
Collaborating Centre for Drug Policy 
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3) Section 15c 
Section 15c is the clause that attracted the most debate internationally. It sets up a system to 
permit the parallel importation of medicines. Parallel importation is' the practice of 
shopping around for the lowest world price patented products. 
If a patent holder sells a product for less money in another country than in South Africa, 
parallel importation would allow the cheaper drugs sold in the other country market to be 
imported to South Africa. Johnson stated, "Without Section 15c the reference pricing 
means nothing. If the company refuses to bring its prices in line with the reference price, 
then a license can be issued to parallel import the drug from another country." 
Another key issue in this court case is generic substitution. "Common in Canada, Holland, 
Japan, and the U.S. - of requiring that a pharmacist dispense a generic version of a 
medicine if it is cheaper than the branded product, unless the patient expressly forbids the 
pharmacist from so doing" (Medecins Sans Frontieres, MSF, 2001). The second part in the 
Act that went into effect requires of the pharmacist to advise patients of generic substitutes, 
although a doctor may indicate that the medicine may not be substituted with a generic. 
A third part of the Act deals with the professional fee, stipulating that any dispenser may 
not make a profit on dispensing medications. The Act will also impact on the 
pharmaceutical industry when the Health Minister sets up the Pricing Committee. Johnson 
pointed out that Section 15c of the Act was crucial to empowering the Pricing Committee. 
d) Pharmaceutical Manufacturers Association 
On 18 February 1998, the Pharmaceutical Manufacturers Association (PMA) representing 
forty-two applicants representing multinational and South African drug companies, South 
African Subsidiaries of Pharmaceutical multinational companies, and a trade organisation 
brought a suit to the Pretoria High Court against the Government of the Republic of South 
Africa. The suit aimed to prevent the implementation of the Medicines and Related 
Substances Control Amendment Act, No. 90 of 1997. 
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The PMA sought an interdict against commencement of the Act until there was 
clarification of its legal status. The PMA's main objections to the Act are parallel imports7 
and patent protection8• If the PMA lost in the Pretoria High Court, then the Act could have 
be challenged through the World Trade Organisation. The Act had instigated the United 
States to place South Africa on a "watch list" of 32 countries that appeared to violate 
intellectual rights and other trade interests, specifically, Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS). In 2000, fonner US President Bill 
Clinton took South Africa off the watch list with a residential executive order. The US 
Health Minister, Donna Shalala, and US Trade Minister, Charlene Barshefsky supported 
this order. This executive order ended the trade protection from the US government for US 
MNC companies. This protection placed more restrictions on parallel importing and 
compulsory licensing as allowed by the World Trade Organization (WTO) agreements. The 
South African Phannaceutical Manufacturers Association (PMA) "argues that Section 15c 
is written overly broadly, in that it expands the powers of the Minister of Health to allow 
her to override patent protection (to issue compulsory licenses) in order to facilitate access 
to affordable medicines" (Medecins Sans Frontieres, 2001). 
e) PMAs case against the Government and the High Court Resolution 
Implementation of the Medicines Act was delayed for three years (1998-2001) after 
pharmaceutical companies challenged its legality in court. The PMA was especially 
concerned with Section 15c (Parallel importing). The case was to be heard from the 5 -13 
March 2001 in front of the High Court in Pretoria. However, in April 2001, three years 
after the PMA action was launched in January 1998, they withdrew their court bid, and in 
return, the minister promised to include them in discussions on how the Act would be 
implemented. The Medicines and Related Substances Control Amendment Act Number 90 
of 1997 went into effect. 
7 Parallel imports allow for the importation of medicines, which are manufactured, under licence, by 
companies in other than the country of origin. 
8 The Act has a provision for the circumvention of statutory patent protections in some circumstances. The 
PMA argue that it constitutes an infringement on intellectual property without compensation. 
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j) South African Medicines and Medical Devices Regulatory Authority Bill 
(SAMJIDRA) 1998 
In 1997, the government passed legislation - the Medicines and Related Substances 
Control Amendment Act (Act No. 90 of 1997) to help realise this goal by making 
medicines more affordable. The Medicine and Related Substances Control Amendment Act 
No. 90 of 1997, was sent to the constitutional courts for repeal. So a new bill, was 
introduced called the South African Medicines and Medical Devices Regulatory Authority 
Bill (SAMMDRA) 1998. The SAMMDRA replaces the Medicines and Related Substances 
Control Act of 1965 and the amendment of 1997. 
It provides for the monitoring, evaluation, regulation, investigation, inspection, registration 
and control of medicines, clinical trials and medical devices. For the first time this Act 
includes provisions for a process to register and regulate complementary medicines. 
SAMMDRA created the new Medicines Regulatory Authority (MRA) that replaced the 
former Medicines Control Council (MCC). 
Significant portions of the Medicines and Related Substances Control Act No. 90 of 1997 
are also repealed by this Act. The result is that the 1998 SAMMDRA bill focuses on 
measures specifically aimed at ensuring that affordable medicines are made available to the 
public. 
Less than three months after President Nelson Mandela signed the SAMMDRA bill into 
law, "The PMA objected to provisions, which allows for the parallel importation of drugs 
and generic substitution of drugs which the industry believes infringes on patent rights." 
SAMMDRA's implementation was administratively bungled and was promulgated without 
supporting regulations, which would have left the door wide open to unregulated trading 
and importation of potentially lethal drugs. This caused the government to challenge its 
own legislation in court. The SAMMDRA legislation that former President Mandela signed 
into law was repealed three years later in 200 1 by the High Court. The court reinstated the 
original 1965 act and Medicines and Related Substances Control Amendment Act No. 90 
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of 1997. In turn in 2001 the PMA reactivated its court challenge to the Medicines and 
Related Substances Control Amendment Act No. 90 of 1997. 
In March 2001, the South African Minister of Health, Dr. Manto Tshabalala-Msimang, 
informed state law advisers that the National Health Department would repeal SAMMDRA 
is Medicines Regulatory Authority Act. The ordered repeal of SAMMDRA came as the 
pharmaceutical industry and government were in a court battle over the Medicines and 
Related Substances Control Amendment Act. The repeal will likely have an effect on the 
present court action by the pharmaceutical industry. The Democratic Alliance (DA) health 
spokesman, Kobus Gous said the repeal '"is a constitutional and a trade matter and about 
the powers granted to the minister to virtually make laws to control medicines on" (the 
STGIEDL). He went on to say, "The pharmaceutical industry is an essential player in 
conquering diseases in poor countries like SA. But they have played this role reluctantly, 
and any compromises have had to be fought for bitterly. On the part of the minister of 
health, badly drawn-up legislation made legal challenge to the amendment act easy and 
inevitable" (Hartley, 200 I). 
31 
3.5 South Africa's New National Drug Policy (1996) 
South Africa in 1994 recognised that it urgently needed a written drug policy that is 
entrenched in legislation to ensure its fair and equal regulation. "It is necessary to ensure 
that all people in the country are rationally treated within necessary drugs and vaccines, to 
enable their protection and cure from common diseases" (National Drug Policy for South 
Africa, 1996). In 1995, the British former British Office of Overseas Development (ODA), 
now the Department for International Development (DFID), had contracted Consultants in 
Health and Development (CHD) to assist the National Health Insurance Committee, and to 
determine the cost of the essential drug needs in South Africa's primary care settings. In 
addition, the South African Department of Health (DOH) requested support from the DFID 
for the development of a national essential drug programme. A first report for such a 
programme, with the title, South African Drug Action Programme, (SADAP) was 
completed in November 1995 by CHD. Meanwhile, in the same year WHO became 
involved, a staff member from WHO's Action Programme on Essential Drugs, Drug 
Action Programme (DAP), attended a National Drug Policy Conference in South Africa 
and assisted in the drawing up of the NDP. The initial draft of the National Drug Policy 
(NDP) was prepared and workshops were held to incorporate a wide range of comments 
from various stakeholders. All Provincial Heads of Health ratified the National Drug Policy 
on 15 February 1996, and it was approved and publicly announced by the Minister of 
Health on 22 February 1996. The main objectives of the National Drug Policy of January 
1996 (Appendix A) include health, economic and national objectives. 'Two of the five 
health objectives include: "to ensure good dispensing and prescribing practices" and "to 
promote rational use of drugs by prescribers, dispensers and patients through the provision 
of the necessary training, education and information." 
In 1996, although the Department of Health was making steady progress towards the 
realisation of the National Drug Policy, it did not have the resources (staff, expertise, and 
finances) that were needed in order to implement the National Drug Policy. The previous 
years of restructuring the Department of Health and the Public Health Service had 
necessitated the use of most of the non-fixed public resources. The total cost of the NDP 
would represent 0.3% of the drug budget for South Africa, but the potential savings would 
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be 35% of the budget. 9 The implementation of a National Drug Policy would have very 
definite and concrete effects not only on the total cost, but also on the outcome of total 
primary care coverage for the entire population, thus having a far reaching impact on the 
health of the majority of the population. The merits of implementing a NDP with its major 
components of an Essential Drug List and Standard Treatment Guidelines were 
outstanding. 
The Ministry of Health published the NDP in January 1996 and launched it in February 
1996. The policy contains the following components: 1. Preface; 2.0bjectives; 3. 
Legislation and regulation; 4. Drug pricing; 5. Drug selection; 6. Procurement, and 
Distribution; 7. Rational use of drugs; 8. Human resources development; 9. Research and 
development; 10. International technical co-operation; I1.Traditional medicines; and 12. 
Monitoring, and evaluation. 
The National Drug Policy incorporates strategies for the effective application of drugs 
within the framework of the National Health Service (NHS). The promotion, "prevention 
and rehabilitative aspects of health care will receive proper emphasis and will not be made 
subservient to the curative aspects, with its reliance on the use of drugs. A broad approach 
to cost containment will be taken to ensure overall cost-effectiveness" (A National Health 
Plan for South Africa, 1994). 
3.5.1 The South African Drug Action Programme (SADAP) 
The South African Drug Action Programme was given support after the Minister of Health, 
Dr. Zuma made a visit to England. 1o The multinational pharmaceutical companies based in 
Great Britain were openly opposed to the support by DFID. Pressure was exerted on DFID 
to step away from South Africa's request for assistance to develop a National Drug Policy. 
However, the British Development Division for South Africa (BDDSA) also known as 
DIFID stepped in with funding for the project of the South Africa Drug Action Programme 
(SADAP 2000). "On the 13 of September 1996 the DFID approved the funding for the 
9 Project Memorandum, South Africa Drug Action Programme (SADAP 2000), British Development 
Division in Southern Africa (BDDSA) November 1996. 
to The South African National DOH had made steady progress toward the adoption of a National Drug Policy, 
but was still lacking the resources (expertise and fmancial) that were needed. 
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SADAP project and requested that WHOIDAP be the executing agency.ll " SADAPI2 is a 
short-term initiative to re-orient national policy toward rational drug usage" (South African 
Drug Action Programme (SADAP 2000), 1996). The Project's goal is to "improve the 
effectiveness and efficiency of health care in South Africa by providing support for the 
implementation of the recently formulated NDP.,,13 The goal of the SADAP is "to ensure 
an adequate and reliable supply of safe, cost-effective drugs of acceptable quality to all 
citizens of South Africa, and the rational use of drugs by prescribers, dispensers and 
consumers" (SADAP 2000, 1996). 
The project duration was initially for 50 months from 1 November 1996 until 31 December 
2001. The mid-term review (November 1998), team recommended that the programme be 
extended for an additional 12 months. DFID financial support is channelled through the 
WHO to "ensure that developments under NDP conform to internationally recognised 
policies and practices." (South African Drug Action Programme (SADAP 2000), 1996) 
The DFID funded the project with GBP £3.6 million. 14 The specific areas of funding are: 
institutional development, legislation, quality assurance and drug regulation, financing, cost 
recovery, and pricing structure, drug selection, procurement, storage and distribution, 
rational drug use: education and training, human resource development and other activities. 
The funds that the DFID provided were in addition to the total contribution of the DOH of 
GBP £1.3 million. IS 
II WHOIDAP - SADAP support mission 9-28 September 1996, mission report, unpublished 
12 The project is based within the National Department of Health in Pretoria and has three dedicated project 
staff members: an internationally recruited SADAP project co-ordinator who was appointed and paid by 
WHO as the senior advisor to the DOH for the duration of the project; a training advisor who is responsible 
for the development, field-testing and implementation of all training programmes at the provincial and 
national levels; and an office manager, who is responsible for the Project's administration. 
13 The NDP's aim is to "ensure an adequate and reliable supply of safe, effective and affordable drugs of good 
quality to all citizens of South Africa; to promote more rational drug use and improved care; and to increase 
the efficiency of procurement and distribution within the public sector." South African Drug Action 
Programme (SADAP 2000), 1996). 
14 DFID support of £3.6 million for international technical assistance and other offshore costs (23%), national 
short-term advisors (29%), and other expenditures (48%). 
1 S This contribution does not include other long term contributions that include secretarial support, 
telephone, fax, accommodation, salaries for Provincial Essential Drug Co-ordinators, training activities, and 
the public sector drug budget that is estimated at R2 billion/year. 
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The SADAP has been a semi-autonomous unit within the Chief Directorate of the 
Registration and Regulation Programme (RRP), and attached to the Pharmaceutical 
Programmes and Planning (PPP), formally called the Directorate Medical Schemes, 
Supplies and Services (MSSS) that will serve advisory and institutional functions. By the 
end of 1998, the second year, the unit activities should have been developed to the point 
where it could be incorporated into the Medical Schemes Supplies and Services (MSSS) 
and at the end of the project the DOH will take over the full funding for SADAP activities. 
SADAP during the first two years concentrated on aspect of the national implementation of 
the NDP including putting into place appropriate legislation. The second phase (2-3 years) 
will be to provide provinces with support in the implementation of the NDP. The 
implementation of the NDP and the responsibilities of both NDOH and SADAP are not 
well defined. The SADAP mid-term review team in 1998 proposed an organogram 
(Appendix B). 
3.5.2 The Standard Treatment Guidelines I Essential Drug List (EDL/STG) 
National Essential Drugs' List Committee and Drug Selection 
The Minister of Health appoints a National Essential Drugs' List Committee (NEDLC), 
composed of experts from all areas of medical and pharmaceutical practice. The members 
are responsible for the selection of drugs to be used in the public sectorl6 (Appendix C). 
The NEDLC drew up an EDL using generic names and based on WHO approved criteriaI7. 
This list was prepared for the three levels of health care providers, namely primary care, 
community, secondary, and tertiary hospital care. The STGIEDL was distributed to all 
health workers in all public settings within the country. Before the NDP with STGIEDL 
guidelines came into effect the Provinces could deviate from the National EDL and make 
Provincial Coding Lists. The current national list of essential drugs is used as a foundation 
16 The Committee will be composed of experts in all spheres of medical and pharmaceutical practice. It will 
include clinical pharmacists, pharmacologists, medical specialists, a paediatrician, professional nurses from 
community practice, medical practitioners involved in primary care practice. In addition there will be a 
member of a drug information centre, a member of the clinical committee of the Medicines Control Council, 
a health professional involved in drug management training and representatives of the provincial EDL 
committees. Additional members may be co-opted on an ad-hoc basis. Consultations will be undertaken with 
all interested parties. 
17 WHO published guidelines on formulating an EDL, the criteria are: meet the needs of the population, 
sufficient scientific data, substantial safety and risklbenefit ratio, mostly products containing a single 
pharmacologically active ingredient. 
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for the basic health care package of the National Health System. The STGIEDL is to be 
used for training doctors, nurses and other health workers in rational prescribing. In 
addition to the STGIEDL, a national Formulary will be created. 18 
The first EDL for primary care (popularly known as the 'green book') was published in 
1996 and was distributed in all nine provinces. Since then, three STGIEDL's, one each for 
primary (2nd edition), paediatrics and hospital (adult) edition books were published in 
December 1998. The South African Drug Action Programme (SADAP) supported the 
development and implementation of the STG/EDL reducing the number of drugs on the 
ELD from 2,600 to 691 drugs (Appendix D). The use of the EDL and policy of 
procurement of non EDL drugs with no more than 10% of the pharmaceutical budget will 
shift scarce resources to benefit the majority of ailments and patients. Each province is 
expected to implement these polices as soon as possible. The more expensive non-EDL 
drugs will be phased out of the health system within an unspecified period of time. After 
several years, the EDL is expected to reduce the total amount of public expenditure on non-
essential drugs. As a part of an EDP, generic prescribing and substitution has been 
launched and introduced into the public hospital sector on 3 December 1998. 
At the EDL launch, in the key note address, Minister Zumal9 (Zuma, 1998) stated: 
I believe the EDL will be printed in numbers to ensure that all prescribing 
personnel have access to a copy. But, I would now like to issue the following 
challenges to the responsible official in the Department and in the provinces. 
Having the book is one thing, ensuring that they are used, and the prescribers 
know how to use them, is another. You must therefore embark on strategies 
to ensure the acceptance of the essential drug concept by consumers and 
health personnel alike. Also, ensure that all health personnel are appropriately 
trained on good prescribing and dispensing practices; encourage compliance 
with the standard treatment guidelines among even the most traditional 
prescribers, develop indicators to help assess the usefulness of the EDL 
in achieving rational drug use and impacting positively on the drugs budget. 
18 Currently there is the South African Medicine Formulary, 4th edition 1997. A Proposal has been made to 
SADAP to write a primary care EDL-based Formulary by Dr. Catherine Orrell at the Department of 
Pharmacology at the University of Cape Town. 
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3.6 Rational Drug Use and Prescribing 
The aim of rational drug use is "To promote the rational prescribing, dispensing and use of 
drugs by medical, paramedical and pharmaceutical personnel and to support the informed 
and appropriate use of drugs by the community" (NDP, 1996). 
The National Department of Health's National Drug Policy for South Africa focuses on 
several areas related to the rational use of drug. The areas of focus include but are not 
limited to, education and training, drug information, appropriate prescribing, dispensing, 
and hospital therapeutic committees (NDP, 1996). The National Drug Policy's goals are to 
promote the rational prescribing, dispensing and use of drugs through the use of the 
STGIEDL as a tool by medical, paramedical and pharmaceutical personnel and to support 
the informed and appropriate use of drugs by the medical community. Generic prescribing 
is a good indicator of the rational use of drugs. The NDP aim of ration drug use could be 
achieved through appropriate training, the provision of scientifically validated drug 
information for professionals and the community, the establishment of hospital therapeutic 
committees, good dispensing practice, and an enhanced role for the pharmacist, and control 
of commercial marketing practices. 
3.6.1 Appropriate or "Rational" Prescribing 
The objective is "that all drugs are prescribed by genenc name m accordance with 
recommendation standard treatment protocols and the Essential Drug List. The Department 
of Health will collect, evaluate and disseminate systematic data on drug utilisation to 
monitor and act on policy adherence" (NDP, 1996). Rational drug use includes appropriate 
prescribing. The goal is that all drugs will be prescribed and dispensed by generic name in 
accordance with the STO and EDL. Although the NDP will not have a direct effect on the 
private health sector, the STG IEDL use is recommended. Barriers to rational drug use 
include (WHO 1992a): 
1) Lack of objective information and of continuing education and training in 
pharmacology 
2) Methods of promotion employed by the pharmaceutical industry 
3) Shortage of well organised drug regulatory authorities 
4) Presence of large numbers of drugs on the market 
5) Prevalent belief that every ill has a pill 
. 6) Attitude of members of the medical profession, who are only too often reluctant 
to change their practices and view any restriction as a threat to their freedom to 
prescribe 
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According to Perez-Curvas et al (1996), Parades et al (1996), and Ofordi-Adjei et al (1996), 
several factors that overall agree with the WHO assessment but are stated with a different 
emphasis and focus on factors that influence physicians to prescribe medicines 
inappropriately. The factors include: 
(a) Shortcomings in both the undergraduate and graduate medical education. The 
predominant education trend supports prescribing medicine to all patients. 
(b) Lack of trustworthy clinical and pharmacological judgement. This is the most important 
factor in influencing physicians' inappropriate prescribing. In medical circles 
worldwide there is a new trend towards 'evidence-based' medicine and prescribing. 
(c) Unreliable and partial sources of pharmacological information from the various 
methods of advertising of pharmaceutical companies. 
(d) Pressure exerted by patients to receive drugs. 
(e) Desire of the patient for the physician to do something and the ease of using medicines 
to fulfil this desire. 
(t) Lack of research and continuing education. 
3.6.2 Drug Information 
The objective is to ensure the provision of practical and scientifically validated information 
on the correct handling and rational use of drugs to health personnel at all levels. This 
includes a regularly updated standard treatment protocols for common conditions with 
essential drugs. The department will produce an annual national Formulary of essential 
drugs for distribution to all health care providers and dispensers. The publication will 
include guidelines to good dispensing and prescribing and information on drug interactions 
(NDP, 1996). 
The DOH has updated and produced a second edition (November 1998) of the STGIEDL. 
Sufficient quantities of these books were produced for use by physicians and nurses who 
prescribe, and pharmacists who work at all levels of care from primary to tertiary care in all 
hospitals and clinics. 
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3.6.3 Hospital Pharmacological Therapeutic Committees (PTC) 
The objective of the policy is " to establish and strengthen the Pharmacological and 
Therapeutic Committee in all hospitals in the country (both public and private) in order to 
ensure the rational, efficient and cost-effective supply and use of drugs. These PTes will 
consist of at least a senior pharmacist, a senior nurse, a senior financial officer and senior 
clinicians or their nominated representatives in their absence" (NDP, 1996). 
In May 1998, MEDVNSA's Prof. Summers met with the Northern Province 
Pharmaceutical Services to discuss the: "school of pharmacy report of a workshop to 
consider the wider implementation of PTCs in the province and associated training needed 
held on 12 May 1998." (MEDUNSA Meeting programme, May 1998). The operation 
levels for PTes in the province are clinics (health centre and community services), Districts 
(including hospitals), Hospitals (regional and tertiary), and provincial (umbrella to 
national). The functions and membership of the committees (Appendix E) would depend on 
the level they are working on: clinic, district, hospital and! or provincial. 
3.6.4 Education and Training 
The objective of the National Department of Health (NDOH) is "to ensure that all health 
personnel involved in diagnosis, prescribing and dispensing of drugs receive adequate 
theoretical and practical training ... A systematic and comprehensive programme of 
continuing education will be developed and implemented. All such initial and continued 
training will be developed and assessed in collaboration with health personnel at all levels " 
(NDP, 1996). 
A systematic and comprehensive programme of continuing education will be developed 
and implemented. WHO/DAP have published books on training in rational drug use, but 
books and training are not enough to change prescribing habits on a long term basis. 
According to Kanji et al (1992), "DAP will need to do a lot more work before seeing a real 
improvement in the rational use of drugs, but in so doing is likely to be constrained by 
governments less interested in enhancing rational use than in supply in the essential drugs. 
In supplying drugs the government can gain politically, for people get the impression that 
the government is helping them. Enhancing rational drug use is far less rewarding activity." 
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3.6.5 Role of Pharmacists 
The WHO has recommended a special role for pharmacists that includes quality assurance 
and safe and effective administration of drugs. "Pharmacists are in a strong position to 
promote the rational use of drugs through their extensive knowledge. Pharmacists will be 
involved in the multi- disciplinary approach to rational utilisation of drugs. Greater 
cooperation between pharmacist and other health professionals within communities and 
hospitals will be promoted to facilitate consensus regarding the choices of drugs and 
treatment protocols. Pharmacists will be required to have available scientific sources of 
references" (NDP, 1996). The Dispensing objective for the pharmacy staff is to ensure that 
all drugs are dispensed according to regulations and good dispensing practice. Dispensing 
will be in accordance with the principles already stated the in section on "The Use of 
Generic Drugs" (NDP, 1996). 
3.6.6 Role of Patients as Consumers 
The rational use of drugs aim includes "to support the informed and appropriate use of 
drugs by the community" (National Drug Policy, 1996). This aim was to be achieved 
through the education and training for the 'general public.' This goal includes, 
collaboration with other bodies responsible for school, adult literacy and other educational 
programmes to integrate in the curriculum basic education that will lead to a better 
appreciation of the benefits and limitations of the role of drugs in health care" (National 
Drug Policy, 1996). 
Although on 1997 South Africa's Pharmacy Council reported that it would spend R400,OOO 
Rand (WHO report on Public Education in Rational Drug Use: WHO/DAPI 97.5 ) on 
patient education of rational drug use. The two patient educational programmes were: 
"Don't take the right medicine the wrong way" and "When receiving medicines you have 
certain rights." The duration of the programme is not known, as there was no data on the 
number of years for the project. 
Considering the consumer behaviour affects the outcome of rational prescribing it is 
surprising that the NDP, 1996 does not include assertions of direct responsibility for patient 
education by provincial health departments, clinics, hospitals and health care workers. 
These stakeholders can share the responsibility for educating the public about the use of the 
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EDL, generic drugs and the importance of taking medicines as prescribed trough the use of 
educational materials such as poster, and leaflets. The provincial government could 
promote public education in rational use of drugs with news articles and radio programs. 
One of the major barriers to patient education about rational drug prescribing is the high 
illiteracy rates and the variety of languages spoken among patients. 
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3.7 The Northern Province 
3.7.1 Land and population (Orkin: 1995) 
The land of the Northern Province covers an area of 124,000 km2, which is 10% of the total 
area of South Africa. The province is divided into six regions; Bushveld, Western, Central 
Northern, Lowveld, and Southern (Appendix F). The population is 44 people per km2, 
which is higher than the average of 34 km2• The languages spoken include Eepedi (57%), 
Xitsonga (23%), and Tsivenda (12%). The population of 4,128,000 is 10.9% of the total 
population. Only 11% of the population live in urban areas (Table 3.3). The Northern 
Province is the least urbanised part of South Africa (Appendix G). 
Table 3.3 Northern Province Population Data 
0/0 OF % LIVE IN 
RACE TOTAL URBAN 
POPULo AREA 
Africans 94.4 8 
Coloured 1.9 92 
White 2.7 69 
Indian 0.1 92 
Source: Dr. FM Orkm: 1995. 
Consistent with living the mostly rural areas, few Africans (17% compared to 33% for 
South Africa) have running water in the households, while 93% of the White population 
have household water. Generally, "since Africans are the poorest race and because they 
represent a much larger portion of the population in the Northern Province, households in 
the Province are considerably less well-off, on average, than those in the country as a 
whole" (Orkin, 1995). 
3.7.2 Health and Health Care 
Life expectancy in 1991 was 62.7 years, an increase from 1980 with 60.1 years. Eighty-
nine percent of the African population uses the public health facilities compared to an 
average of 81 % for South Africa. However, more Whites also use the public health 
facilities (32%) compared to 20% in South Africa. In 1996 the Northern Province had 43 
hospitals (including psychiatric) with 15, 549 beds in the public sector. The private sector 
had only 4 hospitals and a total of 216 beds. The health care services reach a majority of 
the population (80%). Utilisation of free Health Care Services at clinics and hospitals has 
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increased by 13.7% from the total attendance of 640,332 in 1996. In 1997, the total free 
health care (inpatient and outpatient, clinics and hospitals) was 7,448,141 visits. 
Table 3.4 Free Health Care Statistics 1997 
HOSPITAL IN PATS. CLINIC FHCTOTAL OPD OPD 
REGION 
BUSHVELD 7,559 3,753 179,331 190,643 
WESTERN 47,592 17,926 477,059 542,577 
CENTRAL 173,452 59,209 435,188 667,849 
NORTHERN 367,658 215,011 3,257,940 3,840,609 
LOWVELD 112,584 126,654 986,510 12,225,748 
SOUTHERN 109,358 60,715 810,642 980,715 
TOTALFHC 818,203 483,268 6,146,670 7,448,141 
Source: MEC's Annual Report, 1997/98 
The Northern Province Department of Health (NP-DOH) has produced a set of its own 
objectives, indicators and progress points. Specific indicators for the influence of hospital, 
clinics and pharmaceuticals are the financial management, development and 
implementation of policies, plans and legislation. The goal of the NP-DOH was to develop 
one hospital in each of the six regions into a fully-fledged functional secondary level 
facility. The Northern Province has upgraded its hospital services to include 24 hours 
community (level 1) hospital care service in all 37 hospitals and one secondary (Regional) 
hospital in each region. A total of R273 million Rand were allocated to this project. An 
academic hospital is now in place and has been functioning for the last year. A total ofR1.3 
million Rand was spent to upgrade the complex that is shared with the regional secondary 
hospital (MEC,'s Annual Report, 1997/98). 
The referral system from the District hospitals (primary) to the Regional hospitals 
(secondary) to the Central Hospital (tertiary) has been developed and is working well. In 
the hospitals the average length of stay (ALOS) was 4-5 days with a 70-80% bed 
\ . 
occupancy rate (BOR). The Northern Province has a ALOS of 5.7 and a BOR of 67.9%, 
below the target recommended by the Hospital Strategy Project (MEC's Annual Report, 
1997/98). 
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Tableo3.5 Hospital Performance Indicators 
REGION ALOS BOR 
Northern 5.9 67.9 
Province 
Region Average 
BUSHVELD 4.0 73.8 
WESTERN 5.3 63.4 
CENTRAL 8.5 69.5 
NORTHERN 5.4 66.1 
LOWVELD 5.4 71.9 
SOUTHERN 5.4 62.7 
Source: MEC's Annual Report, 1997/98 
The Health Care Support Services including phannaceuticals and motor transport 
(ambulances) had a dedicated budget in 1997 of R1.5 million Rand. The 1998-99 
expenditure on hospital support services was RIOI million Rand. The specific objective of 
the pharmaceutical services is "to supply affordable, cost effective, accessible 
phannaceuticals to all people in the Northern Province." The indicators used were: 
dedicated vehicles for use by all hospital phannacies, at least two inspections per month, 
90% of medicines available in-patient ready packing, 90% of orders satisfied, and 90% 
availability of essential drugs. All of these indicators have been met. The Standard 
procurement list was implemented in June 1996 and was revised in April 1997 to 
incorporate the level of care and was implemented on 1 January 1998. One person per 
clinic were trained for a total of twenty-five clinics and provincial trainers in Effective 
Prescribing (EP) and Drug Supply Management (DSM). In 1997, five of the six regions 
had met their target numbers for training. 
3.7.3 Distribution and Procurement 
Before the 1994 elections, provinces consolidated their fractured health care and 
phannaceutical services. Provinces had their own warehouses and sent estimates of their 
requirements to Co-ordinators Committee for the Acquisitions of Medicines (COMED). 
The provinces paid the supplier directly. 
The Northern Province integrated the drug supply system of four authorities to establish a 
single health authority. The Northern Province evaluated its system in 1994. The evaluation 
led to the decision in 1995 to contract out drug procurement, warehousing, and distribution 
of pharmaceutical supplies to a private company, Vuna Health Care Logistics (Appendix 
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H). Vuna works on an 8.05% commission of the value of the products. The five-year 
renewable contract includes a 2.2% commission for computerisation of hospital phannacies 
and computer training of provincial phannaceutical staff. (Essential Drug Monitor, 1998). 
Since 1996, phannaceutical supplies have been distributed from a single depot. With the 
exception of receiving the goods, the provincial authority is involved in every step of 
procurement. The contractor's responsibility is only at the hospital level. The province is 
responsible for delivery to and inventory control in the clinics. At the clinic level transport 
and information have been difficult at best. " The Department must also ensure that the 
contract is carried out according to the specifications. This necessitates the active 
involvement of provincial staff members in the entire process from database management, 
and procurement to receipt and distribution" (Essential Drug Monitor, 1998: 11). 
3.7.4 Finances 
The National government allots funds according to a formula that takes population into 
account while the Provincial budget is centralised. The Province then makes a budget for 
all public service that includes health services (Appendix J). The health budget includes 
phannaceutical. Budget over spending in other areas led to the withdrawal of funds from 
health services (Appendix J). 
The financial management for procurement of goods and services and payment of salaries 
and benefits has a strict mandate: "expenditure according to budget with a deviation of not 
more or less than 2%" (MEe, 1997). The development and implementation for policies and 
plans that included legislation to provide equitable health services that has been far 
reaching to includes a draft of a Phannaceutical policy document. 
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3.8 Summary of South Africa Background 
Pharmaceutical reform in South Africa started with the Primary Health Care focus with the 
National Drug Policy (NDP, 1996) was adopted in 1997 as a cornerstone of access and 
equity in health care. The NDP includes procurement, storage, distribution, and 
prescribing. Prescribing is the one area that is directly dependent on individual health 
practitioners (nurses pharmacists and physicians). The interventions have been 
administrative, legislative, and managerial. 
The administrative intervention by the National Department of Health was the adoption of 
South Africa's National Drug Policy (1996). The NDP components consists of legislation 
and regulation, drug pricing, procurement and distribution, rational use of drugs, human 
resources development, research and development, international cooperation, traditional 
medicines and finally monitoring, and evaluation. Simultaneously, the South African Drug 
Action Programme (SADAP) was implemented in order to improve the procurement, 
distribution and rational use of drugs by prescribers, dispensers and consumers (SADAP 
2000, 1996). The tools used by SADAP include baseline studies in acquisition, storage, 
distribution and prescribing in clinics and hospitals. 
The legislative intervention included four new laws. The four new legislative interventions 
are: first, the Pharmacy Amendment Bill, [Act No. 28 of 1997]. Second, the Medicines and 
Related Substances Control Amendment [Act No. 90 of 1997]. Third, the Medical, Dental 
and Supplementary Health Services Professional Amendment Act (1998), and forth, the 
South African Medicines and Medical Devices Regulatory Authority Bill [SAMMDRA 
Bill, 1998]. The last five years have been tumultuous for the implementation of 
pharmaceutical legislation. With the repeal of SAMMDRA, the Pharmaceutical 
Manufacturers Association (PMA) dropped the lawsuit against the government. Thus, 
South Africa was designated the new world-wide testing ground for World Trade 
Organization (WTD) legislation, and the new vocal and active Non-Governmental 
Organization (NOO) for access to essential drugs, the legislative process today is still in 
motion. 
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The managerial interventions are aimed at the provincial level. The interventions include a 
voluntary cap on brand name drug spending of ten percent of the drug budget. Education 
and training has been given in Drug Supply Management and Effective Prescribing. Drug 
information and Prescribing tools for prescribers to encourage generic prescribing is the 
Standard Treatment Guidelines / Essential Drugs Lists (STGIEDL) for the primary care, 
paediatric hospital and adult hospital levels, and the use of Phannaceutical Therapeutics 
Committees for hospital institutions. 
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CHAPTER FOUR 
NATIONAL DRUG POLICY RESEARCH 
IN DEVELOPING COUNTRIES 
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4.1 Research on National Drug Policy, and the Essential Drug List 
This section reviews the research that has been conducted on National Drug Policy (NDP), 
Essential Drug Programmes (EDP) and Rational Drug Use (RDU) in various developing 
countries, and specifically in South Africa. Research of NDP in developing countries is 
particularly interesting to this research to determine what has been done, and where the 
research gaps lie. The World Health Organization, Drug Action Programme (WHOIDAP) 
has been involved in promoting National Drug Policies, Essential Drugs Lists (EDL) and 
generic prescribing to its member states, especially the developing countries with limited 
budgets and large populations to serve. 
4.1.1 World Health Organization and the National Drug Programmes 
The WHO Action Programme on Essential Drugs is the main international force for the 
promotion and assistance for the formulation and implementation of National Drug Policies 
and Essential Drugs Programmes for their 181 member countries. The London School of 
Hygiene and Tropical Medicine (WHO 1989) in 1989 assessed the WHOIDAP programme 
and its efforts at pharmaceutical policy development. The evaluation found that the 
achievement of WHOIDAP was the emphasis on and the spread of the Essential Drugs List 
(WHO 1989). However, some of the problems included the limited adoption of National 
Drug Policies, weakness in the Information-Education-Communication component and a 
lack of focus on rational drug use. The study further revealed that WHO is effective in 
identifying and disseminating information on the essential elements of a NDP, but had 
difficulty in promoting the national implementation of new policies. 
4.1.2 National Drug Policy (NDP) Research in Developing Countries 
Few systematic reviews, research and analysis of national and international efforts at 
pharmaceutical policy development and their accomplishments have been carried out. '"The 
analyses of pharmaceutical policy that exists rarely explore the problems of policy 
performance and implementation in a systematic manner" (WHO 97.6, 1997). 
Moreover, there are few publications of collected essays on pharmaceutical problems in 
developing countries (Robles, et al 1992). WHOIDAP has conducted several studies to 
evaluate the impact of the NDP and prescribing practices (MOH Mozambique 1986; 
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Indonesia MHS 1988; Democratic Yemen 1989; and Angola 1990). Overall, the earlier 
studies have revealed a lack of rational drug use by prescribers. 
The only published study of the evaluation of the impact of a NDP with a control group 
was in Yemen by a WHOIDAP staff member (Hogerzeil et aI, 1989). The study found that 
several rational drug use indicators in the programme area were significantly difference 
from the 'control area' (Kanji et al 1992). Specifically the study found that the programme 
area had an average of 1.5 drugs per prescription, with 47.3 per cent of prescriptions 
containing an antibiotic and 24.8 per cent containing an injection, while in the control area 
2.4 drugs were prescribed, with 66.8 per cent prescriptions with antibiotics and 57.8 per 
cent prescriptions with injections. The prescribing results of the intervention were 
significant. In the 1990's, WHOIDAP (1996a; Hogerzeil 1993) convened the only study 
that looked at a cross-section of countries. 
4.2 Pharmaceutical Studies 
4.2.1 The Twelve-Country National Drug Policy Study (WHO 1997) 
The twelve-country NDP study specifically focused on comparative analysis of National 
Drug Policies. The WHOIDAP in collaboration with the Division of International Health 
Care Research in Stockholm, and the Harvard School of Public Health in Boston in 1996 
conducted a comparative analysis of national drug policies (NDPs). The project was 
initiated in "recognition of the need to systematically evaluate national drug policies, both 
on the aspects of policy process and policy output, and to provide recommendations for 
improving policy formulation and implementation" (WHO 97.6, 1997). 
The goal of the study was to assess the performance of national drug policies within the 
twelve chosen countries: Bulgaria, Chad, Colombia, Guinea, India, Mali, Philippines, Sri 
Lanka, Thailand, Vietnam, Zambia and Zimbabwe. The twelve-country research teams had 
two objectives. First, to identify strengths, weaknesses, and political dimensions of 
pharmaceutical policy formulation and its implementation within each country. The second 
objective was to propose effective strategies, both national and international, that could 
improve national pharmaceutical policy implementation. "The research provided a cross 
national, comparative framework and combined formative evaluation strategies (focusing 
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on the process of policy fonnulation and implementation) and a summary of evaluation 
strategies (focusing on policy outcomes) (WHO 97.6, 1997). 
The twelve research teams used two main research tools. Standardised NDP indicators for 
the assessment of the NDP performance and Political Mapping for the analysis of the NDP 
fonnulation and implementation process. The preliminary methodological evaluation 
findings were: 
• A large percentage of the indicators were useful and did not need substantial 
modification. Country teams constructed a few new indicators to better cover certain 
components of the pharmaceutical policy (e.g. rational use of drugs). 
• Two country teams used political mapping to understand what had happened in the 
policy formulation and implementation and the reasons for successes and failures. 
• The two methods used in the research were able to assess the perfonnance of a given 
national drug policy and the policy process. 
Comparatively the results were: "In all countries there were components of the NDP which 
received more attention from decision makers and senior management staff; in most of the 
poorest countries these components were essential drugs lists and public procurement of 
drugs under the (International Non-proprietary Name) INN." Also, the research clearly 
demonstrated that policy-making in order to be effective may be a technical process but 
must also be a political process. Policy-makers need both technical and political analysis in 
order to be effective. Policy-making does not stop with the official adoption of a policy, but 
must continue through the phase of implementation and evaluation (WHO 97.6, 1997). The 
specific lessons from the cross-national NDP analysis are: 
• Certain technical components, when implemented adequately, made a difference in 
outcome. For example, both a bad selection of drugs and an inefficient procurement 
system led invariably to shortage of drugs; on the contrary, a good registration system 
had a positive impact on rational use of drugs. 
• Countries' use of an EDL in the public sector was just a first step in improving 
availability and affordability. These objectives seemed more difficult to achieve in 
countries where the pharmaceutical market was mostly private and where there was no 
regulation of drug prices. 
• Countries with no local industry (national or multinational) could implement the main 
aspects of the NDP with fewer problems. 
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• Improvements of the NDP through radical changes were more likely to happen when 
there were political windows of opportunity. When such opportunities presented 
themselves (e.g. new governments), it was possible to implement quick, radical and 
widespread changes. When such opportunities were not available, it could be better to 
use a systematic approach. 
• Technical soundness and lor economic rationality of a policy did not always imply that 
the policy was politically viable. 
4.2.2 The Thailand Experience: Comparative Analysis of NDP (Ratanawijitrasin, et af 
1996). 
The country study on national drug policy in Thailand was part of the "Comparative 
analysis of National Drug Policies." The Thai NDP study assessed the status of the 
structural and implementation process. The goals were to evaluate the policy performance 
and to identify areas where policy improvements could be made. The objective of the 
policy process study was to explain the formulation and implementation of the Generic 
Labelling and Advertising Policy and to identify lessons learned from this policy. The 
study selected 81 indicators and developed two additional outcome indicators (The NDP 
indicators are 129 in total). In addition, Policy Mapping was employed to look at the 
Generic Labelling and Advertising Policy. The analysis focused solely on the political 
aspects of the policy. "The purpose is to explain the political process of policy development 
using the Political Mapping framework with the aid of the computer program Policy 
Maker. In this analysis, the policy process is divided into two parts corresponding to the 
two policy stages: policy formulation and policy implementation. For the policy 
formulation period, the analysis examines the political dimension of the activities that led 
to the adoption of the regulation. The analysis on policy implementation period attempts to 
identify, from a political perspective, actions made by different players that might have 
resulted in the repeal of the regulation" (Ratanawijitrasin et aI., 1996). 
The Thailand study showed that although the structural indicators were in place with a 
well- established policy structure, the process and outcome indicators for the aspects of 
implementation of the policy lagged behind (the law enforcement is different in various 
jurisdictions). The National EDL covered only the public sector. More than 29,000 drugs 
were registered. The variety of drugs under various brand names caused confusion and 
increased irrational drug prescribing. Several outcome indicators on drug use have shown 
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that prescribers had difficulties with rational drug use. A survey found that a high 
percentage of child diarrhoea cases were being treated with anti-diarrhoea drugs or 
antibiotic preparations. 
The recommendations of the indicator study included several issues that needed to be 
addressed. 
• Policy Information: There was a lack of critical policy information. An important 
factor to rational policy decisions is relevant, up-to-date and accurate information. 
• Policy Implementation: The policy implementation significantly affects the success of 
the policy outcome. Thus, the policy needs to be monitored regularly and emphasis 
placed on continuously assessing how policy activities relate to policy objectives. 
• Decentralisation: provincial health offices need to be given authority, clear, and 
specific mandates, and support from the central agency. 
• Dug Use: Irrational drug use has multiple factors: quality of products, product 
information, qualification of prescribers and prescribing and dispensing behaviour. The 
solution is to provide unbiased drug information and adequate education and training, 
and institute incentives to promote rational drug use. 
• Prospective Policy: The policy operated in a dynamic environment, therefore it needs 
to be forward looking. " With the emphasis in the international platform on protection 
of intellectual properties and the introduction of pharmaceutical product patent in 
Thailand, NDP should take a prospective approach in preparing the country for possible 
price and affordability related problems that may become policy impediments in the 
future" (Ratanawijitrasin et aI, 1996). 
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4.3 Pharmaceutical Studies in South Africa (1996-2001) 
South Africa's research and monitoring needs of their National Drug Policy (NDP), 
Essential Drug Programme (EDP) and the use of Standard Treatment Guidelines / Essential 
Drug List (STGIEDL) are extensive. Research is needed to assess the direction of policy 
during the next NDP and South African Drug Action Programme (SADAP) review in 
2000. Research will allow for a more accurate overview of the current state of the 
implementation of the NDP and the extent of its adoption by those who must carry out the 
policies in healthcare settings. A half dozen or more research projects have been carried out 
in the last six years on the state of pharmaceutical services (in selected provinces). The 
study topics have included: prescribing patterns, prescribing cost, staffing norms in the 
pharmaceutical sector, baseline studies for the evaluation of the implementation of the NDP 
in South Africa's nine provinces, rational drug training and other small studies carried out 
by staff and students. Many of these studies are able to assess the state of pharmaceutical 
services for the first time in South Africa's history. 
4.3.1 Pharmaceutical Studies 
The first pharmaceutical study undertaken in South Africa in 1996 was by the school of 
pharmacy, (MEDICOS) at the Medical University of South Africa (MEDUNSA). It was an 
'Evaluation of the transformation of pharmaceutical and related services in the Northern 
Province'. This evaluation was the first quantified survey of its kind in any province in 
South Africa. The aims and objectives of the project were twofold: to determine the impact 
of rationalised drug procurement and distribution on the quality of pharmaceutical services 
in the Northern Province and to assess its impact. Second, to determine and assess the 
effect of an essential drugs programme on primary care services and monitor its 
effectiveness. 
Performance indicators for six areas were evaluated: 1) selection and procurement of drugs, 
2) distribution and storage, 3) rational use of medicines, 4) financial management, 5) 
human resource development, and 6) quality assurance. The facilities included a 
contracting depot, 10 hospitals, and 14 clinics were selected for inclusion by random 
sampling. The data were collected with collection forms and structured interviews with 
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staff members and patients were conducted. The results of the drug use indicators 
(prescriptions) in hospitals (n=300) and clinics (n=420) were: 
• The average number of items per prescription in hospitals was 2.74, in clinics 2.36 
(goal < 2.0) 
• The average percentage of patients receiving at least one injection in hospitals was 
27%, in clinics 15% (goal varies) 
• The average number of patients receiving at least one antibiotic in hospitals was 51 %, 
clinics 55% ( goal < 25%) 
• Percent of items prescribed by generic name in hospitals was 31 %, and clinic 47%. 
(goal 100%) 
• Percent of items prescribed appearing on EDL 1996, in clinics was 30% (goal 90%) 
The awareness of the NDP and EOL were also assessed by interviews. Staff members who 
were: 
• aware of the NOP, hospitals 60%, and clinics 0%. 
• owning a copy ofNDP, hospital 50%, and clinic 0%. 
• able to recall three aspects from the NDP, hospitals 10%, and clinics 0%. 
• aware of EDL 1996, hospitals 50%, and clinics 7%. 
• owning a copy ofEOL, hospital 30%, and clinic 0%. 
Hospital staff interviewed had a higher awareness rate of both the NDP and the EDL, while 
those at the clinic level had almost no awareness of either. At only one clinic the NDP 
publication was known. Only 28% of the clinics had received a list of drugs intended for 
use at the clinic level. The report concluded that the areas requiring attention were injection 
and antibiotic use, generic prescribing, and compliance with the STG/EDL. Concerning 
human resources, improvements were needed in particular for staff, NOP awareness, 
STGIEDL training on effective prescribing, and drug supply management. Of the final 
eight recommendation, three were directly related to drug use and training. The 
recommendations were (MEDUNSA, 1997): 
1. Prescribing practices must be addressed at all levels. In accordance with the 
National Drug Policy, a campaign to encourage generic prescribing and the use of 
standard treatment guidelines must be implemented. The high use of antibiotics at 
all levels needs attention. 
2. An introduction to the National Drug Policy and the Essential Drugs List IS 
needed for all staff, especially at Primary Care level. 
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3. The training of qualified Primary Health Care clinic nurses in effective prescribing 
and drug supply management, and of pharmacy support staff for registration 
purposes needs urgent attention and central policy direction. 
In conclusion, Professor Robert Summers of the Medical University of South Africa 
(MEDUNSA) stated: "The staff at present are not trained in drug supply management, 
rational drug use or effective prescribing. They have a low awareness of the National Drug 
Policy and Essential Drugs List. Information sources in the clinics are poor." 
4.3.2 South African Drug Action Programme (SADAP) Baseline Study (1996-1998) 
The South African Drug Action Programme I World Health Organization (SADAP/WHO) 
in co-ordination with the National Department of Health and provinces, conducted a 
baseline study of the National Drug Policy (NDP) between 1996 and 1998 (Moller, 1998). 
The intent of the study was to evaluate the efficiency and effectiveness of pharmaceutical 
procurement and distribution systems currently in use in the provinces with the ultimate 
objective of improving pharmaceutical services in the provinces, and to serve as a baseline 
for future studies. 
The survey covered the ten key indicators of the National Drug Policy: selection, 
procurement, storage, distribution, quality control, information systems, facilities and 
equipment, cost implications, human resources development and drug use. The study 
examined the current state of pharmaceutical systems at various levels: depot (5), hospital 
(57) and clinics (120). The first survey was conducted in the Northern Province in April 
1996. Staffs in clinics, mostly nursing staff in clinics and hospitals were interviewed to 
determine the level of knowledge about the National Drug Policy and the Essential Drug 
List. By 2000 eight provinces of nine have completed the local survey. Gauteng province 
has yet to conduct its baseline study. In addition, KwaZulu-Natal was not included in this 
study report because it only completed the survey in November 1998. The results were 
published in First Report: The Impact of the Essential Drugs Programme in Seven 
Provinces in South Africa, Baseline Studies April 1996 to March 1998 (October 1998). The 
results and recommendations are as follows (Moller, 1998): 
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• Awareness of the NDP: 39.2% of all persons interviewed were aware of the NDP, 
29.9% had their own copy. However, only 13.8% could remember 3 key aspects from 
the policy. Generally, the clinic staffs were not aware of the NDP. There was an overall 
lack of awareness of the NDP in South Africa. 
• Combination products not on the EDL were not a problem. However, a list of unwanted 
medicines was prepared and 75.8% of hospitals had at least one of these in stock. 
• The number of items per prescription at the hospital level was 2.5 items. This high 
average suggests that there may be polypharmacy. Antibiotic use was a problem at all 
levels. On average 32.5% of patients received at least one antibiotic. 
• Injection use was a problem at the hospital Out Patient Department (OPD). The 
Northern Province had a 27% rate. 
• Concerning human resource development 7.7% of those interviewed in the hospital 
pharmacy received some form of Diagnosis Standards in Medicine (DSM) training, 
while 9.1 % of those interviewed at the hospital received some training, aimed at 
improving the use of medicines. 
• Sources of independent drug information (South African Medicines Formulary) were 
available to 52.7% of hospital pharmacists. While 29.9% had a copy of the Primary 
Health Care Formulary. The most commonly used sources were the (MIMS) Merck 
International Manual (which is a pharmaceutical industry publication). Only 10% of the 
hospital pharmacies publish a drug information bulletin or newsletter. Of those 
interviewed 33.7%, routinely used a drug information centre. There is an urgent need 
for a cross-reference guide between generic and trade name drugs at the Primary Health 
Care level. 
The baseline study concluded with 12 recommendations, six of which were concerned with 
facility, inventory and storage. The other six were: 
1. The general awareness of the NDP, especially al the clinic level, must improve. 
2. Medicines not on the EDL must be identified and where consumption is not 
possible, returned to a central point for distribution. 
3. Basic financial management principles must be implemented at all levels. 
4. Objective drug information must be made available to all prescribers, as well as 
pharmacy staff. 
5. Training aimed at improving supply of medicines must be designed and implemented at 
both the hospital and the primary care levels. 
6. Training aimed at improving rational medicine use must be designed for and 
implemented at both the hospital and the primary care levels. 
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4.3.3 Pharmaceutical Services at Primary Care Clinics (Kishuna, 1994). 
Aarti Kishuna (1994) studied the Pharmaceutical Services at Primary Care Clinics in 
KwaZulu-Natal. The research question was 'Do hospital-based pharmacists support 
pharmaceutical service delivery at primary health care clinics? If not, how can they?' The 
aims included assessing the provisions for pharmaceutical services determine whether 
differences exist in the provision of pharmaceutical services; identify problems associated 
with the provision of services. The study was conducted in three hospitals. Data collection 
included observations, interviews of patients, and staff (nurse, dispensing staff) and the use 
of three categories WHO/INRUD indicators (availability, quality, and storage; quality of 
dispensing practice; the experience and training of prescribers and dispensers). 
The study concluded: 
• Hospital based pharmacists do not support pharmaceutical service delivery at primary 
clinics in KwaZulu-Natal. 
• Clinic staff lack training in stock management and pharmaceutical services. 
• Nursing staff lacks an understanding of pharmaceutical services and is poorly trained in 
stock management. 
• The quality of dispensing medicines was poor, especially labelling. 
• ·Need to train personnel in ordering and storage. 
In conclusion the researcher identified questions that needed further research in "order that 
pharmaceutical services, within the framework of PHC, becomes rational, cost-effective 
and appropriate to the needs of the community .. .Is prescribing behaviour rational in the 
fonnal health sector?" 
4.3.4 Analysis of Prescription Prescribing Patterns, and Costs (Suleman, 1995) 
Another academic study conducted by Fatima Suleman (1995), titled, Analysis of 
Prescription Prescribing Patterns, and Costs, in Public and Private Sectors within the 
Durban AJetropolitan Area. It was a cross-sectional descriptive study of four patient 
categories within the public and private sectors of the Durban metropolitan Area (DMA) in 
KwaZulu-Natal. The aim of the study was to analyse prescribing patterns and their costs in 
the public and private sectors. WHOIINRUD prescribing indicators were used. The data 
was collected during 10 working days in 4 hospitals (3,589 prescriptions), 15 pharmacies 
(273 prescriptions) and 24 dispensaries from a medical clearing-house (212 prescriptions). 
A total of 4,703 prescriptions were collected for analysis. Significant differences were 
found. First, hospital patients (public) had an older patient profile, prescribed more drugs 
on average than the private sector, and had a disease profile consisting of more conditions 
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that are chronic. Second, dispensing doctors (private) had the highest percentage (24.4%) 
of prescribing generic drugs, antibiotic prescribed (33.7) and percentage of injections. 
The findings, by implication warrant an in-depth qualitative study to investigate the 
underlying factors that affect prescribing. The recommendations are that a database be set 
up and used to continuously monitor drug use. Also, peer review should be introduced for 
prescribers, and that they be made aware of the cost implications of their prescribing. 
Recommendations at the end of the study were (Suleman, 1995): 
• "In absence of a national database/prescription monitoring service, studies on 
prescribing patterns need to be carried out regularly to monitor trends or changes in 
prescribing behaviour." 
• "The study indicated a low percentage of generic prescribing, it is recommended that 
prescribers be made more aware of the importance of generic prescribing prior to the 
proposed legislation coming into effect that all prescription sin both public and private 
sectors be written using the generic names of drugs." 
• "As the result of drug utilisation studies (including this one) have indicated regional 
variation in prescribing, it is recommended that all training programmes be planned and 
conducted at provincial level, with appropriate aims and objectives, to ensure 
standardisation in the development of training programmes." 
• Training for the implementation of the Essential Drugs Programme in the Northern 
Province January-December 1997. 
Suleman, stated in her report (1995) "the document compiled by the National Department 
of Health advocates generic prescribing by all prescribers in accordance with the Essential 
Drugs List. Yet it is the dispensing doctors, rather than the public doctors, that follows this 
method. Also, under the section for human resource development in the NDP document, no 
mention is made of training prescribers with regard to generic names. Thought this may be 
inherent in the modules suggested for training, this factor has not been highlighted, yet it is 
one of the aims of the NDP to facilitate procurement, distribution, supply and use of 
drugs." 
In conclusion (Suleman, 1995), the study highlighted two areas into which detailed 
research is required. The number of drugs prescribed in the public sector; qualitative 
studies to define the factors affecting prescribing decisions; "studies on prescribing pattern 
need to be carried out regularly to monitor trends or changes in prescribing behaviour and 
generic prescribing need to be used to ensure ROU", 
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4.3.5 Research in Rational Drug Use (MEDUNSA,1998) 
In response to two of the recommendations (training in Effective Prescribing and Drug 
Supply Management) of the first pharmaceutical study in Northern Province (1996) an 
intervention was undertaken by MEDICOS/ MEDUNSA (Medical University of South 
Africa). The intervention, a training programme, was developed, implemented and 
evaluated by the same group. A report, 'Training for the implementation for the Essential 
Drugs Programme in the Northern Province, January - December 1997' was published 
(MEDUNSA 1998). The report describes an intervention that was designed to implement 
the training and evaluate its effectiveness. The study'S goal was to train one person in every 
Primary Health Care facility in both Effective Prescribing and Drug Supply Management. 
A training cascade was set up with trainers selected from various regions. In total 45 people 
were trained as trainers. Then 22 Effective Prescribing courses to train 450 people and 16 
drug management courses that trained 339 people were conducted. After the training, 
research was conducted in PHC clinics in the Lowveld Region of the Northern Province. 
The research was a pre-test / post-test intervention study conducted on the effectiveness of 
the Effective Prescribing course. 
A quantitative study of 90 prescriptions was assessed retrospectively for two conditions 
(Upper Respiratory Tract Infection and Diarrhoea & Vomiting). Also, structured patient 
exit interviews were conducted. The results indicated that the prescribing patterns of the 
intervention study group were significantly better than in the control group. The training 
for the study group showed that the prescribing approach taught was carried over from 
conditions covered (URTI) in the training to conditions not covered (diarrhoea & vomiting) 
in the training. The recommendations (MEDUNSA, 1998) of the study were: 
1. Planning for the continuation of the project 
2. Informing management of the training (for support) 
3. Technical supervision and empowerment of trainers 
4. Inclusion of supervisory staff 
5. Training of medical practitioner in Effective Prescribing 
6. Conduct a follow-up survey to measure the impact of the training intervention. 
The participants of the Effective Prescribing course in their evaluation requested that 
additional topics to be included in the course to be: chronic patient conditions prescribing; 
chronic diseases, management of asthma; and more exercises for hypertension and 
diabetes. The other comments and suggestions included: more frequent courses, annual 
follow-up courses, EDL be part of PHC curriculum; doctors and pharmacists should be 
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trained. In addition, training could provide awareness of their preferred 'personal drugs' 
and 'treatment' regiments, since this will allow them a better understanding of how and 
why they could practice poly-pharmacy or non rational drug prescribing. 
4.3.5 The Rational Drug Use Training Project (Orrell, 1998) 
During the same period a Rational Use of Drugs project was conducted in two other 
provinces. The Rational Drug Use Training Project (1997) was based on a MSc thesis 
(Orrell, 1997) by Dr. Catherine Orrell (MBChB, DCH) at the University of Cape town, 
Department of Pharmacology. The title of the research is "The development, initial 
implementation and support of a primary health care training programme in rational drug 
use. " 
The Rational Drug Use Training Project is a District-oriented programme designed to 
improve rational drug use among primary health care (nurse) prescribers in South African 
public sector. The Project was a train-the-trainer; district-oriented programme designed to 
improve rational drug use among Primary Health Clinic (PHC) prescribers in the public 
sector. 
The project began early 1996 with the directive to improve drug use at facility-level. 
Baseline prescribing data was collected at three primary care facilities in December 1996, 
before the first set of training workshops. Data was collected again March 1997 after 
implementation of the training. The training was implemented in three facilities in Region 
B of KwaZulu-Natal. The project had three components: 1) drug use indicators adapted 
from those developed by WHO/INRUD, 2) two-day training workshop in rational drug use, 
3) set of unbiased written resources. 
The program was designed as a train-the-trainer system, training workshop in rational drug 
use using district staff as the trainers for twelve participants. It was a problem-based and 
held on-site in primary health care facilities. "The workshop was divided into four 
modules, which could stand-alone or be taught together. These cover principles of 
prescribing, use of standard treatment guidelines, principles of clinic stock management 
and principles of good dispensing" (Orrell, 1998). 
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The achievements of the workshop intervention were "significant improvements in 
prescribing and dispensing habits. There was an increase in the percentage of drugs 
prescribed by their generic names (25% to 43%, p=O.OOO). In addition, the training resulted 
in an increase in the number of medications adequately labelled (43% to 52%, p=O.OI32), a 
decrease in the cost of prescriptions (R9.27 to R5.39, p=O.0134). In addition there was a 
decrease in the number of prescriptions that did not follow standard treatment guidelines at 
all for that diagnosis (31% to 11%, p=O.OI09). The Mann-Whitney V-Test was used for 
statistical analysis. There were no significant changes in several important areas. First, the 
average number of drugs per prescription (2.76 to 2.68); and second, the percentage of 
drugs from the Essential Drugs List (74% to 77%); and the number of prescriptions that 
completely followed standard treatment guidelines (13% to 14%) (Orrell, 1998). 
The problems with the implementation of the study were due to personnel. "This was a 
difficult study to undertake. The district trainers needed for the cascade approach were not 
available, and therefore clinic sisters, with full-time commitments elsewhere, where asked 
to be trainers for their facilities. These staffs were not people who had been trained to train. 
Although they fulfil their commitment to the study, they were unwilling to carry on with 
this additional role. The few-trained trainers moved on to other posts within a few months 
of the study. At this stage, therefore, the training was not sustainable." 
In addition, "District staff found it difficult to function as a team. There remain many 
hierarchical divisions e.g. hospital-clinic, doctor-nurses, nurse-pharmacist, with poor and 
misunderstood communication between them. The will of district prescribing staff to learn 
was low. No incentives have been provided to nursing staff who are now expected to be 
South Africa's primary care prescribers" (Orrell, 1998). The study found five additional 
conclusions about drug use and prescribing (Orrell, 1998). The five conclusions are: 
1. Clear prescribing policies for districts are not apparent. 
2. A lack of teamwork exists. Doctors behave according to their own rules, as do nurses. 
The hierarchical atmosphere does not facilitate empowerment. ... Nurses do not feel 
supported by doctors. 
3. Patient demand can be overwhelming, especially for cough mixtures and injections 
that promote irrational prescribing behaviour. 
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4. Difficulties in implementation of treatment guidelines. The guidelines for TB 
treatment were inconsistent with the packaging of the medicine received, forcing re-
packing. 
5. There is limited supervision or monitoring of drug use/ prescribing practices within 
the district. 
Orrell stated that cooperation and links between health professions is needed not only at the 
hospital and clinic levels, but also the DOH and university levels. "All programmes need to 
be in step with the department of health. The South African Drug Action Programme is 
beginning this training of trainers in prescribing and drug supply management this year. 
The Rational Drug Use Training Project was in some senses ahead of the department for 
1997. It was difficult to obtain permission for training in some provinces as we were not in 
step with SADAP." In addition, "Universities and other academic institutions could be rich 
resources for the primary care system. People need to be encouraged to share information 
from primary to tertiary level and vice versa. Healthlink helps greatly in this process." 
(Orrell 1998) 
The researcher concluded (Orrell 1998: 1 02), The Rational Drug Use Training Project has 
shown that "rational drug information, using a train-the-trainer approach, with a problem-
based workshop as an intervention, quantitatively improves drug use, as described by the 
prescribing, dispensing and stock management drug indicators." In 1997, the Rational Drug 
Use Training Project expanded to eight other health districts. 
4.3.6 Summary of Research Conducted in Developing Countries 
Few systematic reVIews, research and analysis of national and international efforts at 
pharmaceutical policy development (NDP) and its accomplishments have been carried out 
in developing countries. One published study in Yemen evaluated the impact of the NDP 
intervention with a control group. The results were a significant difference in rational drug 
use indicators between the test and controls groups. 
A comparative analysis study of National Drug Policies in 1996 conducted in twelve 
countries to assess their performance in implementing the NDP. The research was 
conducted in Bulgaria, Chad, Colombia, Guinea, India, Mali, Philippines, Sri Lanka, 
Thailand, Vietnam, Zambia and Zimbabwe. For the study, most of the INRUD, NDP 
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indicators were used, while a few new indicators were added. One country, Thailand used 
political mapping to understand the process of policy formulation and implementation. The 
study showed that policy-makers need both technical and political analysis in order to 
implement effective interventions. 
The Thailand experience showed that more than 29,000 drugs were registered. The 
National EDL covered only the public sector. The Thailand study showed that the NDP 
structural indicators were in place within the policy structure, the process and outcome 
indicators lagged behind, specifically, the implementation of the policy with law 
enforcement. The study revealed that the variety of drugs under various brand names 
caused confusion and increased irrational drug prescribing. Several outcome indicators also 
showed that prescribers had difficulties with rational drug use. 
The most significant findings for the study were first; policy implementation affects the 
success of the outcome. The policy must be monitored regularly and continuously assessed 
for how the policy activities relate to policy objectives. Second, irrational drug use has 
multiple factors that include the quality of products, product information, qualification of 
prescribers and prescribing and dispensing behaviour. The solution is to provide unbiased 
drug information and adequate education and training, and institute incentives to promote 
rational drug use. 
In South Africa, the first pharmaceutical study (1996) was by MEDICOS and MEDUNSA 
evaluated the transformation of pharmaceutical and related services in the Northern 
Province in order to determine first, the impact of managerial control of drug procurement 
and distribution. 
Second, to assess the effect of an essential drug programme on primary care services. The 
study concluded that injection and antibiotic use, generic prescribing, and compliance with 
STGIEDL needed more attention. Human resource issues included staff, awareness of the 
NDP and STG/EDL through training on effective prescribing, and drug supply 
management. 
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The study had three main conclusions and recommendations, first, an introduction to the 
National Drug Policy and the Essential Drugs List. Second a campaign to encourage 
generic prescribing and the use of standard treatment guidelines. Third, training in drug 
supply management and rational drug use or effective prescribing. 
SADAP Baseline survey (1996-1998) of the ten key indicators of the National Drug Policy: 
selection, procurement, storage, distribution, quality control, information systems, facilities 
and equipment, cost implications, human resources development and drug use showed that 
the NDP uptake was small. 
The baseline study concluded with recommendations that include, medicines not on the 
EDL must be returned to depot, the conclusions in drug use were awareness of the NDP 
must improve, objective drug information must be made available, training to improve 
supply and prescribing of medicines and basic financial management. 
A strong commitment to the National Drug Policy by the National of education, and 
training in essential drugs and generic prescribing with the STGIEDL as a guideline tool do 
show some success, but over time do not seem to remain without re-introducing the goals 
through administrative. The use of Pharmaco-Therapeutics Committees (PTC) with the 
entire hospital team represented along with the other interventions allows for a higher 
probability of successful NDP implementation. Overall, the earlier studies have revealed a 
lack of rational drug use by prescribers. What is not known is how to make generic 
prescribing the norm months and years after the training has occurred and the promotion of 
the STGIEDL is not as strong. 
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4.4 Gaps in Research 
The gaps in the research are apparent in 'policy analysis implementation as it is related to 
the health policy of the South Africa National Drug Policy. The focus is based on the top-
down approach to implementation theory and approach to policy analysis and evaluation. 
Few in-depth case studies in the implementation of the National Drug Policy (NDP) in a 
developing country have been competed in the last ten years. A lack of focus in the 
systematic in-depth evaluation of the Knowledge, Attitudes, and Practice (KAP) of those 
on who implement the NDP through the use of the STG/EDL on a daily basis will be one 
of the major evaluative components of this research. The qualitative study through 
interviews specifically address evaluation and analysis of the cause and effect relationship 
to the quantitative results of the drug utilisation. The research addresses both of these gaps. 
Research that has been conducted to date in policy analysis implementation, especially as it 
is related to health policy and programmes outside of Europe and American is apparent 
after the literature review. Most studies of implementation have been conducted in the USA 
and Europe. Of these studies, few focus on the implementation of legislated health projects 
in the public sector. Few implementation studies still have been conducted in Southern 
Africa in the area of health programmes. The research on the impact of South Africa's 
National Drug Policy implementation in public hospital clinics will contribute to the 
literature in the Implementation Theory, with a top-down approach, school of thought. 
Specifically, this research project will fill some of the gaps in both the theoretical literature 
on policy analysis and specifically the use of implementation approach to policy analysis 
and evaluation. 
Second, there is a lack of in-depth case studies in the implementation of the National Drug 
Policy (NDP) in a developing country. Existing studies have shown two main gaps. First, a 
political analysis of the formulation and implementation of the NDP, Essential Drug 
Programme (EDP) and tools that are used (STG and/or EDL). Second, an understanding 
and analysis of the reasons that underline the quantitative study results of the NDP, and 
specifically, Rational Drug Use (RDU). According to International Network of Rational 
Use of Drugs, INRUD, (1996), "Many studies have succeeded in documenting drug use 
problems, but few have examined the factors underlying these problems in a meaningful 
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way. Yet such studies are needed to provide policy makers and managers with useful 
insights into the types of interventions that might succeed in correcting these problems." 
A gap exists in the systematic in-depth evaluation of the Knowledge, Attitudes, and 
Practice CKAP) of those on who implement the NDP through the use of the STG/EDL on a 
daily basis. Therefore, policy implementers have been unable to successfully develop 
innovative ideas and recommendations for interventions in order to improve 
implementation of the NDP outcomes, specifically rational drug use. This research seeks 
to address both of these gaps in the research genre. 
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CHAPTER FIVE 
LITERATURE REVIEW 
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5.1 Introduction of Three Topics 
This literature review summarises previous work on policy analysis and evaluation of the 
implementation of social programmes within the arena of health sector reform. A fuller 
understanding of organisational management and of strategies and interventions for 
changing behaviour will be a prerequisite for successful implementation of rational drug 
prescribing. Successful intervention can only be achieved through analysis of both the 
political and personal forces that influence the adoption of a policy change, and the 
interventions to address the shortcomings of the intended policy. Once this information has 
been collected, analysed and understood, then policy implementation is addressed through 
appropriate interventions. 
Implementation success or lack thereof is defined by the extent to which the policy has 
been adopted by those who are to make it a part of their day-to- day professional lives, and 
the proposed interventions in order to improve compliance with the policy. 
This literature review looks at four topics: 
(I) Organisational Management Theories 
(II) Policy and Implementation Theory 
(III) Rational Use of Drugs 
5.2 Organisational Management Theories 
Organisational Models o/Social Programme Implementation 
This section reviews the literature on theoretical organisational management models, the 
politics of change and the psychosocial adaptations to organisational change. 
An understanding of organizations is central to the analysis of policy andlor programme 
implementation (top-down or bottom-up approach). In the area of implementation theory 
the literature on organizations is diverse and contradictory (Elmore, 1953). As a result the 
knowledge in the field is said to be soft, as it is 'extremely difficult to use knowledge of 
this sort as the basis for analysis. There is no single, coherent body of organisational theory 
that will serve as the basis for analysis' (Elmore, 1953). Since there is not a single model to 
adequately represent the full complexity and breadth of the implementation process, it must 
be viewed from a number of different organisational models. The four models that 
represent the major schools of thought are (Elmore, 1953): 1) systems management model, 
2) bureaucratic process model, 3) organisational development model and, 4) conflict and 
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bargaining model. Each model can be a legitimate analytical tool. In both the systems 
management model and the bureaucratic model, policy is made at the top and implemented 
at the bottom. 
a. Systems Management Model (Elmore, 1953) 
Organizations operate as rational value maximises. The structure is hierarchical control 
and the top management has the responsibility for policy-making. The model starts from 
the assumption that effective rational management is derived from goal-directed, value 
maximising behaviour. Success is based on the extent to which the organisation maximises 
perfonnance of their goals and objectives. Every task can be carried out to its optimal end 
if it is allocated among the most appropriate subunits (subordinates). Implementation is 
carried out with a detailed set of policy objectives and perfonnances monitoring which are 
adjusted when necessary to attain the organizations' goals. Because the emphasis is on 
hierarchical control, no allowance is made for lower-level subordinates to carry out the 
policy at their own discretion. Subunits are held responsible for a reaching certain goals. 
Managers are responsible for achieving these goals with their subunits. This is called sub-
optimisation and it provides a means to exercising hierarchical control. Effective 
implementation requires four main ingredients: 1) clearly specified tasks and objectives 
that accurately reflect the intent of the policy; 2) a management plan that allocates tasks 
and perfonnance standards to subunits; 3) an objective means of measuring subunit 
perfonnance; 4) a system of management controls and social sanctions. The systems 
management model is a theoretical description of how organizations should function. It is 
not intended to describe reality and will work if everyone behaves according to the 
organisation. 
b. Bureaucratic Process Model (Elmore, 1953) 
In this model the organisation has two attributes, discretion and routine. The bureaucratic 
model assumes that the dominant characteristic of organizations is resistance to change and 
that it fights to remain the same. All behaviour in organizations can be attributed to the 
discretion exercised by individuals in their day-to-day decisions and routines. Decisions 
and routines are chosen to maintain or enhance their position of power. Power within the 
organisation is fragmented between many individuals. The more complex the organisation 
the more specialised the jobs and the greater control individuals will exercise over their 
70 
area of expertise. Decisions, like implementing policies, are made through controlling 
discretion and through changing routines. 
Individuals resist the hierarchical management and try to do what they want until a way is 
found to make them change. Delivery of service to the client which allows for discretion 
and routine, is the most difficult to change. The distinctive quality of street-level 
bureaucracy is that discretion increases as one moves down the hierarchy. "Whether or not 
the policy has its intended effect on the client depends in large part on whether the force of 
existing routine at each level of the process operated with or against the policy." Most 
importantly, street-level bureaucrats are usually not included in the policy-makers' 
definition of policy. Instead of being thought of as being central to the implementation 
process, the street-level bureaucrats are ignored or thought to be external to the 
implementation process. "Bureaucratic coping behaviours cannot be eliminated, but they 
can be monitored and directed by rewarding those who most closely conform to preferred 
public objectives and discouraging objectionable practices" (Elmore, 1953). 
c. Organisational Development Model (Elmore, 1953) 
The Organisational Development Model begins from the premise that the needs of the 
individual, rather than those of the organisation, must be considered first. The emphasis is 
on individual motivation and commitment, work in-groups, and an explicit rejection of 
traditional notions or organisational efficiency. The organisation's function is to satisfy the 
psychological and social needs of individuals. The organisation should maximise individual 
control, participation and commitment. To achieve this, the best structure is one that 
minimises hierarchical control and allows for responsibility to be distributed between all 
individuals. Effective decision making is dependent on building consensus and on the 
effectiveness of those who work in a group. Strong and positive interpersonal relationships 
are necessary. Implementation is accomplished through consensus building and 
compromise between policy-makers and implementers. Work is conducted in-group. 
Consensus in goals, individual autonomy, and commitment to the policy are necessary. 
According to organisational theorist Chris Argyris (1960 & 1993) , adult behaviours like 
self-motivation, independence, responsibility for one's actions, courage of ones 
convictions, and honesty that are seen positively outside of an organisation are directly 
contradictory to what is expected inside an organisation. In this model, policy-making and 
implementation have no clear distinction. If there is a failure of implementation, it is 
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because of a lack of consensus and commitment within the group (Elmore: 1953). In short, 
implementers shape the policy, and the behaviour of the implementers is shaped by the 
policy. "The only wayan innovation (or policy) can become established in an organisation 
is for the implementers to learn it, shape it, and claim it for their own" (Elmore, 1953). 
d. Conflict and Bargaining Model (Elmore, 1953) 
In this model, conflict and bargaining (explicit and tacit) are the foundation of 
organisations. Conflict and bargaining occurs within and among implementing agencies. 
There is not necessarily a common purpose within the organisation. Individuals in the 
organisation have specific interests. They compete to gain advantages and resources, and to 
exercise power. The distribution of power is always changing. It changes according to how 
power and resources are shifted to meet the goals of an individual or unit. Decision -
making and implementation occurs through bargaining to reallocate resources. "Much of 
the behaviour in the implementation process is designed to shape the expectations of other 
actors ... the important fact is not whether the rules are enforced or not, but the effect of 
their existence on the outcome of the bargaining process" (Elmore, 1953). Outcomes are a 
result of temporarily bargained solutions that do not necessarily reflect an agreement on 
common purposes. The success or failure of a social programme is dependent on the power 
to force individuals to conform to a single policy. Since the environment is characterised by 
conflict, changes are achieved through bargaining. Overall, success is measured relative to 
the goals and the preservation of the bargaining process itself. 
The model that is most appealing for the implementation of the NDP, STGIEDL tool is the 
Organisational Development Model. In the attempt to change prescribing habits, the 
emphasis on individual motivation, personal commitment and working in-groups seems 
ideal. Since there are strong divisions between professionals who administer policy, 
prescribe, and carry out orders, this model with its co-operative approach would not be 
practical. The model that is the most practical is the Systems Management Model of 
organisations, even though it is not possible to change or control people's behaviour to the 
extent that their every action is oriented to utilisation and maximised towards the 
organisations stated goals. 
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e. The Psycho-social dimensions of change 
Change requires the disappearance of something that was known and brings with it a sense 
of loss, and thus bereavement (lIes, 1997). As groups within organisations are exposed to 
change, reactions to loss and bereavement are well documented. The stages of grief are 
denial, anger, grief, resignation, and acceptance. These stages do not necessarily occur in 
this order or one at a time. One may go between any of these stages until the final 
acceptance of the loss. The evaluation of change in organisations - one of the most 
valuable elements of any policy and/or programme - is often neglected. The following 
questions are helpful in evaluating change (lIes, 1997): 
Reviewing the change: 
• Did the change achieve its objective? 
• How closely did the actuality mirror the plan? 
• How and why did it differ? 
• How do the stakeholders feel about the change? 
• Is there anything else that needs to be done to achieve the objectives or to influence the 
feelings of stakeholders? 
Learningfor the next time: 
• What should be done differently next time? 
• Why and 
• how 
The psychosocial dimensions of organisational management and its review of the change is 
helpful in directing and understanding the difference between the objective wanted and the 
actual outcome. Answers to these simple questions can help with the recommendations for 
the future and a plan of how to more forward. 
Summary o/Organizational Management theories 
This section reviewed the models of organisational management, politics of change and the 
psychosocial dimensions of change within organisations. 
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5.3 Policy and Implementation Theory 
This section reviews the literature on public policy and policy implementation theories. 
This research is located within the field of policy analysis through the evaluation and 
analysis of implementation. South Africa's NDP has a high level of government 
commitment. One of the goals within the NDP is rational drug prescribing to which 
measurable entities and explicit guiding criteria for implementation and evaluation are not 
clearly stated. Explicit targets have yet to be set. Walt (1994) stated: "Severe problems 
have been experienced in implementation of structural refonns in the absence of guiding 
criteria on who should execute policy change and how to implement them." The NDP 
Essential Drug Programme policy of using STGIEDL in all public health institutions and 
specifically its implementation through training to increase the adoption of this RDU tool, 
have yet to be clarified. 
a) Policy 
A definition of policy by Hogwood and Gunn (1984) is: "A policy usually involves a series 
of more specific decisions, sometimes in a 'rational' sequence (e.g. deciding there is a 
problem; deciding to do something about it; deciding the best way of proceeding; deciding 
legislation; etc.). Even when the sequence is more erratic, a policy is typically generated by 
interactions among many, more or less consciously related, decisions." Policy, and policy 
analysis has borrowed techniques from a wide variety of disciplines including political 
science, public administration, economics, sociology and management. For Hogwood and 
Gunn (1984), the role of policy analysis" is not to replace but to supplement political 
advocacy." Analysing public health policy requires various techniques. For Leichter 
(1979), a scheme for analysing public policy is using contextual health factors that never 
act in isolation. Instead, the factors make up a framework of analysis in which there is a 
continuous and simultaneous interplay of factors in both policy fonnulation and 
implementation, which must be considered and evaluated. The type of policy will have a 
substantial impact on the kind of political activity that is promoted by the policy making 
process. The extent, to which a policy seeks to introduce changes in social, political, and 
economic relationships, will have an equal and opposite reaction from those who do not 
want change. 
In both the fonnulation and implementation of a policy or programme, there are four areas 
that must be considered in order to increase the likelihood of success. The four areas that 
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must be considered are the situational, structural, cultural, and environmental context 
(Hogwood and Gunn, 1984). 
(i) Situational: Events or sudden changes like violent events, economic cycles, natural 
disasters, political events, technical change and policy agenda can have a large 
impact on the success of implementation of a new policy. 
(ii) Structural: long-term characteristics and/or features the political system, economic 
base, social demographic composition, and natural resources. 
(iii) Cultural: Values, beliefs, norms that determine interactions. These include national 
heritage, religion, language, political orientation, kinship, and social norms. 
(iv) Environmental (International): factors that originate outside a country. These can 
include foreign trade, policy diffusion, international agreements, scientific 
knowledge, technical assistance, monetary aid, trans-national private corporations, 
international organisation affiliation, environmental impact, etc. 
In short the formulation and implementation of a policy that is to be successful needs to 
take into account the situational, structural, cultural and environmental areas. 
Implementation is a part of policy making and also of policy analysis. Conversely, a policy 
is not better than its implementation (Hogwood and Gunn, 1984). Furthermore, Hill states 
(1993), "to understand the policy process as a whole it is necessary to give attention to 
policy implementation." Hill goes on to say, one is "prone to disregard was the extent to 
which this activity would tend to transform policy, often fundamentally. Recognition of 
this has given implementation studies a crucial importance in the study of the policy 
process." Hill (1993), states that "rather than treating implementation as the transmission 
of policy into a series of consequential actions, the policy-action relationship needs to be 
regarded as a process of interaction and negotiation, taking place over time, between those 
seeking to put policy into effect and those upon whom action depends." 
5.3.1 Policy Implementation Theory 
Implementation should establish the means to allow goals of a public policy to be realised. 
Policy and/or programme implementation is frequently used interchangeably. Policy 
implementation is usually thought to be a necessary link to and part-and-parcel of 
programme implementation. The policy statement of its goals, objectives and means are 
translated into programmes that aim to achieve the policy objectives. Therefore the study of 
policy implementation involves an analysis of the programmes and interventions that have 
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been designed to meet the policy goals. "Overall policy implementation can be evaluated 
by measuring program outcomes against policy goals" (Grindle, 1980). The success or 
failure of the implementation of the policy andlor intervention is determined by whether the 
programmes were delivered as intended. Implementation is a political and administrative 
process. The content of the public policy or programme is one of the important factors that 
determine the outcome and acceptance of initiatives for implementation. The most variable 
factor in any policy and its implementation is the stakeholders some of whom want change 
and others who are opposed to change. The degree of behaviour change that is necessary 
will affect the implementation of the policy. Also, as the number of sites for the 
implementation becomes more dispersed, geographically and organisationally', the 
execution of the programme become more complex and difficult because of the increase in 
the number of people and their decisions to further or hinder the policy. Hill (1993) states 
that when implementation involves innovation and changes that are a major departures 
from previous policies and practices, "there will be a particularly high probability of 
suspicion, recalcitrance, or outright resistance from affected individuals, groups, especially 
if insufficient time has been allowed for explanation and consultation or if any previous 
experience of change has been unfortunate. We cannot (and should not) hope ever to be 
free from such resistance, but we can learn the responses open to administrators from the 
study of individual, group, organisational, and political behaviour." 
5.3.2 Implementation as a Political and Administrative Process 
Implementation is an ongoing political and administrative process (Figure 5.1) of decision 
making by stakeholders that is influenced by both the programme and policy content, and 
the environmental context. Grindle (1980) perceives the implementation process as an 
ongoing process of decision-making that inevitable involves a large number of actors 
(stakeholders). In the daily processes of implementing a policy or programme, stakeholders 
make choices about how to implement the policy in an attempt the outcome. Each of the 
stakeholders has a personal interest in the success or failure of the programme or policy. 
The goals of various stakeholders will be in direct conflict with each other. Only some will 
be ale to reach their goals. Depending on the resources, power, strategies and position of 
the stakeholders. A full analysis of the implementation of a programme or policy must 
include an assessment of the stakeholders' interests, "power capabilities" and resources for 
achieving them. The arrows in figure 5.1 show that decisions made at one point have 
consequences that are important for the decisions that are made later. The arrows with the 
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broken line show that the political and administrative environment in which they are made 
influences decision outcomes. 
Figure 5.1 Implementation as a Political and Administrative Process 
Policy goals 
Outcomes GO~ 
achieved? 1 
Implementing Activities 
/ 
Influenced by: 
A. Content of policy 
a. impact on society, 
individuals, groups 
Action Programmes 1. Interest affected b. change and its 
acceptance Individual projects 
Designed and funded 
, ~ 
p~ogramme implemenfers 
r~ources committed \. 
I.' Programm~ delivered 
! as desigri~d? 
~ ..•. -".-... '''---.----- \\ 
.................. ::~: •.•..... 
2. Type of benefits 
3. Extent of change envisioned 
4. site of decision making 
, 
I 
! 
b. Context ofImplementation 1 
1. Power, interests, strategies of actors :.::',,:,~:i 
2. Institutions and regimes characteristics 
3. compliance and responsiveness 
MEASURING SUCCESS ....................•.................................... ! 
Source: Grindle (1980) Politics and Policy Implementation in the Third World 
5.3.3 Challenges for Organisational and Administrative Policy Implementers 
Organisational and administrative policy implementers are usually faced with two 
difficulties. First, how to achieve compliance with the policy, for example using the 
STGIEDL. Achieving compliance may entail bargaining, compromises, accommodation 
and great conflict. The second difficulty consists of creating a responsive environment that 
provides flexibility, support and feedback. . In programme /policy success "decentralisation 
may be a viable strategy where central authorities retain the capacity to ensure that 
implementing activities remain within the boundaries of the program objectives and 
structures" (Grindle, 1980). Simultaneously, administrators must maintain a level of control 
over the resources for the stated goals of the programme to be achieved. 
5.3.4 Critical Choices in the Implementation Process 
Implementation is an ongoing process of decision making of analysing how and why 
choices are made and the consequences of these choices for the implementation of the 
policy. The three critical choices in the implementation process (Figure 5.2) first the policy 
and programme definitions. Second, implementation strategy and third, resource allocation. 
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Figure 5.2 Critical Choices in the Implementation Process 
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For successful implementation, political and administrative leaders for successful 
implementation need to develop unambiguous goals for programmes to fulfil policies, with 
developmental and incremental objectives (Grindle, 1980). The choices of which 
organisation will implement which part of the programme goals and how, the mechanisms 
for accountability, monitoring, evaluation, and reporting, are all aspects of the strategic 
choices for implementation. Implementation is likely to be carried out by various 
governmental and non-governmental, national and international agencies. The choice of 
which agency will be responsible for which part ofthe implementation is critical. 
5.3.5 Theories on Implementation: Top-Down and Bottom-Up Models 
The two main schools of thought in implementation theory are the top-down approaches 
(Hogwood and Gunn:1984, Hill:1997, Sabatier:1979, Mazmanian & Sabatier:1981, and 
Elmore:1953) and the bottom-up approach (Hjern, and Porter, :1981; Hanf:1982, and 
Brinkerhoff: 1991) that includes implementation policy analysis. The difference lies in who 
makes the policy and who has control over the implementation of the policy; management 
and policy-makers versus street-level bureaucrats. 
a) Top-Down Approach to Policy Implementation 
The top-down approach to the analysis of policy implementation (Hogwood and 
Gunn:1984, Hill: 1997, Lipsky: 1980, Elmore:1978) starts from a policy decision and 
focuses on the extent to which the objectives are attained over time and why. The main 
issues are the effectiveness of specific governmental programmes and the ability of 
officials to guide and constrain the behaviour of target groups. This evaluation requires an 
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analysis of the formally- approved objectives of officials, an evaluation of performance 
indicators, and an analysis of factors affecting performance. 
Implementation studies carried out in the 1970's, used the top-down approach to look at 
factors that undermined 'the perfect implementation' and gave prescriptions about how to 
avoid failure of the 'perfect implementation.' Hogwood and Gunn (1984) assert that 
perfection is an ideal concept or an idea, but can to be achieved. In order for the ideal 
concept of perfect implementation to be achieved, nine preconditions would have to be 
accomplished. These nine preconditions are: 
1. The circumstances external to the implementing agency do not impose crippling 
constraints. 
2. Adequate time and sufficient resources are made available to the programme. 
3. The required combination of resources is actually available. 
4. The policy to be implemented is based upon a valid theory of cause and effect. 
5. The relationship between cause and effect is direct and there are few, if any, intervening 
links. 
6. The dependency relationships are minimal. 
7. There is understanding of, and agreement on, objectives. 
8. Perfect communication and co-ordination. 
9. Those in authority can demand and obtain perfect compliance. 
This theoretical model within top-down approach to implementation research is policy 
centred, rational, prescriptive, and linear. The stages for this approach are circular: 
formulation, implementation, evaluation, and reformulation. The goals of policy makers are 
accepted as valid. The "top-down approach is useful, first in cases where there is a 
dominant public programme in the policy area under consideration or where analyst is 
solely interested in the effectiveness of a programme" (Hill 1993). Sabatier (in Hill 1993) 
goes on to say, "the concern of top-down theorists is with the manner in which legal and 
socio-economic factors structure behavioural options need to be incorporated into the 
synthesis." The top-down approach starts with a policy decision, usually by government 
officials, and then asks a series of four questions (Hill 1993). 
1. To what extent were the actions of implementing officials and target groups consistent 
with the objectives and procedures outlined in the policy decision? 
2. To what extent were the objectives attained over time (i.e. to what extent were the 
impacts consistent with the objectives)? 
3. What were the principal factors affecting policy outputs and impacts, both those 
relevant to the official policy as well as other politically significant ones? 
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4. How was the policy refonnulated over time on the basis of experience? 
The major proponents of the top-down theory are Paul Sabatier (1979) and Mazmanian & 
Sabatier (1983). The last twenty-five years has seen a large amount of research on policy 
implementation with a top-down perspective. Most of the research has been carried out in 
America and Europe. The majority of the American studies consisted in analysis of single 
case studies. Most concluded that the government had very little ability in or control over 
implementation of programmes. The second series of policy implementation studies, 
according to Hill (1993) were comparative in perspective and more analytical, but still had 
a top-down perspective. These studies, like Mazmanian and Sabatier (1983) "started with a 
policy decision (usually a statute) and examined the extent to which it is legally-mandated 
objectives were achieved over time and why." Sabatier and Mazmanian (1979,1983 cited in 
Hill 1993) assert that six conditions must be fulfilled for effective implementation. The first 
three can be influenced in the initial policy decision, while the other three are influenced by 
political and economic pressure that can occur during the implementation. If these 
conditions are met, then the behaviour of the street-level bureaucrats and target groups 
could be kept within acceptable limits. 
The six conditions for effective implementation are (Elmore, 1993): 
1. Clear and consistent objectives 
2. Adequate causal theory 
3. Implementation process legally structured to enhance compliance by 
implementing officials and target groups. 
4. Committed and skilful implementing officials. 
5. Support of interest groups and sovereigns 
6. Changes in socio-economic conditions, which do not substantially undennine political 
support of causal theory. 
Mazmanian and Sabatier (1983) applied and tested this framework to twenty-one studies in 
ten policy areas. The most important innovation of this framework is the "importance it 
attaches to -legal structuring of the implementation process" (Hill 1993). They do not agree 
with the thoughts of Lipsky (1971), Bennan (1995) and Elmore (1978) that it is inevitable 
in 'adaptive implementation' that policy-makers are forced to a large extend to accept to 
the behaviours and preferences of the street-level bureaucrats. Mazmanian and Sabatier 
(1983) reject hierarchical control. They argue that the behaviour of the street-level 
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bureaucrats can be kept within acceptable bounds if the SIX conditions for effective 
implementation were met over time. 
According to opponents there are three problems with the top-down approach to policy 
implementation. First, it is questioned if top policy makers really want to and are able to set 
clear policy goals. Second, the goals that are set are often seen as contradictory. Policies are 
layered on earlier ones. Third, the normative view of the top-down approach is questioned. 
Why should the goal setting come from the top? Furthermore, inevitably policy must be 
adapted to fit the forces backed by ground-level stakeholders and street-level bureaucrats 
(Lipsky 1991, Berman 1978; 1980, Elmore 1978). Its opponents perceive the top- down 
approach to policy implementation research as weak and unresponsive. Specific criticisms 
are of these top-down approaches that it: 
• starts from the perspective of the central decision-makers and neglects other actors 
(e.g. street level-bureaucrats) and the initiatives by them; 
• is difficult to use in situations where there is not a dominant policy or statute; 
• underestimates or completely ignores strategies used by street-level bureaucrats 
• has a distinction between policy formulation and policy implementation. It ignores the 
possibility that organisations are involved in both stages and/or local implementing 
people and target groups often ignore central legislators and administrators and deal 
directly with one another. 
b) The Bottom-Up Approach to Policy Implementation 
The bottom-up approach of policy implementation research (Hjern and Porter 1981, 
Brinkerhoff 1996) is incremental, descriptive, and iterative. The bottom-up approach first 
identifies the actors involved in service delivery (local areas) and asks them about their 
goals, strategies, activities, and contacts. Those contacts are used to develop a network to 
identify local, regional, and national actors involved in planning, financing, and the 
implementation of both governmental and non-governmental programmes. This technique 
provides the bottom-up approach a mechanism for moving from the street-level bureaucrats 
(policy -makers, and management). It is concerned with a policy problem, but not 
primarily the implementation or carrying out of the policy. The focus is on understanding 
actor interaction in a specific policy sector. 
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The scholars of this approach conducted studies from 1975 to 1983, while at the Science 
Center in Berlin, Hjern and Porter (1981), and Hanf (1982) developed a methodology for 
conducting bottom-up implementation analysis. These bottom-up theorists believe that the 
distinction between formulation and implementation is useless (Nakamura and Smallwood 
1980; Barrett and Fudge 1981; Hjem and Hull 1982). The inseparability of the formulation-
implementation process is due to: 
• Organisations are involved at both stages (formulation and implementation) 
• Implementing groups can ignore central policy decisions 
• It is difficult to isolate policy decisions and preferable to look at action and reaction 
(Barrett and Fudge 1981) 
• Policies change as they are implemented, and so is better to evaluate 'policy evolution' 
(Majone and Wildavsky 1978) 
These researchers believe that the bottom-up approach is more useful as it starts with a 
perspective of the street-level bureaucrats. The focus is on the analysis of the street-level 
bureaucrats who are the actors or stakeholders, and interact at the local or operational level. 
The focus of the bottom-up approach is on strategies that each actor uses in order to 
accomplish objectives. The studies that have been conducted showed that the actors often 
effect centrally mandated programmes in their favour to meet their own ends. Barrett and 
Fudge (198lin Hill) argue that "lower level actors take decisions which effectively limit 
hierarchical influence, pre-empt decision-making, or later policies." A case in point is 
Sabatier's (1993) comment on Hjern, Hanf and Porter (1978) study of the Swedish 
manpower training programmes, Sabatier stated the "program success was far more 
dependent upon the skills of specific individuals in 'local implementation structures' than 
upon the efforts of central government officials" 
The strengths of Hjem's approach to implementation evaluation are the explicit and 
replicable method for identifying the implementation structure, the policy network. Second, 
the method begins with actors' perceived problems and the strategies that they develop to 
deal with them. Third, it does not start with a formal policy objective and evaluating its 
attainment, so they have the freedom to see all consequences of the programmes. 
The limitations of Hjern' s approach are the over-emphasis on the ability of the street-level 
bureaucrats (periphery) to frustrate the policy-makers (centre); second, the underestimation 
of the centre's indirect influence over the strategies and goals through its ability to change 
the institutional structure in which the street-level bureaucrats operate. Third, the resources 
of the street-level bureaucrats are taken for granted without inquiring about the how and 
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why of those resources. Fourth, it fails to start from an "explicit theory of factors that 
affects the actors. It relies on the perception and activities of actors, but does not evaluate 
factors that unconsciously, but directly or indirectly affect their behaviour" (Sabatier, 
1993). 
The respective advantages of top-down versus bottom-up approaches to implementation are 
dependent on the type of policy to be evaluated. The top-down approach is preferable when 
there is a dominant public programme or a single public agency that is under consideration 
or where the evaluator is interested in the effectiveness of a programme. It is best used 
when there is a dominant piece of legislation (statute) structuring the situation or the 
research funds are limited (Sabatier in Hill 1993). The bottom-up approach focuses on local 
implementation structures and is very good for assessing the dynamics of local variations. 
This is the better approach when the focus is on the inter-local variations, there is no 
dominant piece of legislation or there are a large number of street-level bureaucrats. If the 
interest is primarily in the dynamics of different local situations, the bottom-up approach is 
preferable. 
Since the focus of this research is on the implementation of South Africa's National Drug 
Policy (dominant piece oflegislation), tools of the Standard Treatment GuidelineslEssential 
Drugs List in public hospital outpatient clinics, the top-down approach is preferable. 
This evaluation focuses on the impact, effectiveness, and outcome tools for rational drug 
prescribing in developing countries. The specific methods used will be discussed in 
Chapter Six, Methods. 
5.3.6 Intervention of Behavioural Approach to Policy Implementation 
Successful implementation of a policy should include strategies and interventions that are 
structured to meet the needs of the street-level bureaucrats/ stakeholders. The stakeholders 
translate policy into actions and ultimately outcomes. The top-down approach to evaluation 
of policy implementation does not take into account those who must implement the policy, 
even through their thoughts and behaviours can affect the success or failure of a policy. 
Widely accepted is the view that what happens in the implementation stage will influence 
the actual policy outcome. Moreover, ''there are limits to what can be achieved by 
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manipulating structures and procedures. Human behaviour and attitude must also be 
influenced if policies are to be implemented." (Hogwood and Gunn 1984) 
Policies are developed for and targeted towards a specific group to carry out its 
implementation. A good example of this is the implementation of the NDP, STGIEDL in 
public hospitals in South Africa. Often little attention and emphasis is given to implement 
the policy and actually put it into practice on a day-to-day basis. A major factor for success 
or failure is the acceptance of the policy. To achieve this, the stakeholders, the professional 
hospital staff, in this research must see a need for the change, agree to it, and then change 
their behaviour. 
Policy acceptance needs to take place at the street-bureaucrat level, because these are the 
people who deliver services to the population, who have to change their behaviour (i.e. 
rational drug use), and who implement the policy. Not all professional hospital staff and 
particularly prescribers will see and adopt the policy as their own. 
If the prescribing stakeholders resist the necessary change for the implementation of the 
policy, the policy will have a much smaller likelihood of success. Hogwood and Gunn 
(1984) state: "Those involved in implementing the policy who are targets of the policy may 
feel that they are being hustled into change because consultation has been too hurried, and 
the national reaction is to try to slow down the process by one mean or another." 
5.3.7 Strategies for Policy Implementation and Intervention 
The co-ordinated implementation model identifies three key capacities for managmg 
changes (Brinkerhoff 1991) looking outward, looking inward, and looking ahead. Looking 
outward Policy makers must see beyond the boundaries of their individual organisations 
and become aware of who and what is out there which may have an impact, or effect on 
what they seek to do. This perspective includes recognising stakeholders, facilitating 
participation, building alliances, partnerships and forging coalitions. There is often less 
emphasis on looking inward, which focuses on the internal structure, systems and 
procedures that are needed for developing or maintaining interventions, the technical 
support for the implementation of a policy. Looking ahead is the ability to keep long term 
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goals and a change in mind, while managing the short tenn and is an invaluable capacity 
for policy implementation. 
Looking inward allows the development of intervention strategies for enhancing 
implementation of a policy or programme and can be carried out on three levels: 
regulatory, administrative, and education for the design of interventions, the focus needs to 
be on improvement of an identified problem. To ascertain an effective intervention, a series 
of questions aimed at identifying the causes of the problem, the motivations and constraints 
of the hospital staff and their resistance to the necessary changed will be needed. 
The most effective interventions combine elements from all three categories. The 
regulatory approach is designed to restrict decision-making and to remove choices about a 
behaviour (drug use behaviour from prescribers), and put them into the hands of the policy-
makers and/or managers. Areas of regulatory approaches in the NDP could include market 
controls, licensing restrictions, prescribing and dispensing controls. Regulatory 
interventions are frequently easier to implement than administrative or educational 
interventions. However, "implementing a regulation without taking into account the 
understanding and acceptance of prescribers and consumers may cause unwanted side 
effects. For instance, generic prescribing policies are in place in public health facilities in 
many countries. When prescribers are not well infonned about the advantages of generics, 
they may not comply with generic prescribing. They may also transfer their negative 
perceptions to patients, which will further jeopardise the implementation of the policy" 
(International Network for Rational Use of Drugs, 1996). The administrative or managerial 
approaches use processes and tolls designed to guide decision-making. Supportive 
processes are designed to make it easier to perfonn a preferred behaviour or through 
barriers against undesirable behaviours or practices. In prescribing practices this can 
include guides for prescribing and dispensing, guidelines, clinical pathways, standard order 
fonns; systems for improving selection, procurement, and distribution of drugs; drug 
utilisation review combined with feedback to health care providers; and financial 
incentives. The educational approaches are based on communicating infonnation and 
persuading health providers (prescribers) to change their behaviour. This approach is the 
most helpful when the problems are knowledge deficit, mistaken beliefs or biased 
infonnation. Behaviour and opinions of peers can be very persuasive in changing 
behaviour. This intervention can be very useful if it is used in peer groups of health 
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providers. Each approach has vanous strengths and weaknesses (Table 5.1). These 
interventions work best when they are combined. Any intervention will need a sustained 
and additional effort, support, and refinements. Interventions need to be monitored, 
evaluated and the results disseminated so that adjustments can be made to the intervention. 
Table 5.3 Strengths and Weaknesses ofIntervention Approaches 
Intervention Strengths Weaknesses 
• Works best ifsafety is an issue, and • Frequently produces 
Regulatory problem behaviours are easy to isolate unexpected negative results 
Strategy and eliminate • May be open to abuse 
• Frequently easy to implement • Often difficult to enforce 
• Can give powerful and rapid results • Impact difficult to measure 
• Best if combined with other approaches 
• Works best when systems can be set up • Open to abuse if administrative 
Administrative to make it easier to follow changes are not accepted by 
Approaches recommended behaviours target group 
• Can be used to support and sustain • Formularies, guidelines, 
educational programmes protocols needed periodic 
• Very effective if target group assessed revision 
own practices • Information systems may be 
• Improved supervision can have positive hard to establish and maintain 
spin-off effects 
• Works best if knowledge deficits are an • Knowledge often cannot 
Educational underlying problem overcome system barriers 
Approach • Best results if message is clearly • Disappointing results with 
focused on specific issue broad messages and large 
• More effective with single individuals groups 
or small groups • Can be labour intensive if there 
• Repetition and reinforcement of is a large target group 
messages strengthens results • Transfer of staff or counter-
promotion by drug companies 
can dissipate results 
Source: INRUD (1996) How to Use Applied QualitatIve Methods to DeSIgn Drug InterventIons 
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5.4 Rational Drug Prescribing 
5.4.1 Introduction 
This section reviews the literature on rational drug use by health professionals and the 
interventions that aid in changing prescribing behaviour. The use of medication in both 
developed and developing countries often reveals a large discrepancy with principles of 
clinically acceptable practice. In developing countries the misuse of medicine ranges from 
travelling drug peddlers and street shops to prescribers in teaching and tertiary hospitals. 
Some of the commonly encountered inappropriate or irrational drug uses of prescribers 
include (International Network of Ration Use of Drugs - INRUD, 1996): 
• Excessive use of injections where oral treatment is more appropriate; 
• Multiple drug prescriptions, such as the use of several items for one condition; 
• The use of drugs when no drug is indicated; 
• The use of the wrong drug for a specific condition requiring drug therapy; 
• The unnecessary use of drugs with adverse effects; 
• The use of overly expensive drugs with cheaper alternatives. 
The public health consequences of inappropriate or irrational drug use include (INRUD, 
1996): 
• Increased morbidity and mortality due to avoidable treatment failures; 
• Increased risk of unwanted effects such as adverse drug reactions; 
• The emergence of drug resistance such as Chlorolquine-resistance Plasmodium 
Falciparum and Penicillin-resistant gonococci; 
• Waste of resources leading to increased costs and reduced availability of other 
vital drugs; 
• Psychological effects such as when patients come to believe that there is "a pill for 
every ill" which may increase demand for drugs. 
For many of the Third World countries, the main lssue is still how to improve the 
availability of essential drugs, but rational drug use does not appear to be a priority for 
many governments (WHO, 1988). To date, in 2002 that has not changed. Hodgkin (1993) 
states that "rational drug policies and rational drug use are an important part of primary 
health care in both developing and industrialised countries, but the consequences of 
irrational drug use are much more serious in situations of extreme scarcity." According to 
WHO, "The rational use of drugs remains an area where progress is needed. There is no 
good system for providing objective information. In most countries, adverse reactions are 
not monitored and continuing education is not carried out systematically, 94% of the 
countries are at level 1 for this indicator" (WHO report, 1988). Level 1 is the lowest level: 
"Continuing education is not systematic." 
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The contextualising, according to Kanji et al (1992) of 'rational drug use' is a major 
challenge to (WHO) DAP. It implies that criteria for 'rationality' cannot be defined at the 
national level and then applied at the district and local levels of health care. It emphasises 
the need for a 'bottom-up' approach to community participation, and methods that are 
advocated for health education in the context of PHC. In order to address the issue of 
rational drug use many governments have emphasised the need for further training for 
health personnel in health policy reform and the National Drug Programme and the use of 
the Standard Treatment Guideline I Essential Drugs List (STGIEDL). The essential drug 
concept meets with substantial resistance from those street-level bureaucrats who are to 
carry it out. 
The availability of drugs is only one barrier to drugs getting to the population. Indeed, 
Foster (1991) states that "In the past few years, it has become increasingly clear that simple 
availability of drugs does not always solve the problem of drug use, and indeed, it often 
appeared in retrospect that supply wasn't the problem after all." Hogerzeil, (1991) agreeing 
with this view states, "adequate knowledge on rational drug use does not always result in 
rational prescribing behaviour. Actual behaviour is therefore preferred as a measurement." 
Hogerzeil (1995) concludes that, "Irrational prescribing is a global problem." Moreover, 
the use of the STG/EDL is not sufficient by itself to change prescribing behaviours. 
Training in the use of the STGIEDL, stock management, and rational drug use are all 
needed to allow health staff to meet the required changes. In addition other interventions 
including regulatory, and administrative or managerial approaches help to make a 
comprehensive, therefore, more likely successful intervention. 
In 1993, WHO for the first time applied internationally developed indicators to investigate 
drug use in facilities. Before this innovation, indicators for the rational use of drugs were 
difficult to identify (WHO, 1988). It is not possible to quantify rational use per se; it has 
been assumed that certain mechanisms have an influence on the use of drugs before the 
development of indicators. Before the development of indicators, Rational Drug Use was 
measured by these mechanisms (WHO, 1988): 
• A functioning system that regularly provides objective information on drugs to 
health workers and patients. . 
• A system of continuing education for personnel dealing with drugs. 
• A monitoring system, covering adverse drugs reactions, and post-marketing 
surveillance. 
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5.4.2 Interventions to change prescribing behaviour 
Indeed, changing prescribing habits is very difficult. The interventions to promote rational 
drug prescribing can be classified in three categories (Hogerzeil 1991) managerial, 
regulatory and educational. Managerial interventions include restrictions on prescribing, for 
example with a restrictive list, a maximum number of drugs per prescription, budgetary or 
cost restrictions and hospital therapeutic committees. Regulatory interventions include 
procedures to evaluate drugs and product information before market approval is granted; 
specifying a minimum level of prescriber or health facility for each drug or scheduling 
drugs for different sales levels. The educational interventions include objective printed 
materials and bulletins, seminars, and face-to-face interventions. Hogerzeil (1991), 
remarked that "An important observation is that printed materials alone hardly influence 
prescriber behaviour, and that any such influence is usually of short duration. Most of these 
interventions assume that the main reason for incorrect prescribing is a lack of knowledge 
and that if prescribers had the correct information, their prescribing would automatically 
improve. This is not always the case in view of the many other factors influencing 
prescribing, like drug promotion, patient demand, international use of placebo drugs and 
prescriber preference based on personal experience rather than peer reviewed standards." 
"The provision of independent sources of both written and oral information on drugs to 
doctors can have a significant effect on prescribing"(Hodgkin 1993). According to Marinka 
& Reilly (1994), a framework of information to facilitate rational prescribing is needed: 
• Class, generic names, and proprietary name of drug 
• Therapeutic actions 
• Data about unwanted effects and interactions 
• Indications and contraindications 
• Recommended doses and regimes 
• Costs 
• Significant differences from previously established drugs in the same class, or drugs 
with almost identical therapeutic intentions 
• A risk-benefit analysis 
• A cost-benefit analysis 
"Both developing and industrialised countries are taking measures to promote rational 
prescribing. Formularies, therapeutic guidelines or limited drug lists are used to influence 
prescribing in advance and monitoring and auditing of prescriptions are due to evaluate in 
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retrospect, prescribing practices. Proven cost-effective interventions are face-to-face 
education focus on a particular prescribing problem in selected individuals, structured 
prescription forms, and focused educational campaigns together with widely discussed and 
frequently discussed guidelines." (Hogerzeil, 1991). Prescribing is assumed to be more 
rational if specific indicators have lower values. These indicators were used in a 10-country 
study for the external evaluation of Drug Action Programmes (DAP) of WHO. Various 
patterns of a lack of rational drug use were found. Moreover, "All the country studies 
showed that there was a lack of training and information on the rational use of drugs and 
that irrational use was therefore to be expected" (Kanji et al. 1992). Various groups in 
South Africa have initiated several programmes to encourage rational drug use for 
prescribers. The programmes have included the "Rational Drug Prescribing Training 
Program " (since January 1996); "Promoting Rational Drug Use" (27 March - 7 April 
1995); "Introduction to Effective Prescribing Course" (13-15 August 1996). The longest 
running programme is the "Rational Drug Prescribing Training Project." It is a "train-the-
trainers initiative that has been running since January 1996. It aims to encourage all 
prescribers at primary care level, be they nurses, pharmacists or doctors, to prescribe and 
dispense medicines in a safe, efficient and cost effective manner" (Orrell 1997). 
The most effective training strategies (Table 5.2) to change prescribing behaviours are: 
Feedback with recommendations (Drug Utilisation Reviews) and Peer Group audit, for 
example a hospital Pharmaco-Therapeutic Committee (PTC). 
Table 5.4 Summary of the impact of different educational strategies 
Educational Strategy Knowledge Prescribing Costs Outcomes 
Printed material, 0 
Individualised Face-to face + ++ ++ 0 
Lectures + + + + 
Raw feedback of data + • 
Peer group audit * + 0 + 
Feedback with 
Recommendations ++++ ++ • 
(DUR) 
Cell indicators: +(positive result); - (null results); 0 (inconclusive); * (no studies in this category) 
Source: Davis (ed.), (1997:78) Contested Ground. New York: Oxford University Press. 
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Drug Utilisation Studies (DUS) can be used to measure the various types of prescribing 
behaviour interventions. In addition to training, Pharmacy and Therapeutic Committees 
(PTC) can be used to change prescribing behaviour. One objective of the NDP is to 
establish and strengthen Pharmacy and Therapeutic Committees in all hospitals in the 
country (both public and private) in order to ensure the rational, efficient and cost-effective 
supply and use of drugs. These therapeutic committees will consist of at least a senior 
pharmacist, a senior nurse, a senior financial officer and senior clinicians or their 
nominated representatives in their absence. Their terms of reference includes responsibility 
for: 
• the accurate estimation, prompt procurement and optimal storage and supply of drugs 
and medical supplies 
• the compilation and preparation of a hospital Formulary 
• cost-effective drug use 
• proper staff establishments to carry out these functions 
In short, changes in the prescribing habits to incorporate rational drug use, according to 
Foster (1991) would allow for the "possibilities for significant savings in most areas of 
drug supply management and use. Potential savings from individual rationalisation 
measures range from 10% -60% or more. The biggest gains appear to come from better 
procurement and better prescribing." 
As South Africa is still in the process of transforming its pharmaceutical policy, the issue 
of Rational Drug Use needs be at the forefront of implementation interventions. Kanji, et al 
(1992) stated in the forward of his book, Drugs Policy in Developing Countries, "It is 
important to raise the issues involved in promoting rational drug policies, especially now 
that Eastern Europe and South Africa are planning their new health systems." 
This section reviewed the overvlew of rational drug use, prescribing behaviours, the 
framework of information to facilitate RDU and strategies for improving the acceptance of 
the National Drug Policy and the use of the STG/EDL. 
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CHAPTER SIX 
METHODS 
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6.1 Introduction 
The scope of the study is the National Drug Policy (NDP), and Essential Drug Programme 
(EDP) is implemented in South Africa. It focuses on the question in how far rational drug 
prescribing and dispensing is implemented by staff in public hospital outpatient clinics (for 
adults). According to Kanji et af (1992), "looking at prescribing practices in government 
health care centres seems to be the most obvious way of measuring the rational use of 
drugs. It is through these centres that governments intend to increase the availability of 
essential drugs. Education and training are most commonly directed at health centre staff 
and health centres often keep record of patients and prescription which can be assessed 
retrospectively." 
To this end, this study focuses on those who implement the EDP and use the Standard 
Treatment GuidelineslEssential Drug List (STGIEDL) in the public hospital clinics of 
South Africa. The rationale for this focus is that the successful implementation depends on 
those who must know, understand and accept, and put into practice the EDP agenda with its 
use of the STGIEDL as its comer stone. The prescribers must change their behaviour in 
order to carry out the NDP rational drug use objectives. For those stakeholders, political 
jostling and competing agendas and the struggle for professional territory, autonomy, and 
power is likely to make the implementation of the STGIEDL extremely difficult. The 
National Department of Health (NDOH) has limited the amount that can be spent on drugs 
that are not generic or on the EDL. 
The 'ten-percent' cap on ordering brand drugs not on the EDL should result in changes in 
the drug budget in ordering, prescribing behaviour, and rational drug use. The ten-percent 
cap is one of the administrative/managerial and regulatory/legislative controls that have 
been adopted to change prescribing. The extent of the change in prescribing behaviour 
with regards to this 10% cap is a focus of this study. 
This research takes a look at the intent of the NDP policy and the reality of its 
implementation. The NDP implementation is evaluated by looking at the policy intent, with 
rational drug use as its main goal, and the actual practice at hospital level, and the reasons 
for this discrepancy. The prescribers may fear a loss of autonomy and a reduction of their 
effectiveness in treating patients. The implementation of the NDP should take into account 
these grass root stakeholders. In the final analysis, staff co-operation is the essential in 
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order to fully and successfully implement the NDP. The most difficult aspect of any policy 
is to attempt to change the behaviour of those involved. 
This study looks at the EDP implementation, a policy that was conceived on a national 
level but must be adopted on a provincial level and carried out by individuals on a local 
level, by physicians, nurses, and pharmacists. Hill (1993) asserts that "on methodological 
grounds, implementation is better studied by looking at the efforts of those at the bottom to 
make sense of these new inputs from the top". This implementation is evaluated through 
qualitative and quantitative methods. Quantitatively, this research uses survey drug 
utilisation indicators, developed by WHO and International Network of Rational Use of 
Drugs (INRUD). These drug utilisation indicators have been used in many countries, 
including Africa, Zimbabwe, Zambia, Mali, and South Africa, to both evaluate and monitor 
National Drug Policies. This study will encompass the top-down approach to the evaluation 
of policy implementation (Sabatier & Mazmanian 1979, Sabatier 1986, and Mazmanian 
1983). Qualitatively, this study evaluates the implementation of the NDP through open in-
depth interviews with hospital' clinic personnel and administrative stakeholders. The 
Knowledge, Attitudes, and Practices (KAP) of health professionals will be evaluated 
through these interviews. Consumer stakeholders were not included in this study. The three 
reasons that consumer / patients were not included are first, there was not a public 
education campaign about the use of generic medicines or the use of the EDL. Second, 
among those in the Northern Province there is a high literary rate, which would make using 
questionnaires quite difficult. Third, the consumers speak a variety of languages that would 
require the use of an interpreter. 
6.1.1 Research Questions 
The main question this research addresses is, "Has the implementation of South Africa's 
National Drug Policy, published in February 1996, with the introduction of the Standard 
Treatment Guidelines20 !Essential Drugs List in 1998,21 resulted in rational drug 
prescribing22 in South Africa's public hospital outpatient clinics?" 
20 Standard Treatment Guidelines (STG) was developed in 1997 for adult care. 
2! Essential Drugs List (EDL), comprised of300 drugs linked to standard treatment guidelines for use in 
hospitals. As of December 1998 there are three STGIEDL's one each for adult, paediatric and primary health 
care, but only the adult list was used for this research. 
22 Rational Drug Use / Prescribing is defined as "patients receive medicines appropriate to their clinical needs, 
in doses that meet their own individual requirements, for an adequate period of time, and at the lowest cost to 
them and the community." WHO, The Rational Use of Drugs, Report of Conference of Experts, Nairobi, 25-
29 November, 1985. 
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A policy analysis implementation approach guides this research of National Drug Policy 
("getting medicines to the people") implementation within a developing country. The 
National Drug Policy was formulated on the national level by the government stakeholders, 
implemented on the provincial level by local department of health, and to be adopted at the 
point of service by prescribers. 
The current political and legislative climate in South Africa continues to be fluid. Indeed, it 
is characterised by fast changes driven by politics within the context of health care reforms, 
including the NDP. 
The framework for this research is a prospective policy analysis of the impact of NDP 
implementation. It adopts a policy analysis model of implementation with one focus on the 
behavioural approach. This model provides a basic and fundamental framework for 
considering the complex and often non-transparent inter-relationships between a number of 
stakeholders. 
This study employed both quantitative and qualitative methods to evaluate both the impact 
of the implementation of the NDP with structural, process and outcome indicators and the 
knowledge attitudes and practice (KAP) of prescribers. The cross sectional study evaluates 
the implementation of the National Drug Policy (1996), Standard Treatment Guidelines 
!Essential Drugs List and its' impact on rational drug prescribing in South Africa's public 
hospital clinics. 
In linking theory with field research the study focuses on three inter-linking approaches. 
The approaches of top-down, behavioural, and intervention policy implementation have 
been adopted. This study encompasses the top-down approach to implementation 
evaluation (Sabatier & Mazmanian 1979, Sabatier 1986, and Mazmanian 1983) that starts 
with a policy decision, usually by government officials, and then asks a series of 4 
questions (Hill 1993): 
1. To what extent were the actions of implementing officials and target groups consistent 
with the objectives and procedures outlined in the policy decision? 
2. Is the impact consistent with the objectives? 
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3. What are the principal factors affecting policy outputs and impacts, both those 
relevant to the official policy as well as other politically significant ones? 
4. How was the policy reformulated over time on the basis of experience? 
The behavioural approach asserts that a successful implementation needs to include 
strategies and interventions that are structured to meet the needs of the stakeholders, who 
translate policy into action, and ultimately outcomes. Stakeholders' thoughts and 
behaviours can lead to success or failure of a policy. In this study attention and emphasis is 
placed on evaluating the extent to which prescribers believe that they are active participants 
in the policy implementation. 
The intervention techniques to change prescribing behaviour are administrative, managerial 
and educational. Information and training are needed. Evaluation of the availability and 
type of managerial and educational interventions is an important part of this research. 
In summary, the methods used to examine the implementation of the NDP policy is through 
both qualitative and quantitative methods. Qualitative methods are according to Mays and 
Pope (1999 &2000) "especially useful in looking at health services in terms of reform or 
policy change from the point of view of the patients, professionals and managers affected." 
Health care reform, and the rapid revision of legislation and the rapid implementation of 
new policies along with the fluidity of the political climate are some of the factors that 
make this research complex. In this environment the qualitative material can provide 
clarification not only of what is happening, but also why it is happening. The qualitative 
description is a prerequisite of good quantitative research, particularly in areas that have 
received little previous investigation (Mays and Pope, 1999 & 2000). This study evaluates 
the implementation of the NDP through twenty interviews with hospital clinic personnel 
and administrators who allowed for a more detailed and varied evaluation of health 
professionals' knowledge, attitudes and practices (KAP). In addition, well-recognised 
survey of indicators developed by WHO and INRUD was used. 
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6.1.2 Aim 
This research addressed the void of objective information and gives an evaluation of the 
implementation of the National Drug Programme in developing countries, and in particular 
the use of tools such as the Standard Treatment Guidelines!Essential Drug List to impact 
rational drugs prescribing. Thus the aim of this research is to describe and analyse the 
processes of the implementation of the NDP and the STG!EDL (adult hospital version) and 
its impact on rational drug prescribing in public hospital outpatient clinics. 
6.1.3 Objectives 
The four objectives of the research are focused on the description analysis of the processes 
and the impact of the implementation of the NDP. 
1. Survey and analysis of rational drug use patterns of prescribers of various levels of 
outpatient hospital clinics. 
2. Assessment of the knowledge, attitudes and practices (KAP) of health personnel 
(physicians, nurses, pharmacists, and administrators) toward the implementation of 
the NDP and their training in the use of the STGI EDL. 
3. Identification of factors, which facilitate or hinder the proposed implementation of 
the use of the STG !EDL for rational drug prescribing within various levels of 
outpatient hospital clinics. 
4. Examination of the policy implications of the research findings. 
These four objectives have been met through several research methods that include primary 
and secondary data evaluation. The data are collected using the National Drug Policy 
Indicator Survey, observation and interviews. The data analysis is through the evaluation of 
the prescription data. Based on the findings of this study and after review of key 
documents, implementation interventions have been developed with will be useful for 
further improvement of the NDP implementation. 
T bl 61 a e . R esearc hOb' f 'Jec lve an d 1\1 th d G 'd e o s rl 
METHODS Data Collection in Data Analysis 
Outpatient Clinics 
OBJECTIVES 
l.Analysis of rational drug use NDP Indicator Survey Evaluation of prescription data 
2. Analysis of knowledge, Open In-depth Interviews Analysis of interviews and 
attitudes and practices (KAP) Non- participant observations 
Observation 
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3. Identitication of factors In-depth interviews with Analysis of interviews and 
which facilitate or prevent stakeholders observations 
proposed implementation of the 
STGIEDL Non-participant 
Observation 
4.Policy implications of the Open In-depth interviews Document analysis 
research fmdings. and result meetings with 
stakeholders 
6.1.4 Hypotheses 
The four hypotheses that have guided this research are: 
1. The use of the Standard Treatment Guidelines / Essential Drugs List will result in 
an increase of Rational Drug Prescribing (RDP) in public hospital clinics at all 
levels. . 
The NDP implementing agencies: 
South African Drug Action Programme (SADAP), the 
National Department of Health (NDOH), and the 
Northern Province Department of Health (NPDoH) 
2. explicitly communicate the objectives and methods for implementation of the 
STGIEDL to the Head of Pharmaceutical Services (HOPS), Provincial Essential 
Drugs Co-ordinator (PEDCO) and personnel, who are to carry out the policy. 
3. The implementation agencies' objectives, organisational structure, and programme 
plans reflect their goal to promote the use of the STGIEDL for RDP at all levels in 
the provinces in addition to providing training in its use. 
4. Training and support for Rational Drug Use, specifically prescribing are encouraged 
and provided for all professional staff who are a part of the chain in the provision of 
medicines to the population. 
6.1.5 Study Design 
This study was designed to furnish both quantitative and qualitative information with 
interviews and observational and statistical data techniques. The field research design 
covered three approaches: (a) the application of a statistical sampling procedure for the 
drug utilisation study (b) participant observation at selected hospital clinics and 
pharmacies; and (c) the interviewing of physicians, nurses, pharmacists and administrators. 
6.1.6 Research Design to Effect Policy 
A longitudinal design would have allowed for the evaluation of the long-term effects of a 
policy. Specifically, if the policy and desired outcome and its applied changes last over 
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time, the best longitudinal studies are before and after an intervention for example (the 
NDP's, STGIEDL for hospital adult level). The longitudinal study design is said to be able 
to show 'the natural growth and trace patterns of change in the individual', and it is also 
asserted that it is the only method which can give a 'true picture of cause and effect of 
relationships over time (Kransz & Miller, 1991). 
Since, a longitudinal study was not practical, the cross-sectional method was chosen 
because of limitations of time and resources, and a need for timely results to allow policy 
makers to change the policy implementation or content. According to Krausz & Miller 
(1991), "The cross-sectional design involves picking different samples or respondents, all 
the samples together providing thorough comparison evidence of relationships between 
variable or evidence of cause and change." This allows for sampling over a wide range of 
groups in order for the results to be applied generally. The research techniques employed 
were based on a cross-sectional study that encompasses three levels of hospital clinics: 
primary, secondary and tertiary and a variety of health personnel, administrators, 
pharmacists, nurses and doctors. Also this cross-sectional study collected data in eleven 
public hospital outpatient clinics in the Northern Province of South Africa. 
6.1. 7 The Case Study 
The study employs a case study approach. Case study evaluations are valuable where 
broad. Questions have to be addressed in complex circumstances. No one method is 
sufficient to capture all the important aspects of an intervention, and case studies typically 
use multiple methods. The case study approach is "most valuable when the question being 
posed requires an investigation of a real life intervention in detail, where the focus is on 
how and why the intervention succeeds or fails (Mays and Pope, 1999 & 2000). In 
addition, several methods that complement the case study were employed including a 
survey of drug utilisation, in depth interviews, non-participant and structured observation. 
6.1.8 Provincial Site Selection Criteria 
Ideally, the study would be a cross-sectional study within all nine provinces. Failing this, it 
would be desirable to have from at least two provinces. After consultation with several 
people in South Africa, the Northern Province was selected for the following reasons: The 
Northern Province has both urban and rural settings with a large population of Africans, 
who lived in former homelands. In addition, the Northern Province has the infrastructure, 
experience, and co-operation of research before and since the implementation of the NDP 
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in 1996. Approval for this research was obtained from the Provincial Department of Health 
for this research. 
6.2 Research Methods and Tools 
In light of the objectives, hypotheses and research questions a mixture of quantitative and 
qualitative methodologies were chosen for this research to allow the cross validation of 
data with triangulation. The tools used include document analysis, an NDP survey, open in-
depth interviews, structured and non-participant observation. The quantitative method of 
the NDP indicator survey was used to supplement the qualitative data of interviews and 
observation. In triangulation three or more methods are used and the results are compared 
for convergence or as part of a multi-method approach which examines a particular 
phenomenon or topic on several different levels (Mays & Pope 1999 & 2000). The 
triangulation of methods that was used in this research is a survey of rational drug use, 
participant and non-participant observation in pharmacy and therapeutic committees, open 
in-depth interviews of hospital personnel. 
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TABLE 6.2 RESARCH QUESTIONS AND METHODS 
Questions Data Collection Method Sources 
Rational Drug Use 
1. What are the prescribing RDU Survey, Patient Records 
behaviours in Clinics?· 
2. Prescribers using STGIEDL (%)? RDU Survey, Observations Clinics 
3. Which drugs are out of RDU Survey Pharmacy records 
stock on the day of the survey? Inquiry of staff 
4. Change of prescribing 
behaviours? KAP, Interviews Prescribers 
5. What is the Attitudes, Knowledge, 
Practices towards the EDL? KAP, Interviews Prof. Staff 
6. Is training & support in RDP 
given to staff? KAP, Interviews Prof. Staff 
7. What are the factors that facilitate or 
prevent STGIEDL adoption? KAP, Interviews Prof. Staff 
STG/EDL Guidelines 
8. Is the STGIEDL being used Observation Prescribers 
on a regular basis? 
9. Is impartial drug Observation Prescribers 
information available? 
Are prescribing books 
used regularly? Which books? Observation Prescribers 
National Drug Policy 
11. What is the impact of the NDP KAP, interviews Prof. Staff 
on RDP in public hospital clinics? 
12. Have NDP implementing agencies Secondary 
communicated the objectives and Objectives, Reports SADAP 
methods for implementing NDP to 
PEDCO, administrators, clinic personnel? 
Notes: 
Eleven prescribing indicators are Mean number of drugs, >2 drugs per prescription, percent generic, percent 
on EDL, percent Brand on EDL, percent of antibiotics, percent analgesic, percentage of injections, chronic 
illnesses: asthma, diabetes, and hypertension. 
RDU Survey: Rational Drug Use Survey, KAP: Knowledge, Attitude and Practice 
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6.2 Methods and Tools 
6.2.1 Sample 
The following sampling method was used fot the RDU survey in order to produce a 
representative sample of prescriptions. Three stratifying variables for the selections were 
the hospital care level (primary, secondary, tertiary), size (number of population served), 
the type of population served during apartheid (race) and geographical area (region) within 
the Northern Province. "In most of the countries, depending on the size of the 
region/districts, four to five geographical units are normally sufficient." (WHO, 1994). 23 
The hospitals were pre-selected according to the level of service into Tertiary (academic), 
secondary and primary, the size, the inpatient beds and the out patient department number 
for both month and year, and the geographical area: the region where the hospital is located 
(seven areas in total). The sample was designed to include hospitals at each level, and size 
in each geographical area. 
6.2.2 Sample Size: 14 
The research sample size is 1,204 prescriptions from eight predetermined hospitals. Of the 
hospitals, there is at least one located in six of the seven regions within the Province. All 
three levels of hospitals (primary, secondary, and tertiary), poli and specialty clinics were 
sampled. The hospitals were chosen on the basis of the region, the former racial status, 
inpatient and outpatient numbers. Finally, the hospital clinics were chosen to represent 
large, medium and small hospital inpatient beds and outpatient clinics. Of the thirty-six 
primary (community) hospitals, three were chosen. The secondary or regional hospitals are 
seven in total and three were chosen. The tertiary (academic) hospital complex is two 
physically separate hospitals in two very ethnically and economically different areas. Both 
hospitals were surveyed. Also there are twenty interviews from professionals: nurses, 
doctors, pharmacists and administrators, from one hospital at each care level (primary, 
secondary and tertiary). 
23 WHO, Indicators for monitoring national drug policies, 1994. 
24 WHO, Indicators for monitoring Drug Policies, recommends a sample of at least 100 prescribers. For 
Prescriptions take the first 30-100 or every 1 in 3. 
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6.2.3 Method one: NDP Indicators Survey 
(Collection of prescription data: Rational Drug Use Survey) 
A. Pre-Data Collection Contact with Hospitals 
The NDP Indicator Survey (WHOIDAP/94.12) with the Rational Drug Use (RDU) Survey 
was carried out at all hospital levels. Six hospitals of the eight in the study were visited 
before the research data collection day. In most cases formal in-person introductions were 
made to various hospital administrators and health care staff. These included the Medical 
Superintendent or the Medical Director of the hospital, the Head Matron or Head Nurse, 
and the head pharmacist. 
Additional introductions were made in-person or by phone by the NP-DOH Research Co-
ordinator, Sinah Mahlangu. In most cases the Superintendent or Matron introduced me to 
the head pharmacist and gave them a summary of the research that would be carried out 
and more importantly, an informal personal approval to encourage pharmacists' co-
operation. Each head pharmacist orientated me to the process that the patient goes through 
from registration at the clinic to the pharmacy. All administrators and pharmacists at the 
hospitals were told that I would be back within a few weeks or months in order to collect 
the data for one day. The actual data collection day was not announced to the staff of the 
hospital so as not to influence prescribing behaviour. 
During the visits to the hospital clinics, I observed that the record keeping methods ranged 
from the most sophisticated with the use of computerised data with base code readers to the 
most basic use of blank white paper in files without basic patient information. None of the 
hospitals had a data base system that would allow the data to be chosen retrospectively, for 
example for a particular day, month or clinic. In all the hospitals the patients' records 
would go through the pharmacy in order for medications to be dispensed. I concluded that 
it was best to collect the prescription survey data at the service point of the pharmacy, as 
the records came in during one entire day of the clinic and pharmacy hours. 
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6.2.4 Rational Drug Use Survey (RDU) 
Rational Drug Use Survey allows the quantitative assessment of the adoption of the NDP 
through prescribing. "Today the most commonly used indicators for assessing prescribing 
practices are average number of drugs per prescription, percentage of prescriptions 
containing antibiotics and percentage of prescriptions containing an injection. The choice 
of these indicators had been conditioned by (a) the relative ease with which the data can be 
collected and (b) the excessive use of antibiotics and drugs injected. This is because the 
main problem associated with drug use related to over-prescribing. Thus, prescribing is 
assumed to be more rational if these indicators have lower values." (Kanji et al. 1992:98-
99) 
Outpatient prescriptions were included in this evaluation of RDU, while in-patient were 
excluded because the prescriptions used to ascertain the most common patient prescriptions 
instead of the patients who are the sickest within the inpatient setting. The hospital clinics 
listed in Table 6.3 were used for the RDU study and interviews of the professional staffs. 
Cross-sectional prescribing data were collected giving a quantitative picture of prescribing 
patterns. These RDU survey data were collected during an entire day (8am to 5pm) at the 
pharmacy. The first patient usually came to the phannacy no earlier than lOam, after a 
consultation with a nurse and/or physician. Before the first patient arrived with his/her 
patient file, I met with the head pharmacist and asked him to inform their staff about my 
presence and the research. 
The goal of the research was explained and also the procedure that all patient files should 
be kept until the appropriate information was extracted and a copy of the prescription 
taken. The prescriptions and diagnosis pages were copied throughout the day at the facility. 
Once this was done the patient was given the file back if it was needed. Using this method, 
only very few files were lost. 
All patient records were evaluated for appropriateness for the study, excluding pre-or-post-
natal visits, children under 14 years old and in-patients. All appropriate records collected at 
the point of the pharmacy when the patient dropped off the record or waited to full a 
prescription, it was copied and given a unique number (1-1,286) in order of collection. In 
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addition, information on age, gender and diagnosis, were either copied or written on the 
copied prescription page. On the RDU survey day, the pharmacy staffs were asked to help 
with the interpretation of the handwriting of the prescriptions. Each pharmacy kept a one-
day summary sheet of the number of clients seen and the number of medicines given. A 
copy of this form was obtained for each research day at the particular hospital. This sheet 
was used for initial evaluations of the total number of clients and the initial calculation of 
drug utilisation. 
This drug utilisation study with rational drug use survey was carried out between 
September 1999 and January 2000. The data were collected during a workday at the 
pharmacy. The eight hospitals with eleven clinics, chosen are in different regions, their 
staff and clients have different socio-economic, ethnic and racial makeup, and the hospitals 
differ with respect to inpatient bed number, outpatient number and patient numbers treated 
per year (Mahlangu, 1998), and the services offered (Table 6.3). 
Table 6.3 ital Clinics (Se tember 1999- Janua 2000) 
LEVEL NAME BEDS OPDlxear REGION DAY 
District Van Velden 50 15,540 Lowveld 20 Jan .. 
Primary F H Odendaal 201 17,477 Bushveld 12 Nov. 
Jane Furse 434 51,540 Southern 6 Oct. 
Regional Mokopane 340 31,168 Western II Nov. 
Secondary St. Rita's 334 100,579 Southern 5 Oct. 
Tshilidzini 450 119,247 Northern 140ct. 
Central: Pietersburg 530 85,741 Central Sept. &. 
Tertiary Mankweng 440 58,148 Central Oct. 
The three primary care hospitals surveyed ranged from small to large, but all have only 
policlinics. The smallest hospital Van Velden hospital with 50 beds, and 15,540 outpatients 
per year was once a segregated hospital in a majority white area in the Lowveld region. F H 
Odendaal hospital in the BushveId region is a hospital has 201 beds and 17,477 outpatients 
per year. These two previously segregated hospitals are located in white-majority 
population. These hospitals have the lowest of outpatients of all the hospitals surveyed. The 
third primary hospital surveyed was Jane Furse hospital, a former religious order hospital 
for the non-white poor popUlation in the Southern region. It has 434 beds and 3 times more 
outpatients, than the other hospitals surveyed. 
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The three secondary care hospitals chosen were previously segregated black hospitals. 
Mokopane Hospital in the Western region had 340 beds, and an outpatient number of 
31,168, while St. Rita's Hospital in the Southern region has 334 beds, but see three times 
more outpatients. The Tshilidzini Hospital in the northern region has 450 beds and 119,247 
outpatients are seen. The two tertiary care academic hospitals officially form one complex, 
but are located more than a thirty-minute drive from each other in two very different areas. 
Pieters burg and Mankweng tertiary hospital complex are both located in the Central area in 
the city of Pietersburg, the largest city in the Northern Province. However, the Pietersburg 
Hospital is located in the city centre, while Mankweng Hospital is located outside the city 
centre in a former black homeland area. 
The two hospitals are very different and managed separately with few shared staff or 
clientele. Both Pietersburg and Mankweng hospitals have Medical Directors who both are 
black African expatriates. Pietersburg hospital has been a traditionally segregated 'whites 
only' hospital that still has a high percentage of white clientele. It has two physically 
separate outpatient pharmacies, one for general clinics and the other for special clinics (e.g. 
oncology). Pietersburg Hospital has 530 beds and had 85,741 outpatients in their policlinics 
and their many specialty clinics that include oncology, neurology, surgery, obstetrics and 
gynaecology, Ear, nose and throat, psychiatry, tuberculosis, ophthalmology, dental, and 
others). The Mankweng hospital has been a traditionally black hospital that still has an 
exclusively black clientele. It only has a few specialty clinics, which are geared more 
towards primary health care. Mankweng hospital has 440 beds and 58,148 outpatients. 
All the hospitals surveyed, except one, had a head or managerial pharmacist. Pieters burg 
Hospital had the highest number of specialty physicians and also pharmacists (auxiliary to 
managerial). On the days of data collection Pietersburg Hospital had more than 30 
pharmacy staff, while Mankweng had five. All except one of the other secondary and 
primary hospital pharmacies had between two and five total pharmacy staff. Tshilidzini 
Hospital had the most under-staffed pharmacy with only two pharmacist- assistants who 
serviced about 250 outpatient clients daily. Also one other secondary hospital pharmacy in 
Jane Furse hospital was exceptional in staff numbers, with thirteen pharmacy staff, but only 
one educated and licensed pharmacist who had been qualified for less than a year. 
6.2.5 National Drug Policy (NDP) Implementation Indicators 
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The National Drug Policy (NDP) indicators and questions (Appendix K) developed by the 
World Health Organization 1 International Network of Rational Use of Drugs 
(WHO/INRUD) has been used in a twelve country comparative study. It has also been used 
in studies conducted in South Africa over the last several years (Moller & Summers, 1996, 
Moller, 1998) Evaluation and analysis of National Drug Policy Indicators25 serves two 
purposes in this research. First, it assesses the implementation of the NDP by measuring 
progress in key components with structural and process indicators. Second, it evaluates the 
outcome ofNDP with outcome indicators. 
6.2.6 Additional NDP Survey Outcome Indicators for Chronic Diseases 
(Hypertension, Asthma and Diabetes) 
The South African governments Reconstruction and Development Programme (RDP) and 
the NOOH have chosen three major chronic diseases as priority chronic diseases. These are 
hypertension, diabetes, and asthma. This study evaluates these three chronic illnesses as 
outcome indicators in rational drug prescribing. 
Upon data collection, it was apparent that all three hospital level clinics treat patients with 
the chronic conditions of hypertension, diabetes (insulin and non- insulin dependent) and 
asthma. Some hospital clinics had special days specifically for one of the above chronic 
conditions, but see patients with these conditions every day in all clinics. It was possible to 
combine the RDU survey data collection with the data collection for chronic diseases. 
A) Hypertension 
Hypertension is a major public health problem in South Africa, as it is in virtually all parts 
of the world. The WHO defines hypertension as having a blood pressure higher then 
160/95 mmHg. It can be asymptomatic and requires a high level of compliance with life 
style changes (diet, exercise, weight control, stress control) and medication. The health 
risks are increased by an unhealthy life style with obesity, poor nutrition, diabetes mellitus, 
excessive alcohol intake, physical inactivity, and smoking. The first level of drug treatment 
consists in a diuretic is low-dose hydrochlorthiazide (12.5 -25 mg once a day). After three 
months if the blood pressure is not controlled then level 2 drugs are added, if they fail in 3 
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months then level 3 drugs are added. The Northern Province in 1998/99 spent R 
3,995,389.16 (-£396,000) on treating hypertension (Appendix Land M). 
B) Diabetes Mellitus (Types I & II) 
Diabetes Mellitus is rapidly emerging as a major public health problem in South Africa. 
The effects of urbanisation and an unhealthy lifestyle are important contributors to the 
rising prevalence. Diabetes Type-II (non-insulin dependent) is often associated with 
obesity, hypertension, and atherosclerosis. Diabetes Type-II accounts for 80%-90% of 
diabetes cases. "It's a multi-faceted disorder and inflicts a tremendous economic burden on 
patients, families and health care providers." (Diabetes, DOH, 1998). Step one treatment 
for those with a certain level of glucose consists of life style modifications, which include 
weight control, weight loss; exercise; cessation of smoking or not starting, and a healthy 
diet. Step 2 treatment on the STGIEDL requires medication. The Northern Province in 
1998/99 spent R 2,774,849.86 (-£275,000) on treating Diabetes Mellitus (Appendix N and 
0). 
C) Asthma 
As the environment becomes more urbanised, more people smoke, and bacterial infections 
become more resistant to antibiotics, the number of asthma cases in adults has increased 
over the years. Asthma is a paroxysmal obstruction of the airways. Air can be taken in, but 
it is difficult to breathe out because the airways are obstructed. In addition too patient 
education, drugs are given. Drugs are given as maintenance therapy and usually consist of 
an inhaler containing Beta-2-stimulants (Salbutamol or Fenoterol, MDI, 100-200 
micrograms, every 4-6 hours as necessary). The Northern Province in 1998/99 spent R 
2,451,531.66 (-£242,000) on treating Asthma (Appendix P and Q). 
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6.2.7 NDP Survey in Hospital Clinics 
The NDP survey process and outcome indicators are detennined in this study, which 
evaluated 1,204 prescribing encounters in eight hospitals with eleven clinic days of 
evaluation carried out between September 1999 and January 2000. The initial collection 
consisted of 1,287 prescriptions. Eighty-four prescriptions were not used because of age, 
date, pregnancy, or incomplete prescription infonnation leaving a final sample size of 
1,204 client prescriptions for evaluation and analysis. This is well above the WHO 
recommendation for a study of this kind which states that, "within these facilities, a 
minimum of 100 prescriptions should be included in the sample to achieve any statistically 
significant comparison from one year to another."(WHO 1994:43) 
Although the clinic facilities differ in size and patient volume, number of staff and the use 
of technology all the hospital clinics in the Northern Province have the same operating 
routines. Patients with and without referrals go to the clinic are first seen by the nurse and 
then by the physician. The data from the visit is entered into the patient record along with 
the medication prescribed. The patients go to the pharmacy whether medications are 
prescribed or not in order to drop off their record. All records counted and compared to the 
patient outpatient list and them were evaluated for the medications prescribed or not. 
Pharmacies vary in their purchasing records and stock control records in both completeness 
and in accuracy. The main Distribution Depot, which is managed by VUNA, a private 
company has all records of medicine orders but would not allow the researcher access to 
their records. 
The number of prescriptions collected for one day in all the hospital clinics had a range 
between 43 and a high of 226 prescriptions. The lowest numbers were both in the 
traditionally white primary care hospital clinics of FH Odenaal hospital with 43 
prescriptions and Van Velden hospital with 52 prescriptions. The traditionally black 
hospital clinic of Jane Furst hospital, with about 200 outpatients per day had 123 
prescriptions. The total number of prescriptions for primary hospital clinics is 214. The 
prescriptions in secondary hospitals were in the same range. The collection of prescriptions 
at St Rita's hospital yielded 142 prescriptions, Mokopani hospital 101 prescriptions, and 
Tshilidzini hospital 127 prescriptions. 
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The total number of prescriptions in the secondary hospital clinics is 370. Data collection in 
the tertiary hospitals was done on several days in order to capture all of the important poli-
and specialty clinics. The tertiary hospital complex of Pieters burg and Mankweng had a 
total of 620 prescriptions. At the Pietersburg hospital, the poli clinics 226 prescriptions 
were written; the first specialty clinic collection day yielded 78 and the second day yielded 
96 prescriptions. At Mankweng the poli clinic yielded 76, while the specialty clinics day, 
145 prescriptions. With both hospitals considered together there were 301 policlinic 
prescriptions and 319 specialty clinic prescriptions. 
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TABLE 6.4 HOSPITAL CLINICS SURVEY ( September J999-January 2000) 
NAME No. BEDS OPD/dav REGION Total Rx. Analvsed Rx 
District or Primary Hospital Clinics 214 
Jane Furse (9) 434 220 Southern 131 123 
F H Odendaal (10) 201 50 Bushvled 43 39 
Van Velden (11) 50 50 Lowveld 55 52 
Regional or Secondary Hospital Clinics 370 
St. Rita's (6) 334 180 Southern 158 142 
Mokopane (7) 340 200 Western 106 101 
Tshilidzini (8) 450 250 Northern 134 127 
Provincial or Tertiary Hospital Clinics 620 
Pietersburg (1) 530 200 Central 237 (P) 226 (P) 
(2) 79 (S) 78 (S) 
(3) 102 (S) 96 (S) 
Mankweng (4) 440 250 Central 83 (P) 76 (P) 
(5) 161 (S) 145(S) 
Notes: Some of the Total Rx. Prescriptions did not fulfil the criteria for inclusion in this study because of patient age, pregnancy, or incomplete 
prescription information. The number of prescriptions included in this study is given in the column Analysed Rx. 
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6.3 Interviews 
Interviews are frequently used to evaluate both the implementation and the acceptance of 
the uptake of the NDP's rational drug prescribing policy. Interviews provide an insight 
into people's behaviour, thoughts, and feelings on important issues. This technique is 
especially good for encouraging a respondent to talk at length on a particular topic. 
Moreover, the successful implementation of the STGIEDL will depend on the 
involvement of several different interested groups. Each group may have a different 
interpretation of the STGIEDL implementation and its usefulness. Capturing these 
different views is often best achieved by using interviews or other qualitative methods 
with a case study design (Mays & Pope: 1999 & 2000). The open in-depth interview 
proved especially helpful in this research, as it allows for loosely structured open-ended 
questions to define the area to be explored initially. More importantly, it is a flexible and 
can uncover new areas or ideas that were not anticipated at the outset of the research. 
The interviews allow for the evaluation of the impact of attitudes or beliefs about 
interventions on actual prescribing practices. The goal of the interviews was to ascertain 
knowledge, attitudes and practices (KAP) of hospital and administrative personnel 
(administrators, pharmacists, physicians and nurses) to complement the NDP indicator 
survey results. 
The advantages of this method are that it is flexible and gives the interviewer more 
opportunity to ask questions. Also the personal contact enhances the possibility of good 
probing. Lastly, it permits the observation of non-verbal expressions of respondents. The 
disadvantages of this method are that it can be difficult to be a good interviewer and 
personal opinions may affect the interviews. In addition, it is difficult to generalise the 
results. 
Of the eight hospitals in the RDU survey, three hospitals were selected based on region, 
former race segregation, hospital level, and the bed and outpatient size. Sixteen 
interviews with hospital staff were conducted on the same day as the Drug Utilisation 
Study (DUS) data collection between September 1999 and January 2000. 
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The lNRUD recommendations from 1996, suggests to assess the KAP a minimum of 
three to four interviews for each group of personnel (administrators, pharmacists, nurses, 
and physicians). In this study twenty interviews with pharmacists, nurses, and 
physicians), sixteen were conducted with health professionals who work in outpatient 
hospital clinics and while four with administrators. Health professionals in hospital 
clinics were randomly asked to give an interview on the day that prescriptions were 
collected. In contrast, administrators were selectively chosen for interviews because of 
their role in the implementation of the NDP and RDU. 
The interviews were guided by a set of questions adapted from lNRUD (1996) (Appendix 
R). All the interviews started with ten basic questions that allowed for elaboration and 
also the possible change of focus (Appendix S). Each interviewee was told that the 
interview was anonymous and confidential. The names of those interviewed were not 
asked or recorded. During the interview the gender, age, profession and years in the 
profession were recorded. The interviews were conducted in a private room with a door 
and no other people present. Each interview was between fifteen and sixty minutes. Each 
interview was recorded on a separate audiotape in order to secure the data and 
confidentiality. 
The primary care hospital chosen was Van Velden hospital where six people were 
interviewed. In the secondary care hospital St. Rita's four people were interviewed, and 
in the tertiary care hospitals, Pietersburg and Mankweng, had total of six people were 
interviewed. In addition four administrators were interviewed. The interviews are 
numbered in sequential order of the actual interview (Appendix T). 
Of the sixteen interviews at the hospital clinic level, seven were at the primary care level 
with three physicians (all male), and two nurses (male and female) and two pharmacists 
(female). At the secondary care level, four interviews were conducted with one physician 
(male), two nurses (male and female) and one pharmacist (female). At the tertiary level, 
six interviews were conducted with four physicians (male), no nurses and two 
pharmacists ( female). At the tertiary level, nurses were approached to take part in the 
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interview, but no interviews were successfully set up. The four administrators 
interviewed were male and worked at the provincial and national levels. 
The administrators were asked directly for an interview and all complied with the request. 
From the Northern Province Department of Health (NP-DOH), both Dr. John P. 
McCutcheon, the Director of Health Care Support and Auxiliary Services and Danie 
Meyer, the Deputy Director of Pharmaceutical Services were interviewed. Also at the 
provincial, but private level, Mischek Dudzai, the Programme Manager of Hospital 
Systems for VUNA Health Care Logistics (drug depot) was interviewed. At the National 
level, Prof. Robert Summers, the Director of RDU training and research and Professor at 
Medical University of South Africa (MEDUNSA) was interviewed. Nine questions were 
developed for the administrators as a guide for further discussion of key issues in the 
implementation of the NDP, STGIEDL, RDU, and rational drug prescribing that were 
used as a starting point. 
6.4 Structured and Non-participant Observation 
An important advantage of observation is that it can help to "overcome the discrepancy 
between what people say and what they do," (Mays and Pope, 1999 & 2000), and give 
insights into the culture, thus increasing the understanding of important variables of the 
data collected. The areas in which this technique has been applied are informal and 
formal meetings and gatherings. These observations were carried out at both National and 
Provincial levels at the Pharmacists Society of South Africa (PSSA) (Appendix U), the 
South African Drug Action Programme (SADAP), Essential Drug Programme (EDP), 
Head of Pharmaceutical Services (HOP) and Provincial Essential Drug Programme Co-
ordinator (PEDCO). Also observations were carried out at the hospital level. In these 
meetings I have been strictly an observer, with an overt presence. During the preliminary 
stage months before the stage collection stage of the research (November 1998 to March 
1999) the research was based at SADAP in Pretoria located at the NDOH. During this 
time key stakeholders were met, pharmaceutical conferences and National EDP meetings 
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were attended and the hospitals were visited. These observations laid the groundwork for 
the field research data collection. 
The three hospitals where interviews were conduc~ed were also used for observation at 
the clinics and pharmacy. Three hospitals were the: 
Primary or Community hospital clinic of Van Velden hospital, 
Secondary or Regional hospital clinic of St. Rita's hospital and 
Tertiary or Central clinics of Pietersburg and Mankweng hospitals 
During the interviews and non-participant observations most administrators involved 
knew the aims and objectives of my research. 
During the collection of some of the NDP structural and process indicators, structured 
observation was also used. The researcher actively looked for a copy of the STGIEDL for 
adults in the clinics, consulting rooms, and pharmacy. Also it was observed if prescribers 
used the STGIEDL. The advantages of this method were that it allowed observation of 
behaviour in context and it afforded the researcher the opportunity to understand factors 
that influence behaviour. 
Observation was helpful in verifying what people do compared to what they say they do 
in interviews. Also it was helpful in validating data obtained by the NDP survey. The 
disadvantages of the method include the problem that the structured format may limit the 
type of information that can be collected. The presence of an observer could affect the 
subjects' behaviour, and thereby bias the data. 
6.5 Literature Review 
Review and analysis of primary and secondary information and documentary evidence 
shares policy statements, programme plans, parliamentary debates, published and 
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unpublished reports and literature, national legislation, professional journals, newspaper 
articles was an ongoing task throughout the research. Specifically documents from four 
areas were be reviewed and analysed: (i) National Drug Policy in South Africa, (ii) South 
Africa Drug Action Programme and (iii) Northern Province Department of Health. Since 
the pharmaceutical policy in South Africa is continually changing fluid a literature review 
was carried out continuously during the research in order to capture research, policy and 
other important milestones. 
6.6 Data entry and analysis 
The qualitative results obtained in interview and observations and the quantitative results 
of the drug utilisation study are analysed in chapters seven and eight respectively. 
6.6.1 Drug Utilisation Study (DUS) 
The quantitative data of individual prescriptions with a unique recorded number were 
separated by hospital mime and clinic specialty. These data were then put into separate 
Excel files. Quantitative Analysis of the NDP survey data (structure, process and 
outcome) includes the evaluation of prescriptions recorded using Microsoft Excel. 
For quality control, the prescription data were reviewed and evaluated for accuracy by a 
pharmacist from Mankweng Hospital and a physician/researcher from the University of 
Cape Town, Department of Pharmacology. The drug utilisation survey was analysed by 
using both SPSS and Stata 6 software. 
6.6.2 Interviews 
Each interview was recorded on audiotape and transcribed into Microsoft word format. 
Analysis of the data has been carried out manually and with the aid of software, called 
(NUD*IST) Non Numerical Data, Indexing, Searching, and Theorising, and the newer 
version 1.1 (April 2000) of Nvivo was employed for data analysis. Nodes, which are 
attributes, themes and data types were created and produced an index system. A node tree 
was created from the themes found in the review of the twenty interviews. The attributes, 
themes and data types were collated from different interviews in order to find similarities, 
commonalties, and contrasts of specific themes and issues. This process was done 
116 
manually and with the help of software. The software has aided in more extensive coding 
and theorising, linking data and ideas, and allowed for innovative approaches to asking 
questions. 
For this analysis interviews were, categorised under various sub-topics. This technique 
often described as a 'cut-and-paste' process in the transcribed interviews are sorted into 
broad and sub-topics. Each category is labelled with an appropriate heading (e.g. Use of 
STG/EDL, Rational Drug Use training, pharmacy treatment committees, etc.). This was 
done for the responses of the different in sub-groups and commonly held beliefs, 
attitudes, or opinions were analysed. 
6.7 Validation16 Techniques 
The main method of validation of research findings is the triangulation the use of 
methods (survey of indicators) and the sources of information (interviews, observation, 
documents, etc.). Triangulation "refers to an approach to data collection in which 
evidence is deliberately sought from a wide range of different, independent sources often 
by different means (for instance, comparing oral testimony with written records)" (Mays 
and Pope, 1999 & 2000). 
This strategy has been used to balance the advantages and disadvantages of the various 
methods used in this study. Several collaborators reviewed the collected data of 
prescriptions for consistency and plausibility. 
A seminar/workshop would be held at the Northern Province Department of Health to 
allow participants in the study and other interested people a forum to learn about and 
comment on the study findings. Those interviewed would be "the same people so that 
their reactions to the evolving analysis become part of the emerging research data" (Mays 
and Pope, 1999 & 2000). The feedback from this workshop session will serve the dual 
26 Validity is the extent to which a measurement truly reflects the phenomenon under scrutiny. (Mays and 
Pope, 1996) 
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purposes of dissemination of information and the opportunity of discussion of the 
research findings. 
6.8 Limitations of this Study 
This study focused on the Northern Province and data were collected in six of the seven 
regions within this province. The Northern Province is different from the other eight of 
South African provinces because of the high percentage of poor, rural, African population 
and the limited health resources. 
The focus of the study was limited to the implementation of the NOP, through the use of 
STGIEOL and its impact on health personnel, and their knowledge,. attitudes and 
practices at the hospital outpatient clinic level. Other factors that can influence RDU 
practice are drug selection, drug stock levels and procurement that are touched upon but 
were not evaluated in depth. 
In addition, the limitations of the study include the limited focus of the Northern Province 
as a case study. As originally planned, with more resources of time, staff and funding, a 
compare and contrast study two provinces Gauteng and the Northern Province. Gauteng 
is the richest, most urban, and White Africans, while the Northern Province, most rural 
with the poorest and majority black African population. Conducting the research in both 
provinces with more resources would have been undertaken to show that although the 
two provinces are quite different in its racial, geographical and economic makeup the 
prescribing patterns were likely to show a lack of adherence to the National Drug Policy 
through rational prescribing. 
If the research could be carried out again in another province I would change several 
features. First, I would allow for up to two years for the entire process. Second, I would 
collect data from more hospital clinics. Third, I would add a component to the research 
design to include the opinions and behaviours of patients who are prescribed generic 
drugs. 
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6.9 Legal and ethical issues 
Approval for this research has been sought and granted from various official bodies. The 
South African Drug Action Programme in Pretoria approved access (October 1998) to its 
office during the initial information gathering phase of the research. The National 
Department of Health has given a letter of support for the research. A presentation (with 
visual aids) was given to the Northern Province Research Committee and the Ethics 
Committee at the regional Department of Health in November 1998. The former 
Northern Province Director of Health, Dr. Nicolas Crisp, granted permission for the 
research in December 1998 (Appendix V). In addition, the ethics committee of the 
London School of Hygiene & Tropical Medicine approved the research in September 
1999. 
To ensure confidentiality data protection questionnaires, surveys, diaries and other 
documents are stored in a private non-accessible location. The Data Protection Act will 
be complied with rigorously. All interviewees were guaranteed anonymity and 
confidentiality. A sequential interview number from one to twenty identified audio taped 
interviews. All interviews were recorded on a micro recorder and for each interview a 
separate audiotape to insure data protection and confidentiality. Interviews occurred in a 
private room with a door for privacy, unless the interviewee requested another location. 
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CHAPTER SEVEN 
DRUG UTILISATION STUDY 
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7.1 Introduction 
A total of 1,242 prescriptions from hospital records were collected and copied on the day 
that they were written at the hospital clinic. After further evaluation, 38 records were 
excluded that did not meet the age, pregnancy status or drug recording criteria and 1,204 
records remained for analysis. The quantitative results will be presented in this chapter, 
while the qualitative results from observations and interviews will be given in the next 
chapter. 
In this representative study of all hospital clinic levels, 1,204 records with 3,551 drugs 
were collected in each region of the six regions of the Northern Province. The newly 
created region of Bushbuck Ridge (Appendix F), former part of the Lowveld Region was 
not included in this study. At least one hospital was chosen in each of the seven regions. 
Representative hospitals were chosen for the level of care (3 Primary care (P) clinics, 3 
Secondary care (S) clinics, and 5 Tertiary care (T) clinics), the region the hospital served 
and the population demographics as well as former segregation are in table 7.1. 
The largest number of patient prescriptions were collected from Pietersburg hospital 
(clinic # 1) a poli-clinic in a hospital that is integrated, but still serves mostly a white 
African population in the capital of the Northern Province. 
The specialty clinics for adults at Pietersburg Hospital (clinic 2 & clinic 3) are true 
tertiary care clinics, for example oncology, surgery, cardiology, dermatology, neurology. 
The specialty clinics at Mankweng Hospital (clinic 5) include hypertension, asthma, and 
ophthalmology. The lowest number of patient prescriptions were collected from F. H 
Odeaal (clinic 10) a primary care clinic in a hospital that still serves mostly a white 
African population in a formally segregated area of Bush veld. 
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Table 7.1 Hospital, care level, population and region 
Hospital Clinic Level Prescriptions % Race· Region 
No 
Pietersburg 1 Tertiary - 224 18.6 W Central 
Poli 
2 T -Specialty 78 6.5 W Central 
3 T-Specialty 97 8.1 W Central 
Mankweng 4 Tertiary - 75 6.2 B Central 
Poli 
5 T -Specialty 145 12.0 B Central 
St. Rita's' 6 Secondary 144 12.0 B Southern 
Mokopani 7 Secondary. 101 8.4 B Western 
Tshilidzini 8 Secondary 126 10.5 B Northern 
Jane First 9 Primary 123 10.2 B Southern 
F. H Odeaal 10 Primary 39 3.2 W Bushveld 
Van Veld en 11 Primary_ 52 4.3 W Lowveld 
11 Clinics 11 5T, 3S, 3P 1,204 100 6B,5W 6 Reeions 
Note: The racIal maJonty of the patIents IS deSIgnated as eIther Black (B) or WhIte (W). 
The 1,204 prescriptions from eight hospitals with eleven clinics are grouped by level of 
care into primary, secondary and tertiary. The number of prescription and the number of 
prescribed drugs for each level are summarised in Table 7.2. The individual clinics will 
be evaluated by using prescribing outcome indicators. . 
Table 7.2 Hospital Clinic Level, Cases and Drugs 
Level Prescriptions Percent Drugs Percent 
Primary 214 17.8 695 19.6 
Secondary 370 30.7 1,023 28.8 
Tertiary 620 51.5 1,833 51.6 
Total 1,204 100% 3,551 100% 
7.2 Prescribing Indicators 
The South African National Drug Policy was adopted by the National Department of 
Health for the Provincial level in the Northern Province. Prescribing indicators are used 
to assess the process and outcomes of the implementation of this policy. 
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Both process and outcome prescribing indicators are used in this study to assess the 
degree of attainment of the Rational Use of Drugs, one of the eight objectives of the 
Essential Drug Program (EDP). Outcome and process indicators are used to measure the 
results achieved at one point in time and the changes that can be attributed to the 
implementation of the Essential Drug Programme, and thus the overall success of the 
National Drug Policy. 
The eight outcome prescribing indicators provide quantitative information about the 
process and the extent to which South African has implemented its EDP, while the 
process indicator assesses the degree of functioning for the process and the achievement 
of specific targets (WHOIDAP/94.12). 
The eight prescribing indicators were adapted for this study after a literature review to 
assess the degree to which the goals and targets of essential drug programme were met by 
prescribers. 
More importantly, the indicators evaluate the prescribing behaviour at the hospital clinic 
level. A low mean number of drugs per prescription, high generic and EDL prescribing 
and a low percentage of prescriptions with antibiotics, analgesics and injections are 
excepted indicators of rational drug prescribing. The eight indicators will be evaluated for 
all prescriptions and separately for those with the chronic illnesses of hypertension, 
diabetes andlor asthma. 
Box 7.1 Eight Evaluated Prescribing Indicators and NDP Recommended Values 
I) 
2) 
3) 
4) 
5) 
6) 
7) 
8) 
Mean number of drugs per prescription 
Prescriptions with two drugs or less 
Proportion of Generic drugs 
Drugs on the EDL 
Drugs prescribed as brand or generic on EDL 
Prescriptions for antibiotic 
Prescriptions for analgesics 
Prescriptions for injections 
(2 or less) 
(95%) 
(90%) 
(90%) 
(90%) 
(10%) 
(15%) 
(5%) 
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7.3 Methods of Analysis 
The eight outcome indicators were analysed for each of the eleven clinics and a rank list 
of the clinics for these indicators was constructed. The degree of adoption of the EDP 
principles by clinics will be reflected in the rank list and can be quantified by an overall 
rank score and analysed in more detail by rank correlations. 
A. Adjusted and Non-Adjusted Models of Age and Gender 
The influence of several factors like age and gender on the outcome indicators was 
analysed using regression models (Table 7.3), a linear regression model for the mean 
number of drugs and logistic regression models for all other parameters. 
The analysis results for the outcome indicator, "more than two drugs per prescription" 
using a logistic regression model are summarised in Table 7.3. The analysis, using model 
II is controlled for gender and age group. The coefficients in this analysis are odds-ratios. 
With the special parameterisation used the order of coefficients will be the rank order. 
The uncontrolled model shows (by definition) the same rank order as a simple ranking of 
proportions. The controlled model demonstrates that gender and age both have effects 
with increasing age, except for the oldest group, the odds ratio for more than 2 drugs rises 
and female patients are more likely to receive more than 2 drugs than male patients. In 
the adjusted rank order furnished by the controlled model the effect of age and gender of 
the patients has been standardised. Adjusted ranks are presented with simple ranks in the 
following tables. 
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Table 7.3 Not Adjusted and Adjusted Models of Age and Gender 
for Prescriptions with >2 drugs 
(Model 1- Not Adjusted and Model 11- Adjusted, • p < 0.05, •• P < 0.01) 
Note: P values oro.ooo are actually <0.001. 
Model I - Not adjusted (Rx >2 Drugs) Model II - Adjusted (Rx >2 Drugs) 
Clinic Coefficient Probability Clinic Coefficient Probability 
1 1.772" 0.000 1 1.674" 0.001 
2 0.414" 0.000 2 0.441" 0.000 
3 0.506" 0.001 3 0.496·· 0.001 
4 1.705· 0.028 4 1.940" 0.009 
5 1.299 0.130 5 1.203 0.300 
6 0.9023 0.538 6 0.875 0.456 
7 0.970 0.877 7 0.923 0.688 
8 0.706· 0.047 8 0.782 0.173 
9 1.149 0.446 9 1.084 0.669 
10 0.774 0.390 10 0.800 0.471 
11 2.210" 0.009 11 2.134" 0.014 
(N:zl,204) Al:e Groul! 
15-39 0.804 0.128 
40-49 0.982 0.905 
50-59 1.333· 0.050 
60-69 1.806·· 0.001 
70-79 1.488· 0.049 
80-99 0.467" 0.001 
Gender 
Female 1.302· 0.044 
(N=1.204) 
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B. Correlation Matrix of Prescribing Indicators 
Positive rank correlations of certain indicators, for example, a close adherence to the 
target mean number of drugs per prescription and the to the proportion of antibiotic 
prescriptions will imply a similar degree of success in the implementation of the NDP. 
If individual hospital clinics have made a concerted effort to implement the Essential 
Drug Programme, then the indicator adherence scores (ranking is from 1 to 11, the higher 
the adherence, the lower score,) should have a high correlation number close to 1.0 and 
would be evidence of EDP implementation success. In addition, for more general 
evidence of programme effort and level of implementation rank correlation between 
hospital clinics should be positive and significant for a number of pairs of indicators. 
Comprehensive Correlation Matrix of Prescribing Indicators are displayed and evaluated 
in Table 7.24. 
7.4 Analyses of Prescribing Indicators 
Three analyses are used to evaluate the eight prescribing indicators and their relationship 
to one another in all eleven clinics for all and chronic illnesses. A Forth analysis, only for 
chronic illnesses and prescribing indicators by clinic level. 
Each of the eight prescribing indicators is evaluated and the results are summarised in 
two tables. The first table evaluates the total number and proportion of the prescriptions. 
The second table evaluates the proportion of drugs, and also includes the "Simple Rank" 
for adherence to the EDP and thus successful implementation of the Essential Drug 
Policy, and the "Adjusted Rank," as previously described. 
The eleven clinics are ranked from best to worse using the criteria of prescription 
indicators (Tables 7-4 to 7-33). Analysis Two evaluates all indicators (Table 7-34 to 7-
35), for all the clinics and compares them to one another. The final table adds up the 
scores for all the prescribing indicators and gives an overall ranking for adherence to 
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EDP principles based on the adjusted rank. Then the clinics are ranked from the lowest 
score, which represents the best adherence to the EDP. 
Analysis Three (Tables 7.36 to 7.37) takes the adherence scores of all the clinics and puts 
them into a matrix correlation table. The correlation table is produced based on the 
adjusted ranking of adherence. As rankings alone may fail to bring out the full story, 
since in any system of ranking there are those first and last, but may not fully reflect the 
relative portions, the evaluation will also compare means of primary, secondary and 
tertiary. 
The degree of implementation of the policy is assured by evaluating the correlate pairs. 
Analysis Four (Table 7.38) evaluates the eight prescribing indicators for those with 
chronic illnesses (hypertension, diabetes and asthma). 
This examines whether the EDP compliance measures are the same for chronic diseases, 
the hypothesis being that prescribing for chronic illnesses lends itself more easily to the 
closer adherence of the EDP practices (Tables 7.27 to 7-33). 
7.4.1 Analysis One: Prescribing Indicators 
Indicator One: Mean Number of Drugs per Prescription 
The mean number of drugs prescribed on each prescription is an accepted indicator for 
rational drug prescribing with a recommended value of two drugs or less per prescription 
as determined by the literature. A higher number of two prescribed drugs is an indicator 
for poly pharmacy, which is not consistent with rational drug prescribing. 
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Table 7.4 Mean Number of Drugs per Prescription 
Level Pietersburg- I Mankweng- Secondary Primary Total 
Tertiary , Tertiarv 
No. Rx 399 I 220 371 214 1204 
No. drugs 1156 I 677 1023 695 3,551 
Mean No. 2.83 I 3.07 2.75 3.24 1.94 drugslRx 
Clinic 1 1 3 -4 5 6 7 8 9 10 Jl Sum 
No.Rx 224 78 97 I 75 145 144 101 126 123 39 52 1,204 
No. drugs 741 173 242 231 446 391 288 344 366 123 206 3,551 
Mean No. 3.30 2.21 2.49 3.08 3.09 2.71 2.85 2.73 2.97 3.15 3.96 2.94 
drugslRx 
Notes: No. RX: Number of Prescnptlons, No drugs: Number of Drugs, 
Table 7.4 presents evidence about the extent of polypharmacy using the indicator of the 
mean number of drug per prescription. The primary level had the highest mean number of 
drugs at 3.24, when it is expected to have the lowest or at least the target of2 or less. 
All levels of care do not meet the mean drug per prescription of two or less. The range is 
from 2.21 to 3.96 drugs per prescription. The average for all the clinics together is 2.94, 
higher than the goal of 2 drugs or less. Therefore all the clinics are over-prescribing 
according to the EDP criteria. Surprisingly, clinic 2 a specialty clinic at the tertiary level 
has the lowest number of drugs per prescription showing that adherence to EDP 
principles is possible at all level of care and for most patients. On the other hand, clinic 
11 is a primary health care facility, would be expected to prescribe fewer drugs but is 
actually prescribing the higher number. 
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Table 7.5 Rank List for Mean Number of Drugs Prescribed 
S-Rank 1 2 3 14 5 6 7 8 9 10 11 
Clinic 2 3 6 
1
8 7 9 4 5 10 1 11 
No.Rx 78 97 144 1126 101 123 75 145 39 224 52 
Mean No. 2.21 2.49 2.71 1 2.73 2.85 2.97 3.08 3.09 3.15 3.30 3.96 Dru~s/RX 
Coeff. -0.649 -0.452 -0.260 1 -0.146 -0.145 -0.015 0.183 0.030 0.177 0.303 0.974 
P Value 0.000 0.000 0.020 I 0.210 0.252 0.896 0.211 0.783 0.373 0.001 0.000 
A-Rank 1 2 3 14 5 6 9 7 8 10 II 
Notes: S-Rank: Simple Rank, A-Rank: Adjusted Rank, Coeff.: Lmear RegreSSIOn 
In Table 7.5, the adjusted model (A-Rank) changes only slightly from the adherence (S-
Rank), which do not affect the clinics mentioned. Clinic 2 and 3, both at the tertiary level, 
but in two separate hospitals are significantly better than the average level of prescribing. 
The coefficients of the adjusted rank (A-Rank) for clinic 2 and 3 shows that they are 
prescribing 0.65 and 0.45 drugs less respectively, than the average. In contrast, clinic I, a 
poli clinic at the same hospital as the best clinic 2, and clinic II,at the primary care level, 
are prescribing significantly more drugs than average, clinic I, 0.3 and clinic 11, 1.0 
more drugs per prescription. 
Indicator Two: Proportion of Prescriptions with More than Two Drugs 
A second indicator for rational drugs prescribing is the proportion of prescriptions with 
more than two drugs, the NDP goal of being less than 5% of prescriptions with more than 
two drugs. If rational drug prescribing were followed it would be expected that clinics 
would have 95% of prescriptions with less than two drugs. 
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Table 7.6 Proportion of Prescriptions with More than Two Drugs 
Level Pietersburg- I Mankweng- Secondary Primary Total 
Tertiary Tertiary 
Total Rx 399 I 220 371 214 1204 
>2 drugs 235 I 150 208 139 732 
%Rx 58.89 I 68.18 56.06 64.95 60.8 
Clinics 1 2 3 14 5 6 7 8 9 10 11 Sum 
Total Rx 224 78 97 75 145 144 101 126 123 39 52 1,204 
>2 drugs 163 30 42 54 96 83 60 65 78 21 40 732 
%Rx 72.8 38.5 43.3 72.0 66.2 57.6 59.4 51.5 63.4 53.8 76.9 60.8 
Notes: No. RX: Number of Prescriptions, No drugs: Number of Drugs, 
Mankweng hospital clinics at the tertiary level have the highest percent, 68. I 8% of 
prescriptions with more than two drugs. In addition, consistent with the mean number of 
drugs in the last tables primary level of care also has a highest percent, 64.95% of 
prescriptions with more than two drugs. If the Evaluating individual clinics, both clinics 2 
and 3 have the lowest proportion of prescriptions with more then 2 drugs with 38.5% and 
43.3%, respectively. The range of prescriptions with more than two drugs is from 38.5% 
to 76.9% (Table 7.6). The highest proportion of prescriptions with more than two drugs 
was from clinic 11 with 76.9% of prescriptions. The majority of clinics have at least 50% 
of the prescriptions with more than two drugs. Although clinics 2 and 3 performed better 
than any other clinic, all have not met the standard of 95% of prescriptions with 2 drugs 
or less. This is clear evidence of polypharmacy, and thus a lack of rational drug 
prescribing. 
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Table 7.7 Rank of Hospitals Proportion of Prescription with> 2 drugs 
S-Rank 1 2 3 4 5 6 7 8 10 9 II 
Clinic 2 3 8 10 6 7 9 5 4 1 II 
No.Rx 78 97 126 39 144 101 123 145 75 224 52 
%Rx 38.5 43.3 51.5 53.8 57.6 59.4 63.4 66.2 72.0 72.8 76.9 
Coeff. 0.443 0.499 0.782 0.771 0.889 0.929 1.084 1.206 1.907 1.684 2.143 
P Value 0.00 0.001 0.171 0.394 0.503 0.688 0.711 0.293 0.010 0.001 0.014 
A-Rank 1 2 4 3 5 6 7 8 10 9 11 
In Table 7.7, the adjusted model (A-Rank) changes only slightly from the adherence (S-
Rank). Clinics 2 and 3, both at the tertiary level, but in two separate hospitals are 
significantly better than the average clinic for the proportion of prescriptions with two or 
less drugs. The correlation for the adjusted (A-Rank) for clinic 2 and 3 show that they 
are 56% and 50% less likely to prescribe more than two drugs than the average. Clinic 1, 
and clinic 11, on the other hand - consistent with the ranking for mean number of drugs-
are 68% and 114% more likely to prescribe more than two drugs than average. 
Indicator Three: Proportion of Generic Drugs 
A third indicator for rational drug prescribing is the proportion of generic drugs, The 
NDP goal being 90%. 
Table 7.8 Proportion of Generic Drugs 
Level Pietersburg- i Mankweng- Secondary Primary Total 
Tertiary I Tertiary 
No Drugs 1,156 I 677 1,023 695 3,551 
No. 368 I 210 342 263 1,183 Generic 
"i. 31.83 I 31.01 33.43 37.84 33.31 Generic 
Clinics 1 2 3 14 5 6 7 8 9 10 II Sum 
No Drugs 741 173 242 1231 446 391 288 344 366 123 206 3,551 
No. 289 42 37 58 152 177 85 80 130 50 83 1,183 
Generic 
% 39.00 24.27 15.28 25.10 34.08 45.26 29.51 23.25 35.51 40.65 40.29 33.31 
Generic 
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The NDP goal is at least 90% generic prescribing in order to match the medicines 
available at the pharmacy. Instead, Table 7.8 shows that overall the primary care level 
has the highest percentage of generic prescription with 37.84%. However, all three levels 
show about a bit more than 30% of generic prescribing. These results are well below the 
90% NDP goal. Generic prescribing for all the clinics is at or below 45% of the total 
drugs. The average for the proportion of generic drugs is even lower at 33.31 %. Looking 
at individual clinics, the best within the group of clinics is Clinic 6 with 45.26% generic 
prescribing. Clinic 3, a specialty clinic at a tertiary care facility, has the lowest percentage 
of generic prescribing. 
Table 7.9 Rank List of Hospital Clinics for Generic Drug Prescribing 
S-Raok 1 2 3 14 5 6 7 8 9 10 11 
Clinic 6 10 11 1 9 5 7 4 2 8 3 
No 177 50 83 289 130 152 85 58 42 80 37 
Ceneric 
0/0 45.26 40.65 40.29 
1
39
.
00 35.51 34.08 29.51 25.10 24.27 23.25 15.28 
Ceneric 
Coeff. 1.838 1.526 1.426 1.380 1.193 1.115 0.922 0.756 0.731 0.687 0.390 
P Value 0.000 0.015 0.009 0.000 0.105 0.284 0.514 0.054 0.061 0.002 0.000 
A- Rank 1 2 J 14 5 6 7 8 9 10 11 
Note: P values of 0.11110 are actually <0.001. 
In Table 7.9, the adjusted (A-Rank) and adherence (S-Rank) models have the same 
ranking. Clinics 6 and 1 0, at the secondary and primary level respectively, prescribe the 
most generics, they are 86% and 53% more likely to prescribe generic medicines 
compared to the other clinics overall. Clinics 8 and clinic 3 are 31 % and 61 % less likely 
to prescribe generic drugs. 
Indicator Four: Proportion of EDL Drugs 
As a fourth indicator for rational drug prescribing the proportion of drugs that are on the 
EOL was analysed. The NOP goal for essential drug prescribing is 90% of all drugs. In 
addition, the proportion of essential drug prescribing is compared with generic drug 
prescribing. 
132 
Table 7.10 Proportion of Drugs from EDL 
Level Pietersburg- I Mankweng- Secondary Primary Total 
Tertiary , Tertiary 
Drugs 1,156 I 677 1,023 695 3,551 
No. EDL 308 I 158 262 208 936 ! 
% EDL 26.64 I 23.33 25.61 29.92 26.35 
Clinics 1 2 .1 14 5 6 7 8 9 10 11 Sum 
Drugs 741 173 242 I 231 446 391 2&& 344 366 123 206 3,551 
No. EDL 267 26 15 i 47 III 139 67 56 102 41 65 936 
% EDL 36.03 15.03 6.19 I 20.35 24.89 35.55 23.26 16.2& 27.&7 33.33 31.55 26.35 
Overall, once again the primary level has the highest proportion, 29.92% of drugs 
prescribed on the EDL. However, all levels have a range of EDL prescribing of 23.33 to 
29.92. All fall short of the 90% goal of drugs prescribed from the EDL. 
Looking at individual hospital clinics, the range ofEDL prescribing (Table 7.10) is quite 
wide, between 6.2% for clinic 3 and 36.0% for clinic I, both at the tertiary level. The 
average is 24.6% of drugs prescribed are on the EDL, far below the NDP goal of 90% .. 
The clinic with the best adherence to EDL drug prescribing is clinic 1 with 36% of drugs 
prescribed. In contrast, clinic 3, the least adherent with only 6.2% of the drugs prescribed 
on the EDL. Overall, the evidence supports a lack ofEDL drug prescribing at all levels of 
the study clinics. 
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Table 7.11 Rank List of EDL Drug Prescribing 
S-Rank 1 2 3 4 5 6 7 8 9 10 11 
Clinic 1 6 10 11 9 5 7 3 4 8 :z 
No. EDL 267 139 41 65 102 III 67 51 47 56 26 
% EDL 36.03 35.55 33.33 31.55 27.87 24.89 23.26 21.07 20.35 16.28 15.03 
Coeff. 1.641 1.618 1.468 1.337 1.108 0.950 0.896 0.797 0.775 0.600 0.549 
P Value 0.000 0.000 0.034 0.044 0.377 0.645 0.412 0.130 0.130 0.000 0.003 
A-Rank 1 2 3 4 5 6 7 8 9 10 11 
Note: P values or 0.000 are actually <0.001. 
In Table 7.11, the adjusted (A-Rank) and adherence (S-Rank) models furnish the same 
rank list. Clinics 1, 6 and 10, which are at all three levels of care are significantly better 
than the average for the proportion of drugs from the EDL. They are 64%,62% and 46% 
respectively, are more likely to prescribe drugs that are on the EDL. The least likely to 
prescribe drugs on the EDL are clinic 8, which is 40% and clinic 2 which is 45% less 
likely to prescribe drugs on the EDL. 
Table 7.12 Comparison of the Proportion of Generic and EDL Prescribing 
Clinic 1 2 3 4 5 6 7 8 9 10 11 
Drug! 741 173 242 231 446 391 288 344 366 123 206 
0/0 39.00 24.27 15.28 25.10 34.08 45.26 29.51 23.25 35.51 40.65 40.29 
Ceneric 
% EDL 36.03 15.03 6.19 20.35 24.89 35.55 23.26 16.28 27.87 33.33 31.55 
% Dirr. 2.97 9.24 9.09 4.75 9.19 9.71 6.25 6.97 7.64 7.32 8.74 
All EDL drugs are generic, but not all generic drugs prescribed are on the EDL. The 
prescribing of generic drugs and EDL drugs should be equal if only generic drugs on the 
EDL are prescribed. Instead all clinics have a higher percentage of generic prescribing 
than EDL prescribing. This is a clear indication that the EDL is not being used directly. 
Even more importantly, generic drugs not on the EDL are not ordered by the drug depot, 
are not in the hospital phannacies, and thus should not be prescribed. 
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Sum 
3,551 
33.31 
27.37 
5.94 
From the evaluation of the drugs prescribed it has been determined that less than 40% of 
the drugs prescribed are generic and even less are from the EDL are the most of the other 
drugs prescribed brand products that are on the EDL in generic form? The fifth indicator, 
the proportion of brand drugs on EDL as generic, will attempt to answer this question. 
Indicator Five: Proportion of Brand Drugs on EDL as Generic Drugs 
The question that now arises is "Are the drugs that are prescribed by their brand patented 
name, also on the EDL as generic or are prescribers requesting drugs for their patients 
that are not on the EDL. The NDP goal is 90% of the drugs prescribed are on the EDL, 
even if they are being prescribed by brand name. 
Although the rate of generic prescribing is higher than the EDL prescribing, the 
evaluation of whether the NDP rational prescribing goal is met is not possible without 
looking at the proportion of drugs that are prescribed as brand and are on the EDL as 
generic drugs. The generic drugs at the pharmacy are usually substituted for prescribed 
brand drugs. The proportions of brand drugs (Table 7.13) take this factor into 
consideration. 
Table 7.13 Proportion of Brand and Generic Drugs on EDL (EDLBRD) 
Level Pietersburg- I Mankweng- Secondary Primary Total 
Tertiary , Tertiarv 
Drugs 1,156 I 677 1,023 695 3,551 
EDLBR 758 I 472 760 505 2,495 
%EDBR 65.57 I 69.71 74.29 72.66 70.26 
Clinics 1 1 J 14 5 6 7 8 9 10 11 Sum 
Drugs 741 173 242 1 231 446 391 288 344 366 123 206 3,551 
EDLBR 507 107 144 I 135 337 328 183 249 292 69 144 2,495 
%EDBR 68.42 61.85 54.96 I 67.10 75.56 83.89 63.54 72.38 79.78 56.10 69.90 70.26 
Note: EDLBR IS the same as EDLBRD 
The secondary level has the highest percentage, 74.29% of drugs prescribed as either 
brand or generic that are on the EDL. The range of drugs on the EDL as a generic 
equivalent for all levels is from 65.57 to 74.29%. These percentages are well below the 
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expected 90% that are expected when 10% of the total drug budget can be spent on drugs 
not on the EDL. At individual clinics, the range ofEDL drugs supplied as generic despite 
sometimes being prescribed by brand is between 83.9 % for Clinic 6, and 55.0% for 
Clinic 3. As expected this is a more realistic and encouraging range from those shown in 
Table 7.12. 
Table 7.14 Ranking of ED LIB rand Drugs (EDLBRD) in Clinics 
s- Rank 1 2 3 4 5 6 7 8 9 10 11 
Clinic 6 9 5 8 11 1 4 7 2 10 3 
Drugs 391 366 446 344 206 741 231 288 173 123 242 
EDLBRD 328 292 337 249 144 507 135 183 107 69 144 
% 83.89 79.78 75.56 72.38 69.90 68.42 67.10 63.54 61.85 56.10 54.96 
Coeff. 2.235 1.685 1.372 1.190 1.035 0.970 0.895 0.788 0.736 0.560 0.557 
P Value 0.000 0.000 0.004 0.140 0.810 0.716 0.410 0.044 0.040 0.001 0.000 
A-Rank I 2 3 4 5 6 7 8 9 10 11 
Note: P values of 0.000 are actually <0.001. 
In Table 7.14, the adjusted (A-Rank) and adherence (S-Rank) models have the same 
ranking. Clinic 6 at the secondary level and clinic 9, at the primary level both have a high 
proportion of prescribed drugs that are on the EDL as generic drugs. Clinic 6 is 124% and 
clinic 9 is 69%, more likely respectively to prescribed drugs that are on the EDL as 
'. 
generic (whether prescribed by brand or generic name). Even though physicians are 
prescribing by brand name, if the drug is on an equal generic drug can substitute the 
EDL. 
In contrast, clinics 10 and clinic 3 have the lowest combined prescribing and are both 
44% less likely to prescribe brand or generic drugs on the EDL. More than half of the 
prescriptions cannot be filled with the drug intended, and the pharmacists have to 
substitute another similar drug for the prescribed drug. 
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Indicator Six: Proportion of Antibiotics Prescribed 
A further indicator for rational drug prescribing is the proportion of antibiotics 
prescribed. The NDP goal for this indicator is less than 10%. 
Table 7.15 Proportion of Antibiotics Prescribed 
Level Pieters burg- I Mankweng- Secondary Primary Total 
Tertiary Tertiarv 
Drugs 1,156 I 677 1,023 695 3,551 
No.AB 144 I 60 103 77 384 
%.AB 12.45 I 8.86 10.06 11.07 10.81 
Clinics 1 2 J 
" 
5 6 7 8 9 10 11 Sum 
Drugs 741 173 242 231 446 391 288 344 366 123 206 3,551 
No.AB 82 30 32 25 35 39 30 34 32 5 40 384 
%.AB 11.07 17.34 13.22 1 10.82 7.85 9.97 10.42 9.88 8.74 4.07 4.85 10.81 
.. Notes: P: Pletenburg, M: Mankweng, No. AD, Number of AntibIotIcs 
In Table 7.15, the goal of prescribing no more than 10% of antibiotic drugs by the 
hospitals overall has been met with 10.81% prescribed. At the tertiary level, Pietersburg 
hospital clinics has the highest percentage of antibiotic prescribing with 12.45%, while 
Mankweng hospital clinics at the same level has the lowest percentage or 8.86%. The 
secondary level clinics also have met the target gaol with 10.06% antibiotic prescribing. 
Of the individual clinics, five of the eleven clinics were over the 10% goal, but only two 
over 13% antibiotics. The primary clinics 9, 10, and 11 are overall the best, while the 
secondary clinics 6, 7 and 8 are closest to the 10% goal. Most of the tertiary level clinics 
that are over 10% mark. Pietersburg - tertiary clinics 1, 2 and 3 prescribe 11.07%, 
17.34% and 13.22% antibiotics respectively. The Mankweng- tertiary clinic 4 fulfils that 
goal of 10% and Clinic 5 is close to it with 10.8% antibiotics. 
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Table 7.16 Ranking of Antibiotic Prescribing for Hospital Clinics 
S-Rank 1 2 3 4 5 
1
6 7 8 9 10 11 
Clinic 10 11 5 9 8 6 7 4 1 3 2 
Total # 123 206 446 366 344 391 288 231 741 242 173 
#AB 5 10 35 32 34 39 30 25 82 32 30 
0/. AS 4.07 4.85 7.85 8.74 9.88 9.97 10.42 10.82 11.07 13.22 17.34 
Coefr. 0.493 0.574 0.987 0.977 0.896 1.051 1.142 1.036 1.357 1.474 1.646 
P Value 0.096 0.069 0.942 0.899 0.547 0.782 0.491 0.865 0.020 0.041 0.013 
A-Rank 1 2 5 4 3 7 8 6 9 10 11 
In Table 7.16, the adjusted (A-Rank) and adherence (S-Rank) models have the same 
ranking. Clinics 10 and 11, both at the primary level are ranked first and second. Clinic 
lOis 50% and clinic 11 is 43%, less likely respectively to prescribe antibiotics. While 
clinics I, 2 and 3 all at Pietersburg-tertiary care clinics are significantly more likely to 
prescribe antibiotics, Clinic 1 to 36%, clinic 3 to 47% and clinic 2 is 65% more likely. 
Indicator Seven: Proportion of Analgesics Drugs Prescribed 
The NDP goal of less than 15% analgesics of prescribed drugs is a further indicator of 
rational drug prescribing. 
Table 7.17 Proportion of Analgesic Prescribed 
Level Pietersburg- I Mankweng- Secondary Primary 
Tertiary Tertiary 
Drugs 1,156 I 677 1,023 695 
-
,-
No.AG 264 , 137 249 130 
0/ •• AG 4.37 I 20.23 24.30 18.70 
Clinics 1 2 J 14 5 6 7 8 9 10 11 
Drugs 741 173 242 r 231 446 391 288 344 366 123 206 
No.AG 159 52 53 
1
54 83 86 83 80 84 24 22 
%.AG 21.46 30.06 21.90 , 23.38 18.61 21.99 28.82 23.26 22.95 19.51 10.68 
!\Iote!: P: PII~tenburg, 1\1: ~Iankweng,l'o. AG, Number of AnalgeSICS 
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Total 
3,551 
780 
21.97 
Sum 
3,551 
780 
21.97 
In Table 7.17, the data for analgesic drug prescription are summarised. At the tertiary 
level, Pietersburg hospital clinic has the lowest analgesic prescribing with 4.37%. At all 
levels with the exception of secondary clinics met the 20% target goal, while the 
secondary was quite close at 24.30%. When looking at individual clinics, all clinics 
except one are over the 15% goal of prescribing analgesics. Only clinic II was 
significantly under the 15% target with 10.68% analgesic prescribing. Clinic 2 had 
30.06% analgesic prescribing, double the NDP goal of 15%. 
Table 7. 18 Ranking of Analgesic Drug Prescribing 
S-Rank 1 2 3 4 5 6 7 8 9 10 II 
Clinic 11 5 10 I 3 6 9 8 4 7 2 
Total 206 446 123 741 242 391 366 344 231 288 173 
#AG 22 83 24 159 53 86 84 80 54 83 52 
"10 AG 10.68 18.61 19.51 21.46 21.90 21.99 22.95 23.26 23.38 28.82 30.06 
Coeff 0.444 0.843 0.900 0.996 0.996 1.037 1.101 1.067 1.115 1.456 1.512 
P Value 0.000 0.160 0.622 0.966 0.980 0.770 0.433 0.608 0.468 0.003 0.009 
A-Rank I 2 3 4 4 6 8 7 9 10 II 
Note: P values of 0.000 are actually <0.001. 
In Table 7.18, the adjusted (A-Rank) and adherence (S-Rank) models have the same 
ranking. Clinic 11, at the primary care level is 56% less likely to prescribe an analgesic. 
While clinic 7 at the secondary level is 46% and clinic 2 at the tertiary level is 51 % more 
likely to prescribe an analgesic. 
Indicator Eight: Proportion of Injection Drugs Prescribed 
The question answered in table 7.19 is "What proportion of the prescriptions are 
injections" and "does it meet the rational prescribing criteria of no more than 5% of all 
drugs prescribed?" 
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Table 7.19 Proportion of Injection Drugs Prescribed 
Level Pietersburg- I Mankweng- Secondary Primary 
IT' Tertiary I ertJary 
Drugs 1,156 I 677 1,023 695 
No. Inj. 25 I 15 34 10 
% Inj. 2.16 I 2.22 3.32 1.43 
Clinics I 1 3 14 5 
! 
6 7 8 9 10 JJ 
Drugs 741 173 242 1 231 446 391 288 344 366 123 206 
No. Inj. 19 5 1 
1
6 9 5 22 7 1 5 4 
% Inj. 2.56 2.89 0.41 ,2.59 2.01 1.27 7.63 2.03 0.27 4.06 1.94 
Notes: P: Pletersburg, M: l\lankweng, No. InJ.: Number of Injections 
At all levels, all the clinics had less than 5% injections prescribed with the exception of 
one. Clinic 7 has 7.6% of injection prescribing, about 50% more than the goal. The 
proportion of injection drugs prescribed ranges from 0.3% to 7.6%, the average being 
2.4%. 
Table 7. 20 Rank of Injections Prescribing in Hospitals Clinics 
S-Rank 1 2 J 4 5 6 7 8 9 10 11 
,,-"~-
Clinic 9 J 6 11 5 8 1 4 2 10 7 
No.Rx 366 242 391 206 446 344 741 231 173 123 288 
No.lnj 19 5 1 6 9 5 22 7 I 5 4 
% Inj 0.27 0.41 1.27 1.94 2.01 2.03 2.56 2.59 2.89 4.06 7.63 
Coerf. 0.157 0.212 0.759 1.157 1.231 0.995 1.446 1.377 1.317 2.474 4.303 
P Value 0.045 0.092 0.543 0.766 0.555 0.990 0.173 0.441 0.539 0.047 0.000 
A-Rank 1 2 J 5 6 4 9 8 7 10 11 
Note: P values of 0.11110 are actually <0.11111. 
In Table 7.20, the adjusted (A-Rank) and adherence (S-Rank) models have slightly 
different rankings. Clinic 9 at the primary level is ranked first and is 84% less likely to 
prescribe an injection. In contrast, clinics 10 and 7 are 147% and 330% more likely to 
prescribe an injection, respectively. 
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Total 
3,551 
84 
2.36 
Sum 
3,551 
84 
2.36 
" 
Table 7.21 Prescribing Outcomes by Clinic Level (Primary, Secondary, Tertiary) 
Analysis of the eight prescribing indicators by level of care (primary, secondary and 
tertiary) to determine if there is a difference in the degree of implementation of the NDP 
Policy and EDP principles between the three levels of care. 
Table 7.21 Prescribing Indicators by Hospital Care Level 
Level Goal Prima~ Secondary Tertiary Overall 
No Drugs 
-
695 1,023 1,833 3.551 
Mean No 2.0 3.24 2.75 2.96 2.94 
%>2 Drugs 95% 64.95 56.06 62.20 60.80 
% Generic 90% 37.84 33.43 31.53 33.31 
% EDL 90% 29.93 25.61 27.39 26.35 
% EDLBRD 90% 72.66 74.29 67.59 70.26 
%AB 10% 6.76 10.07 11.13 10.81 
%AG 15% 18.71 34.34 21.88 21.97 
% INJ 5% 1.44 3.32 2.18 2.36 
Evaluation prescribing indicators (Table 7.21) for the three levels of care, shows that the 
primary level has the highest number of drugs per prescription and > 2 drugs, but the also 
the highest number of prescriptions with of EDL and generic prescribing. Overall the 
primary level has better compliance with EDL principles with the exception of 
prescriptions of brand drugs that are found as generic drugs on the EDL and a high 
absolute proportion of analgesic prescribing, although still at lowest proportion of the 
three levels. 
The secondary level has the lowest number of drugs prescribed and prescriptions with 
more than two drugs but has the highest proportion of analgesics. Conversely, it has high 
number of EDL drugs prescribed by brand name (EDLBRD). Overall that means that 
more EDL drugs are dispensed, even though prescribing is by brand name. At the 
tertiary level, the percentage of generic drugs and of EDL drugs is lower than average, 
while the percentage of antibiotics is higher. This low compliance with the NDP policy 
and the difficulty with the implementation of the EDP principles have several reasons. 
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First of all it is known that specialised physicians at tertiary level are more resistant to the 
implementation of an EDL. Also a higher percentage of referred patients with rarer and 
more difficult diseases, which are possibly not covered in the Standard Treatment 
Guidelines (STGIEDL) and require special drugs not on the EDL. 
Overall, the apparent compliance probably being more to do with the limited range of 
drugs available at the primary level did not adhere to prescribing indicator standards as 
much as expected. 
The next question "Is there a difference in the eight indicators between the two tertiary 
care hospitals. The measure will be a direct comparison between the two hospitals with 5 
clinics and the overall average for all clinics. The hypothesis is that although Pietersburg-
Mankweng hospitals are considered a complex, each serves a very different population 
that could have a significant effect on the outcome indicators. 
Pietersburg Hospital was a segregated hospital that treated only white patients. Today, it 
also treats black patients. It is located in the center of town, only minutes from the 
Provincial Department 0 f Health. Mankweng Hospital still treats only black patients and 
is located about 25 miles away from the center of the town and is surrounded by black 
townships. 
Mankweng Hospital has the higher number of mean drugs per prescription and the higher 
proportion more than (>2) two drugs. Also, it has lower proportion of EDL prescribing, 
but the proportion of EDLBRD drugs is higher than Pietersburg. Overall, the evidence 
does not support that one tertiary complex is better overall. 
7.4.2 Overall Ranking List of Prescribing Outcome Indicators 
Analysis Two 
Now that all eight prescribing indicators have been evaluated separately, and all the 
clinics can be ranked in a final analysis ( Table 7.22 ). This comprehensive table sums the 
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separate indicator scores for a final ranking of the adherence to the EDP with adjusted 
coefficients. The best score would be 8 (lst rank for all 8 indicators), while the worst 
score would be 88 (lIth rank for 8 indicators). In Tables 7.22 and 7.23, the ranking is 
from the most adherent to the EDP with the lowest score to the least adherent with the 
highest score. This overall ranking by adherence provides quantitative evidence about the 
extent of adoption of the EDP principles in the health care system. 
Adherence Ranking (Table 7.22) 
The extent of adoption of EDP principles by the different clinics that use the eight 
prescribing indicators is summarised in Table 7.22 using the non-corrected model. 
Table 7.22 Simple Rank List for Adherence to Prescribing Indicators by 
Clinics 
Overall 1 2 3 3 4 5 5 6 7 8 9 
Rankin2 
Clinic 6 9 J5 11 10 1 8 J 7 2 4 
Mean No. 3 6 8 11 9 10 4 2 5 1 7 
<2 Drugs 5 7 8 11 4 9 3 2 6 1 IO 
Generic 1 5 6 3 2 4 IO 11 7 9 8 
[DL 2 5 6 4 3 1 10 8 7 11 9 
[DLBIW I 2 3 5 10 6 4 11 8 9 7 
Antibiotic 6 4 3 2 1 9 5 10 7 11 8 
AnalgeJic 6 7 2 I 3 4 8 5 10 11 9 
Injection 3 1 5 4 IO 7 6 2 11 9 8 
Total 27 37 41 41 42 SO SO 51 61 62 66 
~cflre 
The scores range from 27 to 66. Clinic 6 has the lowest score of 27 and is ranked first for 
adherence to the EDP, while Clinic 4 was ranked last with a score of 66. This overall 
ranking using all 8 prescribing indicators summarises the data which shows that the 
adoption of the NDP principles Is only in the beginning stages and can be much 
improved in all researched clinics. These results were not unexpected or surprising. 
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Adjusted Ranking (Table 7.23) 
The rank list of adherence to EDP principles using the eight prescribing indicators in the 
adjusted model is provided in 7.23. A low total score signifies good adherence, a high 
total score worse adherence. 
Table 7.23 Rank List Using Adjusted Coefficients of Prescription Indicators 
Overall 1 1 2 2 3 4 5 6 7 8 8 
Ranking 
Clinic 6 8 J 9 5 11 10 2 1 7 4 
Mean No •. 3 4 2 6 7 II 8 I 10 5 9 
<2 Drug5 5 4 2 7 8 II 3 I 9 6 10 
Generic II 2 1 7 6 9 11 3 8 5 4 
EDL 2 10 8 5 6 4 3 11 1 7 9 
EDLBRD I 4 11 2 3 5 10 9 6 8 7 
Antibiotic 7 3 10 4 5 2 1 11 9 8 6 
Analgesic 6 7 4 8 2 1 3 11 4 10 9 
Injection 3 4 2 1 6 5 10 7 9 11 8 
Total 38 38 40 40 43 48 49 54 56 62 62 
Score 
Table 7.23 evaluates the adjusted ranking of adherence to prescribing indicator goals. 
The scores range from 38 to 62. Clinics 6 and 8 have the lowest score of 38 and are 
ranked first, while Clinics 4 and 7 are ranked last with a score of 62. 
The overall rankings in Table 7.22 and 7.23 can reveal a part of the NDP rational 
prescribing implementation. It shows that the goal of rational prescribing and adhering to 
its target goals does not appear to have taken affect by prescribers from the relative 
spread of the sores from 38 to 62. The primary care clinics have the highest adherence 
ran kings and overall the lowest adherence rankings along with a tertiary clinic. 
144 
7.5 Comprehensive Correlation Matrix of Prescribing Indicators 
Analysis Three 
Rank Correlation Coefficients Using the Simple and the Adjusted Model 
In this section, two correlation tables are calculated from the simple ranking and from the 
adjusted ranking of the clinics using the eight indicators for rational drug prescribing. 
Some clinics could be considered more successful at the implementation of the NDP than 
others. This would show in positive correlation of the ranks of several or all the eight 
prescribing indicators. 
Looking at the adjusted correlation (Table 7.24) for all clinics a little closer there are 
some comments worth making. The high and significant correlation between mean 
number of drugs per p~escription and proportion of prescriptions with more than 2 drugs, 
also between proportion of drugs prescribed generically and proportion from the ED list, 
are entirely expected; it would be surprising if they did not occur. No other correlations 
are significant. Of these most correlations with mean number of drugs and with 
proportion of prescriptions with more than two drugs are negative, whereas most other 
correlation pairs are positive. 
Positive correlations are expected although most are insignificant. THe absence of 
significant correlations suggests that there is little evidence of coherent and concerted 
implementation of an EDL policy. For example the weak correlation between 
prescribing from the ED list and reducing antibiotic prescribing (0.26) suggests that a link 
between improving both activities are not well established. 
The negative correlations suggest that hospitals doing well by reducing polypharmacy are 
doing badly on generic prescribing, ED list prescribing, and antibiotic prescribing. This, 
of course, is further evidence against a concerted implementation of policy by suggesting 
that reductions in overall prescribing by some hospitals are not accompanied by reduced 
antibiotic prescribing or greater use of generic or ED list drugs. 
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Table 7.24 Correlation Coefficients of Ranked Prescribing Indicators Using 
Adjusted (age and gender) Model 
Mean No >2 Generic EDL EDSRD AS AG INJ 
Dru~s 
Mean No 1.0000 
>2 Drugs 0.8455* 1.0000 
Generic -0.4909 -0.3636 1.0000 
EDL -0.5182 -0.3818 0.8818* 1.0000 
EDBRD -0. 1364 -0.4455 0.4182 0.3273 1.0000 
AS -0.5364 -0.3273 0.4364 0.2636 0.3182 1.0000 
AG -0.5115 03141 0.4307 0.5832 0.0987 0.4576 1.0000 
INJ 0.3636 0.1182 -0.1364 -0.0727 0.4636 0.0455 0.1256 1.0000 
Analysis three, the comprehensive correlation matrix of prescribing indicators for all the 
clinics showed several significant correlations. However, overall there is little evidence 
of a comprehensive coherent implementation of the EDP by individual clinic. Perhaps 
there is one level of clinics that are doing better .. 
To determine if there is a difference in adherence by level of care between prescribing 
with or without chronic illnesses, a forth analysis will look at the eight indicators by 
hospital clinic level. 
7.6 Chronic Illnesses and Prescribing 
Analysis Four 
7.6.1 Introduction 
Chronic illnesses have become a major factor in the morbidity and mortality of South 
African adults. The three chronic illnesses evaluated for this study are hypertension, 
diabetes, and asthma, and the combination of these illnesses. 
Analysis of the prescribing pattern for these chronic illnesses using the eight prescription 
indicators is important to answer the question if these very common chronic iIInesses are 
treated using STO guidelines and EDL drugs. 
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Overall the study population was 1,204 prescriptions from the same number of 
individuals. Of 1,204 people, 429, or 36.6% of patients were identified as having one or 
more of the three chronic illnesses evaluated. The next question was in absence of a 
facility/professional referral system in which patients are referred from a lower technical 
level of care (primary),"at what level do these patients present themselves (through 
fonnal and self-referral)? The level of care and the eight outcome indicators are 
important components in evaluating and comparing these chronically ill patients to the 
overall patient population of this study. 
Table 7.25 Proportion of the Chronic Illnesses of Hypertension, Diabetes and 
Asthma 
Level Pietersburg- I Mankweng- Secondary Primary 
Tertiary Tertiary 
Total 620 370 214 
- - . 
Cbronic 222 114 93 
% 36.80 38.91 43.45 
Cbron. 
_.-
--
Clinicll 1 2 J 14 5 6 7 8 9 10 J1 
Total 224 78 97 7S 145 144 101 126 123 39 52 
No 106 6 7 20 83 60 29 25 53 14 26 
Chronic 
~. 47.32 7.69 7.22 26.67 57.24 41.67 28.71 19.84 43.09 35.90 50.00 
Chronic 
7.6.2 Chronic Illness, Hospital and Level of Care 
According to the Primary Health Care foundation of the South African Department of 
Health a majority of patients, especially those with chronic illnesses should have access 
and be treated at the primary level. If the treatment is not successful, then a professional 
referral to the secondary level or tertiary level is needed. 
The primary care level is expected to successfully treat the majority of cases of chronic 
illnesses. The secondary level is expected to have fewer cases and the tertiary level, even 
fewer still. This assumption is based on the theory that basic illnesses, especially chronic 
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Total 
1,204 
429 
36.61 
Sum 
1,204 
429 
36.61 
illnesses are treated at the pnmary care level, while the more advanced diseases or 
unmanageable chronic cases are treated at the tertiary level. At the primary care level the 
common chronic illnesses of hypertension, diabetes, and asthma can be effectively 
followed and treated. 
Table 7.26 Chronic Illness and Hospital Care Level 
Level Tertiary Secondary Primary Total 
Patients No. "10 No. "10 No. 'Yo No. "10 
Total Patients 620 51.6 370 30.7 214 17.8 1,204 "10 
Chronic Illness 222 51.7 114 33.5 93 21.6 429 90.88 
> I Chron. Illness 20 4.23 15 3.17 8 1.69 43 9.11 
Total Chronic 242 51.2 129 27.3 101 21.3 472 100 
Hypertension 173 54.4 74 23.2 71 22.3 318 100 
Diabetes 48 52. 37 40.2 7 7.6 92 100 
Asthma 21 33.8 18 29.0 23 37.0 62 100 
7.5.3 Evaluation of the Eight Prescribing Indicators for Chronic Illnesses 
Indictor One: Mean Number of Drugs per Prescription 
The recommended value remains the same for chronic patients, two drugs or less per 
prescription, even though it would seem that those with chronic illnesses would need 
more medications. 
Evaluating these chronic illnesses by level of care (Table 7.27) shows that the primary 
care level had at 37% the highest proportion of those with asthma. In addition, the 
proportion for both hypertension and diabetes was the lowest at 22.3% and 7.6% 
respectively. The secondary level has the lowest proportion, 29.0% of asthma. Overall, 
tertiary care had the highest proportion of chronically ill at 51.1 % of the entire 
population. In addition, it has the highest proportion for hypertension, 54.4%, and 
diabetes 52.1 %. 
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Table 7.27 Chronic Illnesses and the Mean Number of Drugs 
S-Rank 1 2 J 4 4 5 6 7 8 9 10 
Clinic 2 7 J 4 6 5 9 8 1 10 11 
No 16 89 22 63 189 280 188 92 399 65 129 
Drugs 
NoRX 6 29 7 20 60 83 53 25 106 14 26 
DrugIRx 2.66 3.06 3.14 3.15 3.15 3.37 3.54 3.68 3.76 4.64 4.96 
CoctT. -0.906 ·0.422 -0.568 -0.348 -0.430 -0.234 0.011 0.237 0.199 1.016 1.444 
P Value 0.080 0.096 0.239 0.242 0.028 0.169 0.957 0.378 0.202 0.004 0.000 
A-Rank 1 4 2 5 J 6 7 9 8 10 11 
In Table 7.28, there is a difference between the adherence (S-Rank) in the simple model 
and the A-Rank in for several clinics, but most profoundly for clinic 7 which is ranked 
2nd for adherence and 4th for the adjusted coefficient. 
Clinic 2 is ranked first with 2.66 drugs per prescription, 0.9 drugs less than average. None 
of the clinics meet the recommended standard, although some are doing better than 
others. The clinics with the highest number or prescriptions are at the primary level, 
clinic 10 with 1.0 drugs more than average and clinic 11 with 1.4 drugs more. 
Indicator Two: Proportion of Prescriptions with More than Two Drugs 
Analysis of the proportion of prescriptions with more than two drugs is an important 
indicator for the adherence to EDP principles. The value remains the same for chronic 
illnesses, two drugs or less for at least 90% of the prescriptions 
Table 7.28 Chronic Illness and Proportion of >2 Drugs per Prescription 
S-Rank 1 2 J 4 5 6 7 8 9 10 11 
Clinic 2. J 7 8 6 4 9 5 1 10 11 
No. Drug 6 7 29 25 60 20 53 83 106 14 26 
No. >2 3 4 20 16 45 15 42 66 93 13 25 
Of. >2 50.0 57.14 68.97 64.00 75.00 75.00 79.25 79.52 87.74 92.86 96.15 
CoefT. 0.219 0.287 0.681 0.565 0.849 0.966 1.195 0.977 1.911 3.121 7.237 
P Value 0.050 0.093 0.387 0.206 0.644 0.949 0.642 0.941 0.058 0.237 0.041 
A-Rank 1 2 4 J 5 6 9 7 8 10 11 
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The range of prescribing more than two drugs (Table 7.28) is from 50.0% to 96.2% of all 
prescriptions; the average for all clinics is 90.1 %. Nine of eleven clinics have more than 
60% prescriptions with more than 2 drugs. Clinics 2 and 3, at the tertiary level are ranked 
first and second. 
The adjusted (A-Rank) and adherence (S-Rank) models have the same ranking for all the 
clinics. Clinic 2 is ranked first and is 78% less likely to prescribe more than 2 drugs per 
prescription. At the opposite end of rational prescribing, clinic 11 is ranked last and is 
more than 7 times more likely to prescribe more than 2 drugs. 
Indicator Three: Proportion of Generic Drugs 
The question is "What proportion of drugs has been prescribed as generic?" The 
recommended value remains the same for chronic illnesses, 95% or more for generic 
prescribing. 
Table 7.29 Chronic Illness and Proportion of Generic Drugs 
S-Rank 1 2 3 4 S 6 7 8 9 10 11 
Clinic 2 10 6 4 7 1 11 S 3 9 8 
No. Drug 16 6S 189 63 89 399 129 280 22 188 92 
No. 9 3S 96 30 42 188 S3 106 8 60 19 
Generic 
~o Generic 56.25 53.85 50.79 47.62 47.19 47.12 41.09 37.86 36.36 31.91 20.65 
CoetY. 1.610 1.700 1.448 1.186 1.270 1.210 0.911 0.831 0.785 0.649 0.359 
P Value 0.307 0.030 0.023 0.487 0.258 0.122 0.613 0.184 0.559 0.009 0.000 
A-Rank 2 I 3 6 4 S 7 8 9 10 II 
The range of prescribing of generic drugs (Table 7.29) is from 20.7% to 56.3% of all 
prescriptions. The average of generic prescribing is 42.2%, well below the recommended 
value of 95% of all drugs. Clinic 2 at the tertiary level, and Clinic 10, at the primary care 
level are ranked first and second for adherence with 56.3% and 53.9% generic 
prescribing respectively. The lowest level of generic prescribing is 20.7% by clinic 8, at 
the secondary level. 
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The adjusted (A-Rank) and adherence (S-Rank) models have slightly different rankings 
for all the clinics. Clinic lOis 70% and clinic 2 is 61% more likely to prescribe the 
average generically. Clinic 8 is 64% less likely to prescribe generically. 
Overall, the evaluation of prescribing for chronic illnesses does not show evidence of 
higher generic prescribing than the general study population. 
Indicator Four: Proportion EDL Drugs 
The question is "What proportion of drugs prescribed for those with chronic illnesses are 
on the EDL?" The recommended value remains the same for chronic illnesses, 90% or 
more for EDL prescribing. 
Table 7.30 Chronic Illnesses and Proportions of EDL Drugs 
S-Rank 1 2 3 4 5 6 7 8 9 10 11 
Clinic 1 2 10 6 7 3 4 11 9 5 8 
No. Drug 399 16 65 189 89 22 63 129 188 280 92 
No.EDL 181 7 27 78 35 8 21 41 52 76 14 
0/. EDL 45.36 43.75 41.54 41.27 39.33 36.36 33.33 31.78 27.66 27.14 15.22 
Coeff. 1.611 1.387 1.397 1.357 1.287 1.182 0.961 0.902 0.723 0.704 0.351 
P Value 0.000 0.484 0.177 0.064 0.242 0.686 0.879 0.595 0.061 0.019 0.000 
A-Rank I 3 2 4 S 6 7 8 9 10 11 
Note: P values of 0.000 are <0.00 I. 
Table 7.30 the range is from 15.22% to 45.36% of drugs prescribed that are on the EDL. 
All clinics fall below the recommended value of 90%. The clinic closest to this goal is 
still 50% below the rational drug prescribing target. 
Clinic 1, at the tertiary level, is ranked first for both adherence and adjusted ranking with 
45.36% of drugs prescribed on the EDL. Clinic 8, at the secondary level, is ranked last 
with only 15.22% of drugs prescribed from the EDL. 
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The adjusted (A-Rank) and adherence (S-Rank) models have slightly different rankings 
for the proportion of EDL drugs. Clinic 1 is 61 % more likely to prescribe drugs on the 
EDL, while clinic 8 is 65% less likely to prescribe drugs on the EDL. 
The goal for prescribing drugs from the EDL at least 90%, but the results show that the 
clinic with the highest proportion ofEDL prescribing is still 50% lower than desired. The 
other prescribers in the other ten clinics are off the mark by 50% to 80%. Treatment of 
chronic illnesses using the Standard Treatment Guidelines (STG) and EDL drugs was 
expected to be higher than for all illnesses together, since the treatments are widely 
accepted and the necessary EDL drugs are readily available. But, surprisingly, analysis of 
the prescribing pattern for chronic illness shows that the implementation of the STG/EDL 
has not been as successful as expected. 
Indicator Five: Proportion of Brand and Generic Drugs on EDL 
The question is "What proportion of brand and generic drugs prescribed for those with 
chronic illnesses are on the EDL?" The recommended value is 95%. Prescribing in brand 
name is acceptable if there is a generic equivalent drug on the EDL, which can be 
dispensed. Which name is used for a drug is not important as long as it is on the EDL, 
and the patient gets the drug intended. 
Table 7.31 Chronic Illness and Proportions of Brand & Generic (EDLBRD) 
Drugs on the EDL 
S-Rank 1 2 J 4 5 6 7 8 9 10 
Clinic 6 8 4 9 3 7 5 1 11 10 
No. Drug 189 92 63 188 22 89 280 399 129 65 
No. 167 76 52 154 18 71 222 289 93 39 
F:DLRRD 
~. 88.36 82.61 82.54 81.91 81.82 79.78 79.29 72.43 72.09 60.00 
F.DLRRD 
Coeff. 2.087 1.379 1.449 1.233 1.645 1.193 1.141 0.759 0.746 0.409 
P Value 0.002 0.233 0.245 0.293 0.332 0.3497 0.423 0.048 0.151 0.000 
A-Rank 1 4 J 5 2 6 7 8 9 10 
Note: P values of 0.000 are <0.001. 
11 
2 
16 
9 
56.25 
0.375 
0.038 
11 
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The range of brand and generic drugs (EDLBRD) prescribed on the EDL (Table 7.31) is 
from 56.3% to 88.4% of all drugs. The average proportion of drugs prescribed from the 
EDL is 77.6% of all drugs. Clinic 6, at the secondary level, is ranked first with 88.4% for 
prescribing (brand and generic) that are on the EDL. Clinics 10, at the primary level with 
60% of drugs on the EDL and clinic 2 at the tertiary level with 56.3% of drugs prescribed 
on the EDL are ranked last. 
The ranks in the simple (S-rank) and the adjusted model (A-Rank) differ slightly for 
clinics 3, 4 8 and 9. This difference does not affect the overall results. Prescribers at 
Clinic 6 are more than 100% more likely to prescribe drugs (brand or generic) on the 
EDL. Clinics 10 and 2 are about 60% less likely to prescribe drugs on the EDL. 
The target for prescribing drugs in brand or generic name that are on the EDL is 90%. 
The results show that the clinic with the highest proportion of drugs prescribed on the 
EDL is still slightly 12% below the desired 90%. The other prescribers in the other ten 
clinics are off the mark by 20% to 60%. Thus, after accounting for those who use brand 
name or generic drugs, there is little evidence that the NDP is being successfully 
implemented through dispensing generic drugs. 
Indicator Six: Chronic Illness and Proportion of Antibiotics 
The question is "What proportion of antibiotics are prescribed for those with chronic 
illnesses?" The recommended value is less than 5%. The prescribing of antibiotics for 
those with chronic illnesses should be very low, if antibiotics are prescribed for bacterial 
infections. 
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Table 7.32 Chronic Illness and Proportions of Antibiotic (AB) Drugs 
S-Rank 1 2 3 4 5 6 7 8 9 10 11 
Clinic 4 9 6 8 11 1 10 7 S 2 3 
No. Drug 63 188 189 92 129 399 6S 89 280 16 22 
No.A8 0 1 4 2 3 10 2 3 10 I 4 
o/.A8 0.00 0.53 2.12 2.17 2.33 2.51 3.08 3.37 3.57 6.25 18.18 
Coeff. 0 0.655 2.271 2.936 3.260 3.224 4.016 5.078 4.621 8.971 40.408 
P Value 0 0.648 0.139 0.115 0.040 0.001 0.043 0.005 0.000 0.023 0.000 
A-Rank 1 2 J 4 6 5 7 9 8 10 11 
Note: P values of 0 and 0.000 are <0.001. 
In table 7.32 the range of antibiotic drugs prescribed is from 0% to 18.18% drugs. Clinics 
4 and 3, both at the tertiary level are at the opposite ends of the prescribing range and will 
be evaluated in detail. Clinic 4, the Mankweng hospital specialty clinic for chronic 
illnesses, ranks first for adherence with no antibiotics prescribed. On the other end, Clinic 
3, the Specialty clinic for Pietersburg Hospital is ranked last with 18.18% antibiotics 
prescribed. 
All but two of the eleven clinics were below the recommended 5% antibiotic prescribing, 
but clinic 2 is nearly 8 times more likely and Clinic 3 is almost 40 times more likely to 
prescribe an antibiotic to those with chronic illnesses than the other clinics. This 
evidence supports a fairly comprehensive adoption the rational antibiotic prescribing for 
the subgroup of patients with chronic illnesses or the inappropriateness of antibiotics for 
those conditions. 
Indicator Seven: Chronic Illness and Proportion of Analgesic Drugs 
The question is "What proportion of analgesic drugs are prescribed for those with chronic 
illnesses?" The recommended value is lower than or equal to the general study 
population, at 15%. Effective treatment of chronic illness would eliminate the pain 
associated with the illness, and the number of analgesics for those with chronic illnesses 
should be very low. 
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Table 7.33 Chronic Illness and Proportion of Analgesic (A G) Drugs 
S-Rank 1 2 3 4 5 6 7 8 9 10 11 
Clinic 2 11 10 7 5 8 6 1 3 9 4 
No. Drug 16 129 65 89 280 92 189 399 22 188 63 
No.AG 1 12 7 13 44 15 32 69 4 41 15 
a/.AG 6.25 9.30 10.77 14.61 15.71 16.30 16.93 17.29 18.18 21.81 23.81 
CoelT. 0.391 0.607 0.720 0.954 1.024 1.179 1.154 1.187 1.272 1.570 1.856 
P Value 0.320 0.102 0.398 0.877 0.907 0.570 0.525 0.332 0.645 0.031 0.039 
A-Rank 1 2 3 4 5 7 6 8 9 10 11 
The range of analgesic drugs prescribed (Table 7.33) is from 6.3% to 23.8% of all drugs. 
The overall proportion of analgesic drugs, Clinic 2 is ranked first with 6.3% of analgesic 
prescribing, prescribers at Clinic 2 are % less likely to prescribe analgesics. On the other 
hand, clinic 4 is ranked last with 23.8% of the drugs prescribed were analgesics. Indicator 
Eight: Chronic Illness and Proportion of Injection Drugs. 
The question is "What proportion of injection drugs are prescribed for those with chronic 
illnesses?" The value is lower than expected or equal to the general study population, at 
5% of all drugs prescribed. The hypothesis that is prescribing injections for those with 
chronic illnesses should be very low, because effective treatment of the chronic illness 
should be possible by oral medication. 
Six clinics (2, 3, 6, 9, 10 & II) did not prescribe any injections and two (clinics 4 & 8) 
prescribed only one injection. The other three clinics prescribed 5 injections (1.25%) for 
clinic I, (1.07%) 3 injections for clinic 5 and 4 injections (4.49%) for clinic 7. 
7.6.4 Overall Ranking List of Prescribing Outcome Indicators by 
Level of Adherence 
Now that all eight prescribing indicators for chronic illnesses have been evaluated 
separately, all the clinics are ranked for all the indicators except injections, in a final table 
below (7.34). The overall ranking by adherence provides separate quantitative evidence 
to support or negate findings about the extent and pattern of adoption of EDP principles 
for those with chronic illnesses. The ranking is from the most adherent to the EDP, 
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which has the lowest score to the least adherent with the highest score. The clinics are 
presented in their care level categories, because in the treatment of chronic illnesses, the 
level of care is an important factor in evaluating prescribing. Since the indicator of 
prescribing injections was not ranked, it has been taken out of this set of analyses. 
Table 7.34 Chronic Illnesses and Ranking of Prescribing Indicators Adherence 
Clinic 6 2 7 4 3 10 1 8 5 9 11 
Mean No. 3 1 4 S 2 10 8 9 6 7 11 
>2 Drug5 S 1 4 10 2 10 8 3 7 9 11 
Generic 3 2 4 4 9 1 S 11 8 10 7 
EDL 4 3 S 7 6 2 1 11 10 9 8 
EDLBRD 1 11 6 3 2 10 8 4 7 5 9 
Antibiotic 3 10 8 1 11 7 S 4 8 2 6 
Analgesic 6 1 4 11 9 3 8 7 5 10 2 
Total 25 29 35 41 41 43 43 49 51 52 54 
Score 
Overall 1 2 .3 4 4 5 5 6 7 8 9 
Ranking 
A majority of the chronic illnesses should be treated at the primary care level and should 
only be referred to tertiary level clinics, as the disease becomes more complex and 
difficult to treat. The primary care level clinics (9-11) should be able treat many patients 
with a limited number of generic drugs and should rank in the top three for compliance. 
But, Clinic 10 ranks sixth and Clinics 9 and 11, rank tenth and eleventh. 
Conversely, prescribers at the tertiary level are expected to have a lower adherence score 
because of their specialty training and consistent exposure to new brand drugs and 
usually more difficult and rare diseases. But contrary to this expectation, clinic 2 a 
tertiary specialty was ranked second overall. Specifically, Clinic 2, ranked first for the 
lowest mean number of drugs, the lowest percentage of prescriptions with more than 2 
drugs and the lowest number of analgesics prescribed, and ranked second for the higher 
proportion of prescribing generic drugs, and third for EDL drugs. 
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Ranked first for overall adherence to the EDP is Clinic 6 at the secondary level. Clinic 6 
is ranked first in only one category, the proportion of brand and generic drugs prescribed 
on the EDL (EDLBRD). In all other categories the clinic scored third or higher. The key 
to being ranked first overall is that all the indicators are ranked no higher than 6. As a 
result it is overall the best compared to the other ten clinics. 
Table 7.35. Ranking of Coefficient Indicators (A-Rank) of Prescribing Indicators 
for Chronic Illnesses 
Clinic 6 2 7 4 3 10 1 8 5 9 11 
Mean No. 3 I 4 5 2 10 8 9 6 7 II 
>2 Drug! 5 I 4 10 2 10 8 3 7 9 II 
Generic 3 2 4 4 9 I 5 11 8 10 7 
EDL 4 3 5 7 6 2 1 11 10 9 8 
EDLBRD 1 11 6 3 2 10 8 4 7 5 9 
Antibiotic 3 10 8 I 11 7 5 4 8 2 6 
AnalgcJic 6 1 4 11 9 3 8 7 5 10 2 
Total 25 29 35 41 41 43 43 49 51 52 54 
Score 
Overall 1 2 3 4 4 5 5 6 7 8 9 
Ranking 
7.5.5 Comprehensive Correlation Matrix of Prescribing Indicators 
Finally, two correlation tables (7.36 and 7.37) summarise the evaluation of the 
prescribing patterns for those with chronic illnesses. They are produced from simple (S-
Rank) ranking for adherence and an adjusted (A-Rank) ranking by evaluating the 
correlate pairs ofNDP indicators. 
The question, .. Is there evidence of a concerted and coherent implementation process of 
the EDP when prescribing for those with chronic illnesses? 
The expected value would be positive correlation coefficients across the range of 
indicators if the implementation of the EDP policy were coherent. 
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For this analysis, ranks of the seven prescribing indicators for the eleven clinics are 
entered into the analysis program Stata 6.0. If the implementation of the NDP policy is 
being executed in a consistent way, the ranks for several or all indicators should correlate. 
Tables 7.36 and 7.37 show the simple and adjusted correlation tables. 
Table 7.36 Chronic Illness and Simple Model of Correlation Coefficient of 
P 'b' I d' t reserl 109 n lea ors 
Mean No. >2 Drul!~ Generic EDL EDLBRD AB AG 
Mean No. 1.0000 
<2 Drul!s 0.8794* 1.0000 
Generic 0.3266 0.0789 1.0000 
EDL 0.1974 0.0818 0.7981 * 1.0000 
EDLBRD 0.1884 -0.2636 ·.04210 -0.4636 1.0000 
AB -0.3230 -0.3455 0.1491 -0.2909 0.5909 1.0000 
AG -0.0897 -0.0545 0.4122 0.2182 -0.7000* -0.5000 1.0000 
Note: * significance to 0.005, 
The correlations for chronically ill patients show a similar lack of evidence for a coherent 
EDL policy as seen in the all-patients table although there are subtle differences. There is 
a single significant correlation apart from the two expected values; that between ED list 
prescribing (even though prescribed by brand name) and analgesic prescribing. The 
correlation is strongly negative but the correlation pair is not particularly meaningful, 
especially since the other (EDL) Essential Drugs List/analgesic correlation does not 
concur with it; it being weakly positive. It could be that the significant correlation has 
arisen by chance even though the statistical test suggests otherwise. 
Other correlations are weak and positive and negative values appear to be distributed 
fairly randomly in the table, without the bunching of negative values associated with 
polypharmacy seen in the all-patients table. For chronic patients therefore, there does 
seem to be a correspondence between those hospitals better at reducing polypharmacy 
being those better at generic and ED list prescribing - but it is a weak effect and still does 
not hold for antibiotic prescribing. 
The correlation table of simple rank (adherence) (7.36) shows the expected correlations 
of "Mean No. of Drugs" with "More than 2 drugs." Unexpected was the negative 
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correlation between "Proportion of brand and generic drugs on the EDL (EDLBRD)" 
with the percentage of analgesics prescribes. 
When adjusted for age and gender (Table 7.37), the similar results are found. For, the 
adjusted ranks there is slightly more scattering of the negative correlations. In summary, 
evidence of a concerted implementation effort when prescribing for those with chronic 
illnesses is weak. 
Table 7.37 Chronic Illness and Adjusted Model of Correlation Coefficient of 
P ·b· I d· rescn 109 n lcators 
!\lean No. >2 Drug, Generic EDL EDLBRD AB AG 
Mean No. 1.0000 
>2 Drug~ 0.7909* 1.0000 
Generic 0.2091 -0.0273 1.0000 
EDL 0.2182 0.0091 0.8364* 1.0000 
EDLBRD 0.3364 0.3182 -0.4364 -0.3364 1.0000 
AD -0.3636 -0.4091 -0.2182 -0.2455 0.3818 1.0000 
AG -0.0818 -0.0273 0.5545 0.2636 -0.7182* -0.5545 1.0000 
j\iote: * Significance to 0.005. 
7.6.5 Chronic Illnesses and Prescribing Indicators by Clinic Level (Primary, 
Secondary, Tertiary) 
This final analysis evaluates chronic illnesses and prescribing indicators by clinic level 
(Table 7.38). The eight prescribing indicators are evaluated by level of care (primary, 
secondary and tertiary) to show if there is a difference in chronic care prescribing 
between the three levels of care. The question is "If individual clinics have not adopted 
EDP principles is there evidence that different levels of clinic (primary, secondary, 
tertiary) have done so to a different degree? 
Table 7.38 Chronic Illnesses and Prescribing Indicators by Clinic Level 
Level Primary Secondary Tertiarv Average 
Chronic 101 129 242 472 
% Chronic 21.1 27.3 51.2 100 
Mean No 4.33 3.25 3.19 3.5 
>2 Dru2~ 95.2 83.2 82.7 90.0 
Generic 42.2 39.4 45.0 42.1 
[DL 33.6 31.9 37.1 35.2 
[DBRD 71.3 83.5 74.4 77.6 
AD 7.3 10.1 20.0 10.1 
AG 63.9 56.7 62.3 51.6 
INJ 0 7.0 3.0 3.3 
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Evaluation of the eight indicators for the three levels of care (Table 7.38) shows that 
similar to the overall results of all patients (Table 7.22) the primary level care level has 
the highest number of drugs per prescription and of more than 2 drugs. It also had the 
lowest level of antibiotic and injection prescribing. In addition, like the overall patient 
evaluation, the primary care level once again had the highest proportion of analgesic 
prescribing. The most noticeable indicators that are supportive evidence of a beginning 
implementation of EDP principles are antibiotics and injection prescribing. 
The secondary care level had the lowest proportion of generic and EDL prescribing. 
While, similar to the overall study population, it has the highest proportion of Brand + 
generic drugs (EDLBRD) that are on the EDL. Most striking is that the secondary care 
level has the highest proportion of injections much higher than the primary and tertiary 
levels. The low percentage of prescribing generic and EDL and high injection prescribing 
shows that EDP principles have not been adopted at the secondary level. For the tertiary 
care level, more difficult to treat diseases and a hither resistance towards implementation 
of the EDL, it was expected that the compliance with EDP principles analysed by using 
the prescribing indicators for chronic illnesses would be lower. Instead, the results show 
that the tertiary care had the lowest mean number of drugs and proportion of prescriptions 
with more than two drugs per prescription. In addition it also had the highest proportion 
of generic, EDL, and antibiotic prescribing. 
Overall, the evidence supports that on the tertiary level there is overall appropriate 
prescribing which could be interpreted as a small shift towards the adoption of EDP 
principles for patients with chronic illnesses, while at the primary and secondary level 
there is show little evidence of rational prescribing for those with chronic illness. 
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Chapter Eight 
Interviews and Structured Observations 
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8.1 Introduction to Qualitative Results 
This chapter presents data from the interviews and structured observations. The in-depth 
interviews were conducted with 20 health professionals who work in or with the Northern 
Province hospital clinics as nurses, pharmacists, physicians and administrators at various 
levels of care. 
Interviews were conducted with nurses, pharmacists, physicians and administrators to 
gather information about their perceptions of the STGIEOL. The acceptance of the 
STGIEOL and the knowledge, attitudes and practices in these different groups of health 
professionals are important factors for prescriber compliance and the practical 
implementation of the NOP. 
This chapter presents the interviews of health service providers and administrators. 
Health professionals that work in hospital clinic nurses, physicians and pharmacists were 
interviewed between October and November 1999 at the hospital on the day that 
prescribing data were collected. The interviews were conducted individually about their 
experiences of learning about and using the EDL Demographics of these respondents are 
provided in Box 8.1. The second set of interviews was conducted with health 
administrators who work on the provincial and national level. 
In this chapter only issues concerning the implementation of the NOP raised in these 
discussions are identified. Summary details of the administrators interviewed are 
provided in Box 8.2. Interviews were conducted in a private room within the health 
facility with the health providers and at various locations with the administrators. Health 
providers were and recruited for the interviews on the basis oflevel of facility and type of 
provider. 
Box 8.1 Interviews with Health Professionals 
162 
• 16 respondents: 9 male and 7 female 
• 3 Nurses ( 1 male, 2 female) 
• 5 Pharmacists (all female) 
• 8 Physicians (all male) 
• Age range: 20-60+ 
• Level of service: 6 work in Primary, 3 Secondary, and 7 Tertiary Hospital Clinic 
• Years of experience: had between 3 had >1 year; 0 hadl-5 years; 7 had 6-10 
years; 4 had 11-20 years; 1 had 20+ years. 
The four administrators interviewed were chosen for their role in the implementation of 
various aspects of the NDP and RDU in the Northern Province. The administrators were 
asked directly for an interview and all complied with the request. From the Northern 
Province Department of Health, both the Director of Health Care Support and Auxiliary 
Services and the Deputy Director of Pharmaceutical Services were interviewed. Also at 
the provincial, but private level, the Programme Manager of Hospital Systems for VUNA 
Health Care Logistics (drug depot) was interviewed. At the National level, the Director of 
RDU training and research and Professor at MEDUNSA was interviewed. 
Box 8.2 Interviews with Administrators 
• 4 Respondents: all male 
• 2 pharmacist 
• 1 physician 
• 1 manager 
• Age range: 2 are 40-59, and 2 are 60+ 
• Level of responsibility: 3 Provincial, 1 National 
• Years of experience: more 1 with 6-10 years, 3 with than 16 years, 
The interviews were conducted to gain a better understanding of the underlying reasons 
for the results of the drug utilisation study data of 1,204 prescriptions. The four main 
areas explored in the interviews are demographic data, knowledge, attitudes, and 
practices of the hospital clinic staff. 
The nature of the interviews was informal, based on a guiding list of questions 
(Appendix S), rather than a structured questionnaire. The intention of the interviews was 
to allow the interviewees to discuss their own experiences assessing and using the EDL 
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and rational prescribing guidelines. Interviews with health professionals who work at the 
clinic level foc~sed on their experiences with the implementation of the EDL. 
The interview with health administrative, in contrast, were focused on the plans of 
implementation, and the four areas of review, knowledge, the EDL for adults at hospital 
level, including Budget limitations for non-EDL drugs, Pharmaceutical Therapeutic 
Committees (PTC), and Peer Review (PR). The topic "attitude" will include attitudes to 
the implementation of the EDL and brand drugs; training, PTC, and PRo "Practices" will 
include the multiple issues of prescribing. 
In both groups of interviewees the discussion also raised come issues about public 
hospital care, financing and the mandated policy from the national level that is 
implemented at the provincial and local levels. In short, the hospital staffs were 
interviewed with a focus on their knowledge, attitudes and practices of RDU, while the 
administrators were interviewed with a focus on the understanding of the implementation 
of the National Drug Policy and Rational Drug Use. 
After literature review and preliminary discussion with health professional and 
administrators, the three main topics of Knowledge, Attitudes and Practices, were chosen 
to evaluate the understanding of the National Drug Policy. And further, the Rational Drug 
Use implementation process as experienced by the professionals themselves and the 
intentions of the implementation to be carried out by the administrators. 
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8.2 NURSES 
8.2.1 1Introduction 
In hospital clinics, unlike many primary and rural clinics, nurses do not prescribe 
medicine, because usually a physician is available. Nurses, by law may prescribe a basic 
level of drugs, diagnose diseases and determine if a referral to a secondary or tertiary 
hospital clinic is needed. 
8.2.2 Nurses Knowledge of EDL 
To assess knowledge about the STG/EDL, the nurses were asked, "Were you or your 
colleagues informed about the new STGIEDL?' 
All the nurses interviewed said that they knew very little about the use of the new 
STGIEDL at the hospital clinic level. When asked if they were informed about the use of 
STGIEDL for adults at the hospital level (1998) the responses included, 
"Not yet. (I-II), " and "Just a little. We djdn't get that much information. "(1-5). 
Although nurses were not formally informed about the STG/EDL their Attitudes and 
Practices are an important factor in determining the success ofNDP implementation. 
8.2.3 Nurse Attitudes and Practices 
Most of the nurses who shared their attitudes about the use of the EDL and training also 
talked about their role and its connection with other staff, pharmacists and physicians. 
The attitudes are developed especially within the responses about their professional 
practice. The practice issues include a) change in the work environment, b) EDL use, c) 
training, and the use of d) Pharmaco-Therapeutic Committee (PTC) and Peer Review 
(PR). Each will be looked at sequentially. 
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a) Change in Nurses Work Environment 
Successful implementation of the EDL, as a cornerstone on diagnosis and treatment of 
adults in the hospital clinic, would translate in a noticeable change the work environment 
would be noticeable not only for nurses, but also their health professional colleagues. The 
question, is 'Has the EDL affected the way you work?' 
The responses varied from no change to a significant change in the work environment. 
One of the changes is the new EDL (1998) for the hospital level stressed health education 
for patients and at times not prescribing a medicine. However, nurses feel the pressure of 
patients demands for a drug, without the drug they fell that they have not received 
treatment. One nurse stated, 
"Our problem is that patients are used to drugs, and when you give them health 
education you know they don't (want it). For example for a cough and sniffles, this one 
says you must boil water, to get them (to) drink. So patients like the P.H. (public health 
worker to) give them drug, not, you know, health education. They are getting used to it 
now. " (1-2) 
One nurse responded to the question of change in the work environment by stating that 
the changes were not significant. 
"No, not so much. Sometimes there seem there is (no) time to talk about this (EDL), 
because there are a lot of people. We see a lot of patients. I think there's not much time to 
talk about it. It seems, when I checked the new one there was no effect. There was not (a) 
lot of difference It seems as if some of the things (on the new EDL) are (the) non-drug 
treatment it emphasises, but I think it is additional. " (1-2) 
While the nurse (1-2) did not believe that the EDL had an effect on their working 
environment, it did have an impact. 
"This new one (STG/EDL) has more health education to tell these people what they can 
do at home. So this new one talks more of health education" (1-5). 
Another nurse stated, "It has made a difference. I think the EDL is very much 
advantageous because it's simple. According to me it's simple. The MIMS is very 
complicated. We use it when we want some of the drugs. MIMS is drug orientated, but 
this EDL, having this EDL is simple, even though we can not use it most of us. It is 
simplified ... 1 think even this EDL must be for nurses really . ... " (1-2). 
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When asked if they use other materials for diagnosis and prescribing and if they prefer 
these materials. One response was: 
"We have got some notes. We've got some MIMS. We have got some journals from 
workshops. We have some papers from workshops. Those are very good, because 
everything is covered But it is not enough. I think the EDL can do a lot. It is guiding us 
how to prescribe. "(1-2). 
In summary, for nurses, the effect of the EDL in the work environment is.llon-existent to 
small. Since, by law nurses can evaluate and prescribe for patients with minor ailments, 
they feel that in order to do their job well, they need to be included in the adoption of the 
STGIEDL. The EDL did not bring changes in the way they practice or their environment. 
The EDL is seen as simple and advantageous with more drugs on the list, and a new 
emphasis on prevention. 
b) Training in EDL 
Training to increase nurses' knowledge about and the use of the EDL for Primary Health 
Care (1996 Edition) for the primary health care started at the local clinic level in 1996 
(MEDUNSA, 1998). The question is ' Were you or your colleagues trained to use the 
newEDL?' 
Nurses are the professional cornerstones of most community and many primary hospital 
clinics, especially in majority black populous or rural areas. Nurses must examine, 
diagnose, prescribe, and follow-up with patients who are rarely able to get a consultation 
with a physician. Thus, nurses are usually the first to diagnose and treat patients. One 
nurse stated, 
"I think we need to have ... a lot of time (for training), because we are the (main) people 
who are staying with the patients. So, but, it seems that some times they ignore us the 
nurses. " (1-6) 
All the nurses responded that they were not trained to use the new EDL. However, all 
believed that training was imperative to their effective nursing skills. One explained, 
" ... Nurses who are prescribing need some sort of training. It might be a week or two or 
three. Even ifwhen we go to school for this nursing. The schools are not the same. Some 
emphasise pharmacology, some emphasise diagnosis, so what we have here (training/or) 
all people working in the primary health (care, who are) prescribing and diagnosing. 
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Some times the most (difficult) problems are the drugs because the drugs are very 
dangerous. So when need to insure aform of training to all the people working here. " (1-
2) 
Another nurse agreed, "These people must teach (the use of the EDL), we (need) 
education so that we are able to (do) what is expected" (1-5). 
One nurse spoke of the need for EDL training in the context of nurse autonomy to service 
patients, the conflict over professional lines of service, and a team approach. The nurse 
states, 
"We see patients. Now we can diagnose patients. We can see (patients who have the) 
most simple diseases, minor aliments. I think they must allow nurses to decide what they 
must do. But not only decide (treatments from) the pharmacist, the doctors, but (also) we 
nurses. I think because we are doing primary health care nursing, then some of the work 
is advanced because we diagnose. " (1-2) 
When asked about whom should be trained in using the EDL, all the nurses interviewed 
thought that all healthcare workers should be trained. 
"I think (training should be) for both doctors and nurses. Really we must cope with the 
changes, new technical (materials). Yea, (all the) time, things are changing. But if we 
really took some steps with the changes things will be much easier for us" (1-11). 
In summary, overall nurses believe that training is an important component of fulfilling 
their professional role. However, at all levels, few nurses at the hospital level were 
trained or educated about the adult hospital STGIEDL. 
c) Pharmaco-Therapeutic Committee (PTC) and/or Peer Review (PRJ, 
Interdisciplinary meetings 
The two questions are First, 'Have you heard about the PTe committees and/or Peer 
Review? Second, 'Should there be interdisciplinary meetings? If so, with whom, and how 
often? ' 
The Pharmaco-Therapeutic Committee and Peer Review are interventions that allow for 
the participants to assess their. peers and learn from one another. Hospitals staff is 
amenable to participating in an inclusive PTC or PR are more likely to confonn and co-
operate in working as a team, and to adopt RDU prescribing and training 
recommendations. 
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Nurses interviewed were supportive of having PTC in which the entire health team that 
would include physicians would actively participate in assessing difficulties with 
treatments and prescribing. The PTC is useful for both the staff and patients. 
"Maybe we prescribe drugs that are not effective, or even we see their problems. Since I 
have been in this field I can detect what these doctors are doing. I can detect very quickly 
if the doctor is doing something very good. And even he can detect if I am doing good or 
bad. So if we have meetings I think it will be better. The care of the patient will be highly 
improved. "(1-2) 
Currently, nurses are not usually included in PTC or other treatment - prescribing 
meetings. To meet as a multi-professional team is better not only for the staff, but also for 
the patients. 
"They need to be there, the doctors and pharmacists. I think the pharmacist is a ref 
(referee). Even the doctors do not know drugs, the pharmacists, (and) only the 
pharmacist know(s) drugs very (well). We diagnose patients, and prescribe medicines, 
but most of the time, our pharmacists know the drugs. It would be very interesting if the 
pharmacists talked with the doctors. " (1-2) 
Although PTCs with a multi-professional team are recognised by health professional to 
be a great ben~fit, it is not occurring. 
"It is not happening because some of the doctors are not aware that we can even do 
(prescribing), If we can come together to discuss (prescribing), then in time we will be 
very careful for what we are doing. The (PTe) 1 think (will) improve our communication 
and care for patients. "(1-2) 
The PTC meetings with PR are effective when conducted monthly, with representation 
from all staff. PTCs improve staff communication, prescribing, and patient care. 
Summary of Nurse Interviews 
The three nurses interviewed, work at all three hospital levels and have between six and 
sixteen years of experience. Nurses at all three levels said that they did not have useful 
knowledge about the EDL. Thus far their work environment had not changed as a result 
of its implementation. The new EDL has more drugs on the list, but it has a public health 
oriented emphasises on both prevention and health education for patients. Overall, the 
nurses interviewed stated that they think that the STGIEDL is simple and advantageous. 
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In summary, nurses would like to be trained in the use of the STG/EDL. Training would 
allow nurses to respond to the change positively. Also, they would like to actively 
participate with other health care providers on the hospital PTe committee. In order to 
promote improved communication, effective prescribing, monitoring, and thus improved 
patient care. 
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8.3 PHA&\1ACISTS 
8.3.1 Introduction 
Pharmacists were asked the same questions (Appendix S) as nurses, with additional 
attention to the change in their work environment. The work environment change 
includes, filling all prescriptions with generic drugs, regardless of how it was written. 
Pharmacists face pressure from both physicians and patients to order brand name drugs, 
not on the EDL with the 10% of total pharmaceutical budget and to give the rugs in the 
colour and size that they know. 
8.3.2 Pharmacists' Knowledge 
The first question asked in the interview is first, 'Were you or your colleagues informed 
about the new STGIEDL? ' 
All, but one of the hospital pharmacists said that they were informed about the new EDL. 
One pharmacist stated, 
"A regional pharmacist told me about it and then she gave me a book. " (1-15) Another 
agreed, " I think we were informed by our senior pharmacist from head office that we 
were going to launch it (EDL) officially. So we knew about it before it came" (1-8). Only 
one pharmacist interviewed. said "No, I did not hear anything about it (EDL). "(I-I) 
Pharmacists were expected by hospital administrators to distribute the set of STGIEDL 
books, and to encourage and promote its use. Yet, none of the pharmacists felt that they 
had a part in either its development or implementation of the STG/EDL. One pharmacist 
said, 
"I think they (hospital staff) should (have been) consulted. All the nursing staff, the 
professional staff, (and) the pharmacist especially. JJ (I-I) 
Second. 'Do you know about motivatingfor drugs and the 10% cap on ordering non-EDL 
drugs?' 
All pharmacists had knowledge of the 10% budget restriction on non-EDL medicines and 
the "Motivation," the procedure for physician to request drugs not on the EDL. All, but 
one pharmacist had knowledge of the use of Pharmaceutical Therapeutic Committees 
(PTC), while no pharmacists knew about 'Peer Review.' 
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Overall, pharmacist had knowledge about the new STGIEDL, the 10% budget cap on 
non-EDL drugs and PTC. 
8.3.3 Pharmacists Attitudes 
a) Usefulness of EDL 
The questions are "Do you or your colleagues use the STGIEDL?" and "Are there 
advantages to using the EDL? Why or why not?" 
All of the pharmacists interviewed said that the new STG/EDL is useful for themselves 
and for other health professionals. Pharmacists use the set of new STGIEDL books 
regularly. Pharmacists interviewed believed that the STG/EDL is useful for ordering 
drugs, staying within a budget, and decreasing the number of drugs prescribed in each 
patient encounter. 
Useful for hospitals and clinics 
The use of the STGIEDL is good for "basic health care and they are using it at the 
clinics. You get the general prescribing there and general regime for all our clinics and 
hospitals. So you don't get the 'our clinic is going to order something different now' They 
have got their regime to stick to for reference. " (1-16) 
Decreases polypharmacy and Cost- Effective 
"It has made it much better. The EDL has curbed many things like polypharmacy. We 
used to get prescriptions with thirteen items on, four antibiotics. Most recent it has cut 
out and so economically we are saving in a way. Because you know for three antibiotics 
you can give only one according to the guidelines." (1-8) Another pharmacist agreed, 
"It's cost effective. " (1-8) 
Useful, but not used by Physicians 
Although pharmacists believe that the new EDL has promoted overall significant 
changes, they also believe that physicians are not using the EDL. This opinion is based 
on their observation of the prescriptions that come into the pharmacy. One commented, 
"lvlost of them (physicians) don't comply with the EDL. Most of them, I can say sixty 
percent. " (I-I) 
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When asked if the book was used by and useful for physicians, a pharmacist said, it is 
useful "just have the book around. We've got boxes and boxes, all the EDL's are there 
(in the office). In principle they should use it, maybe they don't have time to look up the 
drug. But in principle, each and every doctor has it. Our interns, even the students" 
(were given a set of (STGIEDL) (1-8) 
8.3.4 Pharmacists Practice 
Five areas of practice were covered. Four foci were specifically on the STG/EDL, while 
the other focus was PTC and peer Review. The STGEDL questions about the manner in 
which the EDL has affected the work environment, if they were trained in its use, if they 
use it regularly, and if it is advantageous to use the STGIEDL. The other foci are is PTC 
and Peer Review. 
aj Work environment 
Pharmacists at the public hospitals were the first to see and experience a change in their 
work environment, and their practice as a result of the use of the STGIEDL. 
The work environment evaluation includes 1) Training, 2) Use of STGIEDL Use, 3) 
Generic Substitution and 'Motivation.' 4) Non EDL Drugs cap of>10% of the total 
budget. Pharmacists are expected to be the gatekeeper for the ordering and dispensing of 
EDL and brand drugs. 
When asked had the implementation of the EDL made the job any different. 'Has the 
EDL affected the way you work?' 
"It has. it is easier for me what is on the EDL because it is on code. For me. when it is 
not on code. and with a limited budget. It doesn'l really sit well" (1-15). 
b) Training 
The question is 'Were you or your colleagues trained to use the new STGISDL?' 
173 
Pharmacists interviewed, with the exception of one, have had no or very little training on 
using the new EDL. "There was no training there. No they would give a (EDL) 
list .... "(1-1) 
Another concurred, 
"We only received the new book from our regional pharmacist about three months ago. 
And they were handed out to all the doctors. But we were to go through them by 
ourselves. No, we did not get any formal (training). I think that they did send some 
documentation to us. '(1-16) 
Most pharmacists agreed that training would be helpful not only for themselves, but also 
for other staff. 
"Yes, it would be helpful. Unfortunately, we were not trained, on the EDL. It was just 
{there and} we had to use it, but there was no training involved. Yea, definitely {the 
training would help} it's never too late ... You can train primary health care nurses. It is 
important to train your doctors, to train your pharmacists. Basically, those people are the 
ones that are directly involved with prescribing" (I-8). 
While only one pharmacist said that physicians did not need to be trained on the use of 
the EDL or rational prescribing. 
"No I don't think they really do. We've got very intelligent {physicians}, So it is not really 
necessary to discuss the EDL. They read it and they keep to it. They just do it on their 
own. It's self-explanatory. I know that the regional pharmacist asked (the medical 
director) if he thought it was necessary to give a talk about it. He said that everyone must 
read it first, then if they have suggestions then we can top it up on my suggestion. So 
everybody (has an EDL), there are six or seven doctors on the staff and the HIZ doctors " 
(mandatory service internship for new physicians) (1-15). 
Training could be the key to bring acceptance, ownership and compliance. 
"Maybe if they can be trained (pharmacist and physicians) they would understand it 
differently" {I-I}. 
c) EDL Training and Chronic Illness Patients 
Pharmacists, like nurses thought that the EDL is especially useful and beneficial for 
chronic patients. 
"Most of the time, /ike here in our hospital, most of the patients are referred to the clinic 
some to collect their chronic (illness) medicine. Most of the chronic patients just some 
come here to collect their medicine. Most of the chronic patients see the nurses. The kind 
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of chronic patients that are seen are " hypertensive, asthmatic, diabetic. Even rheumatic 
arthritis patients. Even the fact that those nurses at the clinic, they are prescribing. So 
they can benefit a lot of they can go, if the nurses have training" (I-I). 
d) Useo/EDL 
The questions are first, 'Do you or your colleague use the EDL?' Second, 'Are there 
advantages to using the EDL? Why or why not? 
Pharmacists use the STGIEDL for various functions including, a guide for what is in the 
pharmacy, and a guide for generic substitution. 
Pharmacists use STG/EDL to interpret prescriptions that listed brand name drugs so that 
they could substitute the appropriate generic drugs. When a prescription is sent to the 
pharmacy with brand name drugs, then the pharmacist has several options. First to send it 
back to the physician for a clarification of the drug they desire, or second, the pharmacist 
substitutes a generic drug. One pharmacist said that she goes back to the physician often 
for clarification. I go back to the physician, "if we have any drug falling in the same 
category. But, you have to consult the doctor first. But some of the things we just give. If 
they say (a brand drug), we give the generic. It depends on the substitution" (I-I). 
e) Generic Drugs 
The work environment for the pharmacists did not show a great change with the 
introduction of the STG/EDL. The exception is a physician wants a drug that is not on the 
EDL, then they should complete a 'motivation' form to request the drug. Instead, usually 
the physician asks the pharmacist to order the drug but also to fill out the motivation 
form. It is difficult for pharmacists to deny a request. 
Of the pharmacists interviewed, half believe that generic substitution has changed the 
way that they work in the pharmacy. 
J) Generic drugs and Physician Pressure 
A pharmacist who is also a provincial administrator reflecting on pharmacists filling 
brand name prescriptions with generic medicines stated, 
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"I think that has always been the problem of pharmacists and I don't think that they see it 
as difficult. I think it is a measure of the degree of the failure of the EDL to penetrate to 
whoever is prescribing. Because one of the basic ideas is to (encourage) more generic 
prescribing and that hasn't always happened. And it is also an issue of advertising of the 
user who would rather have their prescribing in a name of a particular brand, and many 
of our medical staff in particular I think are convinced the propriety brand are different 
from the generic, which is so untrue. I think that advertising, rather than logic is being 
subject (ofprescribing rather than) evidence based medicines. "(1-17) 
g) Motivation for brand drugs and Physicians 
Physicians who want brand drugs not on the EDL must fill out a 'motivation' form 
(Appendix W), but many will not and expect the pharmacist of order the drug because 
they want it. A pharmacist from a tertiary institution said, 
Physicians "do have to motivate because we find that most of the time what they need is 
not on the hospital code. So they .. .fill in a motivation form. (They must explain) why they 
want that particular drug, why they can't use the drugs that are available and then we 
send it to our depot. (I-I) 
h) Patients· and Generic Substitution 
The new STGIEDL has changed patients' perceptions about drugs. They do not like 
getting drugs that perhaps they have not seen before. "Now that the patient does not get a 
brand name drug but a generic it is a problem also. I can give you an example with 
asthma patients. 
"They would say, 'no I get this type of pump.' 'Then- the asthma 'medicine, it doesn't 
work.' (You tell them) 'it is just a different company. ' But they will say, 'not this 
(generic, it) doesn't work. I want this'. In this case there is nothing you can do. You just 
tell the patient, 'no, this one is the same. It is just from a different company.' But it's 
hard, really. It happens (all) most every day. Especially if we see this community 
(African, poor & rural). I can say about 60% or our community don't read. (I-I) 
Patient education about generic drugs has been promoted through posters. Other patient 
education could support all hospital clinic health staff who feel obliged to give the patient 
the medicine that they know and want. Patient education is an important component of 
rational prescribing. 
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In summary, the two areas in the work environment that were most affected for 
pharmacists are first, generic substitution and second, the 10% budget cap on non-EDL 
drugs to encourage cost-effective prescribing and dispensing. 
i) Pharmaco - Therapeutic Committee 
The Questions are, First, 'Have you heard about PTC committees or Peer Review? 
Second, 'Should there be interdisciplinary meetings? If so, with whom and how often?' 
Pharmacists interviewed said that they were aware of PTe committees, but have not been 
actively included. 
"We used to have meetings though I must admit, it was called 'Doctors Meetings, , they 
use to invite pharmacists. In fact all the pharmacists. It turned out to be more of a 
doctor's thing and we had ... sit there and they would discuss the cases they had, ... ' it 
didn't involve us, you know, so we had to withdraw. But, it was interesting in a way. If 
there (is) a new drug on the market they would tell you it was there. It was a nice forum. 
But unfortunately it was more for doctors. " (1-8) 
Another said that they were using some form of team meetings to discuss prescribing, 
packing, dispensing, and the EDL. 
"At this stage we have to discuss (these topics) in our meetings now and give feedback 
according to the EDL. Some of our doctors we get back (to them about their prescribing. 
I'll take an example, Flagyl, for an STD use, it is a standard dose of 5 (mg) and we get a 
packet of five and some of the doctors still prescribed (other doses) and we have to do re-
packing" (1-16). 
For drugs not on the STG/EDL, "when (there is a) Pharmaco-Therapeutics Committee 
(PTC), they sit (and) talk about it, (if) they feel that really there is a need then the drug is 
given out, but strictly on motivation" (1-8). 
One pharmacist interviewed thought that pharmacists and physicians need to work 
together, but have not in the past. This creates an additional challenge to the effective 
EDL implementation at the hospital level. 
"I can say I think the main problem is that they (physicians) are not used to working with 
pharmacists. This hospital had hospital assistants, not pharmacists. There were no 
pharmacists. Most of the pharmacists that you see (are) assistants (that) are doing the 
dispensing. So they are not used to working with the pharmacists. (Physicians) just write 
the prescription and they are used to that it goes through to (what they) want" (I-I). 
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Pharmacists believe that all health staff should be trained. Further they believe that they 
and the physicians must work together as a team to get the right medicine to the patient. 
Use were not well known overall none of the pharmacists talked about peer review. All, 
but one said they had knowledge of Pharmaceutical Therapeutic Committees (PTC). 
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8.3.5 Summary of Pharmacist Interview 
Overall, pharmacist had knowledge about the new STG/EDL, PTe and Peer Review, and 
the 10% budget cap on non-EDL drugs. Most pharmacists were given documentation 
about the adoption of the new EDL, but only one pharmacist had formal training. 
Pharmacists were expected not only to give out the STG/EDL set, but also provide 
encouragement, consultation and informal training on its use. The overall attitudes 
towards using the EDL was positive as a guide of what was on code and for cost-effective 
budgeting Pharmacists believe that it helped to decrease polypharmacy and the limit 
ordering of non-generic drugs. Both the work environment and practice of pharmacists 
have changed as a result of the EDL. Pharmacists are experiencing pressure from both the 
patients and physicians to order and dispense brand drugs. 
Pharmacist believe that training and the use of a PTe committee for all staff would be 
helpful, and relieve them of some of the pressures as the enforcer of generic drug use and 
the gate-keeper to brand drugs. Moreover, PTe inter-disciplinary committees would help 
to encourage the whole team, physician, nurse, administrator and pharmacist to work 
together, and provide the best treatment and rational prescribing. 
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8.4 PHYSICIANS 
8.4.1 Introduction 
To determine the knowledge, attitudes and practices, physicians were asked the same 
questions as nurses and pharmacists. However, the interview emphasis for physicians was 
the use of the EDL and other materials that include the South African Medicines 
Formulary (SAMF) and Merck Manual (MIMS) and their prescribing practices (number, 
generic, brand, and motivation for drugs). 
8.4.2 Physician Knowledge 
In implementing the STGIEDL physicians would have been informed, and even given a 
formal introduction and training at a staff meeting. The first step of implementation is to 
find those who are carrying out the policy information. 
The questions were asked to assess physicians I knowledge of the STGIEDL. First, 'Were 
you or your colleagues informed about the EDL? ' and second, 'Do you know about 10% 
cap on ordering drugs and motivating for drugs? I Third, 'Do you know about PTe 
committees or Peer Review?' 
aJ 'Were you or your colleagues informed about the new STGIEDL? 
All physicians received a set of STGIEDL, but only seven of the nine had knowledge 
about the use the new STG/EDL. Of the nine physicians interviewed, seven said they had 
knowledge of the new STGIEDL for adults at hospital level. 
'Do you know about 10% cap on ordering drugs and motivating for drugs? 
For budget limitations, no physician had knowledge of the 10% budget restriction on 
non-EDL medicines. Conversely, all the physicians interviewed had knowledge of 
motivating for drugs not on the STGIEDL. The methods used for improving and 
monitoring prescribing, PTC, Peer Review, 10% budget cap were not well known overall 
none of the physicians talked about peer review and only two said that they had 
knowledge of Pharmaco-Therapeutic Committees (PTC). 
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Do you know about Pharmaco-Therapeutic Committees or Peer Review?' 
Only four of the seven physicians interviewed had knowledge of Pharmaco- Therapeutic 
Committees, only one has knowledge about 'Peer Review and thought that it should be 
used. 
Overall, few physicians had knowledge of PTe and, while none had knowledge about the 
use of Peer review, or budget limitation of 10% cap on brand drugs. 
Physician Attitudes and Practices 
The attitudes and practices of the STGIEDL are paired in this evaluation because 
Their attitude directly shows itself in practice and ultimately in prescribing. 
8.4.3 Physician Practice 
Overall a majority of the physician felt that there was not a change in their work 
environment or the way that they practised. Few, (two) physicians said that generic 
substitution changed the way in which they prescribed. None of the physicians' 
interviews had directly participated in either PTe or Peer Review process, although two 
physicians had heard of it, and one was in the initial process of setting one up at a 
hospital level. 
A. Physician's Environment and Prescribing Practice 
1. Work Environment 
'Has the EDL affected the way you or your colleagues work?' 
The EDL was produced to change the way physicians and other health professionals 
prescribe treatment and medication. The areas of the work environment that could be 
affected by the adoption of the EDL are centred around prescribing, training, and the use 
of PTC and/ or Peer Review. 
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Nonetheless, the work environment for the physicians interviewed did not show a great 
change since the introduction of the EDL for adults at the hospital level. The manner in 
which physician prescribe, usually brand drugs did not change. When physicians wants a 
drug that is not on the EDL or in the pharmacy, then theoretically they must put in a 
motivation form to request the drugs and justify why they need that particular drug and 
can not use the drugs on the EDL. Overall, five physicians believe that there is a change 
in their environment in which they practice. Only, two physicians believe that generic 
substitution change the way that they prescribed. When one interviewee was asked if the 
book affected what he prescribes he responded: 
"Not really, because / was always used that in practice. / know which drugs were the 
most competent ones. What it did (was) to give me extra drugs that we did didn't have 
access to previously. (/-7)" 
Another physician was asked if he thought the 'EDL changed the way he or his 
colleagues worked' he said, 
"/ don't think it is much better. / have been working for ten year so / have quite clear 
ways of treating patients you understand (/-13)." 
Once again, the overall the work environment for physicians had not changed since the 
implementation of the EDL. 
2. Prescribing Practice 
Q. Usefulness of EDL 
The attitudes of the physicians towards the EDL, patient demand, budget restrictions 
directly affect their prescribing practices. The questions asked are: 'Are there advantages 
to using the EDL? Why or why not?' 
Few physicians think that the EDL is useful for them personally. Although, they do think 
it is useful for others, especially as a guide of available medicines, standard treatments, 
and for cost-containment. The usefulness of the EDL as a guideline and for cost-effective 
prescribing is explored further. 
Only one physician said he uses the EDL regularly. 
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" I 
HI always used that (EDL) in practice. I knew which drugs were the most competent ones. 
And what it did was give me extra drugs that we didn't have access to previously (1-12). II 
b) The EDL is useful, but not for me 
The use of the EDL with its generic drugs is a managerial method to change prescribing 
practices and specifically to bring about rational prescribing. The other physician who 
uses the EDL was trained in a tertiary hospital in the richest province in the country. He 
uses it as a guideline for what is available and its generic name. 
Most physicians think that the EDL is useful, for other inexperienced physician and other 
hospital staff, but not for them. Seven of the eight physicians said that the EDL is not 
useful for them. The overall view of EDL usefulness is summed up by one physician, HI 
don't really think so. No "(1-14). Another physician said: 
HI have been working for ten year so I have quite clear ways of treating patients. But, this 
has nothing to do with a drug list as such. This is just a question of how to get started. 
You do everything, gynaecology, paediatrics, surgery, so it is very difficult to get started. 
Once you have a book that really has all these major important cases listed out with 
suggestions for treatment, perhaps it (will) help you a lot. But when it is independent for 
the essential drug list it could be another drug list as well. " (I-B) 
One physicians' statement that apply to most physicians attitude is: 
HMost of the drugs should be on the EDL, but it doesn't affect me (1-7), II stated 
"I must say, not all physicians are using it. They are still going back to their own lists 
and drug treatment schedules. They don't really consult this book, I wish they (would) do 
it. "(1-12) 
Although think that the EDL is a good source for them, many physicians think that it 
would be good for others to use, especially if they also work in private practice. 
"There is a difference because those who are in private practice basically prescribe in 
brand names boxes and they are pushing that name. "(1-4) 
Physicians, especially those at the tertiary level, work In both private and public 
practices. Most physicians think that overall the EDL is useful for others, but not for 
themselves. When asked if the EDL was useful for him personally, he responded 
HI don't really think (so). But this has nothing to do with a drug list as such. This is just a 
question of how to get started. In our hospital you deal with all different kinds of 
diseases. You do everything, gynaecology, paediatrics, surgery, so it is very difficult to 
get started. Once you have a book that really has all these major important cases listed 
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out with suggestions for treatment perhaps it helps you a lot. But when it is independent 
for the essential drug list it could be another drug list as well. " (1-13) 
When asked about the use of the EDL, a specialist stated, 
"There are advantages. 1 am the only oncologist in this whole province, so it would be 
very difficult if there's an EDL for my field. 1 would rule out myself in anY case. 1 think it 
has not affected me very much. My field is so specialised and the drugs that I use, I am 
not very concerned about the other drugs. And here in Pietersburg the situation is that 1 
actually decide/or myselfwhat I want to use "(1-7). 
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Only two of the seven physicians said that they use the EDL and it is helpful. One 
physician who uses the STG/EDL has been worked in primary health care for more then 
fifty years, participated was on the first committee that put out the first EDL for primary 
care. He said, 
"Yes. I use it. (The EDL) has been compiled by people who are really experts in health 
care. The people that compiled this are the best in health care, in the country. I trust them 
and I think it is a good thing. " (1-12) 
c) EDL Useful as pharmacy stock guidelines and cost effectiveness 
Physicians think that the EDL is an 'advantage' as 'good guidelines,' and a tool for 'cost 
effective' prescribing. The STG/EDL is useful for other professionals, including young 
physicians. As a guideline, 
The EDL "would be good ifwe could use structured regimes. lfwe use the same regime 
then you could start to do a study. They are much more accurate if people have used the 
same medications. (1-6) II 
Another physician said, 
"this is a good guideline for the young and not experienced doctors. It is a good 
guideline to know what is available in the country. But that's it. 
For cost effective prescribing, the use of the EDL allows for 'cost effective' prescribing. 
(The EDL) 'makes it more cost effective and makes it more easy for inexperienced 
doctors. For those two benefits I think it is a good thing to have, but not for experienced 
doctors. " (1-13) 
Several other physicians, without prompting identified the cost-effectiveness of using the 
EDL. 
"I personally think we (the EDL committee) have gone through to make things very 
simple and very . cost effective "(1-6). Moreover, another said, "The standard treatment 
guidelines, we have standardised our drug list which makes it much more cost-effective. " 
(1-12) 
A general practitioner stated, 
"I have not used it that much. I would think that here is an advantage to using that one 
because perhaps to contain the costs of the hospitals and to know what's available, then 
you know what to prescribe. Unlike coming out with something that you know is 
standard, but you don't know what to prescribe. Otherwise you don't know what to 
prescribe and you what's available to prescribe ... " (1-9) 
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d) Use of Other Materials for Prescribing 
Physicians prefer to use other professional resource materials when prescribing. These 
include the South African Medical Fonnulary (SAMF) and the Merck Manual (MIMS). 
The book that is used the most, predictably is not the EDL but the SAMF and MIMS. 
" All are using MIMS. All the consulting (doctors) are usingMIMS and we use the 
Oxford, but that is more for treatment or stufflike that or signs and symptoms (1-14). " 
e) EDL Usefulness Summary 
Overall, physicians' attitude towards the EDL is a good reference guide that is cost-
effective guide that can be useful to new physicians, patients, and all other health care 
personnel. 
They generally do not think that the guide is helpful to them personally. Most physicians 
know that the pharmacist will substitute the brand drug prescribed for a generic drug 
unless they submit a motivation fonn. Physicians' attitudes are necessarily linked to their 
type and level of practice. Physicians may think that the EDL is useful for others and not 
themselves. The self-reported practices in the next section will evaluate the environment 
and the prescribing practices. 
Overall, physicians say that they use and do not use the EDL. Those who use the EDL the 
advantage is a list of drugs that are stocked in the hospital pharmacy. Overall, the EDL 
has not changed the environment for the manner in which physician work. There are 
advantages to using the EDL that are minimal, namely as a list of drugs available and 
treatment for chronic illness with know effective and standard regimens. 
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II. Physicians Practice 
Many physicians, as a result of both their knowledge and attitudes have not changed their 
prescribing, diagnosis or treatment regimes. A more detailed look at prescribing, training 
and PTC/ Peer Review should give some clues about why the environment has not 
changed. 
The hospital adult level EDL has 694 drugs and combinations (National Department of 
Health, 1998a). Thequestions are, first, 'Do you use the EDL?' Second, 'Has the EDL 
affected the way you prescribe?', Third, 'Do you prescribe from the EDL?', Forth, 'Do 
you usually prescribe by brand name or generic name?' Physicians described their own 
'Self-reported prescribing practices' (Table 8.1) during the interviews. 
Table 8.3 Physician Self-Reported Prescribing Practices 
Number Percent 
Physicians 8 100 
Prescribing 
Use EDL 2 37 
Do Not Use EDL 5 63 
Generic 1 13 
Brand 3 38 
Motivate 1 13 
Poli pharmacy 0 0 
PubliclPrivate 1 13 
a. Prescribing by Generic Name 
Physicians self reported prescribing practices revealed that only one physician 
interviewed said when prescribing, "I tend to use generic" (1-4). Another physician who 
does not prescribe by generic name thought that it is good to use generic names so that 
the pharmacist knows exactly what the physician wants to give the patient. 
" ... Sometimes you prescribe something and they don 't have (it), they are out of stock and 
there is an equivalent that you can use. So these types of patients they refer (back) to you, 
so you have to prescribe something else. JJ (1-4) 
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Most physicians have their favourite drugs and will write it on the prescription whether it 
is available by brand name or not. 
"We know what we want to prescribe and then we look at what is available" (1-14). 
Almost all the physicians prescribe by brand name in the public and private sectors, 
that they the public and private sectors. Only one physician simultaneously works in both 
while the other seven physicians only in the public sector. The use of generic medications 
is standard in the public sector, yet the EDLISTG has not encouraged help physicians to 
prescribe by generic name. 
"Maybe it's better to use generic names because they (pharmacist) know that. So if you 
are using a trade name chances are that they will tell you, 'you know it's not here. • Or 
else they give a generic instead of tossing the patient back and forth. .. (1-4) 
Since most physicians know that if a brand name drug is prescribed, the pharmacy will 
dispense the generic equivalent. "I think that the pharmacy give the patient the generic 
anyway, whatever we prescribe II (1-14). 
b. Prescribing by Brand Name 
Brand name prescribing is so common and can be fully adopted less than a year out of 
medical school regardless of the practice setting. A young physician interviewed in his 
first year out of medical school stated writing prescriptions by generic name, but changed 
to writing prescriptions in brand name, even though his first job out of medical school 
was in a primary health care hospital. I asked him how he was trained in medical school. 
He responded, 
"In medical school you basically use generics. After you get to the ward you write 
Renitec instead of hydrochlorothiazide (for hypertension). Basically pharmacology is 
based on generic names . .. (1-4) 
When I asked the young physician, how this change in prescribing occurred, he 
recognised the change and was visibly surprised, when he understood that he was using 
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almost exclusively brand name. He said that every month the pharmaceutical companies 
put on lectures and invite the physicians. He has been to these meeting and learned about 
the latest drug on the market. He went on to say, 
"We know that it quickly spreads, to use the trade names (1-4). " 
The young physician interviewed works under the most experienced physician of the 
physicians' interviews, more than 50 years in primary care facilities. He uses the EDL 
and encourages the young physicians under his direction to do the same. He tries to be a 
role model and positive influence, ofEDL for generic prescribing. 
"They don't want to change. They don't use generic prescriptions here. I am trying to 
teach the young doctors to do that now "(1-12). 
Overall physicians are give reinforcement through pharmaceutical seminars and generally 
find it easier to remember the short and memorable brand names when prescribing. 
"We mostly prescribe in brand names, only because it's easier. It is easier to write 
'Renitec', than 'Enalapril '. I wouldn't mind prescribing all generics. It's just that we 
know the trade names better than we know the generic. But we should actually prescribe 
generic I think "(1-14). 
c) 'Motivating' for non-EDL Drugs 
Those who prescribed by brand name or generic continued with very little change. Only 
one physician said that he 'motivates' for a brand name drug. Three physicians said that 
they regularly prescribe brand name drugs, while five admitted to be non-compliant in 
suing the EDL. The positive answer to both the use the EDL and simultaneously, not 
compliant shows the difficulty physicians have in adopting the use of the EDL 
d) Prescribing Antibiotics 
The over prescribing of antibiotics is an indication of polypharmacy and counter 
indication to rational drug prescribing. On the subject of antibiotics, one physician stated, 
"I am in favour that junior doctors should not be prescribing expensive medications, 
particularly expensive antibiotics. 1 think in general (that) antibiotics are over-
prescribed. They're expensive and 1 don't think we do enough cultures as a back up to 
find our what organisms we are treating and what its sensitivities are" ((1-6). 
e) Prescribing influences 
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Patients Demand 
Patient demand is a driving force behind how physicians prescribe. For some the issues 
surround meeting the demands of their patients. A physician, when asked if training 
would help in resisting patient demand, and instead rely on evidence based medicine. 
"No I'm not too sure. / think the main issue for just us doctors is the response (from 
patients). The (reason that we) prescribe so many drugs? We have patients who want 
drugs (/-4). " 
Patients feel that if you do not give them a drug after the visit then they feel that you 
"haven't done something for them (1-4). " 
The expectation of patients for drugs shapes prescribing for some physicians. One 
physician explained, 
"A patient comes in with hypertension. You say, 'OK, I'm not going to give you any drug. 
Come back in two weeks. • 'Oh no doctor. but / want (a specific drug). ' Then they develop 
a reflexive pain. 'Ah / have pain here. there and there. I Then you give them a panadol (1-
4)" (brand name for paracetamol-generic form for pain). 
J) EDL Useful for Chronic Patients 
Several physicians identified the advantage of using the STGIEDL as a good guideline to 
know what is available, and a good tool for cost effective treatments, especially for 
people who have chronic illnesses. The STG can help to assess the level of the chronic 
illness, the type of treatment and be cost effective. 
One physician stated, 
"Chronic diseases, hypertension, diabetes, / personally think we have gone through (the 
assessment of effective treatments) to make things very simple and very cost effective. "(1-
6) 
Another physician stated on using the EDL and cost effectiveness, " ... In medical school 
we were taught primary, secondary and tertiary and it didn't make much sense until one 
gets to the hospital you know hypertension and all those preventable diseases and all that 
training was not in vain. If you can apply (this) then you can save those people a lot 0/ 
money. If you can treat the priority risk, usually people take care o/themselves. Usually 
there is (not) much budget for insurance reimbursement (1-4). " 
Several of the physicians interviewed cited the use of the EDL is especially beneficial to 
patients with chronic illnesses and those who need set regimes. 
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"I am from a tertiary institution from a richer province that has housing all these pills. 
So when I got here I saw these guys have this. I think that the patient feels as well, (if) 
the doctor checks" (the EDL) (1-4) 
"I think there are advantages. The book is supposed to be like a guide managing 
patients, but each patient is difference. Sometime (there are) one or two things inside the 
EDL that go with what I have learnt. You know I went to the US. to train and I do thinks 
more along those lines. Maybe there are some strategies here pertaining to the people 
here. So, I wouldn't like to go against it." (1-9) 
The STG/EDL can also be used to not only for drug and treatment protocols, but also for 
ideas of disease prevention for chronic patients. 
"Perhaps we ought to be more organised and formulated. We as prescribers often don't 
know what is available and we can't see how we prescribe. Chronic diseases, 
hypertension, diabetes, I personally think we have gone though (drug protocols) to make 
things very simple and very cost effective. Rather than treating hypertension for years 
and years, we want to be doing more assessments and saying 'why does this patient have 
high blood pressure. ' Is there an underlying renal disease, (or) a tumour? How is the 
blood pressure changing with exercise? Simple life activities changes the probability, we 
don't pay enough attention to those things ... (1- 6) 
8.4.4 Summary of Physician Prescribing 
To summarise physician prescribing, overall, seven of eight physicians work only in the 
public sector where generic drugs are the norm. Yet all physicians, except one in the 
public sector prescribe by brand name. Only one person said that he motivates for brand 
drugs not on the EDL. 
"It's the RTC factor, you know, 'resistance to change '. You get use to a certain system of 
medical care and you stick to it if it works. They don't want change. " (1-12) 
I. Training and Pharmaco-Therapeutic Committees 
To address rational prescribing, physicians' training, and Pharmaco-Therapeutic 
Committees with Peer Review can have a substantial influence in not only providing 
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information, but also changing perceptions and behaviours about using the EDL and 
generic drugs. 
a) Training 
'Were you or your colleagues trained to use the new EDL?' 
The literature on rational drug prescribing recognises that materials alone, such as an 
EDL list will not change prescribing behaviour and the National Drug Policy states that 
training is of primary importance, each province is left to find the monetary and staffing 
resources in order to implement training. Formal and systematic training of physicians 
has yet to be either developed or instituted. One physician said that training was not done 
because he believes that the EDL "is so comprehensive and clear that you can use that 
for the basis of your treatment"(I-12). 
Without exception all physicians interviewed thought that training in rational drug 
prescribing, the use of EDL for generic prescribing, is a good idea and is of value for 
others, especially the nurses, pharmacists, and young physicians, but not for themselves. 
An example is, "But to say we need trainingfor all doctors, I'm not sure (/-4). " 
Many physicians believe that training would not make a difference in physician 
prescribing. One physician said succinctly, "No, it won't " (/-7). A medical director 
thinks, "young doctors should be trained "from day one ... before the reps (pharmaceutical 
representatives) get to them" (1-11). 
Another physician said, 
"From my perspective, / don't think any training would be necessary. But if people think 
that they need to guide us here and there I would appreciate it. For nurses / think it 
would be helpful on how to prescribe (1-4). " 
In short, one physician stated with accuracy" 
"Honestly, I don't know anything about the EDL. / just saw that, so it didn't really lake 
hold. So if they want to implement it strictly then there should be training, especially for 
the nurses and the doctors who are going to use this one" (1-10). 
c) Pharmaco-Therapeutic Committee (PTC) 
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Clearly, physicians believe that they do not need "training", but are willing to take 
suggestions especially from each other through peer review. If it comes from an outside 
source other than other highly respected physicians, then it is not seen as credible, and 
valuable. 
At the time of the survey none of the hospitals in the Northern Province had an active 
Pharmaco-Therapeutic Committee. One of the primary care hospitals, the medical 
. director had been involved in the development of the first EDL, actively used the hospital 
EDL and encouraged the five physicians practising under him to do the same, with little 
success. He has decided to start a PTC committee. 
"We are in the process of establishing one now. You know its something new ... We have 
had a meeting about that to get it off the ground (1-12). " 
A physician that practices a specialty at the tertiary level IS reluctant to use PTC 
committees for Peer Review. He stated: 
"In theory it (peer review) is a good thing. Again one has to take and think very carefully 
about the context in which the patients, uh are judged on. To give you another example, a 
lot of this stuff (cases) 1 see here is very complex. It's were the other people in secondary 
hospitals in the province here, say Tshi/idzini, Letaba, Mokopani don't feel happy with 
all these complications or complex things. My results often look a bit shabby, but then 1 
look at what 1 have treated So when someone comes in as a peer reviewer and says look 
your results are not as good as someone in a secondary hospital. 1 might appear to have 
bad results. 1 think often you must look at the context of (who) the patient is (and) in what 
situation we work " (1-6). 
The medical director is the driving force to put the PTC in place and has taken on the sole 
ownership in decision-making about who will make up the committee. 
"1 have decided that the pharmacy should be represented, the doctors, the nurses and the 
financial manger" (1-12). 
At the time of the survey, the secondary hospitals did not have a PTe committee and 
those interviewed did not know about PTC committees. At the tertiary hospital level a 
PTC was established and met for a short time, but was stopped. 
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"We had a failed therapeutic committee, a provincial therapeutic committee, which did 
not get off the ground because we organised it from the head office and the specialists did 
not come as required. It must be organised by a group that deals with the university and 
so on" (1-17). 
In summary, physicians need training through an academic or medical professional 
institution. I asked which university wou)d organise the new PTe and was told, 
"MEDUNSA, where many of these specialists are trained. So now we have moved it into 
the academic field. which again will be more acceptable to the specialists because now 
this is a more academic exercise. And so their training outreach will be providing 
additional vehicles with the idea of establishing outreach for training. I think this will 
help a lot to break down the resistance to a logical approach to prescribing" (1-17). 
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8.5 Summary ofInterviews with Nurses, Pharmacists and Physicians 
A review of the interviews with the nurses, pharmacists and physicians show a common 
theme of not being informed about or trained to use the new EDL. All healthcare workers 
received a EDL set of 3 books: primary care, hospital care: paediatric and adult. With 
exception of the pharmacists, few nurses and physicians use the EDL books on a daily 
basis. 
Nurses and pharmacists think that all health workers should be trained, while without 
exception physicians thought that they did not need training, however other health care 
workers need training in using the EDL and rational prescribing. The research has shown 
some evidence that many physicians do not know much about efficient prescribing, but 
rely on their early-formed prescribing regimes. 
The use of the EDL has changed the work environment for nurses and pharmacists, but 
not for physicians. The change includes a ready-made procurement list, cost reduction, 
and a decrease in polypharmacy. Also, pharmacists have learnt to take a brand or trade 
name prescription and interpret the generic drug that can be substituted. Overall all health 
professionals believe that a PTC committee would be helpful and most believed that it 
should include all professionals. 
Some physicians think that Peer Review that can occur during a PTC meeting can be 
helpful in promoting rational drug prescribing. PTC committees could also help to 
support prescribers in their attempt to implement rational prescribing with patients. This 
is especially important for patients with chronic illnesses in clinics that do not want the 
generic drugs, which were once dispensed as a brand. Some refuse to take the generic 
medicine prescribed because it does not look like the one that they are used to. Patient 
education about generic drugs and the new EDL has been limited to posters put up in the 
clinics. The questions that are evoked for administrators are what were the preparations 
and planning for the EDL, what were the implementation challenges and what is the 
vision of the future. 
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8.6 Administrators 
8.6.1 Introduction 
After the interviews with hospital staff were reviewed, and new questions about the 
implementation of the EDL were apparent, including questions about planning, 
preparation, and implementation of the EDL guideline use and training at the national, 
provincial and local levels. 
Four administrators who are responsible for various arms of provincial and national 
offices that co-operate best answered these questions. The questions (Appendix S) are 
based on preparation, planning and challenges to the EDL implementation. 
The three main areas offod are (1) Preparation and planning for implementation, 
(2) Challenges to EDL implementation and (3) Visions and plans for the future. 
8.6.2 Preparation and Planning for EDL 
National, provincial and individual hospital planning, not only for implementation, but 
for evaluation is important for the NDP and specifically for the STG/EDL will take hold. 
A National plan for the implementation of the NDP, EDL at the provincial and local 
levels allows for the successful adoption of rational prescribing. 
a) National Planning 
South Africa's government continues to change and adapt to the new circumstances. 
However there was not an implementation plan that South Africa's nine provinces could 
adopt. When asked why there was not a plan, an answer was 
"Because there isn't generally that service, South Africans' don't plan. You get certain 
perceptions it is a very poor strategic planning. There is' no regional planning 
philosophy. " (/-20) 
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Although the National Drug Policy was well stated, and adopted nationally, specific plans 
for implementation of its various components, including rational drug use was the 
responsibility of the nine Provincial governments. Lack of planning, 
HI think there are two reasons for that. Previously there was no type of initiative or 
incentive to train or to plan. Things just kind of went along half-hazardly. So there's no 
culture of planning. And secondly, particularly in the last three years there have been 
ever diminishing resources. There is more and more work and few and fewer people in 
the public sector ... OK, so now all you get (is) time to do is your service work. You don't 
have time to plan. You don't have reason to have lack of planning, but it doesn't mean 
that people haven't wanted to plan. But the two things, lack of culture of planning and 
lack of time to actually sit down on one side and plan something instead of (responding 
to) the service demands. "(1-20) 
A pharmacist, professor, and developer-trainer of rational prescribing, stated that the 
national government, specifically the health department lacked planning for the 
implementation of the EDL. 
HI think that, I am not talking about the Northern (Province) Government now, I am 
talking about National - The lack of planning. There have been no integrated effort, 
starting from the hospital level, the two volumes, you know the paediatric and the adult 
guidelines for hospitals. They were launched in December 1998. Now what happened 
when they were launched there was no declaration beforehand to say that we are going 
to have a launch date at such and such a time. Before that launch date we should have 
really been developing an implementation program to train people and when the 
document came people could start to use it. But now they've got a book which some of 
them use, in some (cases) use in the wrong fashion because they haven't been trained to 
do so. "(1-20) 
b) Provincial Planning 
Was there a Provincial implementation plan of the NDP, EDL at the provincial and local 
levels? 
The lack of strategic planning for the implementation of the NDP and the use of the 
STG.EDL to encourage cost-effective prescribing is not only at the national level, but 
also at the provincial level at the Northern Province Department of Health. 
HI don't think there was anything specifically envisioned for any province because there 
was only about two or three months before the launch occurred. Nobody had any idea 
that it would actually be launched in December 1998. There was a major thrust within 
their EDL committee and the central government. The planning within the provinces 
should be developed by through a process: this is what we are going to do about it. We 
are going to have training programs in the hospitals. These are the people who are 
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responsible for it. You are going to develop this. You are going to do that. The target 
dates, the number your going reach is ... The lack of planning is in general. To lesser an 
extent because the Northern province (had a) very good strategic leader as you know 
... Nicholas Crisp (former Northern Province Health Director) and during that period a 
lot of progress made including a lot of this training that you've got in the book (nurses 
and pharmacists). So that was 1997, 1998, 1999. " (/-20) 
The launch of the EDL for paediatric and adult levels was planned hastily and was not 
communicated to the Provinces and regions in an effective manner. Therefore, it was not 
possible to plan an implementation strategy at both the hospital and clinic level. 
"The lack of medium term planning. Short term, it no good planning short term because 
it's on you before you know it. You've got to plan for a few years. That is what we are 
trying to do, get a longer-term view. " (/-20) 
So, hospital pharmacists were sent boxes of EDL and were not told what to do with them, 
who to give them to or how to introduce them to their staff . 
.. Yea, well then that was about when people, people then might not have known there was 
going to be a hospital edition launch, except the people involved. Because again there is 
poor communication down to the service level, down to the provinces. We know have the 
P EDCO 's, Provincial Essential Drug Co-ordinator. Each province has one, but the 
provinces differ in the effectiveness in which those PEDCO'S disseminated information 
into their structure. " (1-20) 
Moreover, an administrator said, 
"At the hospital clinic level we did not envision any training. We thought that speaking to 
the doctors we might change their attitudes and in some hospitals it does work. But in 
other hospitals, not. 
Another administrator agrees, 
"Basically in hospital clinics there has been much clearer services within the hospital 
premises. The implementation has been far lower than it has in the primary health care 
community in the districts. So basically there is still a lot of work to be done at hospital 
level. " (1-20) 
At the primary health clinic level there was some planning for training nurses. As a 
carryover benefit from the fist EDL in 1996, 
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"I think in the clinics we have managed to succeed purely by we have managed to put 
out a clinic list and we managed to train the nurses at clinic level on effective prescribing 
and prescribe according to the list. So 1 think there we barley covered the list. " (1-18) 
Overall, planning and implementation of the EDL was not done on the national, 
provincial, or hospital level. As a result the EDL guidelines are rarely used by prescribers 
in hospital clinic and the implementation has not met the targets of rational drug 
prescribing set by the national government have not been met. 
c) What percentages of the prescribers and pharmacist have been trained? 
"But after we did the Effective prescribingfor nurses, we got a very clear signal from the 
nurses that the doctors need to train because they are now in conflict with the doctors 
even at hospital level. Because some nurses are also prescribing at hospital level and 
that is were we realise that we really need to train the doctors in effective prescribing. " 
(1-18) 
"And the other organisation that has been helpful in many of the programs is SA DA P. 
They contract training providers, which we were one. They put out a tender and we bid. 
So we bid for some training programs. But again, there is no medium term strategy for 
that. You know, nobody said, we want to, in 1999 or 2000, we want to train 30 people in 
each province. We did that in '98 and '97, a little bit in '99. But long term, there is no 
long-term vision of where we are going. "(1-20) 
Part of the support is from the University of the North and we are very lucky and SADAP 
also gives us support. If we can work together we should manage put it (Physician 
rational prescribing training) through. " (1-18) 
The Northern Province Department of Health (NPDoH) looks to professional trainers 
who have carried out various training projects before with some success. Nationally, the 
MEDUNSA School of Pharmacy staff are consultants to provinces that want their 
medical staff trained in pharmaceutical management and/or rational prescribing. 
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8.6.3 Challenges of NDP and EDL Implementation 
"What have been some of the biggest challenges to implementation?" 
Besides the lack of preparation and planning, the other challenges of the NDP and EDL 
implementation according to the four administrators includes ten main areas, with 
training as the most multifaceted challenge. The ten area are: (a) Diminished Resources 
of Staff and Budget, (b) Distribution and Stock Control, (c) Beliefs and Attitudes of staff, 
(d) Resistance to Change: EDL adoption and compliance, (e) Communication, (t) 
Partnerships of health professionals, (g) Patient demands, and (h) Prescribing: 
interventions and (i) Training of staff will be looked at in detail with questions that look 
at the vision, implementation, numbers trained and the challenges. In the training of staff 
additional challenges were identified: (1) budget, (2) development of materials, (3) 
logistics, (4) administration, (5) selection of participants, and (6) resistance. 
(a) Diminishing resources: Staff and Budget 
1. Staffing 
Diminishing resources of professional staff and budget is a challenge to EDP 
implementation. All over South Africa, a shortage of professional staff is apparent. 
The shortage is more severe in rural areas with a largely poor Black population, like the 
Northern Province. Most professional health posts are not filled. Those who are 
professionally trained leave for better working conditions and salaries. The Northern 
Province Department of Health (NPDoH) administrator of pharmaceutical services stated, 
"there's 40 vacant (pharmacist) posts. So the number of posts (for the Northern 
Province public sector) is actually one hundred. The number of people in those posts in 
any particular time is sixty (pharmacists). Few-trained pharmacists are willing to work 
in public service hospitals for less pay" (1-20). 
"I just need what everybody else needs. I just need more people, two or three more (full-
time) people ... 1 have to find people. I've got to find the money. My job is not to cut the 
money. It is to help them. If I am going to provide trainingfor people in other provinces I 
need people to do that, whether they are provincial people or my people "(1-20). 
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2. Budget 
The Pharmacology Department Staff from the MEDUNSA were engaged (1999) in the 
preliminary designs of a rational prescribing program for physician in the Northern 
Province. 
"Really (it) takes months of develop a good training program and test it" (1-20) 
Still, the design, pilot test, and implementation of a rational prescribing program is costly. 
At the time of the research the staff did not have a budget to complete the course 
development project for physicians. 
A drug management course was offered to pharmacists with, 
" a three year grant. Now is the year 2000 and its still going on outside funding. So, 
you've got no kind of long term ... (funding) 1 cant give anybody job security . . "(1-20) 
The MEDUNSA administrator was asked how much does it cost for the program and 
how much does it cost per participant, to train a doctor in effective prescribing. The 
answer was, 
"Ah, we don't know how much its going to cost to train the doctors because it will be 
in- service training, its not going to be taken out of the working environment. 1 don't 
think that costly. To develop a program is going to cost about $70, 000 dollars. There is a 
lot of pre testing and tests to be done" (1-18). 
Funding has been sought through South African Drug Action Programme (SADAP). 
Once the program to train physicians is developed and tested then, the program costs 
should go down .. because then the basic training cost will be at the hospital level where 
we will have training as part of the CET" (Continuing Education Training) (1-18). 
(b) Distribution and Stock control 
An administrator that works as a bridge between the central supply depot (Vuna Health 
Care and hospital pharmacists said that one of the biggest challenges to the EDL 
implementation was 
"each (hospital) was very different from the other. So it was quite challenging in that 
way, really different from the other. The people are different." (1-19) 
The Vuna depot staff have regular training sessions for all the management pharmacists 
who work in the public hospitals. The training is in 
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"stock control, (and) the Provincial (procurement and storage) policies. We take groups 
of ten. We provide the accommodation and meals and we go through our stock control 
software and provincial policies a one-week training. Training never ends anyway 
because we have on-site training when ever there are changes to the software. " (1-19) 
The VUNA project manager visits each of the Northern Provinces forty hospital 
pharmacies every month and more frequently if needed. The manager puts a priority on 
keeping contact with the pharmacists. This contact is a very good support for pharmacists 
and helps them to know what is new, and then to disperse the information to hospital 
staff. The challenge for the VUNA manager is to keep up regular contact with each 
pharmacy manager at the hospital, and provide training to each pharmacist on a regular 
basis and ongoing. Currently, there are two VUNA managers to cover all forty hospitals 
each month. 
(c) Beliefs of staff 
For all staff, the desire to help patients with what is available, especially drugs is the one 
most often used. 
"In clinics the biggest challenge is, one of the biggest challenges is trying to teach nurses 
(and physicians) that not every illness has to be treated with medicine. " (I-18) 
With patient demand for medicine it is extremely difficult to convince the patient that 
they have been seen and heard without leaving with medicine. In addition, one 
administrator admitted, 
"Well, what worries Trle is that I think that we have at many of our clinics a demoralised 
otherwise ineffective staff who may be using this as an excuse and saying look we don't 
have many medicines" (1-17). 
1. Resistance to Change: EDL adoption and compliance 
The implementation of the EDP was to distribute the 3-book set to all professional 
hospital personnel at all hospital levels the expectation is that they will not comply with 
it. 
"I think that the secondary and tertiary care hospitals are relatively new to the province 
and you will find that you will find in your research that it hasn't complied easily. That is 
only my impression" (1-17). 
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Physicians, especially at the secondary and tertiary care levels work both in the private 
and public sectors, although it is officially not allowed. Most physicians work in the 
private sector and have access to all brand drugs and usually use a limited set of drugs for 
particular illnesses. The prescribing behaviour from the private sector is carried over to 
the public sector. Physician prescribe brand drugs in the public sector because 
"It is an issue of the effective (of) advertising on the users. (Physicians) would rather 
have their prescribing in a name of a particular brand Many of our medical staff in 
particular, I think is convinced the proprietary brands are different from the generic, 
which is so untrue. I think that advertising, rather than logic or evidence based 
medicine" (1-17). 
When the same doctor who functions in a variety of settings is in the 
"hospital clinics, it's the ultimate in 'doctor know best. ' He is used to using this for this 
condition. All of a sudden, if you take it away, he feels that there is no medicine. Then 
you have a major, major upset. This has been one of the biggest challenges. Physicians 
that can adopt the EDL list as their own and agree to using it because they feel that it is 
the best for their patients can only do so if they believe that they have been involved 
Most of the specialist also involved with MEDUSA, so they do their training." (1-18) 
The specialists from the tertiary hospitals are involved in drawing up a provincial 
medicine code. 
"I have drafted a list of all the medicines we have on our Provincial code and what level 
they are available, and ask them to comment to them. That's how we involve them. But 
we have a provincial committee meeting, so we start with getting the specialist involved. 
But they are very reluctant at this stage. It is causing a bit of a problem. I definitely think 
that this will be a problem starting the treatment of AIDS. " (1-18) 
To get not only physicians, but all hospital staff to adopt the changes. 
"(It) can't be top-down, you have to be participatory. (1-20) 
"At hospitals it is more difficult. Doctors don't like to be (told how to) prescribe. At this 
stage we are developing, with MEDUNSA, a program to teach doctors 'Effective 
Prescribing', as a part of continuing professional development. " (1-18) 
The specialists from the tertiary hospitals are involved in drawing up a provincial 
medicine code. 
"I have drafted a list of all the medicines we have on our Provincial code and what level 
they are available, and ask them to comment to them. That's how we involve them. But 
we have a provincial committee meeting, so we start with getting the specialist involved. 
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But they are very reluctant at this stage. It is causing a bit of a problem. I definitely think 
that this will be a problem starting the treatment of AIDS. " (1-18) 
(e) Poor communication 
Communication of policy from the National to Provinces to Regions governments to the 
Department of Health and then to the hospitals and clinics has been a very serious 
problem from the onset of the EDL implementation. The top-down approach has failed. 
Communication about the NOP policy was to be transmitted from the Regional 
Department of Health to the Provincial Essential Drug Coordinators (PEDCOs): 
"P EDCO'S and down to the district and the facilities. You know again (that) 
communication has not been a good aspect of South African health care, management 
information, (and) communication (from) the National Department of Health to the 
"PEDCO'S, and down to the district and the facilities. You know again (that) 
communication has not been a good aspect of South African health care, management 
information, (and) communication systems of care" (1-20). 
(1) Pharmacists changing role between Partnership & Interventions 
The pharmacist has changed with the implementation of the EDL in hospitals. The role of 
the pharmacists continues to change. Now the pharmacist manager is held accountable 
for interpreting prescriptions written in brand name, dispensing in generic, budgeting, 
spending, ordering and stock, their role has become more complex. Pharmacists are 
expected to get "out of the cocoon to start acting as managers. " 
Pharmacists are expected to be the gatekeeper to the medicines ordered, but many 
pharmacists adopt the tactic: "If it not on the list, but the doctor says he wants it. I'm not 
going to argue with the doctor. " (1-18) 
Pharmacists intervene in what is prescribed because: 
"Sometimes the prescription goes to the pharmacist instead of having the generic from 
the EDL. It will have a brand name on it. Then the pharmacist has to interpret that ... 1 
think that has always been the problem of pharmacists and I don't think that they see it as 
difficult. I think it is a measure of to a degree of the failure of the EDL to penetrate to 
whoever is prescribing. Because one of the basic ideas is generic prescribing and that 
hasn't always happened "(1-17) 
In addition to the prescriber, the pharmacist must explain educate and assure both the 
physician and patient that the generic medicine is equal in quality and will work just like 
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the brand drug. The pharmacist's role has now taken on more responsibility, with few 
tools to keep the prescribing and budget in control. 
(g) Patient Demands 
The cornerstone of health care in South Africa is 'access and equity' in the health services 
and treatments is a policy that has been in place for several years, since 1995. Many 
patients have high expectations to get the treatment and medicine that they had been 
missing for most of their lives. Access, includes treatment with brand drugs. Patient 
demand for drugs has added to the EDL implementation challenges. 
Patient education about the EDL, generics, and medicines had not been planned or 
carried out. Generally, patients go to the hospital clinic not only for diagnosis, and 
treatment, but for medication. Patients have a newfound belief that they should have 
access and equity to both services and medications. Many believe that they should have 
access to what had been denied, for most this is a brand name drug, not a generic drugs. 
Patient demand is one factor that drives prescribing and also makes it difficult to 
implement the use of the EDL. The implementation of the use of the EDL is difficult 
according to one nurse, who said, 
A "major implementation constraint or challenge is that people demand medication. 
They demand a lot of medication but don't understand that good treatment is sometimes 
not to give medicine. They don't understand that antibiotics shouldn't be always given. In 
any case, the (staff) feel constrained and this upsets the whole purpose of the EDL. " (1-
17) 
Patients go to hospital clinics in order to get the best access not only a diagnosis, but 
medicines. When they believe there is not medicine, then they do not go to the clinic. 
"The interesting thing is that the community believes that we have no medicines at our 
institutions. This is frustrating because we believe we do have medicines. " (1-17) 
At times the stocks are low or absent of even the basic medications for chronic illnesses, 
for example, hydrochlorothiaZide for hypertension, and when this occurs the information 
is spread to the community quickly. 
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To review, the challenges of EDL implementation are: (a) the diminishing resources, 
especially staff and budget, (b) Distribution and stock control, (c) Beliefs of the staff 
about the usefulness of the EDL, (d) Resistance to EDL adoption, thus lack of 
compliance, and (e) poor communication at and between all levels of staff, (f) 
Pharmacists changing role between Partnership & Interventions, and (g) Patient demand 
for drugs at every visit and the demand for brand drugs. These seven factors have 
contributed to the difficulty in implementing the use of the STGIEDL at public hospital 
facilities. The seven challenges to implementation of prescribing interventions can be 
partially met with the managerial use of (h) Pharmaco-Therapeutic Committees (PTC), 
Peer Review (PR) and, (i) training in effective prescribing and/ or Evidence Based 
Medicine. The challenges to training will further be reviewed. 
(h) Prescribing Interventions: PTe and Training 
Pharmaco-Therapeutic Committee (PTC) 
A version of the Pharmaco-Therapeutic Committee (PTC) was started at the tertiary 
level, but because of staff resistance it was abandoned. 
"Yes, it is (a PTC), but we are not calling it that. We had afailed therapeutic committee, 
a provincial therapeutic committee, which didn't get off the ground because we 
organised it from the head office, and the specialists did not come as required. It must be 
organised by a group that deals with the university and so on" (1-17). 
After mandating the PTC from the 'Head Office' provincial level, now an approach of 
engagement is used to get physicians to participate and own the process. 
"Yes, we tried something new with the Pietersburg-Mankweng Complex with the head of 
specialities to give them guidelines for certain diseases and started to the specialities 
first. It's a bit of another approach, but we still need a PTC, which will decide on 
everyday 'motivations '. We never had a tertiary complex and its still developing and new 
ideasfor a lot o/people and they see it (PTC) as a whip, and not as a tool. "(1-18) 
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With input from physicians on all levels, the new PTC will be more accepted, and 
perhaps will be used not only for treatment and drug reviews, but also peer review by all 
clinical staff. 
The new PTC will attempt to implement a team approach to treating the patient. The 
focus is on 'Partnerships.' The training of pharmacists, nurses, physicians, and 
administrators attempts to foster this partnership. 
Partnership is "not normally in the public sector. I think the problem is that they haven't 
got much experience with each other. Neither group know the other groups strengths and 
weaknesses. The last program, we had a tremendous kind of results. The relationships 
were starting to develop amongst the pharmacists and the doctors were amazing. They 
didn't have to worry about the other stuff. They were there to work together and 
suddenly, 'You know let's work it through together. ' It is an important principle. " (1-20) 
(i) Training of Staff 
The questions about training were: First, what type of training was envisioned? Second, 
Has the training envisioned been implemented for prescribers and pharmacist? Third, 
Has the training envisioned been implemented for prescribers and pharmacists? Fourth, 
What percentage of prescribers has been trained? Fifth, What are some of the restraints 
to training? The 1998 EDL for paediatrics and adult hospital use was new. The first EDL 
(in the early 1990s) was only for primary health care and used only by PHC nurses in 
local clinics. 
"You put STG and EDL together there is a special case. I think we have to answer that 
specifically because that is new in terms of some treatments. And I think hasn't been a 
treasured part of the system (1-17). 
Training of staff is one of the interventions used to get staff to understand, adopt and 
comply with the NDP concept of generic and rational prescribing. 
"Well the first thing is to train the prescribers in the use of the Standard Treatment 
Guidelines, Essential Drug List because they haven't received any training in either the 
philosophy or the practice of the STGIEDL. So the main objective, the main requirement 
at the moment is training medical physicians" (1-20) 
According to the administrators interviewed, ideally courses should be developed for a 
team of nurses, pharmacist and physicians. 
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"Yea, we are talking about a team which would be a pharmacist, one or two doctors in 
the hospital and the nurse to work together. Trying 10 get them into the team approach. 
They have got to talk to each other. "(1-18) 
The restraints of resources, staff, and budget to implement training have been a major 
challenge at the hospital clinic level. The EDL implementation success is 
"largely dependent on the training. The training has gone reasonably well. And 
particularly the rational prescribing courses with JvfEDUNSA (Medical University of 
South Africa, School of Pharmacy), which is in the region of three or four hundred, 
classified (as) management. The training has extended to hospital staff, three or four 
hundred is still a need for more extensive training of hospital staff, plus nurses and 
doctors. " (1-17) 
In the Northern Province, the two main courses that MEDUNSA have taught to health 
personnel (except physicians) mostly to nurses in primary health care clinics, and some 
hospital pharmacists in drug management and rational prescribing. Most of the training 
for nurses at the local clinic level occurred in 1996-1997. 
"/ know that in our first year in operation (1996) we were most effective and we had two 
courses, rational drug use training for eight or nine hundred (800 or 900) people" (1-
17). 
Later pharmacist, and managers were also trained, but very few, about 50 in total 
(MEDNSA, 1998). The Pharmacists were trained in: 
"drug management, because its no good at all in telling people how to handle the 
essential drug list if they run out of drugs. But of course recognising that the other 
influences are not just prescribing but life style changes. Or other influences. " (1-17) 
Training the health care staff in the Northern Province has four major challenges: 
Budget, (2) Logistics: who, when and where, (3) Development of materials and courses, 
and (4) Resistance. 
I. Training Challenges 
The four training challenges identified by administrators were first, the inadequate budget 
for projects and staff. Second the need to develop course materials for promotion of the 
EDL and Rational Drug Prescribing; third, and the logistics of who can be trained, at 
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what time and place for how long, and fourth challenge is the resistance to change among 
the staff. Each of these challenges is explored. 
1. Budget 
The first training challenge is the lack of a specific budget for carrying out training in 
Drug Management and Rational Prescribing. Sources of Fundingfor Training 
Training has not been pursued with targets and fixed money. The budget for training is 
pursued a course by course, piecemeal manner. A MEDUNSA administrator said, 
"The budgeting is annual. and there's not provision long-term strategic training. which 
includes human resource development. There that was a deliberate attempt by the 
Northern Province working with us. that was worked into the plan. Nobody since then 
has planned a cohesive planning in the Northern Province" (I-20). 
A budget for training on the EDL and rational drug prescribing is 
"Just what we have negotiated from the DIFID funds (SADAP). The training budget, 
is not a specific amount per year. It is what we have on an ad hoc basis had paidfor 
the specific training we set up. So, even the pre budget amount we are sharing 
nationally" (1-17). 
The Northern Province Pharmaceutical Services Director was asked, "What do you think 
your budget was last year for training?" His response was, 
"I haven't got a clue. I haven't got a training budget at all. It is a decision of human 
resource development. Although the NPDoH Pharmaceutical Director and PEDCO is 
very astute and aware of drug spending, he is not aware of what the training budget was 
or the number of those trained last year" (I-I8). 
The Northern Province Department of Health does not have a defined budget line for 
training that is within their department or control. 
"There are little pools of money. The budget for training health staff for compliance to 
the EDL is obtained through several sources. "We do have a budget in the provincial 
office under Human Resources and Development, which we can access, but it is very 
difficult sometimes to get access to that money "(I-18). 
"We. we have to some extent been funded and supported by the Northern Province and 
we believe that will continue" (1-20). 
Also, funding comes from specific grants from the South African Drug Action 
Programme (SADAP). The SADAP has money specifically for training that must cover 
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the activities in all nine provinces. Most of the training grants have gone to the consultant 
team at MEDUNSA for work in several provinces. 
"Sometimes we ask SADAP for funding if the region can not pay. Some regions pay out 
of their budget. In service training is complicated in that with the regions there is a lot of 
them" (1-18). 
"With regard to the academic side that is funded partly from the provincial budget partly 
from a direct nationalfund and the core redistributedfundwhich (was) to build a tertiary 
complex, because this province did not have a tertiary complex. Then there is also afund 
which has changed names, a 'top slice' fund for academic training, tertiary training. I 
can't put a total figure to all these funds. The department has always decided that 
primary health care should be the main thrust of this department for this under-resource 
province with a rural population with quite basic health needs. But most of our money is 
going to tertiary. It is a little bit illogical, because they say that we should have primary 
health care, but we actually spending it on tertiary. And we neglect the secondary. It is 
not a good balance. "(1-17) 
The cost of training one person for one or two courses, 'Drug Management' or 'Rational 
Prescribing' cost about 
"R250 per day, which is for the ten days, two thousand-five hundred (R 2,500) for the 
entire course. In fact the accommodation and everything was extra. If you translate that 
into dollars it is not a great deal. Everything like that it works out to be R250-R300 a day 
for training. The courses were "fundedfrom the Province, the (Northern) Provincefound 
the money for that. There was money within the provincial budget" (1-20). 
Each time that the NPDoH requests the 'Drug Management' or 'Rational Prescribing' 
course, the requesters and the course organisers start their search for funding. The lack of 
planning and budget exclusively for training also affects the staffing for the training 
programs. 
"We had a three year grant. Now is the year 2000 and it's still going, and its still going 
on outside funding. So, you've got no kind of long term ... 1 cant give anybody job security. 
The regular staff they've got it but the other thing you know I can see that we are funded 
for two years. So for two years, after two years I don't know before that. That is where I 
am at the moment. " (1-20) 
Budget, staffing, training are all interconnected. Now that he new EDL has been 
introduced into hospitals, 
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"the service needs is huge. The starting (salary) levels are low, and the resources and 
preparation of the training program are also low because to have a proper program you 
need to have someone full time and you know everybody's got their own program. In our 
program, basically (we) present or prepare pharmaco training for the pharmacist and 
practitioner. Our jobs, all the direct things that we do, are funded from the outside and 
the pharmacy training development project. That's all outside funding. Now I keep 
something /ike you know four or five full time people funded on those project from 
outside funding but I've got to develop a variety of programs for that purpose "(1-20). 
In summary, training of the staff has four major challenges. First, the restraints of budget 
and staff, second, the time and cost for development of materials and courses, third, 
training logistics, and forth, the staff resistance to change in prescribing and procedures. 
Although training to adopt the EDL or change prescribing behaviour was an intricate part 
of the South African National Drug Policy (NDP 1996), a fixed budget line, along with 
Provincial DOH or regional strategic plan for this sole purpose of training was not added. 
Instead, administrators of the Northern Province must seek funding on a project by 
project basis from various small provincial and national funds. Since there is not a set 
budget, the Provincial Director of the Pharmacy Services had no knowledge of the total 
spending on training for the years 1998-99 or 1999-2000. The administrators said the 
budget for in-service training is limited to what can be found in other non-centralised 
monetary resources. The application process for funding is often complicated, tedious, 
and difficult because of the various criteria and restrictions for funding. Thus programs 
that are developed, staffed, implemented and at times evaluated in a non-centralised 
strategic manner. 
(2) Logistics 
The third training challenge is the logistics of training staff away from the hospital. 
Training in one of the two courses in drug management or rational prescribing is either 
one or two weeks long. Staff must take off this time go to another town and stay for the 
entire course. In many hospitals with the shortage of staff taking a professional out of the 
hospital for several days could mean the closing or cancellation of services. Staff, who 
must take off work time for training, are reluctant. This is a big challenge to promoting 
training. Although the training is valuable, it is attended at a high price. 
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"To take people away for training is the problem because we have a shortage of all 
physicians here. lfyou are a nurse, sometimes you are the only nurse you can't take off. 
Or if you've got only one doctor or two doctors in the hospital, one is on call for 24 hours 
a day, for seven days. And the pharmacist is the same, if you have one pharmacist in the 
hospital pharmacy, many of them. And set up a pharmacist for a week. So it becomes a 
problem the shortage. Maybe we could make it so that the pharmacist will help us. And 
them you are stuck with another problem, accommodation for them" (1-18). 
Speaking about the rational prescribing course, the course developer believes that the 
length of the two-week course is necessary, 
"Well, that one we probably do a week (then wait several weeks and then do another) 
week because the first week really teaches them methodology. Understanding and being 
able to investigate the way in which the medicines are being used, in fact more on 
research methodology type of programs. But then because of the way we train we always 
train with the ideology to do the job (by) the time that they go away they have designed a 
project that they take back to their service. They then have to do an initial investigation 
during the interim. And they come back for the second week they actually present the 
results. We then have a discussion on the results. We then give them the next stage. We 
teach them to do intervention, to improve the situation. " (1-20) 
Overall, the time factor is critical to training. Staffs who have had training have had to 
take one or two weeks away from work and home. Most public hospital systems in the 
Northern Province are understaffed, and thus cannot afford to allow staff to go away for 
training. 
(3) Development of Materials and Courses, 
The third training challenge is the development of rational prescribing materials 
specifically for physicians. The materials used for the two courses of Drug Management 
is geared to pharmacists, while Rational Prescribing course was developed for primary 
care nurses, but is used for all nurses and pharmacists. The programmes for nurses, 
pharmacists have unique components that have allowed for some success. However, the 
lack of materials and courses for physicians has become one of the challenges to rational 
drug prescribing. 
In the last four years nurses have had the most training. Now the focus is shifting to 
pharmacists and physicians. Courses materials must also be developed for, 
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"the new training trend has been to "work in pairs. We try to develop a partnership 
between the pharmacist and the doctors and try to train the pharmacist and doctors 
together in rational drug use. Overall we may have trained about twenty doctors and 
twenty pharmacists together. Now, they will at least be comfortable working with each 
other, other than in a direct service environment. So they know they will be able to work 
together in a training environment. "(1-20) 
The development of course materials for physicians that appeal to both the professional 
level and responsibilities of the various staff while imparting the most important aspects 
of evidence- based medicine, cost-effective prescribing and dispensing. In order to 
accomplish this goal the courses must be developed for nurses, pharmacist and physicians 
to be trained separately or as a multi disciplinary team. Courses for each of the 
professions will be looked at sequentially. 
a. Courses for Nurses 
Training courses for nurses had been the main focus after the introduction of the first 
primary health care STG/EDL in 1996. 
"We did train in the firs! year (1997) nearly four-hundred nurses in effective prescribing, 
and the second year (1998) just trained seventy. We had to slow down a bit on 'Effective 
Prescribing' for nurses at clinic level because they were going through a lot of training 
in the last two years. By the time they get back to their working station they have 
forgotten what they've learned. We decided to scale down a little bit until other people 
have finished the (other courses) " (1-18). 
b. Courses for Pharmacists 
More pharmacists, than physicians have been trained in 'Drug Management and Supply,' 
and 'Rational Drug Prescribing,' but still too few have had either course. 
"Pharmacists who work in the public sector are about '300. I don't know how many 
hospitals there are in the Northern Province, but we certainly haven't reached the 
pharmacists in every hospital. We might have reached a majority of them. 1 can't tell 
you. 1 mean 1 should, but 1 can't" (1-20). 
He went on to say, 
"We have had pharmacists passing through our system. They come from a different point 
of view. These two 'training courses, 'Effective Prescribing, ' which is concentrated on a 
few common conditions. (It is) Sort of an algorithm approach of how you would 
approach those conditions. It is not extensive yet. It really was meant to be the principle 
(of the course) andfrom that you can use the EDL booklets" 
Pharmacists are expected to be managers and have been trained thus far, 
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"Probably we have reached 40 pharmacists over two years (1997-99) in the Northern 
Province. At the moment there is around 60-65 pharmacists in the public sector in the 
Northern Province. Well, (the) pharmacist we have trained, more as mentors or guides for 
the medical practitioners. We taught the pharmacist, in 'Drug Supply and Management' 
and 'Effective Prescribing. So they know what the parameters are for good drug use. 
They are also in the position to evaluate the data, the prescribing data and give feedback 
that says basically 'why does every patient that comes into this clinic or into this hospital 
given an antibiotic?' Obviously that is a bad practice. So we train them to do that" (1-
20). 
To meet the new demands, the NP would like to implement another training program 
designed for pharmacists to gain additional managerial skills. 
"I am also looking at another type of training for pharmacists. Training them to become 
managers in the future. We want to give pharmacists management training. This course 
will help them to improve hospitals prescribing because they will be taught, pharmaco-
economics, the basics of being managers and communications skills" (1-18). 
The course aims to assess the difficult task of pharmacist as the gatekeepers to brand 
drugs. The course goals is to give pharmacists more confidence to allow them to be more 
assertiveness with prescribers who ask for drugs not on the EDL, and who want to 
motivate for other more expensive brand drugs, when there is a suitable drug on the EDL. 
The training will take place in "the hospital situation for work-study. In the first 18 
months, the target number of pharmacist to be trained is "approximately forty). It will 
take them about 18 months. Upon completion of the training, pharmacists "will receive a 
management certificate from MEDUNSA, and the University of the North. Only, "once 
you have done the training and the pharmacist managers course you can apply" for a 
pharmacy manager position. If you haven't got this certificate, then you can not become 
a pharmacy manager" (1-18). 
Funding for the new pharmacist management training course has been sought from 
SADAP. Even so, pharmacists 
"will have to pay for it. " The exact cost of the course is not known yet, "the relevant 
funding will cut down the costs. They (the pharmacists) will just have to pay for the 
training materials. 1 think that it will be between R2,500 and R4,000 Rand" (£250 to 
£400 GBP for each pharmacist). lvlany will not be able to meet the cost of training, so 
they will able to apply for a bursary to help to defray the costs" (1-18). 
c. Courses for Physicians 
The National Department of Health and the NPDoH, as a result of poor planning, 
"at the hospital clinic level, did not envision any training. We thought that speaking to 
the doctors we might change their attitudes. 1 n some hospitals it does work. But in other 
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hospitals not. But after we did Ihe 'Effective Prescribing' for nurses, we got a very clear 
signal from Ihe nurses that the doctors need to train because Ihey are now in conflict with 
the doctors even at hospital level. Because some nurses are also prescribing at hospital 
level and that is were we realise that we really need to train the doctors in effective 
prescribing." (1-18) 
Currently there is not a course for rational prescribing for physicians. 
"At hospitals it more difficult. Doctors don 'I like to be (told how to) prescribe. And our 
first thing is that at this stage we are developing with MEDUNSA a program to teach 
doctors on effective prescribing as a part of continuing professional development. At this 
stage my application is with SADAP asking for funding through actually finance the 
budget with SADAP everything in place now 1just have to develop the program" (1-18). 
MEDUNSA is now setting up a continuing education course. It will be "voluntary, but 
because we are going to put is as a part of the CET (continuing education training) for 
the doctors might fall for it because they get points" (1-18). 
The exact type of training that physicians will have in rational prescribing is still not 
known. 
"No. I don't think 1 have too many details. 1 think that it will be in-service. It will be 
monitored by the professionals themselves, so that they can see what they're doing. In 
other words it will be active participation. It is not going to be something which is 
presented to them in the form of a course or a lecture program, but actually involved in 
participation." The training will occur "within their work environment "The basis 
training cost will be a the hospital level were will have training as part of the CET 
(Continuing Education Training). The designers of the intervention believe that face to 
face and active participation will it work, "because there will be a run through a 
cascade, like how we do all our training. We train the trainers, and then they train 
others, so it goes down into their service row" (1-20). 
The exact location of the first Programme implementation for physicians is not known. "1 
don 'I have Ihe hospitals yet. 1 just know that it's the Northern Province" (1-20). The cost 
also has not been worked out. 
"Ah. we don't know how much its going to cost to train the doctors because it will be in 
service training, its not going to taken out of the working environment. I don't think that 
costly. To develop a program as such will is going to cost about $ 70, 000, there is a lot 
of pre testing and tests to be done" 1-18). 
The development of the course for physicians will be developed, and tested in 
"three stages because clearly you have to do a pilot program, you've got to develop your 
materials, pilot test, redefine, review, improve and then take it to the next stage. 1 don't 
know what the cosling might be of the two stages. 1 don't have any figures. But I do know 
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that we are looking for support." (1-20) the NP Pharmaceutical Director, has 
"submitted my application to SADAP for funding (1-18). If the funding were available 
right away, "It shouldn't take two months to develop the program. We have the 
background of what we want to do, we've got the material attached we just have to put 
the materials together and train the trainers. And then we need to test it before we use it 
in other hospitals ... The whole process of the development; the test and evaluation of a 
physician rational prescribing course will be pursued vigorously. "We really want to 
push hard. It shouldn't take us more than six months "(1-18). 
"The prospects of getting a person who is qualified to train physicians full time is a 
difficult task that is made more difficult because of budget constraints. " (1-20) 
Overall courses in evidence based medicine and effective prescribing for nurses, 
pharmacists and physician are thought to be needed by the interviewees with the 
exception of physician who believe that others, including physicians could use training, 
but they do not need it. Administrators who would like the physicians to adopt cost-
effective prescribing, at the time of the interviews were at the initial conception stage. 
The best mechanism (Continuing education credits, On-house rounds, PTC, peer review, 
etc.) to implement training is for physician. For nurses, several courses were given for a 
cascade training effect that did not occur. Training was given to one pharmacist per 
hospital, but almost all of them need to have managerial training. 
With all the challenges to implementation, the administrators were asked about their 
vision for the future ofEDL implementation and training for the future and how that can 
make the vision a reality. 
Resistance to prescribing interventions (EDVSTG Use, Training, and PTe) 
Resistance to prescribing interventions include the use of the STGI EDL, training, and 
PTC committees. Nurses and pharmacists have generally been enthusiastic about 
participating in training, but physicians have consistently stated that others need it, but 
they personally do not need to have training. 
According to Administrators and physicians themselves, many physicians, especially 
specialists, do not believe that the EDL has the medicines that they use regularly use for 
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their patients. In addition, the list does not always coincide with the actual dosage of 
medicines that are available in the hospital pharmacy. 
"The EDL list talks about the medicines to comply with the EDL. The medicine will come 
in 2.5mg, and the EDL will say to use 10mg. Some find it very confusing, even the 
doctors. if a patient needs 5 (mg), what do you do? Do you give them two 2.5 (mg) or do 
you give them a single 5 (mg)? This is causing a bit of a problem, even at the tendering 
site there is a conflict, andfrustration" (1-18). 
The EDL covers many of the tertiary illnesses, but it does not cover the most common 
illness in psychiatry, dermatology, oncology or immunology (HIV/AIDS). On the 
EDUSTG there are 
"Very few dermatology and oncology (medicines) at this time. That is an area that they 
will have to look at. Psychiatric medicine is a bit of a problem. So, psychiatric doctors 
are really up in arms with us. Many physicians believe that the EDL advisory committee 
was not made up of colleagues in their professions. There is also a general feeling that 
they weren't consulted about the changes to the drug lists. Many physicians have adopted 
their own ways of getting around the use of only medicines on the EDL. We think there 
will be changes. Fortunately, within the province we can make up our own list. So we are 
doing that. (1-18) 
Many physicians have their favourite personal list of drugs that they use and do not want 
to change. They are resistant to any form to intervention that focuses on prescribing 
change. 
"Well training is a part of the problem, but I think that old habits die very hard. if you 
have always treated with brand (medicine) then you go on doing it. But if some outside 
body says that it is better for the patients, and believe strongly in certain medications. 
Advertising or some other forms can increase this ... {brand name prescribing influence). 
So, I think that, not here but in other places, it shows that doctors tend to prescribe from 
a very limited range of drugs. " (1-17) 
Rational Drug prescribing course developers believe that once a specific program is 
developed from an academic medical department, the resistance to use generic drugs and 
prescribing will be lessened. 
"One obstacle is that doctors see themselves as superior. What we've got now is a 
tertiary complex with specialists. We have various communities with various professors 
who are starting now to look at local application of various conditions and prescribing 
treatment. This is not very far off the ground, but is a major set (of priorities) in the last 
weeks, which I hope will get done faster. These people are academics, and they will be 
accepted by the doctors. We are hoping that this is the way we will get the training 
accepted by the doctors, rather than using our present pharmacist-nurses approach. "(1-
17) 
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This academic rational prescribing approach for physicians is likely to be developed and 
is implemented with the use of the PTe committee. 
In brief, the resistance to change, being told how to practice medicine, though prescribing 
is resisted by almost all physicians. In addition, specialists believe that the EDL does not 
list medicines that they need for theif practice especially in psychiatry, dermatology, 
oncology, infectious diseases, and immunology. In response to the mandated prescribing, 
physicians have found various ways of getting around or ignoring the use of the EDL. 
The way forward seems to be a new emphasis on physicians who are clinicians and 
academics that can bridge the gap between the administration and the prescribers. 
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8.6.4 Administrators Vision for the future 
The last questions asked to administrators to assess their vision of the future were 
"What do you envision for prescribers and pharmacist a year from now, and how can you 
get closer to making this a vision a reality?" 
The administrators who were asked about their vision for the future, most comments were 
based on the use of the EDL, multi-team practice at the hospital level, training in rational 
prescribing, and an updated STGIEDL every two to three year. The new STG/EDL 
should include medicines in specialty areas that are lacking in the 1998 version. Once the 
1998 STGIEDL is updated, then once again the focus must tum to the implementation of 
its use at all hospital levels. 
"Well if/could have my professional pharmacist trained this year (1999), / think in a 
year or two we should be able to have trained the new doctors because we feel that is 
where we can make a big savings at this stage. But we are not just looking at doctors; we 
see the training for the doctor prescriber is a team effort within the hospital with the 
pharmacist actively involved. But / think that within a year or two we should have at least 
one team per hospital trained" (/-18). 
The number of physicians that would need to be trained is about 500 in total. 
"Well, you know / think that we will be implementing something constructive. The first 
thing obviously is to increase their sensitivity or awareness to the current difficulty both 
in terms of therapeutics. Secondly, from the financial point of view. Although the drug 
companies would not have you believe that good therapeutics often go hand in hand with 
cost management. They would tell you that you must use the best expensive drug. That is 
nonsense. So what / am saying that good therapeutics and good cost management go 
together. So if you can be sensitise the prescribers to both issues and show them that 
their patients are not going to be any worse off with good prescribing rather than with 
fashionable prescribing, then we would have achieved a lot. We have to change that 
whole attitude because they have been so conditioned by the industry, even during their 
undergraduate training. They have a major role in developing pure (brand prescribing) 
practice because of their direct interest in making profits. They are there for the 
shareholders. They are not there for the patients" (/-20). 
The Northern Province has about 500 physicians in both public and private practice. 
"All 500 need to be trained Whether we would train all 500 in one year, / think it is 
unlikely. So, it would be a two year three year period" (/-20). 
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In summary, for administrators the lack of preparation and planning created additional 
challenges to local EDL implementation. The vision for the future includes addressing 
ten challenges listed below and individualised training and courses for nurses, pharmacist 
and physician. In addition, multi-team practice and PTe meetings, EDLISTG updates 
(every 2-4 years) will aid in the NDP implementation of Rational Drug Prescribing. 
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8.7 Structured Observations 
8.7.1. Observations in Health Facilities 
As part of the Drug Utilisation Study (DUS) evaluation during the facility visits, 
interviews and structured observation were used to determine first, the availability of 
EDL. Second the availability of impartial drug list. The set of three books (STG/EDL, 
1998) for Primary Health Care, Paediatric Hospital Care and Adult Hospital Care were 
delivered to all Northern Province hospital pharmacies in the study. The 'pharmacy 
management' staff had various methods of distributing the books. As confirmed in 
interviews and by observation most doctors, who are the primary prescribers, pharmacists 
and nurses in hospitals received the entire set. 
Structural observations at the facilities helped to answer several questions. First, is the 
EDL available for staff use? Second, are the STGIEDL present being used? If so, by 
whom, at which level, and how? Third, is there other impartial drug information available 
and accessible for reference? Fourth, Does the facility have its own drug bulletin? Fifth, 
what drugs on the STGIEDL are not available on the day that the survey was conducted? 
a. STGIEDL available for staff use 
All nurses, pharmacist and physicians were said to be given the set of STGIEDL books at 
all three hospital clinic levels. At one tertiary level pharmacy, there were large boxes of 
STGIEDL books in a copy/storage room. They were available for in all hospital clinics 
observed, bur rarely used. The availability of the STGIEDL along with the number of 
prescribers having direct access to a National Drug Formulary has a direct effect on the 
potential for prescribers to prescribe rationally. 
b. Use of STGIEDL 
The physical presence of the STGIEDL with the person or in the physician office, 
examining room, nurses desk, pharmacy, etc. is good indication that the book is being 
used for patient consultation. If the STGIEDL book were used regularly, then it would 
show warn or bent pages and other indications that it had been used. Instead, almost all of 
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the books used by physicians and some nurses looked new. It was apparent that the books 
had not been regularly used by some nurses and only two physician observed and 
interviewed. In contrast, the book was found in constant use at most of the pharmacies 
observed in the study. 
8.7.2 The Use of Other Impartial Drug Information 
Both the primary and the tertiary hospital clinics that were observed did not have 
impartial drug information with the exception of several textbooks and the EDL. At 
tertiary hospitals, pharmaceutical companies provided most of the drug information. 
Partial drug information was the norm. 
In contrast, the secondary hospital clinic (#6) had impartial drug material and its own 
regular EDL bulletin for all the staff (Appendix X). At the time of data collection, the 
pharmacist manager was enrolled in the 'Rational Prescribing' Course given by 
MEDUNSA. The pharmacist produced a monthly EDL bulletin for the hospital personnel 
as a way to impart information on EDL changes and the rational for the changes. 
8.7.3 Training of Staff 
In the quantitative analysis, the hypothesis that the availability or lack of training and/ or 
impartial drug information contributes to irrational drug prescribing. 
In addition to impartial drug information and a hospital level drug bulletin, the 
availability of training sessions can positively contribute to promoting rational drug 
prescribing. The assessment is determined by number of training session on drug use for 
prescribers in the last year, out of average number of training sessions organised in the 
past three years give a good indication of the actual population coverage of training. This 
includes the number of prescribers that have attended at least one training session in the 
last year, out of total number of prescribers surveyed. 
8.7.4 Summary of Observations 
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Overall the staff did not feel or behave as if the use of the EDL was beneficial to them or 
the patients with the exception of pharmacist who used it to substitute brand name drugs 
on prescription with generic drugs. In order for the health staff to use the EDL and 
prescribe rationally they must believe and feel that they have a part in the development, 
implementation of the EDL and the evaluation of their peers. 
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8.8 Summary of Qualitative Chapter 
The quantitative chapter explored the knowledge, attitudes and practices of the hospital 
staff and administrators through observation and interviews that allowed the staff to give 
their views in their own words. First the demographic information of nurses, pharmacists, 
and physicians was collected. The main group of questions centred on Knowledge, 
Attitudes and Practices with the EDL, Peer Review, PTC and training. The practice 
questions centred on changes in the work environment, including use of EDL, generic 
substitution and prescribing. 
Not all staffs were officially informed about the implementation of the new EDL and the 
Policy to prescribe drugs by generic name on the EDL. Some staff were sent a memo, 
while others were given the set of three EDL books. All the staff interviewed, with the 
exception of one, had not received training in the use of the EDL, evidence-based 
medicine or rational prescribing. 
Overall, the nurses and pharmacists thought that the EDL and training in effective 
prescribing was useful for all professional staff, while physicians thought that it is useful 
for other physicians, but not them. Consistently, with this view, the work environment 
changed for both nurses and pharmacists, but not for physicians, since the official launch 
of the EDL. 
After sixteen of the hospital staff were interviewed, new questions arose. Specifically, 
questions concerning plans for implementation, training, and visions for health staff and 
training in the future. Thus, specific administrators were chosen in order to answer the 
questions about a national or provincial plan for the implementation of the NDP and 
EDL, as well as the percentages of the prescribers and pharmacists who have been 
trained. These administrators were asked about what they consider to be the biggest 
challenges to the implementation of the NDP and EDL. Their answers can be categorised 
as follows: 
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(1) Diminishing resources, (2) Distribution and Stock Control, (3) Resistance to Change, 
(4) Beliefs of staff, (5) Communication, (6) Partnership of health professionals, (7) 
Patient Demands, (8) Prescribing interventions, (EDL, generic dispensing, and PTC), 
and (9) Training of staff. 
The administrators concluded that training must be directed to a particular professional 
audience through professional channels that are acceptable within the profession. Once 
this criterion is met there are still six challenges to training staff that include (I) budget, 
(2) material development, (3) logistics, (4) administration, (5) participant selection, and 
(6) resistance. 
Administrators envisioned training for prescribers and pharmacists, as a means to make 
the vision a reality. Envisioned is a budget line funding for trainers, courses and 
interventions that are tailored to the specific health care audience (physicians, nurses, 
pharmacists, administrators, and consumers). The courses would encourage team care at 
the hospital level and the use of inter-disciplinary practice and PTC meetings. In addition, 
the EDL must be updated regularly. 
Observation of the study facilities revealed that although all the staff was given a set of 
EDL with the exception of the books. The pharmacies also had the ELD set of books, but 
they were not present in other parts of the hospital clinic. Only one prescriber interviewed 
in a secondary hospital carried the books with him. At the same hospital, the pharmacy 
manager produced an EDL bulletin for health professionals on a regular basis and had 
other independent drug literature available. 
In order to explore the link between the qualitative and the quantitative data in chapters 
seven and eight, the drug utilisation and prescribing will be analysed and discussed in 
chapter nine, to answer the basic eight questions on the answers of which additional 
inquiry and analysis will be based. These basic questions were how many drugs were 
prescribed, how many drugs were from the EDL, generic, brand, antibiotic, analgesic, 
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injections. The answers to these questions were also evaluated for chronic illness In 
chapter seven. 
226 
CHAPTER NINE 
Discussion 
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9.1 Introduction 
This chapter will review the objectives of this thesis and summarise the findings. The aim 
of the research was to assess the availability of objective information about the South 
Africa's National Health Policy and evaluation of the top-down approach to its 
implementation. In top-down planning, "setting goals, identifying options, and choosing 
among options all occur at the senior level. Top-down planning is more appropriate for 
strategic planning, in which the basic mission and goals must be defined". Top-down 
planning requires input from all levels. Top-down planning is less appropriate for 
operational and project planning, in which the purpose and major goals are clear. 
The overall objective of this thesis was to evaluate the implementation of South Africa's 
National Drug Policy (NDP), the use of the Standard Treatment Guidelines/ Essential 
Drugs List (STG/EDL) and its impact on rational drug prescribing in public hospital 
outpatient adult clinics. The main question is has the implementation of South Africa's 
National Drug Policy and the use of the STGt EDL resulted in rational drug prescribing 
in South Africa's hospital outpatient clinics, specifically in the Northern Province? 
9.2 Analysis of Drug Utilisation Study (Objective One) 
The first objective was to survey and analyse patterns of drug prescribing at three levels 
of outpatient hospital clinics. The Drug Utilisation Survey (DUS) focused on eight 
Prescribing Indicators at eleven clinics in eight hospitals. The eight indicators were I) 
mean number of drugs, 2) prescriptions with two drugs or less, 3) proportion of generic 
drugs, 4) proportion of drugs on EDL, 5) proportion of drugs prescribed as brand or 
generic on EDL, 6) proportion of antibiotics, 7) proportion of analgesics, and 8) 
proportion of injections. These indicators were evaluated for the overall population and in 
addition for patients with chronic illnesses. 
The results of the DUS study showed that overall the three levels of care were quite 
similar in their adherence to EDL principles with the following exceptions. The primary 
care levels overall showed better compliance to EDL principles, although still not 
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meeting the EDP goals. This small success at the primary care level can be attributed to 
familiarity with a limited number of generic drugs, a limited stock, and introduction of 
the EDP concepts and training many years before the implementation of the NDP for all 
levels. 
The overall ranking for rational prescribing of the eleven hospital clinics did not show a 
specific pattern. Hospital clinic #6, St. Rita, a secondary hospital was ranked first for 
adherence to prescribing indicators. In contrast, clinic #7, Mokopani, also a secondary 
hospital and #4 Mankweng, a tertiary poli-clinic ranked last in adherence. 
St. Rita's clinic #6 ranked first of the eleven clinics, in both adherence and by the 
coefficient evaluation. It ranked first for generic (GEN) prescribing, and the number of 
drugs prescribed by brand name on the EDL as generic (EDLBRD). St Rita's clinic 
ranked second for the number of drugs prescribed on the EDL. 
St. Rita's first rank is not a surprise when reviewing the interviews and observations 
during the data collection. The Managerial Pharmacist at St. Rita has a finn commitment 
to the use of generic drugs, the EDL and rational prescribing. At the time of the interview 
she was preparing a small DUS study for her class in Rational Prescribing. In addition 
she produced a monthly newsletter on rational prescribing (Addendum X). The nurses 
and physicians who used the STGIEDL and carried it around during their patient visits 
shared this commitment to generic prescribing. 
9.2.2 Chronic Illnesses and comparison with overall prescribing indicators 
Generally, the majority of chronic illnesses should be treated at primary care facilities 
and only the more complex cases should be referred to a tertiary care facility. Of the 
general study population, 39.2% had a documented chronic illness of hypertension, 
diabetes and/or asthma or a combination of these illnesses. 
In contrast to the goal of treatment of chronic illnesses by Primary Health Care facilities, 
54% of those with hypertension and 52% of those with diabetes were treated at tertiary 
care facilities and only 37% of those with asthma were treated at primary care facilities. 
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Overall as for the general population, the clinics that were the least adherent for those 
patients with chronic illnesses were both at the primary care level, Jane Furst hospital 
clinic #9 and van Velden hospital clinic # 11. (Comment: Misleading - does not allow for 
different sample sizes) 
Once again, St. Rita's clinic #6 ranked first overall, even though they ranked first only 
once in prescribing drugs by brand name, which are on the EDL as generic (EDLBRD). 
St Rita's clinic ranked second for the number of drugs prescribed on the EDL. Ranked 
second overall, Pietersberg poli-clinic #2, ranked first in mean number of drugs, 
prescriptions with two or less drugs, and the proportion of analgesics prescribed, but it 
also ranked last in prescribing drugs by brand name that are on the EDL as generic 
(EDLBRD) and antibiotics. 
Prescribing for those with chronic illnesses did not show better rational drug prescribing 
or a concerted effort to adopt the use and principals of the EDL at any of the three levels. 
Evaluating the prescribing indicators by facility level for those with chronic illnesses is 
similar to the overall results. At the primary care level the mean number of drugs was the 
highest, but in contrast to this the level of prescribing antibiotics and injections were the 
lowest. Overall this evidence does support the hypothesis that at the tertiary level there is 
a trend towards the adoption of EDP principles, while at the primary and secondary level 
there is little evidence of adoption the EDP. 
9.2.3 Comprehensive Correlation Matrix of Prescribing Indicators 
For both the general population and those with chronic illnesses the pattern of the 
comprehensive correlation matrix was the same. The high correlations between the mean 
number of drugs and prescriptions with two or less drugs and between prescribing from 
the EDL and generic are expected. Worth noting is that there are no other significant 
correlations. In summary, there is little evidence of a concerted implementation of the 
EDL policy. 
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9.2.4 Knowledge, Attitudes, and Practices of Health Professionals 
(Objective Two) 
The second objective was to assess the knowledge, attitudes and practices (KAP) of 
health professionals (nurses, pharmacists, physicians and administrators) concerning the 
implementation of the NDP and their training in the use of the STG/EDL. 
Interviews 
Overall, the interviews with nurses, pharmacists, and physicians show a common 
experience of not being informed about or trained to use the new EDL, although all of 
them said that they received the set of three books. Although every health care provider 
received the books, most phannacists but only a minority of nurses and physicians use 
the EDL as part of their working routine. 
The implementation of the EDL in general has slightly changed the working environment 
for nurses and phannacists, but not for physicians. These changes in the professional 
environment for nurses include the addition of public health issues and non-drug 
treatments, and for pharmacists automatic generic substitution, a ready-made 
procurement list for ordering, cost reduction, and a decrease in polypharmacy. 
Nurses and phannacists believe that all health professionals need the EDL and training in 
rational drug use, while physicians believe that the others need training while they do not. 
In addition all health professionals believe that a multi-teamed PTe committee would be 
beneficial to both staff and patients. 
The different groups of health care providers had different challenges with the EDL, 
generic drugs and rational prescribing. These will be summarised separately. 
aJ Nurses 
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Nurses were given the new STGIEDL for hospital adult care. None were given a briefing 
about when or how to use it. All were given books, but none of them had training on 
rational prescribing or the use of the new STG/EDL. 
Overall nurses, who were given the first primary health care EDL (the green book) in 
1995, thought the STGIEDL was simple, useful and advantageous because it included 
preventive care and public health tips. Even with the use of the new EDL, few felt as if 
their work environment had changed as a result of its implementation. However, all felt 
that they did not have the knowledge needed to use the STGIEDL to their full advantage. 
All expressed that they would like to be trained. In addition, they thought that active 
participation, for example in Pharmaco-Therapeutic Committees (PTC), as a part of a 
health care team would give them the input that they need and also allow for better 
patient care. 
b) Pharmacists 
All pharmacists said that they had received the set of STGIEDL books. All had 
knowledge about the new STGIEDL because they were expected to give these books to 
all health personnel and to inform them about their use. Nonetheless, only one pharmacist 
interviewed, at St. Rita's Hospital, had formal training in Rational Drug Prescribing. 
Pharmacists are expected to be the gatekeeper of the drugs available from the pharmacy 
and to educate the prescribers on how to use the EDL and write prescriptions with 
generic names. Pharmacists found the EDL was a positive guide that helped them to limit 
the amount of drugs ordered that are not on the EDL. They use the EDL as a way to 
reduce pressure from both patients and physicians to order and dispense brand drugs. In 
addition, pharmacists use the EDL as a guide of what to order. 
The pharmacist is expected to stay within the budget, while supplying all the drugs 
needed for all the specialities, to order mostly generic drugs, to spend only 10% of the 
budget on brand drugs, to motivate prescribers to use drugs on the EDL, and generally act 
as enforcer. Nonetheless, only one pharmacist received formal training on how to fulfil 
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these duties. Pharmacists would like to receive formal training and also to be active 
within inter-disciplinary PTC committees. 
Currently, the pharmacist is expected to be the manager, gatekeeper, accountant, and 
teacher, and to motivate the staff to adopt the EDP and rational drugs prescribing, all with 
little or no training in management, rational prescribing or budgeting. 
c) Physicians 
All physicians interviewed received a set of STGIEDL books. The overall knowledge of 
physicians about the use of the new STGIEDL, motivating for generic drugs, Peer 
Review and Pharmaco-Therapeutic Committees (PTC) are limited. Of the physicians, two 
said that they did not have knowledge of the new EDL and generic prescribing. In 
contrast, all physicians know about 'motivating' for drugs not on the EDL, while none 
had knowledge about the 10% budget cap on ordering drugs not on the EDL. One 
physician talked about Peer Review and only four said that they had knowledge about 
PTC committees. None of them had participated in either a Peer Review or PTC 
committee. The Pietersburg Hospital administration said that they once had a PTC 
committee that failed because of its focus only on physicians' experiences with patients. 
The administration will attempt to set up a multi-team PTC. 
The working environment for physicians should have changed as a result of the EDL 
adoption, for example by prescribing more generic drugs, less pol i-pharmacy, 
participation in training, PTC committees and Peer Review. Physicians said that their 
environment had not changed since the introduction of the EDL. 
Most physicians interviewed thought that the EDL was not useful for them or their 
practice. Only one physician changed the way he practised medicine by prescribing by 
generic name. The only change for some physicians is that now when they order brand 
drugs, they must fill out a justification fonn to 'motivate' 'the pharmacist to order the 
brand drug for a particular patient. The most telling interview was with a young physician 
who was practising medicine at a primary care hospital for less than a year. He said that 
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in his six years of medical school in South Africa he learned to prescribe only by generic 
name. Within less than a year and with medical seminars sponsored by drug companies 
only once a month, he prescribed by brand name most of the time. 
Several physicians thought the EDL is useful for young and lor inexperienced physicians 
or as a list of what is available in the pharmacy. Physicians interviewed did not 
experience a change in their work environment, although two physicians said that generic 
substitution changed the way they prescribe. Overall physicians said that the EDL is a 
simple and cost-effective reference tool that is good for young physicians, patients, 
especially those with chronic illnesses, and other staff who should be trained to use it. 
However, they do not think that it is a helpful guide for them personally and thus it has 
not influenced their prescribing practices. Physicians interviewed overall did not adopt 
rational prescribing practices like using generic names or prescribing fewer drugs 
including antibiotics, analgesics, and injections. Physicians practice, diagnosis, 
prescribing or treatment regimes overall had not changed. As one administrator 
summarised the physician practice environment, "It's the RTC factor, resistance to 
change" (1-12). 
9.3 Administrators 
After the interviews with the hospital clinic staff, administrators were interviewed to gain 
a better understanding for the planning, preparation, and implementation goals of the 
NDP and the evaluation of the degree of success. The three main foci were I) preparation 
and planning for implementation, II) challenges to EDL implementation, and III) visions 
and plans for the future. 
9.3.1 Preparation and Planning 
Overall strategic or programme planning and implementation of the EDL did not occur 
on the national, provincial or hospital levels. Administrators stated that there was no 
implementation plan because in South Africa's health care system' there is no culture of 
planning'. The planning for the implementation of the NDP was left to the Provincial 
Departments of Health (DOH) within the nine provinces. The new EDL was launched in 
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a ceremony In Pretoria on 3 December 1998 by the National DOH, but the Nine 
Provincial DOH were not informed in advance. Thus there was no time to prepare the 
drug depots, pharmacists, and prescribers. Boxes of EDL books were sent to pharmacists 
without information, guidance or training. 
9.3.2 Challenges to the NDP and EDL Implementation 
The lack of preparation and planning are the cause of the current challenges that have 
impeded the successful implementation of the NDP. This topic will be explored in detail 
in the third objective, which identified factors that had hindered or facilitated the 
implementation of the NDP, and of rational prescribing or the use of the STGIEDL. 
9.3.3 Factors Hinder or Facilitate NDP Implementation (Objective Three) 
The third objective of this thesis was to identify factors that facilitate or hinder the 
implementation of the NDP, the rational prescribing of drugs, and the use of the 
STGIEDL. Factors that hinder the implementation of the NDP and rational prescribing 
include a lack of strategic and programme implementation planning on the National and 
Provincial levels, diminishing resources of staff and budget, distribution and stock 
control, patient demands, communication, staff resistance to change, lack of training and 
continuing education. For this discussion several of these factors will be analysed in more 
detail. 
The factors that have helped to facilitate the NDP implementation and rational 
prescribing include continuing education in 'Rational Prescribing and Drug Supply 
Management' for the pharmacist manager. At the same clinic, a regularly published 
bulletin and a commitment by the nurses and physicians to use the EDL as a tool for 
rational and cost-effective prescribing. 
a) Factors that Hinder NDP Implementation 
Factors that hinder the implementation of the NDP and rational prescribing at the national 
level are the neglect of allocating resources to the implementation process and the non-
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existent promotion of the NOP implementation for health care workers in all nme 
provinces. Making a policy at the national level with little input from those who need to 
enforce it at the provincial, local and public health institutions has led to only minimal 
success. The main factors that will be explored in this discussion are a) the lack of 
implementation planning, b) distribution and stock control, c) staff resistance, d) patient 
demands, and e) the lack of training and continuing education. 
h. Lack of Implementation Planning 
The lack of implementation planning including strategic and programme implementation 
planning for the NDP has resulted in an ineffective tool and limitations on what could be 
accomplished. Planning is defined as ''the first step in the management cycle, the process 
of assessing needs, establishing goals, setting objectives and targets, and determining the 
strategies, responsibilities, and resources needed to achieve the objectives" (DSM, 1997). 
To maximise the chances of successful implementation of a plan, those involved in the 
practical implementation of this plan should participate in the plan formulation. It is 
important to establish the planning team at the outset. For strategic planning, this team 
should include policy makers and senior staff. For programme and work planning this 
should include all involved key people in the unit. The three levels of planning differ in 
their purpose, level of detail and time frame (DSM, 1997) 
Figure 9.1 Levels of Planning: the Planning Pyramid 
Strategic Plaooing 
Long term 
Focus on mission and goals 
National development plans 
National health and drug policies 
Programme Planning 
Medium term 
Focus on goals and objectives 
Master plans 
Project plans 
Work Planning 
Short term 
Focus on activities and tasks 
Annual work plans 
Task-specific plans 
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During the planning process four key questions need to addressed at all three levels. 
(DSM, 1997) 
1. Where are we now? Assessment of the current situation and needs 
2. Where do we want to go? Statement of intent to describe the expected outcomes: 
mission, goals, and objectives. Objectives are the results that the plan seeks to achieve 
defined by the mnemonic 'SMART': 
Specific: to avoid differences of interpretation 
Measurable: to enable monitoring and evaluation 
Appropriate: in relation to overall objectives or goals 
Realistic: available resources 
Time-bound: deadlines 
3. How will we get there? Methods used for achieving specific targets, objectives and 
goals: 
Strategy: Promote rational prescribing through strengthening formal 
education, continuing education, and supervision. 
Activity: Conduct a workshop on rational prescribing. 
Tasks: Prepare session notes and overhead transparencies at least four 
weeks before workshop. 
4. How will we know when we have arrived? Monitoring and evaluation of the 
achievement of objectives and long-term goals. Indicators help to measure 
changes directly and indirectly and also used to assess the extent to which 
the targets and objectives are being attained. 
c. Distribution and Stock Control 
Vuna HeaIthcare Logistics is a private for-profit company, which was contracted by the 
Northern Province DOH to control the orders, distribution, and training for pharmacists 
who were to be the gatekeepers to the Northern Province hospital pharmacies. One 
project manager had contact with all the pharmacy managers during their intense one-
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week course on Provincial ordering policies and the software for stock control training at 
Vuna headquarters and afterwards with on-site training. In addition, Vuna published its 
own bulletin 'Vuna Vision' (Appendix Y) to keep pharmacists and health care providers 
informed about staff, drug changes, and policy changes. 
Although the ordering and stock system is set up to capture mistakes and correct them 
quickly, several hospital pharmacies were found to be lacking in basic generic drugs in 
doses needed during the Drug Utilisation Study (DUS). The most striking example of the 
failure of this system was at the tertiary complex Mankweng Hospital, which serves a 
mostly black patient population. 
During the DUS at the hospital pharmacy it was found that hydrochlororthiazide 
(HCTZ), a generic medicine for hypertension was not in stock that day. Most of the 173 
people (54.4%) with one or more of the three chronic illnesses were seen at the tertiary 
care facility at Mankweng, where the basic drug for treatment of hypertension was not 
available. When I asked the pharmacist why the drug was not available, I was told that 
there were several problems. First, when a drug is out of stock, many times the pharmacy 
staff must pick up the drugs and there is not sufficient staff or vehicles to complete this 
task. Second, when an entire stock of drugs are ordered and received, the hospital 
pharmacy must then supply the primary health care clinics. 
To compound the difficulties, the depot has not been able to find a supplier of the drug 
with 12.5mg ofhydroclorothiazide (HCTZ), even though the STGIEDL states that this is 
the correct dosage to treat hypertension. Instead, Vuna orders the available 25mg of 
HCTZ. Most patients do not cut them in half. Instead they take the whole pill that 
contains double of what is needed. 
d. Staff Resistance 
Staff resistance to change was expected, especially after they had not been included in the 
formulation, implementation or evaluation of the NDP. The STGIEDL books, generic 
medicines and restrictions on brand medications are seen as just another mandate from 
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the top administration in Pretoria that will pass when the political situation changes and 
posts are given to new people with new agendas. The largest resistance comes from 
professionals who work in secondary and tertiary institutions and mostly from physicians. 
Professionals, especially physicians believe that they should not be told how to practice 
medicine. Although only several physicians admitted in the formal interview that they 
work in both public and private practice, many physicians consider this an economic 
necessity. Understandably, this creates a conflict of how physicians practice medicine, 
diagnose and treat patients. In private practice, physicians are expected to use the best 
treatments and drugs available, but in public practice they are expected to use only some 
treatments and generic drugs. 
This resistance manifests itself in a lack of rational prescribing, which can negatively 
affects patient care and cost effectiveness. The prescribing study showed that overall 
there was very little evidence that the NDP implementation was taken up by health care 
professionals. These results are consistent with a study conducted in South Africa two 
years before the NDP implementation. This study, reviewed in chapter four (Orrell, 
1998), concluded: 
1. No clear prescribing policies for districts exist. 
2. Lack of teamwork. Doctors behave according to their own rules, as do nurses. The 
hierarchical atmosphere does not facilitate empowerment. Nurses do not feel supported 
by doctors. 
3. Patient demand can be overwhelming, especially for cough mixtures and injections, 
and promotes irrational prescribing behaviour. 
4. Difficulties in the implementation of treatment guidelines. The guidelines for TB 
treatment were inconsistent with the packaging of the medicines that required re-packing. 
5. Staff resistance could be reduced through the implementation of several initiatives, 
including, but not limited to, independent drug information, for example bulletins, books, 
and centers. In addition, Pharmaco-Therapeutic Committees, Peer Review and continuing 
training and education would also reduce resistance to these changes. 
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e. Patient Demands 
Education of the public about the implementation of the NDP and the use of generic 
drugs also was also not planned. Many patients have been denied both medical care or 
prescription drugs for most of their lives. Now, they demand to have access and equity of 
medical treatment including brand name drugs. Patients perceive the brand drugs as being 
better and the generic drugs as being not as good. Patients in hospital clinics included in 
this study get their medicines without a fee. 
Generally, patient demand is one factor that increases the number of drugs prescribed. If 
a certain drug is not prescribed, the patient believes that they did not receive correct 
treatment. In addition, patients see antibiotics as the cure-all pill for illnesses. Many 
patients go to the clinic with a certain drug name already in mind and they believe that if 
they do not receive this drug the treatment will not be effective. 
Most patients go to the clinic mainly for drugs, not for diagnosis and non-drug treatment. 
During this study, when hypertensive patients went to Mankweng Hospital for their 
monthly dose of hypertension medication, hydrochlorothiazide, and found it was not in 
stock, they believed that the hospital did not have drugs at all. It is likely that this false 
information spread throughout the community quickly. One administrator said, ''the 
interesting thing is the community believes that we have no medicine at our institutions. 
This is frustrating because we believe we do have medicines" (1-17). When there is no 
medicine at the clinic for their illness, many patients either change the way they medicate 
themselves or go to traditional healers to medicate their illness. 
j) Lack of Training and Continuing Education 
For the implementation of the NDP, the National Department of Health committed to "a 
systematic and comprehensive programme of continuing education which would be 
developed and implemented to "ensure that all health personnel involved in diagnosis, 
prescribing and description of drugs receive adequate theoretical and practical training". 
In addition, all initial and continued training would be developed and assessed in 
collaboration with health personnel at all levels (NDP, 1996). 
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To date there is no official continuing education system on the rational use of drugs for 
prescribers and dispensers. Health personnel have not "received any training in either the 
philosophy or the practice of the STGIEDL" (1-20) according to one administrator. It is 
understood that NDP implementation success "is largely dependent on training" (1-17). 
Several courses in Rational Prescribing and Drug Supply Management have been given, 
even though only a few of the hospital clinic staff in the Northern Province had been 
trained. The challenges for staff training are budget, logistics, and course materials and 
staff resistance. The National Department of Health claimed to be committed to "a 
systematic and comprehensive programme of continuing education" without giving 
funding or guidance about how to find funding for the implementation of the training. 
The difficulty is that the "budget is annual, and there's not a provision of long-term 
training, which includes human resource development" (1-20). 
The only source of funding that was not from the Provincial budgets was from SADAP. 
Only one stakeholder, MEDUNSA, provided training and sought funding from SADAP 
as well as from the Provincial Health Departments to train a limited number of people in 
all nine provinces. 
In addition, the logistics of having a class during normal working hours, outside of the 
hospital, perhaps in another province for one or two weeks is a strain on the already 
limited human resources of hospitals. Most physicians have many patients and not much 
time, so the pharmacy manager is usually the only qualified person. Shortage of staff, the 
demand of time, and the lack of funding contribute to the fact that training and continuing 
education is virtually non-existent in the Northern Province. 
A randomised controlled study (MEDUNSA, 1997) conducted by MEDUNSA and 
SADAP in all nine provinces of South Africa showed that the Effective Prescribing 
Training produced significant improvement in prescribing practices of primary care 
nurses. This short course given by Pharmacy staff for primary health care nurses on 
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rational drug use, supply and management was successful. The costs of the courses are 
usually paid through grants provided by SADAP and/or the provincial budget. Enrolment 
in the course is decided by the head of the pharmaceutical department within the 
provincial department of health. MEDUNSA held workshops for health care workers and 
administrative staff that were attended by 156 participants in 1998 bringing the total 
number to 508 countrywide. 
In the Northern Province, by the end of 1999, a total of 159 people have been trained in 
effective prescribing and 419 in drug supply management. Of those trained by 1998, one 
was a pharmacist, twenty-six were pharmacist assistants, nurses and health service 
managers. In 1998 refresher courses were conducted in the Northern Province that 
included an Effective Prescribing course attended by 14, Drug Supply Management 
courses attended by 8 and Training of Trainers attended by 26 people (MEDUNSA 
1998). A Drug policy course was conducted in 1998 and once again in 2000 by 
MEDUNSA with an international faculty for 30 participants from twelve countries. The 
topics offered for health care personnel by the MEDUNSA School of Pharmacy staff are: 
a) Training of Trainers in Drug Supply Management (l week) 
b) Effective Prescribing (1 week) 
c) Promoting Rational Drug Use (2 weeks) 
d) Drug Policy Issues (2 weeks) 
In order to address the lack of continuing education and training for health professionals 
several points are important. First, a designated budget for NDP and EDL training with 
designated targets and outcomes is essential. Second, materials and courses specifically 
for Pharmacist Managers and for Physicians have to be developed. Third, the logistics of 
training have to be addressed enabling health professionals to participate on a regular 
basis. 
b) Factors that Facilitate NDP Implementation 
Factors that facilitate the implementation of the NDP and rational prescribing at the 
national level will be explored in this discussion are a) Independent Drug Information, b) 
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Drug Bulletins, c) Drug Information Centre, d) Standard Treatment Guidelines IEssential 
Drugs List, and e) Pharmaco-Therapeutic Committees and Peer Review. 
a. IndependentDrug Information 
Independent drug information is one component of promoting Rational Drug Use. The 
NDOH foci included producing independent drug information. The sources of 
independent drug information include a drug bulletin for health personnel and 
administrators, an independent drug information service, and a regularly updated 
STGIEDL for distribution to all health care providers and prescribers. 
h. Drug Bulletin 
An independent drug bulletin giving the latest information about drugs added or removed 
from the EDL, doses, and case studies could be beneficial to hospital personnel, 
prescribers, administrators and patients. To date there is no independent and objective 
drug bulletin in South Africa. 
c. Drug Information Centre 
A Drug Information Centre is located in the Pharmacology Department at the University 
of Cape Town in South Africa. Several pharmaceutical companies finance the centre. 
Mostly health professionals who are in the more developed areas of South Africa and 
have access to a phone with long-distance services use this service. As a result of limited 
resources the drug information centre is not able to provide regular information on drugs 
to prescribers and dispensers in the nine provinces of South Africa. 
d Standard Treatment Guidelines IEssential Drugs List 
The NDOH of South Africa compiled and published its first National Standard Treatment 
Guidelines and Essential Drug List (STGIEDL) for primary health care in 1996. Since 
then it has produced a follow-up STGIEDL in 1998 for primary health care and added 
two additional books one each for paediatric and adult patients at the hospital level. The 
methods to promote STGIEDL adherence include (DSM, 1996). 
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The goal of the NOOH was to publish new books every two years to incorporate drugs 
that were reviewed and deemed necessary for inclusion in order to meet the needs of the 
population. Since the 1998 set of STGIEDL were published and given to all public health 
care personnel, another set has not been produced. 
From interviews conducted for this study, the staff believed that the EOL was a good 
guideline about what was in store at the pharmacy. Yet, that it was lacking in medicines 
for entire categories of illnesses, including dermatology, psychiatry, oncology, infectious 
diseases, just to name a few. 
Since the promised inclusion of additional drugs from evidence based medicine has not 
happened and the STGIEDL has not been updated for six years, prescribers feel they have 
only few options, other than prescribing and if necessary 'motivating' for drugs not on 
the EDL. 
To reach the goal of limiting brand drugs to no more than 10% of the entire 
pharmaceutical budget, the system of adding medications and publishing lists every two 
years would have been imperative. 
Since the NDOH has not followed through with their commitment to update and publish 
the STGIEOL every two years, prescribers have started using pharmaceutical sponsored 
references which are usually free, heavily subsidises and up to date. The most popular 
books used by health professionals are the South African Medical Formulary (SAMF) 
and the Merck Manual (MIMS). 
e. Pharmaco-Therapeutic Committees and Peer Review 
The PTe is responsible for developing policies and procedures to promote rational drug 
use. Members of the PTe should include representatives from the medical, pharmacy, 
and nursing staffs, administrators, and the quality assurance coordinator. Its functions 
include: 
1. Management of the approved drug list (STGIEOL) 
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2. Ongoing drug utilisation review (Rational Prescribing) 
3. Medication error reporting and monitoring (Patient Care) 
The drug use process has the four components prescribing, preparation and dispensing, 
medication administration, and monitoring the effects of drugs. The first two areas were 
analysed for this research. Drug prescriptions in hospitals are mostly the responsibility of 
the physician who is in charge of the patient's care. Frequently, these physicians 
prescribe and order medicines not on the EDL. The responsibility for assuring 
appropriate prescribing within the hospital falls within the domain of medical staff 
committees, which can include a PTC. The policies and procedures for medicine 
preparation and dispensing by pharmacists should be reviewed and approved by the PTC 
(OMS 1996). 
In the Northern Province, Pharmaco-Therapeutic Committees (PTCs) were initiated and 
held only at the tertiary level. After a short period the PTC ceased to exist. The 
reinstatement of the PTC committees was said to be underway at the time of the 
interviews. The PTCs would have a new approach concerning its stafT make-up and its 
goals. 
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9.4 Visions and Plans for the Future 
For administrators who are responsible for the implementation of the NOP, the vision and 
plans for the future all centred around strategic and programme planning, budget and 
goals for training staff. 
Specifically the administrators saw strategic and programme planning and the 
encouragement of team committees for the training of health professionals as important 
factors. Training would increase sensitivity and awareness about prescribing. In addition, 
they felt that rational prescribing, good therapeutics and cost effectiveness are 
inseparable. The goal would be to train all pharmacists and all 500 physicians in public 
and private practice in the Northern Province. Also the STG/EOL should be updated at 
least every two years. 
These goals for the future are attainable with commitment to not only theoretical 
improvements, but also allocation of financial resources in order to fulfil the goals of the 
NDP implementation. 
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CHAPTER TEN 
Conclusions and Recommendations 
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10.1 Health Policy Implications (Objective Four) 
This chapter will outline the implications of these findings for health care policy and 
suggest an agenda for future research. 
The fourth objective is to examine the health policy implications of these research 
findings. Policy implementation is an intricate part of programme implementation. The 
South African government first had to change the legislation to harmonise with the 
National Drug Policy formulation and implementation. 
Legislative groundwork must be implemented before policy and programme 
implementation and evaluation can occur once again. Once this has been completed 
successfully, then the strategic planning for programme development, implementation 
and evaluation can take priority. The commitment of resources, both staff and finances 
are imperative for success. 
10.1.1 Legislation 
In order to implement a National Drug Policy in South Africa, the legislative ground had 
to be changed to redefine roles, responsibilities and the use of resources for both public 
and private entities. These changes were accomplished through changes and updates to 
previous legislation and the introduction of new legislation. 
The four health legislation bills that were introduced into Parliament in 1997-1998 are: 
1. The Pharmacy Amendment Act [Act No. 28 of 1997] 
2. Medicines and Related Substances Amendment Act [Act no. 90 of 1997] 
3. The Medical, Dental and Supplementary Health Services Professions Amendment 
1998 
4. South African Medicine and Medical Devices Regulatory Act (SAMMDRA) 1998 
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Of these bills the most important and influential for success of the NOP are the 
Medicines and Related Substances Amendment Act [Act no. 90 of 1997] and the South 
African Medicine and Medical Devices Regulatory Act (SAMMORA). 
The Pharmaceutical Manufacturers Association (PMA), three years after taking the 
government to the Pretoria High Court (2001) in order to stop the adoption of the 
Medicines and Related Substances Amendment Act [Act no. 90 of 1997], withdrew its 
complaint and the Act went into effect. Meanwhile, with the assistance of SADAP, the 
DOH formulated and passed the South African Medicine and Medical Devices 
Regulatory Act (SAMMDRA) to replace the Medicines and related Substances Control 
Act of 1965 and the amendment of 1997. This act is specifically aimed at ensuring 
affordable medicines for the public. 
The PMA objected to the provisions that allow parallel importation and generic 
substitution of drugs and the government challenged it own legislation and the law was 
stuck down. Then the PMA reactivated its original court challenge to the Medicines and 
Related Substances Amendment Act [Act no. 90 of 1997]. Today as a result of these 
legislative failures, South Africans are living with legislation from the original 1965 Act 
brought into effect by the governments and sentiments of apartheid, without the 1997 
amendments. 
10.1.2 Policy and Programme Implementation 
The policy statement of its goals, objectives and means are translated into programmes 
that aim to achieve the policy objectives. Thus the study of policy implementation 
involves the analysis of the programmes and interventions that have been designed as 
vehicles for the policy. 
a) Resources for NDP Implementation 
The National Department of Health instituted the NDP and expected the Provincial 
Departments of Health to find the resources in their tight budgets for the training of staff 
and patients about the use of generic drugs, the EDL and the 10% cap on brand drugs. 
249 
The NDOH gave a mandate without considering the lack of resources. For Provinces that 
have few private hospitals or paying patients, the NDP could have been a life-line for 
'getting medicines to the people' and promoting rational prescribing, but without staff 
and financial resources specifically allocated to the NDP, patient education and rational 
prescribing, there was only very limited implementation of the NDP. 
b) Staff Adoption of NDP 
The most variable and unpredictable aspect of implementation of the NDP was the 
attitudes and practices of the stakeholders, nurses, pharmacists and physicians. The large 
degree to which the stakeholders would have to change their behaviour had a direct effect 
on the NDP policy implementation. Nurses' and pharmacists' prescribing behaviours 
were affected the least, as they were able to adapt the most. While physicians' prescribing 
behaviours were affected the most and the most difficult to change as seen in the research 
results. Without convincing physician of rational prescribing, the success of the NDP 
implementation has been limited. 
In addition, the staff need access to updated STGIEDL information on a monthly basis 
and new lists yearly that can be accessed on-line or an updated set of books every two 
years as originally intended. The last update was in 1998. They are already five years out 
of date. 
In conclusion the legislation failed, the resources of staff and money were not allocated 
for implementation, and a set of books was not enough to change perceptions or 
behaviours or staff of patients. 
To improve the National Drug Policy and the National Drug Programme 
implementation, the policy recommendations are: 
1. Legislation on health and drug policy be revised, evaluated for constitutional rigor and 
passed by the policy makers within the South African government. 
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2. A dedicated set budget (no matter how small) from the National Department of Health 
be allocated to each Provincial Department of Health for training in the NDPs goals of 
rational prescribing, drug supply management, and patient education. 
3. The continued implementation of the NDP through the bottoms-up approach to policy 
(from the health workers to administrators to policy makers) to re-evaluation and 
implement rational drug prescribing and the use of an STGIEDL. 
4. The National Department of Health develops a continuing education course for 
physicians with direct physician-to-physician feedback, a course for pharmacy managers 
and nurses be developed and that full time trainers implement this education. 
5. Education of consumers about rational prescribing and the EDL through Posters and 
radio announcement to combat the barrier of illiteracy and medicine demands. 
6. The STGIEDL is updated every two years in paperback and every year online. 
10.2 Recommendations for future research 
The research agenda for South Africa as it adopts NDP tenants and evaluate 
implementation are varied. Research projects could include: 
1. Intervention study: Intended versus actual behaviour regarding drug use. 
2. Evaluation of the use and impact of the STGIEDL 
3. A study of where and how guidelines have been used, what factors are conducive or 
obstructive to their use and whether they had any impact on drug prescribing 
practices. 
4. Evaluation of the impact of drug bulletins on rational drug prescribing. 
5. Evaluation of the impact of public education on the acceptance of generic drugs. 
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6. Cost effectiveness of different intervention strategies, such as face to face, interactive 
group discussions (PTC), and feedback from prescribers. 
7. Interventions addressing other problem drugs, such as painkillers, vitamins, coughs 
and colds, or injections. More intervention research is needed on drugs, which are not 
essential but widely prescribed and utilised. 
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APPENDIX A 
SOUTH AFRICA'S NATIOANL DRUG POLICY 
The initial draft of the NDP was prepared and workshops were held to incorporate a 
wide range of comments from various stakeholders. All Provincial Head of Health 
ratified the National Drug Policy on 15 February 1996, and it was approved and 
publicly announced by the Minister of Health on 22 February 1996. The main 
objectives of the National Drug Policy (January 1996) include health, economic and 
national objectives. 
Health objectives: 
1. To ensure the availability and accessibility of essential drugs to all 
citizens 
2. To ensure the safety, efficacy, and quality of drugs 
3. To ensure good dispensing and prescribing practices 
4. To promote rational use of drugs by prescribers, dispensers and 
patients through provision of the necessary training, education and 
information 
5. To promote the concept of individual responsibility for health, 
prevention and informed decision making 
Economic Objectives: 
1. to lower the cost of drugs in both the private and public sectors 
2. to promote the cost-effective and rational use of drugs 
3. to establish complementary partnership between Government bodies 
and private providers in the pharmaceutical sector. 
4. To optimise the use of scarce resources through co-operation with 
international and regional agencies 
263 
National Development Objectives 
1. to improve the knowledge, efficiency and management of 
pharmaceutical personnel 
2. To re-orient medical, paramedical, and pharmaceutical education 
toward the principles underlining the National Drug Policy 
3. To supply the development of the local pharmaceutical industry and 
the local production of essential drugs 
4. To promote the acquisition, documentation and sharing of knowledge, 
and experience through the establishment of advisory groups in 
rational drug use, pharmaco-economics and other areas of the 
pharmaceutical sector. 
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APPENDIX B 
Proposed Organogram of NDP/ EDP Implementors (SADAP and DOH) 
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APPENDIXC 
SELECTION OF EDL DRUGS 
The selection of drugs on the National Essential Drugs List Iwill be based on the 
following criteria: 
• must meet the health needs of the majority of the population sufficient proven 
scientific data must be available regarding the effectiveness of any such product 
should have a substantial safety and risklbenefit ratio 
• the aim, as a general rule will be to include, as far as possible, only products 
containing single pharmacologically active ingredients. 
• combination products may, as an exception, be included where patient compliance 
becomes an important factor or two pharmacologically active ingredients are 
synergistically active in a product when two or more drugs are equivalent in the above 
respects, preference will be given to those which have: 
1. the best cost advantage 
2. the best pharmacokinetic properties 
3. has been the best researched 
4. the best patient compliance 
5. the most reliable local manufacturer 
Note: In exceptional circumstances, drugs outside the essential drugs list may be requested for specific 
patients. A standardized procedure for such requests will be developed. Care will be taken to ensure that a 
minimal portion of the drugs budget is spent on such drugs. These drugs will be included on a 
supplementary list for that facility, drawn up and regularly reviewed by the Pharmacy and Therapeutics 
Committee of the facility concerned. 
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LIST OF EDL DRUGS FROM ADULT HOSPITAL CARE 
STGIEDL 1998 
ESSENTIAL DRUGS LIST 
HOSPITAL LEVEL 
A ALIMENTARY TRACT AND METABOUSM 
AOI Stomatological pr. paratlon. 
ChlorhlXldino gluconate mouthwash 0.2% 
Nystatin lozenge. 100000 IU 
A02 Antacids, drugs lor treatment of peptic ulcer .nd 
IIatuiance 
AluminIum hydroxide 2SO II1lIimao trtsRlcate 500 mo tab 
Aluminium hydraxide susp 300 1I1lIi5 mL 
Clme1kllne tab 200 mo 
Clmetidlne tab 400 mo 
Omeprazole 20 mo cap (examplo 01 etass) 
Simelhicono 
Sucralfalltab 1 g 
A03 Andspasmodlc and .ntlchollnerglc . gonts and 
propulslvea 
Glycopymlnium bromide Inj 0.2 mg/mL 
HyC>S<:iM bu1ylbromid. ~ 20 mglmL 
Metoelop<amlde in! 10 moI2 mL 
Metoc/opramide tab 10 mg 
Propantn.,1ne btomide tab 1 S mg 
~ u xallves 
• O,.,..,.rino suppositories adult 
G,.,..,.nne oral solution 
uctuloc. oral syrup 3.3 gl5 mL 
• LIquid para/fln 
Magneslum sulphalO oral powder BP 
Paratfln liquid 
Sennoslde. A and B In alcohol 7 % (v/v) 
Sennoside. A and B tab 7.s mg 
Thiamine inl 100 mglmL 
• Thiamine lab 100 mg 
Thlamine tab 50 mg 
, Vilemin B comple. Inj 2 mL 
• Vitamin B complex tab 
Vitamin B 12 Inj I 000 mc:glmL 
A 12 Mlnerll . upplement. 
CaJe/um carbonal. tab 
CaJdum chloride in) 19110 mL 10 % 
CaJc:iym gluconate Inj 1 gil 0 mL 10 ,.. 
lAagneslum sulphal. 111/ 50 % 
Potassium chloride in! 10 mL 15,.. 
Potassium phosphal. in! 
POlaa.ium supplement in! 1 g 
Potassium supplement lab (not onleric coaled) 
Sodium blcarbonala Inj 8.5 % 
Sodlum bicaJbonate powder 
Soditnl chloride 0.45 % 
Sodium chloride 0.9 '!. 
Sodium chIorid. 5 % 
Sodtul'n citrate powder 
B BLOOD AND BLOOD-FORMING ORGANS 
B01 Antlthrombotlc I genll 
Heparin sodium 1 000 IUImL 
Hopariin sodium inj 25 000 IUlml 
Heparin sodium Inj 5 000 IUlmL 
Streploldnasolnj 1 500 000 IU/IIIai 
Warflrin tab 5 mg 
B02 Antlhaemorrhl glea 
Amino caproic: add Inj 250 fII9'ml 
Amino caproic: acid tab 500 mg 
VItamin Kl in! 10 mglml 
B03 Antl.naemlc preparation. 
EpoetIn ."",. In! 2 000 IUIO.5 ml 
A07 
A09 
A10 
A11 
Sodium pho'phale 6C 
mgIml , 3.5 mL one'" 
SorbH0I70 % S 
Anlldlarrhoeals, In 
. ntl-Infectlve ager 
L.operamide tab 2 "'II 
Prednisolone retendon enema 20 mot 1-. " 
SuKauJazlM tab 500 mg 
Dlga.llv •• , Including enzym •• 
Pancrelln cap 300 mo 
8rugs used In ell. beI .. 
• GUbenciemide lab 5 mg 
Gllclazlde tab 80 mg 
Gllpizid. tab 5 mo 
Insulin biphaslo , 00 unltslmL 
InsuIJn Intermediate acting 100 unitslmL 
Insulin long acting' 00 uniWml 
insulin rapid acting 100 lMlHsImL 
lnaulln short ac1Iog tOO unHslmiL 
• IAeWormln tab 500 mg 
"'ottormln lab 850 mg 
Tolbutamide tab 500 mg 
Vllllmin. 
A.scorbIc add In) 500 mgI5 mL 
AscorbIc: acid tab 100 mg 
CaJcIleroi SO 000 IU 
GaJcitrioI cap 0.25 meg 
NlcotinamJd. tab 100 mo 
Pyrtdoxlne tab 25 mg 
FelTOUI .ulphat. 0ftIJ 200 mg (85 mg elomontal iron) 
Folic acid tab 5 mg 
805 PI •• ma . ubslllut .. and perluslon solutlonJ 
Amino acids with doxtrosa with or without oloctro/yla. 
(several fonnulatlons) 
Oaxtrosel 0 % 
Dextrosa 20 '!. 
Cextra" 3.5 % 
Dextrose 5 % 
Cextrose 5 %lsodlum chlot1de 0.9". 
o.xtrosa 50 % 
Electrotyteltrace element formulation 
MamHoIlnj t 2.5 glSO ml 25 % 
Ringor·lacIato solution 
Soya oil 10 % /phosphollpid/glycerol omulslon 
Soy. 011 20 %/phospholIpid/glyCerol emulsion 
Soya 011 emutsiontmedlUm chain triglycerides 10 % 
Soya oil emulslonlmedlum chain triglyceride. 20 % 
C CARDIOVASCULAR SYSTEM 
C01 cardiac IherIIpy 
AdonoIIne In! e mgI2 mL 
Amiodarcne inj I SO mg/3 mL 
AmIodarone lab 200 mo 
Atropine inj 0.5 mglml 
Atropine In) 0.6 m~mL 
8retyl/llm tosUat. inj SO mglmL 
O/oOldn Inj 0.5 mg/2 ml 
Digoxin tab 025 mo 
OoIJutam4ne Inl2SO mgl20 ml 
Dopamin. Inj 200 mgl5 ml 
Dopamine inj 40 mIYmL 
Etiletriin" HClInj 10 mO'ml 
Glycery1 trinitrat. inj 10 mg/l0 mL 
GIyceryt lrin1trata inl 25 mgl5 mL 
------------------ _ .... _._ - _. -
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304 
304 
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010 
011 
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Gtycef'1l _atalab sublingual 0.5 mg 
1~1Ina Inj 0.2 mglmL 
IlOIOftIda dlnilrate tab ~ mg 
__Ie tab sublingual 5 mg 
_ mononitrata tab 20 mg 
P~phr1na In! 10 mglmL 
C02 Antlhypert.nslv .. 
Amlodplna tab 10 mg 
Atnlodplna tab 5 mg 
Olhydrala2ine Inj 25 mg 
OiII\azom tab 60 mg 
Hydralulne tab 25 mg 
'-Aotl1y\doPa tab 2SO mg 
P1uooin tab 1 mg 
Prazosin tab 2 mg 
Praza.in lab 5 mo 
Reserpine tab 0.1 mg 
COl 
SedIum nilrop,.. . "'. Intuslon 100 mg 
Diuretics 
Furosemide inj 10 mglmL 
Furostmlda tab 40 mg 
• HydIocIIIoroCt1 tab 12.5 mg or 25 mg 
SpilOnotactone tab 25 mg 
crn eata blocking agents 
coe 
AtenoIoIlnf 5 mol10 mL 
• AtenoIoI tab 100 mg 
AtenoIoItabSOmg 
Catvedilol tab 25mg 
EamoIoIlnJ 10 mgImL 
r PropranoIoIInf 1 mglmL 
ProptanoIoI tab 10 mg 
ProptanOIoI tab ~ mg 
Calcium c"'nnel block .... 
NHedipine cap 5 mg 
CNomexldine .akJtton 0.5 "" in water 
Elhyi alcohol 
Hydrogen paroxide 3 % (10 volUme) 
I'oIy;tdc>N lodIna craom 5 % 
PotuIlum pennong_t. IIOIution In wtler 0.01 'JI, 
AntHcM pre.,.,..tlona 
Benzoyl parotddo topical gel 1 0 .,. 
Banz<¥ ,,",oxide IopIeaJ gel , 'JI, 
Other dermatological preparations 
IIlc:hIoracetlc acid 
PodophyttIn 25% In compound benzoin tincture 
T_tlcacld 
OENrro-URINARY SYSTEM AND SEX 
HORMONES 
Ot"'r gynaecologlcals 
Olnoptostona (prostaglandin E2) tab 0.5 mg 
Oxytocin Inj to IUImL 
OxytocIn iii 5 tlJAonl. 
Sex hormon .. and modulatora 01 the genital 
system 
CIomIfano tab SO mg 
Cyp<OIerone acetata tab 10 mg 
I Estrogen conjugated Inf 25 rngMal 
EaItOg~ste""'" CHRT) 
EItrOgene conjugated tab 0.825 mg 
EsIrogena oonjugated tab ' .25 mg 
Elhinyla tracioI tab 0.02 mg 
Elhlnylaatradol tab 0.5 mg 
Lovonorgollral 0.0510.07510.125 mgtotNnylootradioi 
O.~.04IO.03 mg 
(trtphulc) 
LOVMOtgastrei 0.0510.125 mgletNnytottnSdiol 0.05 mg 
(bjphasIc) 
LAYonorvos"eI O. '5 mgtatNnylo&lI1IdIoI 0.03 mg 
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H 
H01 
H02 
H03 
H04 
C09 
o 
002 
004 
005 
006 
007 
008 
Nlfadlpine iongactJng lab 30 mg 
Verapamillnf 2.5 mgImL 
Verapemil sustained retease teb 120 mg 
VarapamY tab ~ mg 
Verapami tab 80 mg 
Agents acting on \he renln-anglotenaln system 
Perindopril tab 4 mO (oxample of d .... ) 
Ramlprtf tab 1.25 mg (exampl. of da .. ) 
Ramlp" tab 5 mg (example of dua) 
OERMATOLOGICALS 
Emollients and p.-otectants 
Ung. Emuisilicans ~ (UEA) 
Antlp.-urttlca and topical anaesthetics 
UclocaIne gel 2 % 
Udoc:aine topical spray 10 mglmetered do.e 
Antlpsortatlca 
Coaftar 2%lSalIcytIc acid 2% ointment BP 
DUN_ 0.1 % In white paraffin 
SalicylIc acid 2 "" In whit. paraffin 
Antibiotics and chemotherapeutic. lor 
dermatologlCllI use 
'-AupIrocIn ointment 2 % 
SUver luttadlazlne cream 1 % 
Cortlcoaterolda, dermatological preparation. 
Betametha5onoo to % in UEA 
Betamethuone 20 'JI, In UEA 
a.tamethuone valerate cream 0.1 "" 
Betamethasone vurale ointment 0.1 % 
Hydrccortisone cream 1 % 
Hydrocortisone ointment 1 % 
Antiseptic. and dlslnfectanta 
Cotrlmide solution 1 'Yo 
ChlorIlllJlldino cream 1 % 
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Medro"VPfogesterone acetale Inl I SO mllimL 
Medroxyprogesteron. tab 10 mg 
Norolhiaterone 1 mgtestradlol 2 mg tab 
Norelhisterone tab 5 mg 
Norgestral 0 mgIO.S mgtostradlol 2 mgI2 mg 
No<ges"eI 0.5 mgtethlnyl .. ,tradlol 0.05 mg 
Oestradiol valerate tab 1 mg 
Progesterone i~ 
T.stoste~ esl.,. 100 mgfmL 
Urological. 
Anasteride tab 5 mg 
Mist PotC~ BP 
NaJIdlxlc acid tab 500 mg 
Oxybulynin lab 5 mg 
SYSTEMIC HORMONAL PREPARATIONS, 
EXCLUDING SEX HORMONES 
Pituitary and hypothalamic hormones 
Oesmoprasaln Intmlsal solution 0.1 ~mL 
Octreotldo In) 50 rncgImL 
Cortlcolt.rolds for Iyst.mlc use 
Betarnethaaona inj 3 mglmL 
Oexamolhaaone in) • mglmL 
o.xamethasone tab 0.5 mg 
Fludroc:onisone acetate tab O.t mg 
Hydrococ1laone sodium succinate iot 100 rna 
Hydrocor1lsone tab 10 mg 
I.4eIhytprodnisoton Inj 40 mgImL 
Prednisone tab 5 mg 
Thyroid therapy 
CarIlImazoie tab 5 mg 
~Ine tablet 100 meg 
lAWIhyroxine table! 50 meg 
Lugar. iodine drops 
Pancr.aUe hormones 
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Glucagon 1 m~aJ 
H05 Calelum homeostasis 
Alendrcnic acid lab 10 mg 
Pamldrcnic acid inj 15 mgIS mL 
J GENERAL A~NFEcnVES FOR SYSTEMIC USE 
J01 Antibacterials lor systemic use 
J05 
Joe 
J07 
L 
L01 
AmIkacin Inj 100 mg12 mL 
Amlkacln In) 500 mg/2 mL 
Amoxlclilin cap 250 rng 
Amoxic/llln cap 500 mg 
Amplcllllninj 1 0"YiaI 
Ample"11n In! 500 mgMal 
Benzathlne ben<ylpenlclllin Inj 1.2 MUMsl 
Benzy1ponic:iRln Inj 1 MUIvI.1 (-600 mg) 
Cefazolin InJ 500 ~., 
C.'olaXiml Inj 1 ~aI 
Co'oxilin inJ 1 ~ 
Ceflazldime In; 1 ~aI 
Clflazidim. Inj 250 ~I 
Coflazidlme In! 500 tn\YIilal 
Coftriaxone Inj 1 ~ 
Chloramphenicol cap 250 mg 
Chloramphenicol inj 1 ~aI 
CIpt"oI1oxacln Inlu$lon 2 mg/l mL 
Clprotloxacln lab 500 mg 
• Ciprofloxacfn lib 750 mg 
Clindamycin cap 150 mg 
Cllndamycin Inj 150 mglmL 
• Clo.acUlin Inj 250 rngMaJ 
CIo.acl"1n In! 500 mgMaI 
Doxycycline cap 50 mg 
• Doxycycflne cap/Iab 100 mg 
Erythromycin inj 1 ~aI 
Ety1I1romydn 11 •• ,.,. tallleap 250 mg 
RI'amplcln Inj 600 ~al 
AHamplcln cap 600 mg 
Streptomycin InJ 1 g/3 mL 
Antiviral. 'or systemic us. 
Aclc/ovtrlnfualon 250 m~ 
AdcIoYlr lab 200 mg 
FamclclcMrlab 250 mg 
LamivudIne lab 150 mg 
ValacyclOlllrl1b 500 mg 
ZIdoYudina lab 100 rng 
Immune sera and Immunoglobullna 
Antl-l).lmmunoglobuHn In! 100 mcgI2 mL 
BocmIIang anllvenom lnj 
CIoItr1dlum Botulinum lrivalenl antiTOxin 
Hepalitla B immunoglobulin Inj 200 IUI2 mL 
POIyValenl anllvenom Inj 
RabIes imrnunogIoI>ufln (AIG) Inj 
Scorplal anllvenom Inj 
Silkier anIlvenom In! 
Te1anua lmmunoglobuNn human In! 250 IU12 mL (TIG) 
V.rlcella 1OI1.rlmmunoglobulln lnj 
Vaccines 
BCG vaccine 
H .. mophiIus Inftuenz •• type b conjugaled vacc:ine (Hib) 
lnj 
~111iI B vllCdn. inj 
"'-mococeaI V1ICCine Inj 0.5 mL 
AabIea vaccine Inj 
Rubell. vacclnelnJ 
TlOIAnUIloxoid 10U/O.5 mL (Iltanu. adsorbed 
IOllOId _)TT In! 
ANTlNI!OPLASnC AND IMMUNOMODULATING 
AGI!NTS 
Cytostatic agenU 
w 
APPENDIXD 
J02 
J04 
L03 
L04 
M 
MOl 
AucioxacUiIn cap 250 mg 
Fusidlc acid lab 250 mg 
Gentamicin Inj 40 mg/mL 
Gentamicin In! 80 mg/mL 
ImJpenem 500 mg/dlastatin 500 mg/II1al 
Mltrcnldazcle supp 500 mg 
Neomycln tab 500 mg 
Ot1oxacfn in'us 200 mg/l00 mL 
PhenoxymelhylpanlcUIin lab 250 mg 
Piperacillin inj • ~aJ 
Procaine paniclUIn Inj 3 MUll0 mL 
Sodium fusldall IV Inlus 500 <nO 
Sodium lusldal. tab 250 mg 
T etracyctlne cap 250 mg 
T obramycin Inj 40 mg/2 mL 
Tobramydn Inj 80 mg/2 ml 
Trimelhoprlm 80 mglsulfamelhoxazole 400 mg tab 
Trimethop/im lab 100 mg 
VIlIlCOITI)'Qn inj I ~aI 
Vancomydn 500 mgMal 
Antlmycotlcs 'or systemic us. 
Ampholeridn B Inj 50 ~aI 
Arnp/Ioterlcln B toz 10 mg 
Clolrimazole vaginal tablel 100 mg 
Fluconazole cap 150 mg 
Keloconazole tab 200 mg 
Antlmycobaterl.,. 
CloIa.zImlne cap 100 mg 
Dapsone lab 100 mg 
Ethambutol tab 400 mg 
Isoniazid lab 100 mg 
RIfampicin 120 mg/lNH 60 mg/py'azlnamlda 300 mgt 
Ithambutol 200 0' 225 mg 
AHamplcln 150 mgIINH 100 mg 
RHamplcln 300 mgllNH 150 mg 
Adrtamycln (doxorublcln) 
Aspallgin8Se 
Bleomycin 
Busulfan 
Carboplalin 
Chlorambucil 
Chlonnethlnl (nitrogen Musta,d) 
Cisplatin 
Cydcphosphamlde 
Cytatablne 
Daunorublcln 
Docelax.' 
Etoposide (yP 16) 
AuorouracU 
Hydroxycarbamlde (l\ydroxyurea) 
lfosfamidl 
lomusline 
Mliphalan 
Mathotraxat. 
Mitomycin 
Mhoxantrone 
Procarbazine 
Thlolepa 
T"UnoIn (aft I,ans ,eUnole actd) 
Vinblastine 
VIncri5Iina 
VinonIIbine 
Immunomodulatlng agents 
Inlerf.ron alpha 
Immunosuppreslve agants 
Azathloprin. tab 50 mg 
MUSCULOSKELETAL SYSTEM 
Anti-Inflammatory and antirheumatic products 
lbupt"c'en tab 200 mg 
307 
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Ibuprofen lab 400 "'II N02 ~~ 309 IndomeII\odr1 cop 25 mg • lab (scxnd) 300 mg 1 __'00mg CodeIne p/IoIphare lab 30 "'II 
Penicillamine tab 300 mg Dihydroergotamine in! 1 m¢nI.. 
MOO Muacie ntlaunls Ergotamine 1 "9'ealleln. tab 100"'11 
AIouronUn Ir4 lD mgI2 mL MorphIne injlD "'IVml 
DanltOleno rj 20 rnW70 mL IAotphIne tab 10 mg 
PancurcnIum bromide in! • mg/2 mL Paracotamol 500 "'IVCOdelno pllosphale 10 mg tab 
s..xam.1honIum chloride inj 100 rngI2 mL • Paracatarnollab 500 mg 
Vecuronium bromide • "'IVmL Pottridlne in/ too mgI2 mL 
Vecuronium bromide rj 10 mgI5 ml Ha3 
Pethidine inj 50 "'IV mL 
Mo. Anllgout pntparallons Anlleplleptlca 
A11opurinoI lab 100 mg Calbamazopine lusp 100 mgI5 mL 
CoIctIIcine lab 0.5 "'II cart>amazapino lab 200 mg 
PI'Obonocid lab 500 mg EthoslJldmide cap 250 mo 
N CEHTRALNERVOUSSYSTEM 
Phenobatt>itaJ leb 30 "'II 
Phenytolo cap.1eb 100 "'II 
HOl ""-!helle. Phenytoin inj 250 mgI5 ml 
AItac:ut1um inI Valpmat. sodium lab 200 "'II 
IIupMocatno Ir4 0.5 % vWIhout _a""lIne 
H04 
Valproat. sodium lab 500 mg 
BupIvacaJno Ir4 0.5 '" willi dexlrolo Anllpar1dnsonlan agenls 
Drop.l1doIlr4 2.5 rrVmL 8enzh .. 01 tab 2 mo 
E_te rj 2 rno'I'nl BIper1den inj 5 "'IVmL 
Fentanyt Ir4 81per1den tab 2 mg 
HaIothanIIlnhalallon liquid 8mmocrtpdne tab 2.5 "'II 
1.aIIutane Wleldan liquid leYodapa 100 "'IVC8Ibidapa tab 25 mg lab 
K-.erj lovadapa 200 mg,ben&.razlde 50 "'II tab 
UdacaIne rj 0.5 '" OrphenIIdIinetab50mg 
Udacalno rj 1 '" NOS Psycholeptics 
LIdocaIne rj 2 % Clonazopam lab D.5 "'II 
UdacaIne 111 2 '" willi adrenaline Clonazoparn tab 2 mg 
lidocaine inj 5 % with d .. trosa Diazepam inj 10 mgI2 mL 
PrapoJaj intuaJon 10 rrVmL Diazepam tab 2 "'II 
Th/apenlal1Od1um In) 0.5 gMa/ Diazepam tab 5 "'II 
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F1upendxol decanoata depallnl 20 "'IVmL Primaquine phosphat. tab 13.2 mg (baH 7.5 mgt 
~ daCanoat. inj 25 ~L QuInIne loj 300 m!)lmL 
HaIopetIdoIIn) 5 rno'I'nl 0uinIn0 sulphato tab 300 mo 
HaIopericIaIlab D.5 mg Sulladax1ne 500 "'IVpyrimethamin. 25 mg tab 
Halapel1dollab 1.5 mg P02 Anthelmlntlcs 
HaIapeI1doI tab 5 mg AlbendaZoi. tab 200 mg 
UtnIum cartonato tab 250 "'II Praziquantat tab 600 mg 
t.atazopam tnj • "'IVmL 
R RESPIRATORY SYSTEM t.atazepam tab 1 mg 
t.atazopam lab 2.5 mg ROl N .... praparallons 
I.tldazaIam rj 5 mgI5 ml Oxymetazolln. nooedrops 0.05 "'-
Oxazepam lab 10 mg R03 Anll-a.lhmallc agenta 
Oxazepam lab t 5 mg AdronaNno InJ 1 mg/ml 
Oxazepam lab 30 "'II Aminop/tytnna I", 250 m~1 0 mL 
ZUcIopenIhIxoi ocetat.lnjso ~ Budasonlde Wlelet' 100 mc~octu81lon 
Noe psychoanaiepticI Budesonldo Inhaler 200 mcvactuation 
AIn/ItipfyfIno tab 10 "'II Fenateratlnhaler 100 mcgIInhalallon 
AmIIt1>IvInO lab 25 mg Fanal.rat UOV solution 0.5 mg/2 mL 
Clomipramine lab 25 mg Fonatorot UDV soIullon 1.25 rngI2 mL 
Auo •• Une cap 20 mg HI.cprenaNne infusion 25 mc!)l10 mL 
Imipfamine tab 10 mg Iprotropium brami<le meterod _e ,nhaIM 40 mc!i 
tmIptamIne tab 25 mg acluatlon 
N07 OIMr nervous Iy.tam drugs Ipratroplum _I respirator soIutJan 0.25 ...:gImL 
AKontanit 0.5 m¢nl tpratropium bromide UOV solution 0.25 ~ mL 
N_tIgmIno bromide 0.5 ~L Salbutamot metered daoo Inhale< lOOmc:g1actuatlon 
p~ rj 0.5 rngImL SaJbutamoI _. 2.5 m~.S mL 
Pyltdaltlgmlne btamlde tab eo "'II Salbutamol nobUte. 5 m~.5 ml 
s-nnelq Theophylline .ustalned rot .... tab 200 "'II 
SuMntanl 5 mcvml Theaphyllne sustained rolea .. tab 300 "'II 
P AHT1PARASmC PRODUCTS 
ROO Antlhl.tamlne. for -vlltamlc usa 
Chlofp/lonlramlne lab 4 mg 
POl Antlprotozoal. Promethazine rj 25 "'IVmL 
CNaIoquino lab 200 mg (b ... I50 "'II) Prometllazlna tab 10 mg 
loIetton1aazo1o InIuIian 500 11'0'100 ml Promothazlno tab 25 "'II 
IAeIronIdazota tab 200 "'II 
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5 
501 
V 
V03 
ICD-10 
N91·N93 
004 
L'!Jl. 
E 
E27 
Fl0.l 
A06.4 
099.0 
064.9 
R57.9 
F41.9 
J45 
J45 
N40 
E51.1 
F31.9 
T63.4 
N39.4 
J47 
T30.0 
637.9 
149.9 
ISO.9 
L03.9 
APPENDIXD 
SENSORY ORGANS 
Ophthalmological. 
Ac&tazolamide InJ 500 mg 
Ac&tazOlamide tab 250 mg 
AcicIovir eye ointment 30 msYg 
Chloramphenicol eye drops 0.5 ". 
Chloramphenicol eya ointment 1 'to 
Cydopantolato 0.2 'toIphlnylephrine 1 'to eye drop. 
Dexamethaoone eye drops 0.1 'to 
Dipivefr1ne eye drops O. 1 'to 
Flurbiprolen eye drops 0.03 'to 
Gentamicin eye drops 0.3 'to 
Lanolin anhydrous tiquid eye '""tmenl 3 % 
paocarplne eye drops 1 'to 
T elrac:aJne eyldrop. 5 mglmL 
Tetracyctlne eye ointment 1 ,.. 
TlmoIoI OYe drope 0.25 % 
TlmoIoI eye drops 0.5 'to 
VARIOUS 
All other therapeutic producte 
Actly/cyslelne inl 2sYl 0 mL 
Chsrcoai activated oral 
CitJic acid powder 
Deteroxamine mesytale inj 500 mg 
DioobaJt _tata Inj 300 ~ mL 
Dimercaproi inj 50 msYmL 
Disulllram tab <400 me 
Electrolyte solution 
Ipecacuanha syrup BP 
Methionine powder 
Melhy/ena blue 
Naloxone Inj 0.4 mg/mL 
SodIum niIIft. 3 'to inj 10 mL 
Sodium polystyrene sulphonale powder 
V08 
ICD NUMBERS 
Guideline 
Abnormal uterine bleeding 
Abortion, complicated, therapeutic, legal 
Acne 
Acromegaly 
Adrenal Insufficiency 
Alcoholism 
Amoebic liver abscess 
Anaemia In pregnancy 
Anaemias 
Anaesthetics 
Anaphylactic shocl<lShock 
Anxiety disorder, generalised 
Asthma, acute 
Asthma. chronic persistent 
Benign Prostatic Hyperplasia 
Beriberi 
Bipolar disorder 
Bites and stings 
Bladder DyskineSia 
Bronchiectasis 
Bums. complicated 
Candidwis, systemic and others (In HIV) 
Cardiac arrhythmias 
Cardiac failure syndrome 
CeilulitislErysipelaslPyoderma (Impetigo) 
J44.9 
K51 .9 
B59 
Q24.9 
K56.4 
K50.9 
645.9 
E24.9 
F34.0 
E84.9 
F03 
F03 
024.9 
E23.2 
Ell 
E16 
El1.2 
AOS.9 
EB7.4 
645.7 
EB7.SlB 
E78 
Sodium Ihiosulphale In/50 ". 
Contrast media 
Barium sulphale poWder 98 ",100 g 
Banum sulphatlt susp ""ama 93 g 
lohexol 300 mg VmL 
311 
Meglumln" amldotl1zoala 68 glsodIum amidelnlcate 109 
Meglumlne letha/amale 
Sodium lepodale cap 500 mg 
Sodium lolhalamatlt Inlus 20 '10 250 mL 
Chronic obstructive airways disease 
ColitiS, ulcerative 
Community aCQ. pneumonia and 
Pneumocystis carinli pneumocystosis 
(in HIV) 
Congenital heart disease. adults 
Constipation I faecal impaction 
Crohn's disease 
Cryptococcal meningitis in HIV 
Cushing's disease 
Cyclothymic disorder 
Cystic fibrosis 
Delirium 
Delirium. non psychiatric 
Diabetes and glucose intolerance in 
pregnancy 
Diabetes insipidus, central 
Diabetes mellitus 
Diabetes. pancreatic 
Diabetic renal disease 
Diarrhoea. Infective I Food poisoning 
Disorders of acld·base balance 
Disseminated cryptococcosis inc!. 
MeningitiS (in HIV) 
Disturbances in potassium balance 
Dyslipidaemia 
311 
312 
312 
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APPENDIXE 
FUNCTION AND MEMBERSHIP FOR PTC COMMITTES 
AT FOUR LEVELS 
CLINICS/COMMUNITY SERVICES (Primary Care Hospitals) 
FUNCTION 
• Committee to familiarise providers with NDP (EDLISIG) 
• Compile formulary form EDL for local use 
• Provide comments and feedback on EDL to the PTC 
• Share the information with district PTC 
• Educate and create an awareness among practitioners about EDL. 
MEMEBERSHIP 
• PHC practitioner (1) 
• DHWS- one member (ILC) 
• District pharmacist ex officio 
• Medical doctor 
DISTRICT (Secondary Care Hospitals) 
FUNCTION 
• Flow of information 
• Communication process 
• Hospital formulary and other items 
• Capacity building 
• Advisory 
• Monitor and evaluation of drug use 
• Budget control 
• ADR (monitor and record) 
MEMBERSHIP 
• Superintendent 
• Pharmacist 
• Matron 
• Secretary 
• Community matron 
• Medical officer 
• Ad hoc member 
• Community representative 
272 
REGIONAL (Tertiary Hospitals) 
FUNCITONS 
• Evaluate, implement and promote decision taken by provincial PTC (including 
protocols and local restrictions) 
• Educate - rational cost-effective prescribing 
• Provide information resources 
Customised needs (relevance) 
Information bulletin (regular) 
• Monitor prescribing pattern with the objective of budget control (e.g antibiotic use, 
key drugs) 
• Collaborate / liaise with existing committees (information control etc.) and 
establish surgical and management (budget) 
• Prepare, evaluate and submit non-formulary requests form clinicians 
PROVINCIAL (Department of Health) 
FUNCITONS 
• Review national EDLs 
• Review drug purchases in light of budgetary restrictions 
• Coordinate drugs appropriate to level of care 
• Decide on additions and deletions to procurement list 
• Make recommendations to national EDL process and facilitate national consultation 
• Facilitate decision on whether to withhold treatment for certain conditions 
• Facilitate DUEs and reviews of antibiotics resistance patterns 
• Supervise and monitor other PTCs 
MEMBERSHIP 
• Head of Pharmaceutical Services 
• Procurement manager 
• Pharmaco-economist 
• Clinical pharmacologist / pharmacist 
• Medical specialists (physician, paediatrician, surgeon, family medicine, co-opted 
specialists) 
• PTC specialist 
• Other co-opted members 
• Secretary (professional 
• Regional Representative 
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APPENDIXF 
Health and Welfare Regions of the Northern Province 
.... , 
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HEALTH AND WELFARE REGIONS OF THE NORTHERN PROVINCe II UULY 1998 
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Northern Region 
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Bushveld Region 
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APPENDIXF 
Map of the Northern Province with six regions 
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APPENDIXG 
FACTS AND FGURES ON NORTHERN PROVINCE AND SOUTH AFRICA 
POPULATION NORTHERN SOUTH AFRICA 
PROVo 
Female 57 51 
African 95 76 
Non urban 89 50 
Young (>15yrs) 48 40 
No formal education 27 13 
Females 19 11 
Males 32 15 
Unemployed 41 29 
Employment 25 17 
informal 
Earn> 999 Rlmonth 33 31 
AFRICANS 
Female 41 31 
Live in brick house 63 73 
Live in shack 3 7 
Live in traditional 28 14 
house (hut) 
Electricity 31 51 
Running water 17 33 
Flush toilet 9 22 
Telephone 12 32 
Use public health 89 81 
facilities. 
Source: Living in the Northern Province. Selected findings of 1995 October 
Household Survey. Central Statistics Service (CSS), 1998, Dr. FM Orkin, Pretoria). 
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'DID YOU t1NOW? 
rn people died or mlliarill i\ It\c rounlry 11IS1 yell/'. or whJc" 39 people were rrom It\c Northern Provir\(c. 
25092 (65C.S or malaria were reported rounlrywidC. or whom 3674 were rrom It\c Northern Provi\(e. 
Recently two ~resentattves from the 
Nr--hern ProvInce Phmuaceuttal ServIces 
a~ed a training course on the technial 
upects of v..cdne procurement; 1I0rage Uld 
distributIOn lIimed at district level 
The objectives of the tralnlng course thlIt 
w' funded by the South Afrian Drug 
A~n ProgriUllDle Wal to Introduce the 
pOIrttdpants to: 
1. s..slC prtndples of cold chlIln 
IDilDagemenl: 
2. s..alC prindpa1s of vaccine procurement 
3. Minimum reqUirements for record 
keeping , 
4. StOIndOIrd procedures for the dispoul of 
'\rlIal _ste 
,-,,' 
S. NottftatlOn and monitoring of ;adverse 
events. 
The m;aIn overa1l objecttve of the course 
1Ir.I1 to prepare an lICtton pl.1n for phmua· 
ceutlcai servICes to Improve cold chain mm-
lIgement at district leveL 
The first Northern ProvInce TechniclIl Cold 
CIWn tralnlng course II pl.1nned for the end 
of April 1999. The urge! group for !hII 
course will be ph.umllCeutiai and primary 
hwth are m;an;agement ilt district Irvel. 
The Southern pOIrt of the ProvInce will be 
Urge!ed first. 
Any enqulrtei' OD the courSe an be done' 
With Mt D van Wylt at 01S-m 0325. 
w~ ili LETTER RECEIVED FROM SAAHIP 
o 
Our Mt'Ren1er Bothll • 
Vum Hulthare LogistICs 
On ~b..lf of SAAHIP It gives me grat plea-
IU-..D thank you for attending the meeting 
to establish a branch for SAAHIP In 
Mpum1ianga. M you IYve experienced. It 
Wal a most successful occaslon. Hospital 
and Institutional Phmuadlts joined lYnds 
to make !hila historical day. 
VHL baa ;again showed III trull In 
PIwrmcists and In wlYt they do. by your 
company's generous contributIOn to sponsor 
this occasion. This was blghly appredOlted. 
TIYnIt you for your poSitiVI! mes&1g1!. you 
will surely always be counted as part of !hII 
team/ 
~rds. Luln Erasmus 
(Chairperson SAAHIP Mpuma1anga) 
N GOING HOME, , 
Ms Cathy Lynch. a pb.mnadst at TshiI1dzlnl 
baa gone back to Queenal.1nd. Australla. 
after R'!Vtng the ProvInce for two ye.trs. 
During her atay at TshlllcWnl. Cathy. 
tov.-ther With her motivated ~sSlstants, 
~'--' ed thlIt the computerllation of the 
hOSPital plYrlDilcy ran smoothly. ThIs pI.1ced 
Tshi1Jdzlnl In line to receive an award aI 
one of the best·m.maged plYrmades In the 
Province. 
In addition to her plYrmacy managerial 
duties she became a Drug Supply 
Management Trainer for the Nonhern 
Region. By the end of 1993 she and 
Mr M.lkhado (plYrmactst at Siloam) trained 
a tota1 of 203 nursing and plYrmacy per. 
IOnneiln DSM. • 
Cathy Wtn be sadly missed In the Province. 
Complied by: EmIly a-npne 
ExIr!l.1 rmn: Ole I'm 29/1/99 
PROMOTING 
RATIONAL 
DRUG USE 
(PRDU COURSE) 
The PROe course was hdd for the 
full time 111 the Northern ProvInce at 
the Prota Park Hotel In 
Potgietersrus. The cowse wu 
offered by Medial university of 
South Afrta (MEDUNSA). The fIrIt 
put of the course was hdd on the 
.14-15 September and ~. second and ' 
I.1st put on the 19-23 October 1998. 
Doctors. professional nurses and 
pharmacists &om all seven regIonS 
pOIrtidpated In the course plus three 
pharmacists &om the Western Cape, 
Three of the province's professIOnals 
helped faqllute lOme of the ses-
sIOns, They are Judith MuhLuhl 
(Nlthensanl Hospital), Margareth 
ThupOIna (Southern RegIon) and 
Razeeya Ihan (PIetersburg Hospital). 
The mal1l objective of the PROU 
course II to guide professlona1s to 
identify and make Interventions 
whenever drug use problems occur 
In our hospitals. At the end of the 
workshop ach regIOn formul.1ted I 
proposal on bow to address selected 
drug use problems. for example the 
Western Capes' Proposal ntle Is: 
Improving Correct Use of Metered 
Dose InlWers In Adult Patients 
with Moderate and seftre Asthma. 
requlrlnll conrlnUOUl Therapy, In 
the Western Cape. The results of 
this study will be publlshed for all 
Interested pOIrttes. 
Complied by: ME IWengaae 
VUNA Healthcare Logistics Newsletter 
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APPENDIXH 
DID YOU KNOW? 
rn people died or IT\lIIar!a n Iflc counll'\J k1slyclY. or whk.tl39 people were rrom Iflc Norlhcm Provi\(c. 
25092 Cll5CS or IT\lIlaria were reported munlrywidc, or whom 3674 were rrom Iflc Northern Provi1(c. 
fxlrlll rrom: Die /'os 2!JI1/99 
Il.ecently two representatives from the 
N\","bern ProvInce Pharmaceutical Servu:es 
.a~ed .a tnIDlng course aD the technlal 
up«ts of v.acdne procurement: ItoRge ind 
dlstributlon .aimed it district level. 
The objectives of the tnIDlng COIUR !hit 
...... funded by the South Afrtan Drug 
~n Programme was to Introduce the 
partldpaota to: 
1. BasIC prtnclples of cold chain 
UWlOIIement 
2. BasIC prtnctpm of vacdoe procurement 
3. MlDImwn requlmDenli for record 
keepln8 ,_ 
4. Standard procedures for the dIspoaal of 
'inial waste 
-..: 
S. NotIficatlOD and monltortng of adverse 
eventa. 
The maID 0\'eRIl objective of the course 
was to prepare an act10n plan for plwma-
ceutlcal servICes to Improve cold chain min-
,agement ilt district level. 
The first Northern PrOYlnce TecbnIcal Cold 
ChaIn tralnlng course Ia planned for the end 
of April 1999. The target 8l'oup for thta 
course wtII be pharmaceutical and primary 
health care UWlOIIement .at district lrveL 
The Southern part of the ProvInce wtlI be 
tatgeted first. 
Any encjulrtea -OD the Counie can be' done' 
with Mr D vm Wyk at 015-223 0325. 
~ LETTER RECEIVED FROM SAAHIP 
Dear Mr Renier Botha -
VUDol HealthColre Logistics 
On hdlalf of SAAHIP It gives me areat pka-
su.,.....'J thank you for .attending the meeting 
to estabIJsh a brinch for SAAHIP In 
Mpwnalanp. As you hilve expertenced. It 
was a most NCcessful occasion. Hospital 
and Instltutlon.aI P!wmadata joined bands 
to make thta .a htator!cal day. 
VHL hils igiln Ihowed It I trust 10 
PbarmaClall and In what they do. by your 
company's generous contrlbutloo to aponsor 
thta occasion. ThIa wfi highly appreclited. 
Tbaok you for your positive message. you 
will surely always be counted as part of thIS 
team/ 
Regards. ~rtn Rasmus 
(CbaIrpmoo SAAHIP Mpum.alanga! 
GOING HOME 
Ms ~thy Lynch. a plwmadat .at Tshl1ldztni 
has gone hack to Queensland. Auatrali.a. 
after R"YIng the ProvInce for two ye.an. 
During her stay .at Tshllidzlnl. ~thy. 
~her With her motlv.ated assIstmtl. 
~ ed WI the computerlaatloo of the 
~ta1 plwmacy no smoothly. Thta placed 
Tshilldzlnl In line to receive an .aw.ard .as 
one of the best-managed pharmacies In the 
ProvInce. 
In additlon to her philrmacy mioage11al 
duties she bec.ame a Drug Supply 
MaDolg~ment Trainer for the Northern 
Region. By the end of 199& she and 
Mr Maltb.tdo (phirmaclst .at StIo.am) trained 
a total of 203 nunln8 and pharmacy per-
IOnnelln DSM. -
Cithy wtlI be sadly missed In the ProvInce. 
Compiled by: l!mIIy hIengaoe 
PROMOTING 
RATIONAL 
DRUG USE 
(PRDU COURSE) 
The PRDU course was held for the 
first time In the Northern ProvInce .at 
the Protea Park Hotel In 
Potgletersrus. The course Will 
offered by Medical university of 
South Afr1c.a (MEDUNSA). The first 
part of the course was held on the 
J4-1& September.and f!!e. second.and 
last part 011 the 19-23 October 1995. 
Docton. pro(esslon.aI ounes and 
phiIrmaCIaII from all seven regions 
participated In the course plus three 
pbannaclsts from the Western ~pe. 
Three of the provInC~" professlonais 
helped f.acllitate some of the ses-
sions. They are Judith Muhlarhl 
(Nkh~osanl Hospital!. Margareth 
Thupaftil (Southern Region! and 
Razeeya Khan (Pletmburg Hospital!. 
The main objective of the PRDU 
course IS to lUide professlon.als to 
identify .and mike Interventions 
whenever drug use problems occur 
In our hospitals. At the end of the 
workshop eilch region formubted a 
proposal on how to address selected 
drug use problems. for eJtaDlple the 
Western ~pes' Proposal ntle II: 
Improving Correct Use of Metered 
Dose Inhalen In Adult Patientl 
with Mockrate and severe Asthrn.a. 
requlrlDg continuous Therapy. In 
the Western ~pe. The resuIli of 
thla study wtII be publIShed for all 
Interested parties. 
Compiled by, ME bHnpne 
281 
APPENDIX I 
PHARMACEUTICAL EXPENDITURE PER PROVINCE 1998/99 
Province Per Capita Population Pharmaceutical 
, Per capita.'" %0£ Health 
__ "1 :11'_ , Health 
.-;..,.' ~ r ~ Expenditure Expenditure on Pharmaceuticals 
Expenditure 
.' , . ,,' . , , 
Gauteng 773 7,171,000 471,775,685 65.79 7.60% 
Free State 510 2,470,000 159,876,721 64.73 8.70% 
Western Cape 707 4,118,000 190,976,916 46.38 4.90% 
Kwazulu- 418 7,073,000 316,480,381 44.74 7,90% 
Natal 
Eastern Cape 444 5,865,000 198,837,284 33.90 12.70% 
Northern Cape 543 746,000 19,999,998 26.81 6.60%, 
North West 417 3,043,000 80,000,000 26.29 6.30% 
Mpurnalanga 263 2,646,000 60,420,152 22.83 10.70% 
Northern 309 4,927,368 100,724,860 20.44 8.50% 
Province 
National 487 38,059,368 1,599,091,997 42.02 8.21% 
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APPENDIXJ 
NORTHERN' PROVINCE PHARMACEUTICAL EXPENDITURE 1998/99 
ANTIBIOTICS 
Amoxycillin Caps 250Mg 
Phenoxymethyl Penicillin Tabs 250Mg 
Erythromycin Tabs 250Mg (Prp 20) 
Oxytetracycline Polymixin Eye Oint 5G 
Phenoxymethyl Penicillin Susp 250Mg/5ml 
Ceftriaxone Inj 250Mg 
Cefoxitin Inj IG 
Amoxycillin Susp 125Mg/5ml 75MI 
Cloxacillin Caps 250Mg 
Cloxacillin Susp 125Mg/5mll00MI 
DROPS, AEROSOLS AND 
INHALANTS 
Salbutamol Inhaler Complete 100Meg 200 D 
Beclomethasone Inhaler Complete SO Meg 
Sodium Hyaluronate 10Mg/ml Inj O.SMI Syr 
Sodium Cromoglycate Eye Drops 2% 10MI 
Flurbiprofen Eye Drops 0.3Mg/mI5MI 
Levobunolol Eye Drops 0.5% 7.5MI 
Antazoline Naphasoline Eye Drops 15Ml 
Betaxolol Eye Drops 5Mg/mI5MI 
Ipratropium Udv 0.5Mg/2mI 
Ipratropium Inhaler Complete 200Dose 
FAMILY PLANNING 
Norethisterone Inj 200Mg/ml Long-Acting 
Oral contraceptives 
Medroxyprogesterone Inj 150Mg/ milMI 
Intra Uterine Device 375 
Intra-Uterine Device Short 
Desogestrel Oestradiol Tabs 150/20Ug (Me 
I ALCOHOL, AETHER AND 
Expenditure Group Total % of 
1,293,516.88 
1,176,382.44 
1,148,048.67 
1,046,614.19 
898,610.65 
886,119.92 
755,811.00 
739,347.32 
719,193.45 
Expe 
nd 
716,814.49 17,264,834.11 23.83 
% 
Expenditure Group Total % of 
800,266.68 
494,108.28 
240,437.48 
173,016.00 
128,058.96 
109,170.47 
91,033.12 
88,584.68 
83,450.15 
Expe 
nd 
82,580.43 3,000,850.93 4.14 
% 
Expenditure Group Total % of 
3,737,694.18 
1,592,599.44 
1,476,256.00 
3,732.44 
1,387.64 
Expe 
nd 
91.21 6,811,760.91 9.40 
% 
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GLYCERINE 
Expenditure Group Total % of 
Expe 
nd 
Alcohol 96 % 25L 70,408.40 
Ether Technical 500Ml 3,914.84 
Glycerine B. P 500MI 2,871.85 
Ether Technical 2SL 1,673.40 78,868.49 0.11 
% 
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APPENDIX K 
NDP EVALUATION INDICATORS AND QUESTIONS 
INDICATORS 
I. Structural Indicators 
Data Source: Analysis of Documents 
• Drug regulatory authority whose mandate includes registration and inspection 
• A Licensing system to regulate the sale of drugs 
• Phannacist legally entitled to substitute generic drugs for brand name products 
• Legal provisions for penal sanctions 
• Control on drug promotion based on regulations and consistent with the WHO 
Ethical Criteria for Medicinal Drug Promotion 
• National essential drugs list (EDL) using INN officially adopted and distributed 
countrywide 
• Official committee whose duties include updating the national essential drugs list 
(EDL) 
• F onnal procedures for registering drugs 
• Drug regulation committee 
• Drugs usually procured in the public sector though competitive tender 
• Procurement in the public sector limited to drugs on the national essential drugs 
list (EDL) 
• National publication (formularylbulletins/manuals, etc) revised within the past 
five year, providing objective information on drug use 
• National therapeutic guide with standardized treatments 
• The concept of essential drugs part of the curricula in the basic training of health 
personnel 
• Official continuing education system on rational use of drugs for prescribers and 
dispensers 
• Drug information unit 
II. Health Facility Indicators 
Data Source: Prospective NDP Indicators, collected at facility visits 
Analysis of facility indicators ofEDL drug use 
• Availability of Standard Treatment Guidelines? Essential Drugs List 
• Availability of impartial drug information 
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III. Prescribing Indicators 
Data Source: prospective (facility visit) and retrospective (baseline studies by 
MEDUNSA) 
• Percentage of drugs prescribed by generic name 
• Percentage of drugs prescribed from essential drugs list 
• Percentage of drugs prescribed by brand name, but dispensed as generic 
• Assessment of three rational drug prescribing indicators: 
1. Percent of prescription with one of more injectables 
2. Percent of prescriptions with one or more systemic antibiotics 
3 . Average number of items per prescription 
IV. Process Indicators: 
Qualitative information on the processed by which a nation drug policy is 
implemented. The indicators assess the degree of functioning for the processes in the 
seven key components an,d the progress being achieved over the time towards specific 
goals. 
• Number of drugs from the national essential drugs list (EDL) prescribed, out of 
total number of drugs prescribed. 
• Number of drugs from the national essential drugs list (EDL) sold, out of total 
number of drugs sold. 
• Number of prescribers having direct access to a (national) drug formulary, out of 
total number of prescribers surveyed 
• Number or training session on drug use for prescribers in the last year, out of 
average number of training sessions organised in the past three years. 
• Number of prescribers have attended at least one training session in the last year, 
out of total number of prescribes surveyed. 
QEUSTIONS 
Structural Questions· 
Qualitative information to assess the pharmaceutical system's capacity to achieve its 
policy objectives. These indicators are intended to check if the structures necessary to 
implement a pharmaceutical policy exits. These structural indicator questions are 
answered with a "Yes or No" based on information available at the central level 
(WHO,1994). 
1. Are pharmacists legally entitled to substitute generic drugs for brand name 
products? 
2. Is there control on drug promotion based on regulations and consistent with the 
WHO Ethical Criteria for Medicinal Drug Promotion? 
3. Is there a National essential drugs list (EDL) using INN officially adopted and 
distributed countrywide? 
I From WHO, Indicators for Monitoring National Drug Policies, 1994 
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4. Is there an official committee whose duties include updating the national essential 
drug list(s) (EDL)? 
5. Are drugs usually procured in the public sector though competitive tender? 
6. Is procurement in the public sector limited to drugs on the national essential drugs 
list (EDL)? 
7. Is there a National publication (formularylbulletins/manuals, etc) revised within 
the past five year, providing objective information on drug use? 
8. Is there a National therapeutic guide with standardized treatments? 
9. Is the concept of essential drugs part of the curricula in the basic training 0 f 
health personnel? 
10. Are there official continuing education system on rational use of drugs for 
prescribers and dispensers? 
11. Is there a drug information unit? 
Process Questions: 
Process questions will provide qualitative information on the processes by which the 
National Drug Policy is implemented. The indicators assess the degree to which 
activities are being effectively implement and the progress over time. Process 
information can be used by national-decision makers to monitor the progress in the 
implementation of drug policy with reference to goals and targets established at the 
national level. This information is available through either the central level and/or 
obtained trough surveys (WHO, 1994). For this research project, the latter will be 
used. 
12. What is the availability of key drugs on EDL (list 20-30 drugs to be constructed2)? 
13. What is the availability of copy of essential drugs lists? 
14. What is the availability of Standard Treatment Guidelines? 
15. What is the availability of impartial drug information? 
16. What Percentage of drugs are prescribed by generic name? 
17. What Percentage of drugs are prescribed from essential drugs list? 
18. What Percentage of drugs prescribed by brand name, but dispensed as generic? 
19. Assessment of three rational drug prescribing indicators: 
2 WHO has a list of 10 drugs that is used for PHC facilities. Perhaps this list can be used as a guideline 
for a new list that is tailored to the hospital adult level. 
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a. What percentage of prescriptions with one or more systemic antibiotics? 
b. What number of drugs prescribed are from the national essential drugs list 
(EDL)? 
20. What number of training. session on drug use for prescribers occurred in the last 
year, out of average number of training sessions organised in the past three years? 
21. What number of prescribers have attended at least one training session in the last 
year, out of total number of prescribers surveyed? 
22. What is the number of special hospital pharmacy and therapeutic committees? 
23. What is the number of resource books / drug use information? (Can three major 
sources of information be found relatively easily in the facility?) 
24. What is the number of drug bulletins/newsletters published in the province? 
4.4 Outcome QuestionsJ 
Outcome indicators measure the results achieved and the changes that can be 
attributed to the implementation of a national drug policy. They measure the effects of 
implementation on the overall objectives of the national drug policy, but for this 
research, it will measure the 'rational use of drugs.' This information is available at 
the central level and lor obtained through survey (WHO, 1994). Eight outcome 
indicators were chosen: 5 from WHOIINRUD and 3 specifically for this study) 
25. What is the average number of items per prescription? 
26. What percentage of prescription are antibiotics? 
27. What is the average cost per prescription? 
28. What is the percentage of adherence to the EDLISTG? (Drug and dose) 
29. What is the percentage of generic prescribing? 
30. What is the number of adults with hypertension are receiving the protocol 
treatment based on the STGIEDL? 
31. What is the number of adults with diabetes type II are receiving the protocol 
treatment based on the STGIEDL? 
32. What is the number of adults with asthma are receiving the protocol treatment 
based on the STGIEDL? 
3 Several of these outcome indicators were used in the evaluation of the EDP baseline studies 
conducted by SADAP and MEDUNSA. 
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APPENDIX L 
Hypertension Treatment 
Essential Drugs List Hospital - Adult 
3.9. HYPERTENSION ' 
Treatment guidelines 
Non-drug 
treatment 
Drug treatment 
Management 
Extensive health education is necessary. This is 
baseline treatment 
Lifestyle modification 
Moderate exercise 
Comments 
Referral criteria 
• If the patient is compliant 
with therapy, and the 
blood pressure is 
refractory while on drugs 
from three different 
classes , one of which 
being a diuretic. 
• All cases where 
secondary hypertension is 
suspected . 
Special investigations : 
These are indicated in 
complicated hypertension and 
where secondary causes are 
suspected, especially in young 
adults, sudden onset of moderate 
to severe hypertension and first 
onset after the age of 50 years . 
Also indicated when complicated 
by target organ involvement. 
Diuretics: Hydrochlorothiazide, oral, 12.5 mg daily. In First line therapy for all patients 
patients with fluid retention : increase to 25 mg daily. To reduce blood pressure to less 
than 140/90 mm Hg in all patients, 
and to less than 160/95 mm Hg in 
the elderly with no co-morbidity. 
Furosemide, oral, 40-120 mg daily, if unresponsive to For eodamatous subjects or 
above those in CCF or resistant or in 
renal failure. 
Reserpine, oral, 0.1 mg daily Continued from primary care as 
additional therapy. 
Atenolol, oral, 50 mg daily, can be increased to 100 In addition to 
mg daily in patients with insufficient beta blockade hydrochlorothiazide 
May be beneficial in the 
following conditions: 
Angina, after myocardial 
infarction, tachydysrhythmias , 
and pregnancy 
~CE-inhibitors e.g. Perindopril, oral, 4 mg daily Use if target blood pressure is 
not achieved with the above-
listed medications. Also for: 
Heart failure 
Left ventricular hypertrophy. 
After myocardial infarction 
(remodelling prevented) 
Diabetes with micro-albuminuria 
Alpha blocker e.g. Use for chronic renal failure and 
Prazosin, oral, 1-5 mg 2-3 times daily, maximum heart failure 
dose: 20 mg daily. Start with low dose, titrate This is a third-line anti-
289 
upwards. A first dose hypotensive effect can occur. hypertensive drug 
Calcium channel blockers e.g. Extra benefits: 
!Verapamil, oral, 40-80 mg 3 times daily ~ngina pectoris, peripheral 
or vascular disease, in elderly 
!Verapamil sustained release, oral, 120-360 mg one patients, systolic hypertension 
or twice daily These drugs are metabolically 
Nifedipine*, oral, 5 mg, can be repeated. Short term, neutral 
emergency use only) *Nifedipine is a third-line drug 
or used for emergency lowering of 
Nifedipine long-acting, oral, 30-90 mg daily blood pressure. 
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APPENDIXM 
EXPENDITURE ON HYPERTENSION 1998/1999 
NORTHERN PROVINCE PHARMACEUTICAL SERVICES 
GENERIC NAME 
Amiloride 2.5Mg Hydrochlorothiazide 
25Mg 
Amiloride 5Mg Hydrochlorothiazide 
50Mg 
Atenolol Tabs 50Mg 
Atenolol Tabs 100Mg 
Captopril Tabs 25Mg 
Disopyramide Caps 100Mg 
Enalapril Tabs 5Mg 
Enalapril Tabs 10Mg 
Enalapril Tabs 20Mg 
Hydralazine Tabs 10Mg 
Hydralazine Tabs 25Mg 
Hydralazine Tabs 50Mg 
Hydrochlorothiazide Tabs 25Mg 
Indapamide Tabs 2.5Mg 
Methyldopa Tabs 250Mg 
Nifedipine Caps 10Mg 
Nifedipine Caps 5Mg 
Nifedipine Tabs 60Mg Slow Release 
Perindopril Tabs 4Mg 
Prazosin Tabs 1Mg 
Prazosin Tabs 2Mg. 
Prazosin Tabs 5Mg 
Quinapril Tabs 10Mg 
Reserpine Tabs 0.25Mg 
ANNUAL PROVINCIAL COST 
UNITS 
ISSUED 
184,000 
6,549,061 
537,208 
348,068 
4,400,932 
12,500 
414,680 
762,720 
308,560 
95,500 
103,500 
140,000 
5,698,980 
6,540 
12,110,000 
1,844,462 
292,200 
300 
90 
57,300 
77,000 
45,630 
1,120 
478,296 
COST 
7,643.36 
138,461.56 
49,354.14 
49,007.82 
855,767.77 
3,591.52 
127,533.00 
435,792.00 
352,200.00 
3,726.40 
3,821.71 
9,525.54 
201,565.45 
632.54 
1,374,664.19 
236,778.73 
41,580.03 
550.00 
47.76 
5,497.02 
12,398.21 
21,040.32 
440.00 
23,770.09 
3,955,389.16 
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APPENDIX N 
DIABETES TREATMENT 
~.5. DIABETES MELLITUS 
iTreatment guidelines 
.' 
" 
l 
Non-drug 
reatment 
Drug 
treatment 
Management 
Education for self-care and to 
prevent complications 
Dietary therapy and weight 
loss is the corner stone of 
reatment of patients with 
NIDDM (Type 2) 
Increased physical activity 
within limits. 
One drug initially, but 
combine with metformin or 
insulin if targets are not 
achieved. 
Oral anti-diabetic agents: 
iSulphonylureas: e.g. 
Irolbutamide, oral, 250 mg 2-
3 times daily, up to 1 500 
mg/day 
OR 
Glipizide, oral, , 2.5 mg once 
o twice daily, up to 30 
mg/day 
~R 
Gliclazide, oral, 40 mg once 
o twice daily, up to 320 
mg/day 
OR 
Glibenclamide, oral, , 2.5 mg 
once to twice daily, up to 15 
mg/day 
~ND/OR 
Biguanides: Metformin, oral 
500 or 850 mg 1-3 times 
klaily, total maximum daily 
klose: 3 000 mg 
Comments 
Definition 
A syndrome caused by a relative or absolute 
deficiency of insulin. 
Pathogenesis 
Insulin deficiency can be either primary or 
secondary. 
Irypes 
Non-Insulin Dependent Diabetes Mellitus 
(NIDDM) 
(Type 2) 
Insulin-Dependent Diabetes Mellitus (100M) 
(Type I) Pancreatic diabetes mellitus 
Referral criteria 
• Serious complications 
• Associated diseases 
• Pregnancy (see appropriate guideline) 
• If condition is difficult to control. 
Monitor response clinically and by blood 
glucose 
Use if glycaemic targets are not reached after 
lifestyle modification for 3 months OR in newly 
idiagnosed patients with very high blood 
~Iucose levels (15-20 mmollL) who are not 
idehydrated or in keto-acidosis. 
These drugs stimulate insulin secretion. 
Hypoglycaemia can be a problem. 
NB. Not to be used in pregnancy or in impaired 
renal or hepatic function . 
Caution with long-acting drugs in elderly 
people. 
Use if glycaemic targets are not reached after 
lifestyle modification for 3 months OR in newly 
(jiagnosed patients with very high blood 
glucose levels (15-20 mmollL) who are not 
dehydrated or in keto-acidosis They enhance 
insulin action peripherally. They are useful in 
_pbese patients. 
OR 
Insulin: - insulin protocols: 
rvery rapid acting: onset of 
!action: 10 min, peak action: 1 
hour, duration of action: 3 
hours; injections daily, 
immediately prior to meals. 
Use for: 
• All Type I diabetics (IDDM) 
• Type 2 diabetics (NIDDM) with poor 
glycaemic control on oral agents; or 
during stress or intercurrent illness or 
infections or peri-operative, after 
trauma, during pregnancy, with 
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~hort-acting: onset of action: pancreatitis, severe organ failure and in 
~O min, peak action: 2-5 hyperglycaemic emergencies. 
hours, duration of action: 5-8 lTitrate dose according to blood glucose 
hours, injections daily, 30 min response 
prior to meals. 
Intermediate-acting: onset of 
action: 1-3 hours, peak 
action: 6-12 hours, duration 
jof action 16-24 hours, 
injections: 1-twice daily. 
Biphasic mixtures e.g. 30170, 
!Onset of action: 30 min, peak 
!action: 2-12 hours, duration 
pf action: 16-24 hours, 
Injections: once to twice daily. 
Ketosis: Electrolytes and fluids: To be given only in exceptional cases as 
~odium chloride solution jeorrection of dehydration usually makes this 
~.9%, IV, 1-2 L initially, unnecessary. 
ollowed by sodium chloride rro be prescribed by a specialist only 
solution 0.45%. Potassium to 
be monitored and given if 
necessary. 
~hen blood glucose reaches 
10-14 mmollL change to 
~extrose 5% in water to 
prevent hypoglycaemia. 
Insulin, ,regular, IV, titrate 
!according to response, given 
hourly and change to SC 4-6 
hourty until a decision is made 
!for further treatment Sodium 
bicarbonate 8.5% for IV use, 
~uided by bicarbonate deficit 
!as estimated e.g. HC03 = 
~.50 x weight (kg) x desired 
HC03 - deficit. 
Monitor carefully during 
reatment. Titrate dose to pH. 
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APPENDIX 0 
EXPENDITURE ON DIABETES 1998/1999 
NORTHERN PROVINCE PHARMACEUTICAL SERVICES 
iGENERIC NAME 
Acarbose Tabs 50Mg 
Glibenclamide Tabs 5Mg 
Gliclazide Tabs 80Mg 
Glipizide Tabs 5Mg 
Insulin 100iul ml 
Insulin Inj Device 3MI Cartridge 
Insulin Needles 
Insulin Syringes 
Metformin Tabs 850Mg 
Test Strip Blood Gluc(haemo) Visual 
OrR 
Test Strip Blood Gluc.(Lenstr.)Sg018 
Test Strip Blood Glucose (Ames) 
Test Strip Glucose In Blood (Refloflux 
Test Strip Glucose In Blood 
(Accutrend) 
Test Strip Glucose In Urine (Lens trip) 
Test Strip Glucose Ketones Protein 
Suo15 
Test Strip Glucose Prot.Ket.(Combur 9 
Test Strip Glucose Protein Ketones 
Tolbutamide Tabs 500Mg 
ANNUAL PROVINCIAL COST 
UNITS 
ISSUED 
1,800 
3,594,650 
1,160,712 
1,700 
89,910 
1 
70,600 
962,962 
1,693,800 
3,550 
142,250 
247,000 
4,950 
38,750 
93,350 
162,700 
524,500 
127,500 
87,800 
COST 
630.00 
110,254.09 
164,405.98 
184.91 
1,480,450.94 
11.25 
15,206.76 
298,210.04 
151,150.00 
3,592.60 
87,742.45 
172,900.00 
3,719.65 
29,697.24 
17,641.50 
38,598.60 
152,728.35 
37,639.00 
10,086.50 
2,774,849.86 
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APPENDIXP 
ASTHMA TREATMENT 
10.2. ASTHMA, CHRONIC PERSISTENT 
Treatment guidelines 
Management Comments 
Non-drug Patient education Referral criteria 
~reatment Psychological support • · To assess and confirm diagnosis 
when in doubt 
• · To optimise therapy 
• · To treat complications 
• · Patients not responding to 
optimal therapy 
• · Acute severe non-responding 
attacks of bronchospasm 
Drug Beta-2-stimulants, e.g. rrhe doses of beta-stimulant MDls, i.e. 
reatment Salbutamol or fenoterol, 100-200 micrograms 4-6 hourly should 
Maintenance MDI, 1 00-200 micrograms, 4- not be exceeded in chronic asthma except 
herapy: ~ hourly as necessary in acute severe attacks, as higher doses 
PR may be hazardous, especially in the 
Salbutamol, nebulised, 2.5-5 ~Iderly and those with cardiac disease. 
mg undiluted given over 3 Concomitant use of preparations of the 
minutes, repeat 4-6 hourly same pharmacological classification is 
OR hazardous and must be avoided. 
Fenoterol, nebulised, 1.25-2.5 Nocturnal asthma is usually indicative of 
mg undiluted given over 3 poor control and treatment adjustment 
minutes, repeat 4-6 hourly. ~hould be considered. 
AND/OR Exercise-induced asthma may be an 
Ipratropium bromide, MDI, isolated symptom of asthma and may 
40-120 micrograms 6-8 require the use of an inhaled beta-2-
hourly stimulant 15-20 minutes before the 
exercise. 
ITo be prescribed by a specialist only. 
o 0 
PLUS, IF REQUIRED Dosages of more than 800 micrograms 
Budesonide, inhaled, 200 per day are reserved for pulmonologist 
. micrograms twice daily, if no only, and should not normally be used, as 
peak flow or other lung higher dosages cause significant 
function test assessment metabolic adverse effects. 
available. Higher doses ~II inhaled corticosteroids should be 
should be based on lung administered via a spacer. 
function test and evidence of Cromoglycate and nedocromil have no 
clinically meaningful improved benefit over corticosteroids. 
response. 
PLUS, IF REQUIRED 
. Prednisone, oral, 5-10 
mg/day, or 15 mg on alternate 
days. Doses of 20-40 mg 
daily for 7 days may be 
needed for short term 
exacerbations in patients not 
responding to the above. 0 
!Theophylline slow release, Higher dosages of theophylline should be 
oral, initially 400 mg/day in 2- guided by blood level monitoring. The 
3 divided doses 8-12 hourly, elderly are more susceptible to 
ollowed by increments of heophylline toxicity and theophylline 
150-200 mg/day every third dosages need to be reduced by about 
295 
day until a maximum dose of 30% 
14 mg/kg/day, or a maximum Combinations of xanthine derivatives with 
of 900 mg/day, has been ephedrine-like substances and sedatives 
achieved. have no place in the treatment of asthma. 
Intercurrent IAntimicrobials may be used 
bacterial "or 7-10 days, e.g. 
infections: Doxycycline, oral, 100 mg 
Itwice daily PR 
IAmoxicillin, oral, 500 mg 8 
hourly PR 
[rrimethoprim/sulfamethoxazol 
~ 80/400mg, oral, 1 tablet 
~icedaily. 
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APPENDIXQ 
EXPENDITURE ON ASTHMA 1998/1999 
NORTHERN PROVINCE PHARMACEUTICAL SERVICES 
GENERIC NAME UNITS 
ISSUED 
Aerochamber Adult 170 
Aerochamber Child 396 
Aerochamber Neonate 141 
Beclomethasone Inhaler Complete SOMcg 70,592 
Beclomethasone Rotacaps 100Mcg 5,880 
Beclomethasone Rotacaps 200Mcg 1,560 
Budesonide Inhaler 200Mcg 300Dose 333 
Fenoterol Udv 1.25Mg/2ml 420 
Fluticasone Diskhaler 36 
Fluticasone Disks 250Mcg 938 
Ipratropium Inhaler Complete 200Dose 4,830 
Ipratropium Udv 0.25Mg/2ml 31,500 
Ipratropium Udv 0.5Mg/2ml 63,420 
Ketotifen Fumarate Syr 200MI 1,598 
Salbutamol Inhaler Complete 100Mcg 200 164,892 
D 
Salbutamol Rotacaps 200Mcg 29,340 
Salbutamol Rotacaps 400Mcg 3,360 
Salbutamol Rotahaler 600 
Salbutamol Sy_r 2Mg/5ml500M! 6,723 
Salbutamol Tabs 4Mg 1,981,000 
Salbutamol Udv 2.5Mg/2.5Ml 51,864 
Salbutamol Udv 5Mg/2.5Ml 15,655 
Sodium Cromoglycate Inhaler Complete 9 
5Mg 
Sodium Cromoglycate Spinhaler 99 
Theophylline Caps 60Mg (Anhydrous) 11,100 
Theophylline Caps 125Mg (Anhydrous) 38,040 
Theophylline Syr 200M! 84,678 
Theophylline Tabs 200Mg (Anhydrous) 1,257,000 
Theophylline Tabs 250Mg (Anhydrous) 155,000 
Theophylline Tabs 300Mg (Anhydrous) 1,241,500 
ANNUAL PROVINCIAL COST 
COST 
4,505.00 
21,166.13 
7,559.01 
494,108.28 
2,860.62 
1,068.08 
10,926.03 
399.14 
529.20 
4,355.00 
82,580.43 
33,157.62 
83,450.15 
78,659.15 
800,266.68 
7,732.79 
1,247.68 
9,000.00 
50,124.10 
75,136.59 
37,993.16 
13,270.73 
427.05 
1,490.94 
3,355.90 
11,703.64 
287,630.31 
127,731.98 
10,306.14 
188,790.13 
2,451,531.66 
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SAVINGS 
ON METERED DOSE INHALERS 
Beclomethasone Inhaler Complete 50Mcg 
Salbutamol Inhaler Complete 100Meg 200 D 
TOTAL FOR CURRENT PROTOCOL 
Budesonide 200cmg 300dose 
Salbutamol Inhaler 100Meg 300 Dose 
TOTAL FOR NEW PROTOCOL 
IpOSSIBLE SAVING 
GENERIC NAME 
Aerochamber Adult 
Aerochamber Child 
Aerochamber Neonate 
Ketotifen Fumarate Syr 200MI -
Salbutamol Syr 2Mg/5ml 500Ml 
Salbutamol Tabs 4Mg 
Theophylline Syr 200Ml 
ANNUAL PROVINCIAL COST 
SAVINGS ON METERED DOSE 
INHALERS 
Beclomethasone Inhaler Complete 50 Meg 
Salbutamol Inhaler Complete 100Meg 200 D 
TOTAL FOR CURRENT PROTOCOL 
I Budesonide 200cmg 300dose 
70,592 
164,892 
11765 
109928 
UNITS 
ISSUED 
170 
396 
141 
1,598 
6,723 
1,981,000 
84,678 
70,592 
164,892 
560,500.48 
1,203,711.60 
1,764,212.08 
469,436.80 
1,021,231.12 
1,490,667.92 
273,544.161 
COST 
4,505.00 
21,166.13 
7,559.01 
78,659.15 
50,124.10 
75,136.59 
287,630.31 
524,780.29 
560,500.48 
1,203,711.60 
1,764,212.08 
111765 1 469,436.80 
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Salbutamol Inhaler 100Mcg 300 Dose 109928 1,021,231.12 
TOT AL FOR NEW PROTOCOL 1,490,667.92 
273,544.16 
798,324.45 
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APPENDIXR 
INRUD QUESTIONS 
QUESTIONS TO GIDDE QUALITATIVE ASPECTS OF THE STUDY 
(Source: INRUD, How to use Applied Qualitative Methods to Design Drug Use Interventions, 
1996:2-7 and 2-8) 
Describes the Problem in Greater Detail 
1. Do practices vary greatly by location, health facility, or health provider? 
2. Do deficits in knowledge contribute to problem practices? 
3. What specific areas of knowledge are deficient: diagnostic procedure, drug 
efficacy, drug dosing, etc.? 
4. Do health providers think: their practices are the same or different from their 
peers? 
5. Do problem practices vary by diagnosis, type of patient, time of month, etc. 
Feasibility of Proposed Intervention 
6. Are there severe constraints in the work environment that would prevent health 
providers from changing their behaviour? 
7. Are there proper drugs available at all times? 
8. Are health providers interested in improving their practices? 
9. Are the administrative authorities supportive of the types of changes proposed? 
Target the Intervention 
10. Are there features of the social, cultural, or behavioural context that could be used 
to influence the practices of individual health workers? 
11. Are there particular people whose opinion is especially influential with health 
providers? 
12. Would it be possible to recruit these opinion leaders to assist in implement the 
intervention? 
13. Is it possible to reduce the general problem of interest to more specific behaviours 
or practices that it would be easier to change? 
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Define Specific Intervention Messages 
14. Can specific myths about practice be identified that it is possible do debunk with 
scientific facts? 
15. Are there specific areas of miscommunication between administrators and health 
providers (pharmacists, doctors, nurses)? 
16. What kinds of educational material are available to health providers? 
17. When health providers or patients have changed in the past, what was it that 
caused them to change? 
18. How do health workers respond to prototype intervention material? 
To Decide Format and Style of Intervention 
19. What source of information do health providers use to learn about health problems 
or drugs? 
20. What educational programmes have health workers already attended? 
21. What model of continuing education is most highly rated: group seminars, 
workshops, visits by medical experts, etc? 
22. How often do health workers interact with drug company representatives? 
23. Is information from drug companies considered to be biased? 
24. Do health workers have access to any unbiased sources of drug information? 
25. Are there any ways for health workers to review their practices for the problem 
of interest: regular utilization reports, practice audits, practice & therapeutic 
committees, departmental reviews, etc.? 
26. How do health workers respond when they are given summaries of their 
own practices? 
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APPENDIXS 
Guiding Questions for Interviews 
Questions for Health Personnel 
1. Were you or your colleagues informed about the STGIEDL? 
2. Were you or your colleagues trained to use the new STGIEDL? 
3. Has the STGIEDL affected the way you work? 
4. Are there advantages to using the STGIEDL? Why or why not? 
5. Do you know about 10% cap on ordering drugs and motivating for 
drugs? 
6. Have you heard about PTe committees? 
7. Should there be interdisciplinary meetings? If so, with whom and how 
often? 
8. Is there something that we have not discussed, that you think is 
important? 
Questions for Administrators 
1. What is your view about the implementation of the STGIEDL in hospital 
clinics thus far? 
2. What have been some of the biggest challenges to implementation? 
3. What type of training was envisioned? 
4. Has the training that was envisioned been implemented for prescribers and 
pharmacists? 
5. What percentages of the prescribers and pharmacists have been trained? 
6. What are some of the restraint to training? 
7. What do you envision for prescribers and pharmacist a year from now? 
8. How can you get closer to making this vision a reality? 
9. Is there an area that I have not covered, that you think is important? 
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Interview 
II 
V 
XI 
I 
III 
VIII 
XV 
XVI 
IV. 
VI. 
VII. 
IX. 
X. 
XII. 
XIII. 
XIV. 
XVII 
XVIII 
XIX 
XX 
Notes: 
Surg. = Surgerty 
Oncol. = Oncology 
Gender 
Female 
Male 
Male 
Female 
Female 
Female 
Female 
Female 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Male 
Int. Med. = Internal Medicine 
Denn = DennatologyX. 
Age 
26-35 
APPENDIXT 
List of Interview 
Yrs. Exp. 
NURSES 
11-16 
36-40 6-10 
26-35 11-16 
PHARMACISTS 
>25 <1 
26-35 6-10 
26-35 6-10 
51-60 20+ 
>25 <1 
PHYSICIANS 
26-35 6-10 
36-45 11-20 
41-50 11-20 
26-35 6-10 
26-35 6-10 
60+ 40+ 
26-35 6-10 
26-35 >1 
Level 
Sec. 
Tert. 
Prim. 
Tert. 
Sec. 
Tert 
Prim 
Prim 
Sec. 
Tert.- Surgery 
Tert.-Oncology 
Tert.- Int. Med 
Tert. 
Prim 
Prim 
Prim 
ADMINISTRATORS 
51+ 16+ Prov 
41-50 16+ Prov 
41-50 6-10 Provo 
51+ 16+ National 
Venue 
St. Ritas 
St. Ritas 
FH Odeaal 
Mankweng 
St. Ritas 
Pietersburg 
FH Odeaal 
FH Odeaal 
St. Ritas 
Pietersburg 
Pietersburg 
Pieters burg 
Pieters burg 
FH Odeaal 
FH Odeaal 
FH Odeaal 
DoH 
DoH 
Vuna 
Univ. 
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APPENDIX V 
Letters for support of Research in South Africa 
Northern Province 
DEPARTMENT OF HEALTH & WELFARE 
(0152) 291 2637 
(0152)295285112 
(0152) 295 2987/8 
(0152)2915961 . 
(0152) 291 5146 
PRIVATE BAG X9302 
PIETERSBURG 
0700 
Enquiries: Sinah Mahlangu 
Ms Ariel King 
Reference: Research & Quality 
Improvement 
1 December 1998 
South African Drug Action Programme 
273 Proes Street 
PRETORIA 
0001 
DearMsKing 
AN EVALUATION OF THE FORMULATION AND IMPLEMENTATION OF THE 
NATIONAL DRUG POLICY. ESSENTIAL DRUG LIST AND STANDARD 
TREATMENT GUIDELINES IN PUBLIC HOSPITALS. A CASE STUDY OF 
GAUTENG AND NORTHERN PROVINCES 
1. Permission is hereby granted to conduct a study on the above topic in 
the Northern Province 
2. The Department of Health & Welfare needs a copy of the research 
findings for Its own resource centre. 
3. The researcher should be prepared to assist in Interpretation and 
Implementation of the recommendations where possible. 
4. Implications: Permission should be requested from regional and 
Institutional management to do research. 
Sincerely. 
)' 0<crfoQ.y:' Oo/I>/?O SU'~~~EJo;~T _ GENERAL 
DEPARTMENT OF HEALTH & WELFARE 
NORTHERN PROVINCE 
DR JAN MOOLMAN BUILDING 
34 HANS VAN RENSBURG STREET 
PIETERSBUAG 0700 
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APPENDIX V 
Letters for support of Research in South Africa 
Verw/Ret: 
AAN/TO: CHIEF DIRECTORS FromNan: CHIEF DIRECTOR: 
Your ref: 
Dated: 
RE: RESEARCH: MS A KING 
REGISTRATION AND 
REGULATION 
Enquiries: OMB PHAAASI 
Telephone: 312-0355 
Office No: 923 H 
Date: 
TO WHOM IT MAY CONCERN 
This is to introduce to you Ms Arial King. PhD student at the London School of Hygiene 
and Tropical Medicine. Ms King is doing her PhD on the implementation of the South 
African National Drug Policy. and specifically she will investigate the impact of the 
introduction of the Essential Drug Ust tor hospitals In the Northem and Gauteng 
Provinces. 
I recommend that you support Ms King in her research efforts as the topic is of 
importance. 
Kind regards 
CHIEF DIRECTOR: REGISTRATION AND REGULATION 
DATE: I 2-11 I 9 l 
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APPENDIXW 
Motivation Form for Ordering Brand Drugs 
D~artment of Health and Welfare: Northern Province 
NAMED PATIENT MOTIVATION FOR A NON-FORMUWY MEDICINE OR SURGICAL MATERIAL 
REQUEST 
Kindly cempl.'!e "' sections. PI.:= conUct yoW' P!:W1:cist for wisl.w:e. Submil complrled (oem to ph~'lmCY. 
To: The Secretary. 
Provincial Therapeutics Committce!I"herapeutics Control Committee 
From: ........................... hospilal/district manager Tel: ...... Fax ...... 
Note:.) If more than one dru: required rOC' same condl~on, complele a Itparatc mO~\'adon a.,d atta,!\. 
b} For sUT(lwIlUlICri:W, complclt onl1 ihe .edions IIIAIVd with an asterisk(·). 
c) Dtparnntnt of Hcslch 4< Welfare dot'!!2! .crept ILtbWcy ror WI1Irtll.ltd Indlc.don('~ 
1. Patient details (please complete all fields) 
Nilme ................................................... .. 
Sex Ward type (.ur;iW fIC.) ......... : ......... . 
2. Medication required 
Age 
Patient No 
Order no ....... : .. 
Indication/condition ........................................................................................................... .. 
J. Tender details: Tender number RT.. .. 1..... Spec. No ... : ..... Item No ............. . 
4. Is treatment for this indication approved/licensed by MCC? 
If "NO: are you prepared to accept liability? 
S/>JM/ATC or pharrrulcological classification 
YES/NO 
YES/NO 
Price ........ .! ...... 
.Approved name ..................................... ·Proprietmynarne ............................................ .. 
Strength 
Dose (onn 
·Quantity required ................................... . 
Dose 
·Treatrnent period ............................................. . 
·Currentlpre,·ious treatment ...................... , ...................................................................... .. 
.................. , ................................................................................................................. . 
.................................................................................................................................... 
* Reason wby patient rcquim new treatment (attach copy oftabor3tory antibil>gram if requesting an 
anti-infective agent) ............................................................................................... : ......... .. 
.................................................................................................................................... 
••• • , •••••••• : ••••• '0' ••••••• 0. ,,, ••••••••••••••• '" ••••••••••••••••• , •• , ••••••••••••••••••••••••••••••••••••••••• , •••••••••••••••••• 
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Motivation Form for Ordering Brand Drugs 
S. Drug lItUiutioD data 
Is product listed in most retent edition of public:1tioDS listed below? 
SAMF 0'" ed.) YES I NO WHO Essential Drug list (1996) YES I NO 
Reason fOl litis request Rfjerence(s): 
a. 
b. 
c. 
d. 
e. 
f. 
g. 
h. 
Improved eos~nefit ratio 
Improved benefit/risk ratio 
Branded/proprietory product 
YES/NO 
YESfNO 
YESINO 
. ............................•............................. 
. ......................................................... . 
. ........................................................... . 
If a branded/proprietary product is requested, kindly supply details a.nd re[erences of bio-
availability data ...................................................................................................... . 
. . 
................................................................................................................................ 
Increased potency/efficacy YES/NO . .......................................................... . 
To improve compliance YES/NO . ........................................................... . 
Special pharmacokinetics YES/NO . .......................................................... . 
Alternative not in (onnulary YES/NO . ........................................................... . 
1f alternative product not ill formulary then please SUte what procedures/iotervcntions etc. were 
previously used at rout hospital ...................................................................................... . 
........................................................................................................................... 
Other (please specify) . ........................................................................................... . 
Date ...... 1 .... .1 ........ .. PresCribers signature .................................. . 
Not.: I. Only crit,ri~ bAud moIi ... tions will b<I consid.:r.d. 
2. '!mi.' rcquind (or omcrg.n<:r usc .. ill be rcr.rrod 10 • P= IfOUP. all ollIen ID neX\ PTe n\~.1i"&. 
,Approved ....................................... . Approved ......................................................... .. 
: (Chaimwt: HOS\liul TCC) (Secretary: Hospiul TCC) 
6. For PTCrrCC use oaly 
FormuliJry dite,"ative List No. Cost: formulary iuml Cost: requested item 
1. .......................... .. . ............................ . .............................. I .............................. . 
2 ........................... .. .. ............................ I ............................ .. 
7. PTC recommendatioo(s) Appl'O~'cd: YES I NO R:asonlcomments ............................... . 
............................................................................................................................................. 
Date .... J .... .I ....... Chairman ................................................ . 
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1\i:(.lUISITI()N N IIM III ·: R : .....•.... 
.. 
IT'~M ~~I~~ I.IQlIID / . <)II/\N'J'I'J'V J(EQUII!ED STIU:NCiTII 
,J • ONII ,n·. 
hLEX ~~'-'1 ~ 
U ---
WAIW / NAME cw l'A'I1ENT 1\( iE IIOSI'IT"' . NII. l'I.ASSIFIC/\ TIlIN 1)4ISE 1lllll Al'ION OF 
. SI:CI"II )N <IF I'II'I'II;NT (JI; I'ATII '.NI 'IUEATMENT 
GtJeJ) Eu2.~~ tc$fJC/j- 'li('S , 1VrSD 0 gfX; 4tlV) "'f m. 
, 
'" 
IlIj~J\1> 01: J)EI'AUTMENT: (Jl lt!~!IoC I,rilll) . ...... .. . . . ........ . ... . "AN": ....... . . 
Tfl lS 1··OI(M MilS'!' BE ."I·N!' TO '1'11/'; 1'11t\I(MD('\' WITII 'll1J:: . .J.:tlJlI:K.['-'i ... J::J.L.I:: 
~{~ ~~~ 
, v . 
M()'IlVA·Il()N:./for. .&.[f.D!f}ftft .. ;1I. .. l4W14 ... ~trL ... @TlI1rm.4L·~%.4P~~&.~ ... 'Q~~. 
. . . 
.. . ... . .. .. . ......... ........................ . ............... ,., .................. , ............ . . ...... . ........ . ...... .... .... . . .. ... 1 0 
OIUlE"W "Y: I pi"" ~;"I ... !!1o.i/Y'J.p.:7 J.... ... JANK: .Med! 11:11& ... <!<iNA.I1I1<Ef!j! .. ... : .......... . 
IlEAl) OF IlEI'ARTMENT: (flh:.1.1C prinl). ... ... . ..... ...... RANK: ....... .......... : •. ;:\ SI(iNII·I III\E: .. ... ............ ...... . 
TillS '''OI!M MIIST III': SI':r~T TO TilE '''''''(MAC\' II'ITII TII.I~J':\TII'}IT'S F'I.I~ 
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EDP 
. 
NEWS 
Contents 
...... 
EBBl'D.IOJ. 1BIMAB.T CAB! num\IJ) 'l'RfA.1.'Marr GamE .... 
LDtES AD DSER'1'IAL J)W&5 LrST 
~mixtures-
, why ,are ~ no cou6j1 mixtures on the 
~? 
In otd!r 'bO ~ til, • bllmd 
!be of ~ lllidurtl-fromb EDl 
need to know ft'IOI\I ibet.lt c:wghing and ¥Itt 
IlS VIet .1bin Is SIOmc!JJilg ill 11'6 ilIr ~It is 
initIliilg to Iftj rnp. 
Cough has bHn :ported to be on. cl1h, 
,., 51 hquant rR5lll'IS fur I plotifJrt !o mit '. 
llea1l1'1car'! ~ I'n JImtra'Ja ' Is 11\. single 
jjitI~ altftmon· rNSOftJ ." a ~tnt to I 
~ and w:ounts fllr lMI'.! 1~ C all 
~t5. ~ sWlslfa hi1i'8 iShown 'thit 
taugtlltl~ ""/1/19 ttl! ftve mot! etltftmon 
rRSOnS for paISIrls to 'iIsIt a dCId.I:W &rid ~ it 
M'I:O\i,"IIJ fat 10 rill 10ft 0'II\c4 .. ~ 
tiI,dlS.. 
C04ltfF. mi)dl;,tl'i~c/N! ~er-tisted 
~: - ~ you !Pi it dt>es 
not wor/Q 
Min)' Qmmgn ~inller1 O!I/Id~ 
n QOughinO is JlronJnt:ITC act ., r . 
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By now all clinics shoUld haw their cOPIes of the second edition 
of tlre EDLmt nq,W ,~tudes diagnmbc fiuwdi:agrams I" belp 
you to dct¢rmine wb.¢th-;r to treat or liefer. 
The oUter WI)' hclpf'll :feature • ,tMllhc dosC5 of mcdica:tinn for 
~hilcb:m N'C more 5'pet:il:i~. 
,QMNGES TQ DiE EDL 
All tablcfs and syru~ used fur tho mmagcmcnt of As-thma arc 
now phased out.Only imW.m Me .wilAble.PIease check tho EDL 
for 'dm management of As1hma. 
1ilcR are no cough ~ on the EDI..Choc.k EDP news for 
more infonnaUon. 
A oomomation of RilimpK.inJ;J'ri2irWtUde,Isonhuid It1d 
Ethambutol is mow avaitaMe.1'h!e combination is. llIed Rititer 
.. and will be 'used to f S()tft~ pat1ent§ 
BODGEI 
Your lIlottthIy and )'t!lliy allowaiiOn of the budget bu been gJwn 
to you.l11is; win help ,mI to etltUrQ· f()'Hf" OM't elillic bu~t 
CheCk your in\~c:e cVerYtlme you :rca:r.'e stock. 
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STOCK ABQUTTQ EXPIRE 
IfsQtnt mcdi.catioJu aM .oollllQ a.pitc and 'Will .not used before 
thce~ d.ate,pt~e tefil:th 'then to ~ pharmacy. tnOAtll 
be€oro cxpity. 
GINJqUCS 
Let" s go 'C)'encril;:8. 
Let U'J get mod to Chc perle namcs.AlwllY5 we pcrio namcs, 
'-" durins pn:scribins md ~t of tho phamulcylmedl.cal 
cupboard. Usc the attdled :fC.fCI'eI'I.CC leit whcn probtcn"lS U1) 
,I.CWWltered wiCh gm.cric names or c4D. tnc phlllmacy. 
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NGWARITSI MAKHUDU 
THAMAGA TUBATSE 
STEELPOORT DISTRICT 
CL1NlC REFERENCE LIST 
GENERIC NAMES 
~ 
CiptoflanGin 
Ctoxaoillin 
Co-Trimanzolc 
~~ 
GriIcoll.ahic 
PbCQQ~pcaioilliD 
Aluminium.t:magnc:trum 
AIpft\ 
A.tc:ool.ol 
Chlarpbc:ninaaUDo 
Fa . cn"Ou.t tUmarate 
TRADE NAMES 
Amaxil 
~ 
CLoxiD 
~.CQZDle 
~1in 
Puanyoia.Emu-V 
Gri3eoti.m"i2l 
PenVK 
GeluaiJ 
"'Pitin 
Tmblala 
AlIcrgex 
Feiol 
315 
